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During my training for neurologist I treated only a few patients with status 
epilepticus (SE). Most responded well to therapy with benzodiazepines 
and/or phenytoin. It was during my ﬁrst year as neurologist working in the 
Intensive Care Unit of the University Hospital that I came in contact with 
cases refractory to ﬁrst line drugs and I was struck by the lack of treatment 
protocol, not only in our but also in the referring hospitals. The importance 
of a treatment protocol and the risks when such a protocol is lacking is 
illustrated by the following case-report.
Case report
Patient A suffered from partial epilepsy with tonic-clonic seizures caused by 
a severe head trauma at the age of 4 years. The prescribed anti-epileptic drugs 
were taken irregularly. At the age of 20 years he suffered from a generalized 
tonic-clonic seizure that lasted 60 minutes. He remained unconscious 
and from time to time showed clonic jerks. Two and a half hours after the 
start of the seizure his family called the general practitioner who injected 
10 mg of diazepam intravenously. He was transferred to a local hospital six 
hours after the start of the seizure, still in coma. On admission his Glasgow 
Coma Scale EMV-score was 3, his blood pressure was too low to measure, 
his body temperature was 38.7 C°, he showed a shallow breathing pattern 
and was cyanotic. He was treated with intravenous (i.v.) ﬂuids containing 
bicarbonate (pH was 7.29) and corticosteroids. After this treatment he 
reacted to pinpricks, his body temperature declined to 36.9° C and his blood 
pressure increased to 120/80 mm Hg. A lumbar puncture showed normal 
pressure. His coma, however, did not improve and the next day, as he 
showed asymmetrical pupils, he was transferred to the intensive care unit 
(ICU) of a University hospital. At admission, he was in coma, his EMV-score 
was 3, he showed signs of respiratory insufﬁciency, and his right arm was 
severely swollen. Laboratory investigations showed hyperkaliaemia, renal 
and hepatic insufﬁciency, hypoxia and a CPK of 150.000 U/l.
An EEG showed generalized slow wave activity, especially on the left, 
with every two seconds spike-wave activity with phase-opposition over 
the left temporal area, but sometimes also over the right. A CT-scan was 
normal. A muscle needle-biopsy of the right arm showed severe necrosis. 
Treatment consisted of intubation, mechanical ventilation, administration 
of clonazepam and phenytoin iv, corticosteroids iv and dialysis. However, 
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he died six days after the start of SE after a period of severe intracranial 
hypertension with pressures over 80 mm Hg. Neuropathological 
examination of the brain showed severe ischaemic lesions with oedema of 
the cerebral cortex and thalamus and to a lesser extent of the hippocampus. 
The pons and medulla oblongata showed only minor changes, whereas the 
cerebellum appeared normal. In the kidney myoglobuline was present in 
the renal tubulus.
This patient with partial epilepsy and compliance problems developed 
generalized tonic-clonic SE; due to family and doctor delay, treatment was 
started too late and, moreover, was also inadequate. In the local hospital, 
attention had been focussed on the coma. The possibility of subtle generalized 
tonic-clonic SE with minor clinical convulsive signs, coma and continuing 
epileptic discharges had not been considered. In this patient, almost all 
possible medical complications were present: respiratory insufﬁciency, 
hypotension, hyperthermia, renal failure, hepatic failure, rhabdomyolysis, 
intracranial hypertension, acidosis and hyperkaliaemia. The exact cause of 
death was, however, difﬁcult to determine; the mechanisms underlying the 
neuropathological ﬁndings in this patient were the epileptic discharges, the 
medical complications or both.
In the Dutch medical literature few case reports and reviews have been 
published within a period of 45 years on generalized convulsive SE (Frederiks, 
1969; Hootsmans, 1954; Lorentz De Haas, 1960; Verjaal and Goor, 1969; van 
Huffelen, 1983), absence SE (Visser, 1970), simple partial SE with aphasia 
as the main symptom (Jongsma and Vanneste, 1991), complex partial SE 
(Storm and Casteelen, 1999), the Landau-Kleffner Syndrome (Stroink et 
al, 1997) and treatment with clonazepam (van Huffelen and Magnus, 1976). 
The importance of a treatment protocol has been stressed in one review in 
the Dutch medical literature (van Huffelen, 1983). 
Most cases of SE are successfully treated with ﬁrst line drugs, such as 
benzodiazepines (BDZ) and/or phenytoin (PHT). Refractory cases of SE 
are relatively rare. This may be an explanation why treatment of SE lacks a 
consistent protocol. 
This lack of a protocol is not limited to the Netherlands. In the UK 
little agreement about treatment of SE exists. Guidelines were absent 
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or inadequate in 14 different centres in the UK, in only 5 centres speciﬁc 
timing for drug treatment was mentioned (Martland et al, 1998). Also, the 
management of refractory generalized convulsive status epilepticus (GCSE) 
in three European countries by epileptologists and critical care neurologists 
appeared heterogenous in many aspects (Holtkamp et al, 2003). Finally, 
a prospective study in Ireland showed considerable variability in the 
management of convulsive SE (Najam et al, 2004).
Personal experience (see case-report), the lack of a consistent treatment 
protocol and the high percentage of poor outcome in patients with refractory 
SE have been the reasons to make a study of SE in the Netherlands, to make 
a concept of a time-scheduled protocol for the treatment of SE (Scholtes and 
Dries, 1986) and to promote consensus on treatment of SE.
At the start of the study the following facts were obvious: 
1.  No information is available on the frequency of the various types of 
status epilepticus in the Netherlands.
2.  No information is available on causes, therapy and outcome of the 
various types of status epilepticus in the Netherlands.
3.  There is a lack of protocol in the treatment of status epilepticus, especially 
in cases refractory to ﬁrst line drugs in the Netherlands.
For this reason we started a retrospective study to investigate the extend of 
this problem in the Netherlands. After an extensive study of the literature 
on this topic we analysed a representative sample of cases with status 
epilepticus (SE) in adults and children.
With regard to outcome we looked at factors, mentioned in the literature, 
which may inﬂuence outcome: duration of SE, aetiology, presence of medical 
complications and quality of treatment. Finally, we analysed SE in special 
subgroups: mentally retarded patients, children with cognitive deterioration 
and electrical status epilepticus during slow sleep and patients admitted to 
the intensive care unit because of generalized convulsive SE. 
The ultimate goal of this study was to provide data on outcome of SE in 
the Netherlands and to investigate whether these results would advocate the 
need to promote treatment of SE according to a time-scheduled protocol.
Chapter 2 
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The incidence of status epilepticus (SE) in the Netherlands is not known. 
SE may occur at home in a person known with previous epilepsy and 
recurrent periods of SE, controlled by rectal diazepam or clonazepam. This 
patient will not be admitted to a hospital. The same goes for patients with 
mental retardation and epilepsy, institutionalised in an asylum or epilepsy 
centre with their own care-unit. Only cases refractory to ﬁrst line drugs 
will be transferred to a general hospital for further treatment. One of the 
epilepsy centres has an Intensive Care Unit of its own and internal transfers 
from wards of the centre to the ICU are not reported to the SIG, the Dutch 
documentation centre which coordinates and collects nationwide hospital 
statistics.
In the same vein cases of SE in patients already hospitalised because of 
another medical problem are difﬁcult to trace. These secondary cases are 
often not mentioned in the dismissal form or instead of SE only epilepsy is 
mentioned.
Only admissions to hospitals are reported to the SIG. If a patient is 
admitted to the hospital for SE, the medical condition will be classiﬁed 
according to the International Classiﬁcation of Diseases of the World Health 
Organization, ICD-9. Patients with SE receive the code 345.2, 345.3 or 
345.7 and are reported to the SIG. The Central Bureau of Statistics (CBS) 
collects mortality ﬁgures in the Netherlands of any cause; patients who died 
because of SE will be reported to the CBS. For our study we asked both the 
SIG and the CBS how many cases of SE they recorded per year, during the 
period 1980 - 1987. During the period 1980 - 1985 the percentage of general 
and university hospitals in the Netherlands that report their diagnosis (with 
age and gender) to the SIG increased from 95 to 100% (SIG, 1989).
The ICD-9, however, distinguishes only three possible types of SE: petit 
mal status epilepticus (345.2), grand mal status epilepticus (345.3) and 
epilepsia partialis continua (345.7). Both petit mal SE and grand mal SE are 
terms no longer accepted in the classiﬁcation of the International League 
Against Epilepsy (ILAE). A separate code for complex partial SE or tonic 
SE is not available. One can only guess how a case of complex partial SE 
has been reported: perhaps as petit mal SE or when clonic jerks have been 
present even as grand mal SE? It is up to the imagination of the physician 
how to document a case of elementary partial SE with aphasia as the sole 
presenting sign. 
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Apart from the problem that all cases of SE in a certain period are hard 
to trace and the limited possibilities of a proper ICD-code there is another 
problem: Which deﬁnition of SE has been used? Which duration of the 
seizure is considered to be minimal in order to diagnose SE?
Finally, some cases of SE will die before reaching the hospital or will not 
be admitted because they have not been recognized as such: cases of absence 
SE or complex partial SE may be mistaken for behaviour or psychiatric 
problems.
For all these reasons it is impossible to detect all cases of SE in a certain 
year. With these restrictions in mind, we tried to trace as many as possible 
admissions because of SE to a number of hospitals, in the period 1980-1987. 
Selection was based on size and geographical distribution. Also, cases from 
2 of the 3 epilepsy centres in the Netherlands were collected. 
Next we asked the SIG how many cases of SE had been reported during 
that same period 1980 - 1987. The ﬁgures provided by the SIG represent the 
number of hospital discharges and we took only notice of SE if it was the 
major diagnosis. 
We asked the cooperation of neurologists in 50 different hospitals, 
spread all over the country, to supply their material about this subject. 
Fourteen hospitals agreed to cooperate, two of which could not be used, 
because adequate documentation of admissions and discharges was not 
present. We visited every hospital and made an on the spot investigation of 
the patient ﬁles. Only cases with minimum seizure duration of 30 minutes 
or an established succession of generalized convulsive seizures without 
regaining consciousness between the seizures were included. The patient was 
given a number to prevent any possibility of recognition and the following 
data were gathered: age, gender, duration of SE, type of SE, results of EEG 
investigations when performed, previous epilepsy or not, causes of previous 
epilepsy, causes of SE, precipitating factors, medical complications, therapy, 
admission to Intensive Care Unit, results of treatment and outcome.
Outcome has been deﬁned for this study as the condition at discharge 
from the hospital, morbidity as all new neurological signs occurring because 
of SE and calculated per event. Outcome was good when SE had been 
successfully terminated and the patient returned to baseline level. 
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The causes of morbidity and mortality were classiﬁed as:
a) The underlying causes (cause).
b) The seizures themselves and accompanying medical complications 
(SE).
c) Cases in which the contribution of the underlying cause or the seizures 
themselves could not exactly be established (unknown). 
Therapy was considered insufﬁcient when:
a) An insufﬁcient dose had been administered.
b) The route of administration was wrong (e.g. intramuscular diazepam).
c) Unnecessary delay was present (e.g. waiting for more than one hour 
after diazepam injection, while seizures continued).
d) Mechanical ventilation was not started despite signs of respiratory 
insufﬁciency or the presence of various medical complications.
e) EEG monitoring was not performed in cases treated with anti-epileptic 
drugs together with curarisation.
In order to ﬁnd out whether the number of patients we analysed from 
the medical ﬁles, which were transmitted to us by the several hospitals, 
corresponded to the number the SIG had published, we took a sample from 
5 hospitals we had visited. The SIG reported a number of 126 discharges in 
the period 1985 - 1987; in the corresponding period we collected 116 in the 
same hospitals, a 92% agreement.
Our cohort of patients in 12 hospitals and 2 epilepsy centres amounts to 
576 adult cases and 112 children. In the corresponding period the average 
annual number of cases reported to the SIG were for generalized convulsive 
SE 469 (±69), for absence SE 36 (±6) and for epilepsia partialis continua 
50 (±17). Our number of cases admitted because of SE can be considered 
representative for the situation in the Netherlands. This representative 
sample has been used for further analysis of causes, treatment and outcome 
of SE in the Netherlands.
Chapter 3 
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3.1  Deﬁnition of status epilepticus
One of the earliest descriptions of status epilepticus (SE) has been found 
on Babylonian clay tablets, which were part of a medical diagnostic series, 
known as Sakikku (“All Diseases”) and which date back to the period 
1067 - 1046 B.C. (Kinnier Wilson and Reynolds, 1990).
Since then SE has received only little attention in the medical history. 
Hippocrates (fourth century BC) described several medical complications 
after longstanding seizures and stated that a severe ﬁt could kill a person 
(Temkin, 1971). Galen (second century AD) did not mention conditions 
resembling SE. Caelius Aurelianus (ﬁfth century AD) described several 
patients with prolonged seizures, but thought it hardly possible that this 
disease should assume an unremitting form (Drabkin, 1950). It was only 
after the start of the separate hospitalization of patients with epilepsy in 
the beginning of the 19th century, that systematic studies of epilepsy and 
SE could start. The several types of seizures were described, including SE, a 
term generally conﬁned to grand mal status or état de mal: “C’est ce que les 
malades l’appelent entre eux” (Temkin, 1971). This term état de mal, coined 
by the patients themselves, was described for the ﬁrst time by Calmeil (1824) 
in his dissertation. The expression SE appeared ﬁrst in the translation of 
Trousseau’s lectures on clinical medicine in 1867. SE was described as a 
succession of generalized convulsive seizures (Calmeil, 1824) or prolonged 
convulsive attacks (Turner, 1907). Other types were not acknowledged 
(Gastaut, 1967). According to Hunter (1960) the frequency of SE increased 
after the introduction of bromide by Locock in 1861. Gowers (1901) described 
7 patients who died because of SE caused by sudden withdrawal of bromide. 
Whether this may explain why SE was so infrequently reported before that 
time is doubtful, because it is known that most cases of SE occur in patients 
without a history of previous seizures and is often caused by cerebral 
problems such as infections, brain tumours or stroke (CVA). The discovery 
of the EEG (Hans Berger, 1924) stimulated further research of SE with major 
consequences for therapy and classiﬁcation. Important in this respect was 
the discovery of the EEG-correlates of petit mal status (Lennox, 1945) and 
psychomotor SE (Gastaut et al, 1956). The conference in 1962 in Marseille 
on SE (Les états de Mals Épileptiques) proposed a deﬁnition, which was 
approved by the International League Against Epilepsy (ILAE) in 1970: 
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“A condition characterized by an epileptic seizure which is so frequently 
repeated or so prolonged as to create a ﬁxed and lasting epileptic condition” 
(Gastaut, 1967). Another important statement at the conference was that 
there were as many types of SE as there were types of epileptic seizure. This 
deﬁnition was comparable to the description in 1903/4 by Clark and Prout: 
“A typical case showed the maximal development of epilepsy, in which one 
paroxysm follows another so closely that the coma and the exhaustion are 
continuous between the seizures. It may be successive or a prolonged tonic 
or clonic spasm lasting one hour or more or until death.” 
At the symposium in Santa Monica in 1980 (Delgado-Escueta et al, 1983) 
much attention was paid to mechanisms of brain damage and to treatment. 
It was stressed that the deﬁnition of SE should include a minimum duration 
of 30 minutes. The limit of 30 minutes was not at random; beyond this 
period various pathophysiologic changes occur, starting in the substantia 
nigra (Nevander et al, 1984; Nevander et al, 1985). These pathophysiologic 
changes occur mainly in generalized convulsive SE and are important with 
regard to outcome. It is of interest to note that in an experimental setting 
the critical period needed to trigger self-sustaining limbic SE by continuous 
hippocampal stimulation was found to be between 30 and 60 minutes 
(Lothman, 1990). This observation provided an experimental underpinning 
for the empiric clinical choice of 30 minutes as the time frame for delineating 
SE.
The discussion about the deﬁnition of SE has gained much attention 
lately. In his excellent monograph on SE, Shorvon (1994) suggested the 
following operational deﬁnition: “Status epilepticus is a condition in which 
epileptic activity persists for 30 minutes or more, causing a wide spectrum 
of clinical symptoms, and with a highly variable pathophysiological, 
anatomical and aetiological basis.” Shorvon avoided the term epileptic 
seizure, because there are types of status in which no overt seizure occurs 
(e.g. nonconvulsive epileptic confusional states, subtle generalized SE, 
electrical status epilepticus during slow sleep, Landau-Kleffner syndrome). 
The minimum limit of 30 minutes, based on physiological changes, makes 
the deﬁnition clinically useful. He also stressed the fact that it may be 
difﬁcult to measure this time limit accurately. Shorvon considered SE as a 
separate entity, and not simply the repetition or prolongation of seizures. 
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Recent pathophysiological research has made clear that important changes 
may occur much earlier than 30 minutes of continuous discharges (Mello, 
1997). Other arguments to adjust the operational deﬁnition of SE came from 
clinical practice: 
1. A single tonic-clonic seizure has in the majority of cases a duration of 
less than 2 minutes (Theodore et al, 1994). 
2. Seizures in children (with new-onset seizures) with duration of more 
than 7 minutes do not stop spontaneously (Shinnar et al, 2001). 
3. Nearly 80% of the patients treated with placebo in the pre-hospital phase 
still showed seizures on arrival in the hospital, suggesting that seizures 
with duration of more than 5-10 minutes do not stop spontaneously 
(Alldredge et al, 2001).
A proposal for adjustment of the operational deﬁnition has been put 
forward (Lowenstein, 1999): in patients of 5 years of age or more: the 
minimum duration is 5 minutes or the patient has two or more tonic-clonic 
seizures without recovery of consciousness; in children younger than 5 
years less information is present; a minimum duration of 10-15 minutes 
has been suggested. Apart from the operational deﬁnition a mechanistic 
deﬁnition was proposed: a condition in which there is a failure of the normal 
factors that serve to terminate a typical seizure.
A prospective clinical study compared outcome in patients with prolonged 
seizures (10-29 minutes) to patients with SE (>30 minutes). Mortality in 
patients with prolonged seizures was signiﬁcantly lower than in SE. Adult 
and elderly patients (not children) may die having prolonged seizures. 
Mortality increased signiﬁcantly, especially in elderly, with duration. Half 
of the cases with prolonged seizures stopped spontaneously with seizure 
activity (DeLorenzo et al, 1999). This clinical study has controversial results 
with regard to the possible adjustment of the deﬁnition of SE: on the one 
hand patients may die during prolonged seizures, suggesting to adjust the 
time limit to 10 minutes; on the other hand mortality increased signiﬁcantly 
in cases with duration of more than 30 minutes, suggesting to maintain the 
current time limit. Another important ﬁnding was that children showed no 
mortality in prolonged seizures, in contrast to adult and elderly patients. This 
is also an argument to adjust the current classiﬁcation of SE, as proposed 
by Shorvon (1994).
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The present discussion about the deﬁnition of SE has not resulted in an 
overall accepted adjustment; until then the current deﬁnition of SE remains: 
a seizure with a minimum duration of 30 minutes; any seizure type may 
evolve into a SE. A succession of generalized convulsive seizures without 
regaining consciousness is considered SE too (Delgado-Escueta et al, 1983). 
In neurological practice, however, treatment will start when the duration of 
the seizure exceeds 5-10 minutes.
3.2  Classiﬁcation of status epilepticus
The ﬁrst systematic classiﬁcation of SE has been proposed in 1962 during 
the ﬁrst ever meeting about SE in Marseille (Gastaut, 1967). Important was 
the hypothesis that there were as many types of SE as there were types of 
epileptic seizures. Three main categories of seizure type had been identiﬁed, 
distinguished by both clinical and EEG features: partial, subdivided into 
elementary and complex; generalized, subdivided into convulsive and 
nonconvulsive; and unilateral. SE was similarly classiﬁed.
This classiﬁcation was presented at the Santa Monica conference in 1980 
without important modiﬁcations (Gastaut, 1983). Apart from somato-motor 
SE or epilepsia partialis continua other types of elementary partial SE were 
mentioned such as aphasia or somato-sensory SE.
A classiﬁcation based exclusively on symptoms has the advantage that 
it corresponds to the current semiological classiﬁcation of seizures. This 
clinical classiﬁcation offers possibilities for practical use, provided that for 
each type a separate code is present, which, however, is not the case. There 
are, however, types of status without overt seizures: e.g. subtle generalized 
convulsive SE and Electrical SE during Slow Sleep. Such conditions are not 
easily categorized into the seizure type classiﬁcation. Some seizure types 
may occur in different clinical contexts; e.g. myoclonic SE in coma, mental 
retardation or in progressive myoclonic epilepsies has signiﬁcant differences 
with respect to form, course, prognosis and treatment. Classiﬁcation by 
clinical context gives physiological coherence to the clinical appearance, 
in contrast to classiﬁcation by seizure type. Classiﬁcation by seizure type 
does not offer information about aetiology or prognosis. It also needs an 
adaptation for particular age groups. A particular type of SE may be less 
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differentiated in children than in adults, and this may also be the case in 
patients who are mentally handicapped. Shorvon (1994) proposed a new 
classiﬁcation based not only on seizure type, but also on age, level of cerebral 
maturity, pathophysiological mechanisms and clinical features (including 
EEG). Most reviews, however, still use the classiﬁcation (or minor variants) 
as proposed by Gastaut (1967). This classiﬁcation is easy to use, well known 
and more appropriate for the use of the present available ICD-coding. The 
revised classiﬁcation is also easy to use in clinical practice and offers also 
information about aetiology and prognosis. An adjustment of the ICD codes 
is necessary, however, for appropriate documentation. Future revisions of 
the ILAE syndromic classiﬁcation schemes will also have to address the 
problems of classiﬁcation of SE.
A recent attempt based on the semiological seizure classiﬁcation contains 
rather confusing new terminology (Rona et al, 2005). One may wonder 
whether this extensive proposal will be practical enough to be accepted in 
general practice.
Table 1: Classiﬁcation of status epilepticus (seizure type)
1. Generalized status epilepticus a. Generalized convulsive status epilepticus.
   Tonic-clonic status epilepticus.
   Tonic status epilepticus.
   Clonic status epilepticus.
   Myoclonic status epilepticus.
b. Generalized nonconvulsive status 
   epilepticus.
2. Unilateral status epilepticus
3. Partial status epilepticus a. Elementary partial status epilepticus. 
b. Complex partial status epilepticus.
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Table 2: Revised classiﬁcation of status epilepticus (Shorvon, 1994)
Status epilepticus conﬁned to  
the neonatal period
1. Neonatal status epilepticus.
2. Status epilepticus in neonatal epilepsy  
   syndromes.
Status epilepticus conﬁned to  
infancy and childhood
1. Infantile spasms.
2. Febrile status epilepticus.
3. Status epilepticus in childhood myoclonic  
   syndromes.
4. Status epilepticus in benign childhood  
   partial epilepsy syndromes.
5. Electrical status epilepticus during slow  
   sleep.
6. Syndrome of acquired epileptic aphasia.
Status epilepticus in childhood  
and adult life
1. Tonic-clonic status epilepticus.
2. Absence status epilepticus.
3. Epilepsia partialis continua.
4. Myoclonic status epilepticus in coma.
5. Speciﬁc forms of status epilepticus in  
   mental retardation.
6. Myoclonic status epilepticus in other  
   epilepsy syndromes.
7. Nonconvulsive simple partial status  
   epilepticus.
8. Complex partial status epilepticus.
9. Boundary syndromes.
Status epilepticus conﬁned to  
adult life
1. De novo absence status epilepticus of late 
   onset.
3.3  Epidemiology of status epilepticus
3.3.1 Case-ascertainment
Several studies have attempted to quantify the frequency of SE in various 
clinical populations. These surveys were until recently retrospective with 
all their inherent inaccuracies. Apart from the retrospective nature of most 
studies there are several other potential problems one should consider:
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a.  The diagnosis of SE in clinical practice is not always easy. When one 
observes a seizure, this may be a single seizure or part of serial seizures 
or part of SE. The post-ictal clinical presentation may offer problems 
too: has the seizure stopped entirely (an EEG is not always available), 
will another seizure start? 
b.  The diagnosis is not always considered, especially non-convulsive SE in 
mentally retarded patients or patients with confusion, mistaken for a 
psychiatric diagnosis.
c.  A number of cases will not reach a hospital; they are treated outside 
neurological services. This is e.g. the case in patients known with 
epilepsy and mental retardation, living in an asylum. When they develop 
SE, they will be treated locally and only admitted to a hospital when SE 
is refractory to ﬁrst line drugs.
d.  SE in patients already admitted because of another medical problem 
will not always be documented as such.
e.  Duration of seizures will not always be recorded; short status episodes 
may be categorized as seizures, not as SE. 
f.  In clinical practice therapy is not awaited for, but is instituted especially 
when an acute exacerbation is present in a patient known with previous 
epilepsy, or when serial seizures are present. An incorrect dismissal 
diagnosis of SE is not rare in these cases.
Recent prospective studies have mentioned the problem of under-
ascertainment (DeLorenzo et al, 1995; Knake et al, 2001). Studies like these 
must adhere to the rigid deﬁnition of SE; probable cases must be excluded. 
This is e.g. the case in patients controlled in 10-30 minutes, which, most 
likely, were cases of SE. The studies in Virginia (DeLorenzo et al, 1995) and 
in Germany (Knake et al, 2001) calculated a rate of under-ascertainment in 
the area outside the primary service area of the investigating hospital of 67% 
respectively 73,6%. Many cases of SE will not be brought to the attention of 
the adult and paediatric neurological staff and remain unidentiﬁed. 
Several other studies underline this problem of case-ascertainment: 
– In patients with epilepsy attending a university hospital the diagnosis 
was false negative (CVA, confused, tremor, other) in 25 of 32 cases and 
false positive (subdural hematoma, partial seizure, tumour) in four: the 
role of the neurologist was important for a correct diagnosis (Berger et 
al, 1999).
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– A 24-hour-status-epilepticus-team conﬁrmed the diagnosis of 
generalized convulsive SE in 57 of 77 cases, but not in the other 20 
patients. In 29 cases with movements suggesting SE, in only 8 patients 
the diagnosis of SE was conﬁrmed; in 21 patients another diagnosis was 
present (Handforth et al, 1993). 
– A comparable result was mentioned by Garnett et al (1994): the regular 
staff did not recognize SE in 13%, this was corrected by the status-
epilepticus-team. 
3.3.2 Incidence and prevalence
The annual number of admissions because of SE has been estimated as 
1-8% of all hospital admissions for epilepsy (Hauser, 1990). Several studies 
concerning adult patients and/or children have conﬁrmed this for both 
university hospitals and general hospitals (Pilke et al, 1984; Krumholz et al, 
1989; Smith et al, 1996; Berger et al, 1999; Reuber et al, 2000). A retrospective 
chart review of patients presented to 12 emergency departments showed 
that 6% of the patients with seizure-related presentations (= 1,2% of the 
total patient group) were in SE (Huff et al, 2001).
SE may be the presenting symptom of epilepsy (initial SE), occurring 
during the course of epilepsy (intercurrent) but also in cases without any 
history of epilepsy (isolated). In children SE is often the ﬁrst epileptic event, 
reﬂecting the high incidence of acute aetiologies and febrile status (Aicardi 
and Chevrie, 1970; Phillips and Shanahan, 1989). In the elderly, after the 
age of 60, SE is also often the initial epileptic manifestation, with a high 
percentage of focal structural cerebral pathology. In a prospective study 
of 204 patients with a single unprovoked seizure (10% < 16yrs) 18 cases 
showed SE as the ﬁrst seizure (9%). SE was not a risk factor for recurrence 
of seizures (Hauser et al, 1998). 
Important factors that may inﬂuence the frequency of SE are age, the 
presence of a mental handicap, the presence of symptomatic epilepsy and 
frontal lobe pathology (Shorvon, 1994).
The number of cases with SE shows a slight peak at less than one year 
and gradually declines until early adulthood. Thereafter the number of cases 
increases as the population ages (DeLorenzo et al, 1996). The prospective 
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study in Virginia found an incidence of 41 per 100.000 inhabitants; the 
incidence in children with an age of less than 1 year was 150 per 100.000, 
in the elderly (>60 years) 60 per 100.000 (DeLorenzo et al, 1996). The 
retrospective study in Rochester mentioned an incidence of 18 per 100.000; 
in children (< 1 year) 135 and in the elderly 62,5 per 100.000 (Hesdorffer et 
al, 1998). Of all the children with SE 40% is less than 2 years of age (Shinnar 
et al, 1997).
The proportion of patients with SE who are known with previous epilepsy 
depends on age and the cause of epilepsy. In idiopathic epilepsy this 
number is 1,6%, in symptomatic epilepsy 9% (Janz, 1961). Between 0.5-1% 
of patients with established epilepsy will experience at least one episode 
of SE annually; within 5 years of initial diagnosis of epilepsy, 20% of 
patients will experience an episode of SE (Hauser, 1990). The incidence of 
SE in patients with established epilepsy in adults is lower than in children. 
Literature before 1980 mentioned 5-10% occurrence of SE in adult patients 
with previous epilepsy (Turner, 1907; Lennox, 1960; Janz, 1961); in children 
the occurrence was 10-20% ( Aicardie and Chevrie, 1970; Yager et al, 1988). 
In a long-term follow-up study during 30 years in 245 children with active 
epilepsy, 78 showed SE (32%). In 20 children SE was initial, 44 cases had 
recurrent SE. Remote symptomatic epilepsy was present in 44% of the 
children with SE, idiopathic/cryptogenic in 20% (Sillanpää et al, 1998). In 
recent population-based studies SE was present in 10% (Berg et al, 2004) 
to 27% (Sillanpää and Shinnar, 2002) of the children with epilepsy. The 
occurrence of SE in these children did not inﬂuence mortality or remission 
of epilepsy (Sillanpää and Shinnar, 2002). The incidence of SE in 3 cohorts 
of patients with complex partial seizures, not in remission, was for all types 
of SE in children 9-11% and in all age groups 9%. A history of SE was present 
in 33-38% of the children and in 27% of the group with all ages ( Shinnar et 
al, 2001). In cases with intractable epilepsy, SE occurs more often, 44%, in 
patients with clustering of seizures, than without clustering, 12,5% (Haut et 
al, 1999).
A retrospective study by means of interviews in 598 patients with 
epilepsy mentioned a lifetime prevalence of SE (generalized convulsive 
more frequently than nonconvulsive) of 17%. The debut of epilepsy in cases 
with SE is earlier (Schwaner and Fountain, 2000). 
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Recurrence of SE occurs in adults in 13% and in children in 38%, especially 
in children younger than 5 years, with neurological abnormalities and 
decreased serum levels of anti-epileptic drugs (DeLorenzo et al, 1993). The 
recurrence rate of SE in children is related to the cause of SE: in febrile and 
idiopathic cases the recurrence rate is 3-4%, in acute symptomatic cases 
11%, in remote symptomatic cases 44% and in progressive neurological 
disorders 67% (Shinnar et al, 1992).
According to Shorvon (1994) the risk of SE in patients with epilepsy and 
mental retardation is high. Little information about prevalence and 
incidence of SE in patients with mental retardation is available, however. 
Some studies mentioned the prevalence of SE in mental retardation. In a 
group of 98 children of 6-12 years with epilepsy and mental retardation SE 
occurred in 37 (37%); recurrence rate was 35% (Steffenburg et al, 1996). In 
a population of children and adults with mental retardation the prevalence 
of convulsive SE was 18,7% (Forsgren et al, 1990). These ﬁgures are not 
very different from those in the total population with epilepsy (Hauser, 
1990). It should be noted, however, that many cases of SE in patients with 
mental retardation would not be documented. This is especially the case for 
non-convulsive SE, a diagnosis easily overlooked in patients with mental 
retardation. 
In the period before modern imaging frontal lobe pathology was often 
mentioned in patients with SE (Whitty and Taylor, 1949; Oxbury and Whitty, 
1971; Janz 1964). Pathological examinations in 91 patients with SE showed 
frontal damage in 77 patients (Peiffer, 1963). Apart from Aminoff and 
Simon (1980) more recent reviews did not mention an excess of frontal lobe 
pathology in SE (DeLorenzo et al 1992; Barry and Hauser 1993; Treiman 
1993). 
A genetic predisposition to SE has been suggested by twin studies: the 
risk of SE in the monozygotic co-twin of an affected individual was 90x 
higher in comparison to the dizygotic co-twin (Corey et al, 1998; Corey et 
al, 2004). 
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Recent epidemiological studies
Until recently little was known about the incidence of SE in the general 
population. Some information was published from hospital records, 
reviewed retrospectively. Both Hauser (1990) and Shorvon (1994) calculated 
the annual incidence of SE in various groups of patients and of various types 
of SE. The ﬁrst prospective study was performed in Virginia (DeLorenzo et 
al, 1996). Two more prospective studies have appeared since then (Coeytaux 
et al, 2000; Knake et al, 2001), and one adequate retrospective (Hesdorffer 
et al, 1998).
DeLorenzo et al (1996) found an incidence of 41 per 100.000 individuals per 
year, exclusive neonates < 1 month; white 20, non-white 57. The incidence in 
young children, less than 1 year, and in the elderly, older than 60 years, were 
signiﬁcantly higher: 150 respectively 86 per 100.000. Cases from community 
hospitals were underreported (33%). Based on the frequency of the various 
major seizure types and the total incidence one can calculate the incidence 
of the different types of SE (table 5). Mortality (table 3) in cases of <1year 
was 13,2%, morbidity 9,4% (Morton et al, 1998). Mortality was related to 
the cause of SE: in adults death-rate in anoxia was 72%, in hypoxia 51%, in 
CVA 33%, in metabolic causes 30%, in alcohol 20%, in remote symptomatic 
causes 14% (especially by CVA) and in low anti-epileptic drug levels 4%. 
Mortality in idiopathic cases (3% of the causes) was 25%. In children 
mortality occurred only in cases caused by infections (5%).
Another study in the USA has been performed in Rochester (Hesdorffer et 
al, 1998). This population-based study was retrospective; it was not reported 
whether neonates (age < 1 month) were excluded or not .The age-adjusted 
incidence of SE was 18,3 per 100.000. The incidence increased from 13,9 
during the period 1965 - 1974 to 22,4 in the period 1974 - 1984. The increase 
was due to an increased incidence of acute symptomatic SE due to anoxic 
encephalopathy in the elderly. The difference in incidence with the study 
in Richmond (DeLorenzo et al, 1996) was partly explained by the larger 
non-white group in Richmond (57% versus 4%). The incidence in the male 
population was twice the female.
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Excluding febrile SE (16 cases), SE was generalized without focality in 28% 
of the cases, secondary generalized in 17%, and partial only in 41%. Absence 
and myoclonic SE were less common: 3 and 10%. Complex partial SE was 
not mentioned separately. 
Incidence rates per 100.000 for the various seizure types of SE (excluding 
febrile status) can thus be calculated: generalized SE 8,2; partial 7,5; absence 
0,6 and myoclonic 1,8. A second episode of SE occurred in 36 cases (18%), 
especially in acute symptomatic causes (15 cases). Previous epilepsy was 
present in 46% of the cases. Duration was <24hrs in 75%; 38% lasted less 
than 2 hours. The risk of SE of longer duration was greatest in children less 
than 1 year and in the elderly. The cumulative incidence at 60 years of age 
was 2 per 1000 and at age 85 years 5,7 per 1000; an increase of 62% was 
noted between 60 and 75 years and of 44% between 75 and 85 years.
A population-based study of SE in the French-speaking part of Switzerland 
found a crude incidence of 9,9/100000 and an age-adjusted of 10,3/100000 
(Jallon et al, 1999; Coeytaux et al, 2000). Cases with post-anoxic 
encephalopathies were excluded. The incidence was highest in the area of 
Geneva (16,3), which could be explained by perfect ascertainment of the 
cases. In this area EEG monitoring was possible 24 hours a day and 7 days 
a week. This prevented under-diagnosis of cases with non-convulsive SE. 
Incidence of SE outside the canton of Geneva was 7-10/100000. Taken into 
account the exclusion of post-anoxic cases in this study, one may conclude 
that the incidence in the area of Geneva corresponds to the incidence in 
Rochester and to the incidence in the white population in Virginia. The 
male/female ratio was 1.47. The age-speciﬁc incidence rates showed the 
same bimodal distribution as in Rochester and Virginia. The lower rate 
in the elderly in this study could be attributable to the exclusion of post-
anoxic cases. The cumulative incidence at age 85 years was 2,5 per 1000. 
The incidence in children less than 1 year was not mentioned. Incidence 
is children less than 4 years was 38.7/100000, in children (0-14 years) 
20,6/100000, in adults (15-59 years) 5,2/100000, and in the elderly (> 60 
years) 15,3/100000.
The most frequent initial seizure type was partial (44,8%). About one-
third of these evolved to secondary generalized SE. Primary generalized 
tonic-clonic SE was present in 33,1%, simple partial in 18,1% and complex 
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partial in 26,7%. Other seizure types included absence, tonic and hemi-
convulsive (in children only). Duration of SE was less than 24 hours in 
66,7%. A previous period of SE was present in 48% of the cases with previous 
epilepsy. 
Total mortality was 7,6%; in the canton of Geneva mortality was 6,6%. 
The exclusion of post-anoxic cases and the prompt management starting 
before admittance to the hospital may explain the low mortality rate in this 
study. In 58,7% therapy started during transport to the hospital. 
A recent prospective population-based study of SE in Germany was 
restricted to adult patients (Knake et al, 2001). The crude average incidence 
rate per 100.000 in the primary service area was 15,8 and the age-adjusted 
incidence 17,1. The incidence in the elderly was 54,5 and 4,2 in the group of 
18-59 years. It was higher in the male (26,1) than in the female population 
(13,7). The crude average incidence rate in the area outside the primary 
service area was only 4.5. This suggested a rate of under-ascertainment of 
73,6%; this corresponds to the rate in community hospitals in Virginia of 
67% (DeLorenzo et al, 1996). The incidence rate in the primary service area 
in this study (17,1) corresponds to the retrospective rate in Rochester (17,4 in 
adults older than 20 years). A comparison with the studies in Virginia and 
Switzerland is difﬁcult because these studies included children. Seizure type 
was mainly partial (76%), with (19,3%) or without secondary generalisation 
(57%). Duration varied from 0,5-430 hours, with a mean of 18,6 hours. 
Previous epilepsy in the primary service area was present in 33%, outside 
this area in 55,9%. The causes of SE were remote or acute symptomatic in 
most cases (74%). Mortality rate (< 30 days) was 9,3%. The age of those who 
died was not mentioned.
A comparable incidence rate of GCSE to the studies in Rochester, Switzerland 
and Germany (table 5) has been found in California (Wu et al, 2002). The 
case fatality was 10,7%; this was considerable lower than in Virginia, but not 
very different from Germany and Switzerland.
A study in Bologna, Italy, found an incidence of 13,1 per 100.000 for 
patients older than 20 years, including cases with onset inside the hospital 
(Vignatelly et al, 2003). This study mentioned a high 30-day case fatality of 
39%, which was explained by inaccurate patient management.
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3.3.3 Conclusions
The recent population-based epidemiological studies of SE suggest an 
annual incidence of SE of 18-41 per 100.000 (table 5 and 6). The incidence 
in the male population is twice the female. Previous epilepsy is present 
in about 40% of the patients. Duration of SE is in most cases less than 
24 hours. The cause is acute symptomatic in more than 50-60% of the 
cases. The most frequent seizure type is generalized convulsive, especially 
secondary generalized, and partial; absence and myoclonic SE are relatively 
rare. The incidence of SE, based on the population-based studies, should de 
estimated on 20 per 100.000 at the least (Chin et al, 2004). One may expect 
at least 3000 new cases of SE in the Netherlands (16 million inhabitants); 
the results in Virginia and the calculations of Shorvon (1994) indicate an 
even higher incidence: 6500-10000. The associated number of deaths is 
hard to deﬁne; extrapolating the ﬁndings of Virginia, this number may 
vary between 660 and 1430 annually in the Netherlands. The results in 
Switzerland are exclusive the post-anoxic group, which in most cases have a 
bad outcome. The study in Germany was restricted to adult patients. When 
one extrapolates the ﬁndings in Germany to the Netherlands (about 12 
million people older than 17 years), the annual number of cases with SE in 
the age group older than 17 years will be about 2052; the annual number of 
associated deaths about 190. 
Table 3: Some characteristics of status epilepticus in the Richmond 
study* 
Previous epilepsy (%) Recurrence rate (%) Mortality (%)
Children 38 35   2,5
Adult patients 54  7 14 
Elderly patients 30 10 38 
Total population 42 13 22 
* (DeLorenzo et al, 1996)
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Table 4: The incidence of status epilepticus per 100.000 individuals by 
age and aetiology*
Age 
(incidence)
Acute 
symptomatic 
Idiopathic/
cryptogenic 
Remote 
symptomatic 
 Febrile 
< 1 (135 ) 87 5 19 24
 1 – 4 ( 35 ) 11 5 5 15
 5 – 9 ( 12 ) 6 3 3 0
10 – 14 ( 3,7) 0 1 2 0
15 – 60 ( 5,5) 19 7 9 0
> 60 ( 62,5) 114 26 44 0
* (Hesdorffer et al, 1998)
Table 5: Incidence of status epilepticus per 100.000 individuals in 
prospective studies, per seizure type
DeLorenzo  
et al (1996)
Coeytaux  
et al (2000)
Knake  
et al (2001)
Total Geneva
Total incidence 41 10,3 16,3 17,1
Tonic Clonic 29,1  3,4 5,4  5,3
Simple Partial  9,4  1,9 3,0  2,1
Complex Partial  1,2  2,8 4,4  6,9
Tonic  0,2 0,4
Absence  0,4  0,4 0,6  1,0
Table 6: Incidence of Status Epilepticus
 Per million 
Shorvon, 1994 (calculation)  441-646
Delorenzo, 1996 (prospective)  410 (excl. neonates)
Hesdorffer, 1998 (retrospective )  183
Coeytaux, 2000 (prospective)  103-163 (excl. post-anoxic)
Knake, 2001 (prospective)  171 (age >17)
.
A review of the literature on status epilepticus
31
3.4 Neurophysiology and neuropathology of 
 Status Epilepticus
3.4.1 Introduction
The neurophysiological processes that initiate status are, by common 
agreement, similar to those producing isolated seizures (Shorvon, 1994). 
The sudden cessation of epileptic activity at the termination of an ordinary 
epileptic seizure is, however, absent during status epilepticus (SE). Failure 
of cessation of seizure activity may be caused by changes in GABA-
receptors, by changes in the Na-K-ATPase system, by membrane defects 
with abnormalities in ion-movements or by other impairments of GABA-
ergic function. 
Many neurochemical studies of epilepsy and SE have been focussed on 
the actions of GABA, the major inhibitory cerebral neurotransmitter, and of 
glutamate, the major excitatory amino acid. Other cerebral neurotransmitters 
that may be involved in SE are acethylcholine and aspartate (excitatory), 
dopamine, noradrenaline, adrenaline, serotonine, taurine, glycine and 
opioids (all inhibitory). Abnormalities have been found with almost all 
neurotransmitters that have been studied.
Gamma amino butyric acid (GABA) is an important inhibitory 
neurotransmitter, which has shown to increase the threshold for seizures, 
and to inhibit seizure spread. GABA-mimetics (vigabatrin) have shown to be 
anticonvulsant. But paradoxal ﬁndings have been mentioned too, which may 
be due to variations in regional susceptibility to GABA or to differences in 
the mechanism of focal and generalized seizures (Lortie et al, 1993). GABA 
is released from GABAergic neurons and binds to several types of GABA 
receptors: GABA-A, GABA-B and GABA-C. GABA-A receptors mediate the 
majority of fast inhibition in the central nervous system. During SE GABA-
inhibition decreases; in the hippocampus reduced GABA-A mediated 
inhibition has been found, which may contribute to the self-sustaining 
nature of the epileptic discharges during SE (MacDonald and Kapur, 1999). 
The pharmacological properties of GABA-A receptors have been shown 
to depend on subunit-subtype composition. There are 5 subunits with a 
varying number of subtypes. The composition of the GABA-A receptors is 
determined by genetical properties. The properties of the GABA-A receptors 
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include formation of a chloride channel, enhanced by barbiturates and 
diazepam. Benzodiazepine sensitivity requires the presence of a γ-subunit, 
the subunit location of the barbiturate-binding site is unknown. During 
treatment of SE in rats, diazepam, but not phenobarbitone, showed a rapid 
loss of efﬁcacy, because of rapid modiﬁcation of the functional properties of 
GABA-A receptors during SE (MacDonald and Kapur, 1999).
This is in agreement with results in human clinical studies.
The most important excitatory neurotransmitter is glutamate, whose 
actions are complex. Several subtypes of glutamate receptors have been 
demonstrated: N-methyl-D-aspartate (NMDA), kainate, α-amino-3-hydroxy-
5-methylisoxazole-4-propionic acid (AMPA) and several metabotropic 
receptors (Meldrum, 1994). Apart from anticonvulsant activities, glutamate 
receptor antagonists have also shown to inhibit neuronal damage in 
experimentally induced SE (Clifford et al, 1990; Bertram and Lothman, 
1990). The role of glutamate in neuronal damage during SE will be discussed 
in the chapter on neuropathology.
3.4.2 Neurophysiological changes during generalized
 convulsive SE
Most of the studies on physiological changes in SE concerns generalized 
convulsive SE and in particular tonic-clonic SE (TCSE). The physiological 
changes during TCSE may be the result of the neuronal discharges, affecting 
the hypothalamus and brainstem centres, and/or the secondary effects of 
increased motor activity on the blood circulation. The increased demand by 
the cerebral tissue for oxygen because of the continuous seizures, causes an 
increase of cerebral blood ﬂow (CBF) of 200-600%, mediated by the increase 
of systemic blood pressure and a decrease of cerebro-vascular resistance. 
The increase of CBF shows regional differences (Horton et al, 1980).
A prompt increase in epinephrine and norepinephrine plasma levels 
contribute to peripheral vasoconstriction, the rise of systemic blood 
pressure and the occurrence of cardiac arrhythmias. ECG investigation 
during and after SE shows a high percentage of abnormalities, such as axis-
changes, conduction abnormalities, ischaemic patterns or arrhythmias. 
These changes may be responsible for myocardial dysfunction or ischaemia 
and may occur during but also after SE. ECG monitoring is necessary until 
24-48 hrs after the SE has been arrested (Boggs et al, 1993).
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During the ﬁrst 30 minutes of SE a prompt fall of blood pH occurs because of 
lactate production, inducing motor paralysis can markedly attenuate this.
Cerebral metabolic rate for oxygen (CMR-O) and glucose (CMR-gluc) 
are increased, especially in known vulnerable regions; cerebral energy state 
remains stable. With ongoing seizure activity, however, the cerebral energy 
state declines after 60-90 minutes of TCSE. Important in this respect is 
the decline of cerebral auto-regulation after 30 minutes. Cerebral perfusion 
pressure becomes dependent on systemic blood pressure. After 40-50 
minutes of SE blood pressure starts to fall, despite ongoing seizures and 
very high levels of plasma catecholamin-concentrations. Deterioration of 
vascular reactivity in ongoing SE results in decreased ability to deliver oxygen 
to focal areas of metabolically hyperactive cerebral tissue. These episodes 
of local transient hypoxia may contribute to neuronal damage (Kreisman 
et al, 1983). Other medical complications become apparent too: respiratory 
depression, hyperthermia, decrease of systemic and cerebral glucose levels 
with ongoing increased CMR-gluc, excessive sweating, increased salivary 
and bronchial secretion, pulmonary edema, disseminated intravascular 
coagulation and hepatic failure. Metabolic problems include hyponatraemia 
and hyperkalaemia. Hormonal changes other than the increase of 
epinephrine and norepinephrine include an increase of cortisol (Calabrese 
et al, 1993). Prolactin levels do not change signiﬁcantly (Lindbom et al, 
1993). Insulin and glucagon levels rise because of stimulation of autonomic 
neurons. The increased levels of epinephrine and norepinephrine also cause 
glucogenolysis. The net result in the early phase of SE is hyperglycaemia, 
but during prolonged seizures, hyperinsulinemia causes hypoglycaemia 
(Wasterlain et al, 1993).
Excessive motor activity and local trauma due to pressure in a comatose 
patient may cause rhabdomyolysis with increase of creatine phosphokinase 
(CPK), tubular necrosis because of accumulation of myoglobin and renal 
failure. Intracranial hypertension is caused by the increase of CBF, the 
loss of autoregulation, the decrease of pH (vasodilatation), oedema and the 
discharges themselves (Gabor et al, 1984). Leucocytosis is frequent, even 
in the absence of an infection. Investigation of cerebral spinal ﬂuid may 
show pleiocytosis and increased protein content. Pleiocytosis during SE is 
especially determined by the underlying cause; in cases in which the causal 
factor is usually associated with normal CSF, the number of cells was low 
(Barry and Hauser, 1994).
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Vomiting, urinary or bowel dysfunction, inhalation and asphyxia because 
of secretions or vomit, loss of weight, trophic abnormalities and bedsores 
may be present. 
It is obvious that these medical complications may contribute to neuronal 
damage and should be adequately treated (Meldrum, 1983; Glaser, 1983; 
Simon, 1985; Lothman, 1990; Brown and Hussain, 1991; Shorvon, 1994).
The physiological stages in TCSE may be divided into two phases: phase 
I is the early (compensated) stage and phase II the late (decompensated) 
stage. The shift from phase I to phase II usually occurs after 30 minutes, 
although great variation is seen in clinical practice, depending on aetiology, 
the location and severity of the seizures and the instituted therapy. The 
decline of cerebral auto-regulation after 30 minutes is of importance with 
respect to the shift of phase I to phase II. The various physiological changes 
during TCSE are mentioned in table 7 (phase I) and table 8 (phase II). 
In an experimental setting it was found that hyperthermia in rats 
caused an increase of the level of glutamate with corresponding decrease 
in seizure threshold (Morimoto et al, 1993). Lowering of body-temperature 
to 28°C caused a decrease by 50% of the ictal discharges in rats with SE 
caused by kainic acid. Hippocampal cell loss was observed in all rats with 
SE and normal body temperature, but in none with a temperature of 28°C. 
Hyperthermia caused an aggravation of seizures and of brain damage (Liu 
et al, 1993). In earlier experiments the role of hyperthermia with regard 
to cerebellar damage had been established (Meldrum and Brierley, 1973). 
In ventilated and paralysed animals, not only hyperthermia is less severe, 
but also hypotension and acidosis, with less cardiac arrhythmias. However, 
control of various parameters, such as blood pressure, pO2, pH, pCO2 and 
temperature, does not prevent neuronal damage in ongoing SE. Despite 
these optimal circumstances, neuronal damage may occur after 30 min. 
in the substantia nigra pars reticularis, after 45-60 min. in the third and 
fourth layer of the cerebral cortex and in special areas CA1 and CA4 of the 
hippocampus (Nevander et al, 1984; Nevander et al, 1985; Meldrum, 1983; 
Siesjo and Wieloch, 1986). This selective vulnerability may be determined 
(among others) by the abundant number of NMDA-receptors of vulnerable 
neurons in these areas (Wasterlain et al, 1993). During experiments with 
controlled respiration, bloodpressure, temperature and treated acidosis 
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gross energy failure is not present, therefore the neuronal damage may 
be caused by the hyperexcitation. An exception is the cell necrosis in the 
substantia nigra (pars reticularis), which is probably caused by excessive 
energy failure and massive accumulation of lactate (Siesjo et al, 1986).
The reduction of GABA synthesis in the substantia nigra pars reticularis 
during SE in rats may be of importance with regard to seizure spread and 
maintenance (Wasterlain et al, 1993).
These observations in animal models suggest that patients with ongoing 
generalized convulsive SE should be intubated, mechanically ventilated and 
paralysed. Several studies about the incidence of morbidity and mortality in 
humans suggest that these procedures should at least start 1 hr after onset 
of SE (Aminoff and Simon, 1980; DeLorenzo et al, 1992). Hyperthermia 
and hypotension are less severe then and muscle necrosis is prevented, the 
possibility of renal failure and cardiac arrhythmias is decreased. Rapid 
termination of SE and adequate treatment of the medical complications will 
contribute to improved outcome of patients with TCSE.
Table 7: Physiological changes in phase I of TCSE* 
Cerebral changes Metabolic changes Autonomic and 
cardiovascular changes
• Increased blood ﬂow.
• Increased metabolism.
• Increased lactate  
  concentration.
• Increased glucose  
  concentration.
• No mismatch between  
  energy requirement and  
  oxygen/glucose supply.
• Hyperglycaemia.
• Lactic acidosis.
• Hypertension.
• Increased cardiac output.
• Increased central venous  
  pressure.
• Massive release 
  catecholamines
• Tachycardia, cardiac  
  arrhytmia.
• Salivation, vomiting, 
  incontinence.
• Hyperpyrexia.
* (Shorvon, 1994)
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Table 8: Physiological changes in phase II of TCSE*
Cerebral changes Metabolic changes Autonomic and 
cardiovascular changes
• Failure of cerebral 
  autoregulation.
• Hypoxia.
• Hypoglycaemia.
• Falling lactate 
  concentrations.
• Falling energy state.
• Increase of intracranial
   pressure, cerebral 
  edema.
• Hypoglycaemia.
• Hyponatraemia.
• Hyperkalaemia.
• Metabolic/respiratory 
  acidosis.
• Hepatic and renal 
  dysfunction.
• Rhabdomyolysis, 
  myoglobulinuria.
• Multi-organ failure.
• Leucocytosis.
• Systemic hypoxia.
• Falling bloodpressure.
• Falling cardiac output.
• Respiratory and 
  cardiac impairment. 
• Hyperpyrexia.
* (Shorvon, 1994)
3.4.3 Neuropathology in Generalized Convulsive Status 
 Epilepticus
Experimental results in animals have shown that generalized convulsive 
SE may cause neuronal damage, despite optimal treatment of respiratory 
insufﬁciency, hyperthermia, hypotension and other medical complications. 
The ongoing discharges themselves appear responsible for neuronal 
damage in particular vulnerable regions of the brain: the hippocampus 
(especially CA1 region), the neocortex (layer 3 and 4), the thalamus and the 
cerebellum (Meldrum and Brierley, 1973; Meldrum et al, 1974; Meldrum, 
1983; Nevander et al, 1984; Nevander et al, 1985; Siesjo and Wieloch, 1986; 
Lothman, 1990). Not only generalized convulsive SE, but also complex 
partial SE may cause selective damage too, especially in the CA1 and hilar 
region of the hippocampus and the thalamus (Lothman, 1990; Meldrum, 
1993; Ben-Ari, 1997).
The cellular damage induced by glutamate is possibly related to high 
intracellular calcium concentrations. The increased amount of extra-cellular 
potassium during ongoing seizure activity causes an increased release of 
glutamate. Stimulation of the N-methyl-D-aspartate receptor by glutamate 
causes an increase of intracellular calcium and intracellular edema, mediated 
by excess of sodium chloride and water. When this exceeds the capacity 
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of the neuron to sequester or transport calcium, mitochondria take up 
calcium, which ultimately leads to irreversible mitochondrial damage; cell 
metabolism will be disturbed. Calcium overload leads to an increase in the 
activity of various proteases, phospholipases and endonucleases. Lipolysis 
and proteolysis will follow, which will result in membrane damage, receptor 
dysfunction and cell necrosis (Meldrum, 1983; Siesjo and Wieloch, 1986; 
Siesjo, 1989; Clark, 1989; Lipton and Rosenberg, 1994). The possibilities of 
preventing neuronal damage by excess calcium are under investigation. This 
concerns the role of calcium entry blockers, such as nimodipine and NMDA 
receptor antagonists such as MK-801, ketamine and CPP in the treatment 
of generalized convulsive SE (Clifford et al, 1990; Bertram and Lothman, 
1990; Prasad et al, 2002). Glutamate receptor-mediated neurotoxicity in 
humans has been demonstrated after domoic acid intoxication (Teitelbaum 
et al, 1990; Cendes et al, 1995). Other mechanisms which may also be 
involved in the pathogenesis of epileptic brain damage are: free-radical 
release, the activation of synaptic phospholipases, such as phospholipase A2 
(Bazan, 1997), the activation of immediate early genes by epileptic activity 
(Dragunow, 1997); seizures activate many other genes, such as genes coding 
for growth factors, but also reduction of Glutamate-R-B gene reduction has 
been found, which causes enhancement of calcium inﬂux in CA3 region of the 
hippocampus (Ben-Ari, 1997), the breakdown of membrane phospholipids, 
which gives rise to a massive increase of arachidonic acid and other free 
fatty acids.
Experimental results in animals show that neuronal damage becomes 
especially evident after a recovery period of several days (Nevander et al, 
1984; Nevander et al, 1985). Neuronal damage after generalized convulsive 
SE in animals has not been found in animals killed immediately after (Brown 
et al, 1980) or 1-2 hrs after (Atillo et al, 1983) generalized convulsive SE. The 
cascade of events from intracellular calcium accumulation to membrane 
damage and cell death takes time. 
Status induced cerebral damage may lead to chronic epilepsy in 
primates, rodents and cats (Lothman and Bertram, 1993; Sloviter, 1999; 
Coulter, 1999). In clinical (human) studies this is hard to prove because of 
the confounding factor of underlying cause. Apart from selective neuronal 
loss as a result of SE, other contributing factors to the development of 
spontaneous recurrent seizures are sprouting (reactive synaptogenesis) of 
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mossy ﬁbers in the dentate gyrus and altered properties of GABA receptors 
of surviving neurons.
The immature brain is more prone to the development of seizures, which 
propagate to distant sites rather readily and may last for longer periods of 
time. The increased excitatory drive of the immature brain is necessary for 
normal brain development (enhanced learning, synaptogenesis, neuronal 
plasticity). The overshoot in expression of functional glutamate receptors 
is likely to play a major role in the increased excitability of the brain in the 
early postnatal development. The functional GABA-ergic inhibition shows 
a delayed onset; GABA-A activation in the early postnatal period causes 
depolarisation rather than hyperpolarisation. Neurotransmitters that are 
inhibitory in the mature brain are excitatory in the developing brain. Because 
of delayed glial development extracellular potassium may accumulate and 
contribute to the hyperexcitable state. Other possible contributing factors 
are a lower level of cerebral norepinephrine, age related differences in the 
nigral GABA-sensitive system and the high level of CRH (corticotropin-
releasing hormone)-receptors (Moshe et al, 1991; Moshe, 1993; Mizrahi, 
1999; Sanchez and Jensen, 2001).
The immature brain is more prone to seizures, but less vulnerable to the 
longterm effects of prolonged seizures; protection of the developing brain 
from seizure induced damage is, however, not absolute. Apart from acute 
neuronal damage, seizures can induce long-lasting, potentially adverse 
functional changes in the immature brain that may not appear acutely as 
injury (Sanchez and Jensen, 2001). The incidence of seizures in the neonate 
is very high (1,8-5,1 per 1000 live births). It is estimated that about 33% 
of the neonates with seizures show SE. Outcome in neonates is especially 
determined by the aetiology (Mizrahi, 1999).
The results of investigations of the human brain are less conclusive than 
the results of animal experiments. Not in all cases of prolonged generalized 
convulsive SE neuronal damage has been found, albeit that in patients with 
epilepsy who did not have a period of SE elective necrosis may be present 
(Meencke and Veith, 1997). One should consider the following factors in this 
respect:
− SE may result from, but can also cause pathological changes.
− The use of different deﬁnitions of SE.
− The treatment employed.
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− The results of secondary systemic effects of SE.
− The inﬂuence of associated pathology in the individual case. 
An example of the dispute about the relation between seizures and 
neuronal damage is the discussion about the signiﬁcance of mesial temporal 
sclerosis (MTS) with respect to febrile convulsions (FC): is MTS cause or 
consequence of seizure activity?
Already in 1825 Bouchet and Cazauvieilh mentioned a small indurated 
hippocampus in half of a group of 18 chronic epileptics. More than a 
century later Falconer suggested that severe febrile convulsions (FC) caused 
unilateral MTS followed by epilepsy (Falconer, 1974). A signiﬁcant lower 
number of neurons were found in the hippocampus of patients who as a 
child had shown severe convulsions, especially before the age of three. A 
relation was present between the degree of neuronal loss and a duration of 
more than 30 minutes, a restriction to one side of the body or when followed 
by a transient weakness on one side (Sager and Oxbury, 1987). Other studies 
support Falconer’s suggestion that prolonged childhood FC may cause MTS, 
which is the cause of partial epilepsy in later years (Kuks et al, 1993; Cendes 
et al, 1993). The relation between prolonged duration of FC in childhood 
and subsequent development of temporal lobe epilepsy was established in 
a study of six families (Maher and McLachlan, 1995). The incidence of this 
problem is not known, but probably will be low. One should bear in mind 
that hippocampal sclerosis (HS) or MTS may be present in cases without 
seizures, and that MTS may be accompanied by other abnormalities, 
such as heterotopias and subtle migration defects. Pre-existing alteration 
of medial temporal lobe structures may contribute to febrile convulsions 
and subsequent hippocampal sclerosis (HS) in patients with temporal lobe 
epilepsy and antecedent FC. This is suggested by a family-study of FC with 
MRI investigations (Fernandez et al, 1998).
A follow-up MRI study of children with FC has provided evidence that 
prolonged FC can cause hippocampal sclerosis (VanLandingham et al, 
1998).
The neuropathological results of studies of the human brain of patients 
who ever had generalized convulsive SE or died during or shortly after 
generalized convulsive SE conﬁrm several results of animal experiments. 
Especially the predilection of neuronal damage to vulnerable regions such as 
hippocampus, cerebral cortex, thalamus and cerebellum is evident. A longer 
Chapter 3
40
duration of generalized convulsive SE, a younger age and the presence of 
medical complications appear to be related to the occurrence of neuronal 
damage (Scholz, 1951; Meyer et al, 1955; Small and Woolf, 1957; Peiffer, 1963; 
Norman, 1969; Rademecker et al, 1967; Rowan and Scott, 1970; Knopman et 
al, 1977; Veith, 1980; Corsellis and Bruton, 1983; Soffer et al, 1986; Leiffer 
et al, 1991; Mori et al, 1992; De Giorgo et al, 1992; Stafstrom et al, 1996; 
Fujikawa et al, 2000).
3.5 Status epilepticus in adult patients
3.5.1 Generalized Convulsive Status Epilepticus (GCSE)
The various studies about Generalized Convulsive Status Epilepticus 
(GCSE) are mostly retrospective, highly selective with patients from 
university hospitals or specialized neurological inpatient services, and with 
considerable differences in age groups (Rowan and Scott, 1970; Oxbury and 
Whitty, 1971; Heintel, 1972; Celesia et al, 1972; Aminoff and Simon, 1980; 
Celesia, 1983; Pilke et al, 1984; Goulon et al, 1985; Sung and Chu, 1989; 
Lowenstein and Alldredge, 1993). With respect to aetiology the distinction 
between cause and precipitating factor is not always clear; aetiology is often 
considered multi-factorial. Most studies do not make a distinction between 
causes in patients with previous epilepsy and those in which status is the 
ﬁrst epileptic event; causes of status in pre-existing epileptic and previously 
non-epileptic cases are different (Shorvon, 1994). In the more recent studies, 
including the prospective series, other types of SE besides tonic-clonic are 
included (Goulon et al, 1985; Sung and Chu, 1989; DeLorenzo et al, 1996; 
Hesdorffer et al, 1998; Coeytaux et al, 2000; Knake et al, 2001). Finally, the 
duration of follow-up is highly variable (table 9). These limitations make it 
hard to compare the various studies with respect to outcome and cause of 
GCSE. From table 9 one may conclude that outcome in studies of SE with a 
high percentage of cases with previous epilepsy is better than in studies with 
high percentages of de novo SE. This is related to the underlying cause. 
The most frequently occurring type of GCSE is TCSE. Other types of GCSE 
(tonic SE, clonic SE, myoclonic SE) have been described only occasionally 
because of their relatively rare occurrence (Gastaut, 1967; Roger et al, 1974; 
Celesia et al, 1988; Parisi and Shabrough, 1993; Shorvon, 1994; Othahara 
and Ohtsuka, 1997). 
A review of the literature on status epilepticus
41
3.5.1.1 Tonic-Clonic Status Epilepticus (TCSE)
The most frequent type of GCSE is TCSE, which in most cases has a 
partial onset with secondary generalization. Some patients exhibit only 
partial or subtle signs of convulsive activity with a marked impairment 
of consciousness and bilateral ictal discharges on the EEG. These cases of 
subtle GCSE (Treiman, 1984) occur in patients with severe encephalopathies 
caused by underlying systemic illnesses, primary brain lesions such as 
massive cerebral infarctions or infections, or prolonged uncontrolled overt 
GCSE. The physiological changes in SE should be anticipated in order to 
prevent serious medical complications and consequently a worse prognosis 
(chapter 3.4).
TCSE can occur in patients with previous epilepsy (intercurrent SE), 
precipitated by systemic infections, non-compliance, sleep-deprivation and 
a miscellaneous group of more rare possibilities (Rowan and Scott, 1970; 
Heintel, 1972; Aminoff and Simon, 1980; Pilke et al, 1984; Janz, 1983; 
Goulon et al, 1985; DeLorenzo et al, 1992; Martin and Millac, 1994).
An acute symptomatic cause, such as a brain tumour or CVA, in a patient 
already known with epilepsy should be considered too (Aminoff and Simon, 
1980; Goulon et al, 1985; Lowenstein and Alldredge, 1993). In a substantial 
number of cases the cause remains unknown. The most common mentioned 
precipitating factor in cases with previous epilepsy are non-compliance, 
alcohol and systemic infections (Janz, 1961; Rowan and Scott, 1970; Pilke 
et al, 1984; Aminoff and Simon, 1980; Leppik, 1990; Lowenstein and 
Alldredge, 1993; Martin and Millac, 1994; Coeytaux et al, 2000). Studies 
in both children and adults with SE have shown that low anti-epileptic-
drug levels as a cause of SE may not be so frequent as presumed (Barry and 
Hauser, 1994; Maytal et al, 1996).
SE may also be the presenting sign of an acute symptomatic brain lesion 
(initial or isolated SE), especially in the older age group. Acute symptomatic 
causes are more prevalent in older age groups, with corresponding worse 
outcome (Celesia et al, 1972; Sung and Chu, 1989). The most often occurring 
causes are CVA, encephalitis, head trauma, brain tumour, metabolic 
disturbances and toxic causes, including alcohol (table 10). The reviews 
show no obvious differences with regard to the various possible causes, 
although the frequency of brain tumours as a cause of SE appears to 
decline. Lowenstein and Alldredge (1993) compared the causes during the 
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period 1980-1989 with the period 1970-1979, no apparent differences were 
mentioned. Recent population-based prospective studies have reported 
comparable causes of SE; these studies are difﬁcult to compare because of 
differences in age distribution or exclusion of a certain cause. In all three 
studies no detailed distinction has been made with respect to cause between 
patients with or without previous epilepsy. (DeLorenzo et al, 1996; Coeytaux 
et al, 2000; Knake et al, 2001). 
Table 9: Generalized Convulsive Status Epilepticus: characteristics 
from 14 studies
Author Number Age 
(yrs)
Previous 
Epilepsy (%)
Mortality
(%)
Duration 
follow-up
Clark/Prout 
(1903/4)
 42 10-60 100 14 Unknown
Oxbury/Whitty 
(1971)
 86 11-80  71
   8,1
14
End of status 
6 months
Heintel (1972)  83 0-69  62 25
Discharge  
from hospital
Celesia 
(1972)
 17 >40  35 35 3 months
Roger et al 
(1974)
100 20-60  44 37
End comatose 
phase
Aminoff/Simon
(1980)
 98 14-83  52 16 Unknown
Celesia (1983)  78 19-80  22 23 10 months
Pilke et al 
(1984)
 71 16-80  83    2,4
Discharge  
from hospital
Goulon et al 
(1985)
282 >15  29 35 Unknown
Sung/Chu (1989) 102 >60 0 35 Unknown
Lowenstein/
Alldredge (1993)
154 17-98  56 14 Unknown
DeLorenzo et al 
(1996)
166
>30days
16-59
>60
42
54
30
22
14
38
30 days
Coeytaux et al 
(2000)
172 all 43    7,6
Discharge  
from hospital
Knake et al  
( 2001)
150 >18 50    9,3 30 days
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Outcome in TCSE
The early studies of SE reported the results from a period when treatment 
was rudimentary; they helped to deﬁne the natural history of TCSE in 
patients with previous epilepsy. Outcome in the early studies of SE was 
mentioned as mortality; morbidity was in most studies unrecorded. 
Mortality was especially high in institutionalised patients (35-50%). The 
seriousness of status was well recognized (Clark & Prout, 1903/4), but by 
no means universally fatal: in their study of 52 patients with 100 status 
periods, 14 died; a mortality rate of 14%. Despite improvements with regard 
to the care of patients with SE it is remarkable to note that recent studies 
of SE did not show a decline in mortality rate during the last 20-30 years 
(table 9). As has been discussed in the introduction of this chapter, several 
points must be stressed, however: most studies were retrospective, included 
different age groups and used different periods of follow-up. Furthermore 
it is important to mention that most ﬁgures have been derived from 
specialized hospital settings, where more severe cases have been treated, 
which may overestimate the risk of death (Hauser, 1990). This suggests that 
the published ﬁgures must be considered maximum estimates; this is also 
illustrated by the fact that especially in retrospective series cases with a 
short duration will have been missed and that therapy in early status will 
have been successful in most cases.
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Table 10: Causes of initial and isolated TCSE (%)* 
Author Oxbury/ 
Whitty 
1971
Roger 
1974
Aminoff/ 
Simon 
1980
Celesia 
1983
Janz 
1983
Pilke 
1984
Goulon 
1985
Sung/
Chu 
1989
Lowenstein/
Alldredge 
1993
Number of 
patients
24 56 48 43 93 14 201 102 67
CVA 16 12 23 16 15 43  20  35  6
Brain tumour 42 20  8 12 33 43  6  8  9
Head Trauma  4 39  4 18 17 14  3   21  9
Toxic  0  0 21  0  0  0  10  0 18
Metabolic  8  0 10 12  0  0  12  10  7,5
Encephalitis 21  0  8  2 13  0  10  2 15
Anoxia  0  0  0  5  0  0  18  0  9
Alcohol  0  0  8 12  0  0  0  0 21
Unknown  4 12  8  0  9  0  0  13  7,5
Other  4 17  0 23 13  0  20  11  0
* Cases of SE in patients with previous epilepsy are not mentioned.
The recent prospective studies did not entirely overcome the several 
problems present in the discussion about the risk of death in SE (DeLorenzo 
et al, 1996; Coeytaux et al, 2000; Knake et al, 2001). Mortality rates were 
reported irrespective type of status and the presence of previous epilepsy or 
not (table 9). The study in Virginia made a distinction with respect to outcome 
in age groups; the study in Switzerland gave an overall mortality percentage 
for all age groups, excluding cases with post-anoxic encephalopathy, which 
have a grave prognosis. Mortality in the Swiss group was 7,6%; the low rate 
was only partly explained by the exclusion of patients with post-anoxic 
encephalopathy, prompt and intensive therapeutic management in the pre-
hospital setting was important too in reducing mortality (Coeytaux et al, 
2000). The study in Germany reported a mortality rate of 9,3% in the adult 
patient, a percentage considerable lower than in Virginia. The lower mortality 
cannot be explained by differences in the populations that have been studied; 
the population in Virginia had a considerable non-white contribution, which 
was not the case in Germany. However, mortality in whites was higher (31%) 
than in non-whites (17%). Is also known that outcome in adult patients 
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from university hospitals is comparable to outcome in community based 
hospitals (DeLorenzo et al, 1992). A difference of importance with respect 
to outcome was the distribution of seizure types; in Virginia generalized 
(primary and secondary) SE was present in about 65% of the adult patients, 
in Germany in only 33,3% (table 5). A considerable percentage of patients 
in the German group were diagnosed as complex partial SE (43,3%), which 
has a better outcome than GCSE. Again this illustrates the importance of 
adequate differentiation of results with respect to outcome in the various 
groups of patients with different seizure types. An interesting study on long-
term mortality showed that SE itself did not modify long-term mortality; 
mortality increased with duration and the presence of an acute symptomatic 
cause (Logroscino et al, 2002).
Another problem is how to calculate the relative contribution of the 
underlying cause and SE itself to outcome. In many cases this may be 
impossible to disentangle. Death attributed to SE itself has been reported by 
several authors, with percentages of only 1.3-2% (Oxbury and Whitty, 1971; 
Aminoff and Simon, 1980; Pilke et al, 1984; Lowenstein and Alldredge, 
1993; Towne et al, 1994). It is not always clear why the cause of death has 
been attributed to SE itself; sometimes it is only mentioned that the patient 
died during or just after SE (Aminoff and Simon, 1980; Towne et al, 1994). 
In other reports speciﬁc medical complications have been mentioned, which 
occurred because of SE and caused death (Pilke et al, 1984; Lowenstein and 
Alldredge, 1993). Most reviews, however report only an overall mortality 
percentage with too little details for correct conclusions.
The same problems are present when discussing morbidity in TCSE. Ketz 
and Meier (1979) mentioned sequelae in 39% of 78 admissions, but only 9% 
appeared deﬁnitive. It was not mentioned, however, at what moment the 
sequelae had been considered deﬁnitive. In some reviews good outcome 
may also include minor neurological deﬁcits (Lowenstein and Alldredge, 
1993). Information from retrospective studies mentioned morbidity varying 
from 26% (Rowan and Scott, 1970) to 4.8% (Pilke et al, 1984). Rowan and 
Scott made no distinction between sequelae because of SE or underlying 
cause; they suggested that the longer the duration the higher the risk of 
morbidity. Oxbury and Whitty (1971) described 5 cases which undoubtly 
deteriorated after SE, two of them because of SE itself (one of them appeared 
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severely demented after SE). Aminoff and Simon (1980) described 12 cases 
with sequelae after SE, eight of them probably because of SE itself. Six of 
them showed intellectual impairment. Pilke et al (1984) mentioned one 
patient with ataxia, probably because of SE itself. A lower level of cognitive 
functioning after SE has been suggested by Dodrill (1986); a prospective 
study however, was less conclusive (Dodrill and Wilensky, 1990).
The development of epilepsy after an initial SE in children is usually 
associated with cerebral damage, often related to underlying pathology 
(Aicardi and Chevrie, 1970). The risk of epilepsy following SE in children is 
increased in acute and remote symptomatic cases, but not in idiopathic SE 
(Gross-Tsur and Shinnar, 1993). In adult patients less conclusive information 
is present about the risk of epilepsy following SE. 
Controlling for age, sex and cause, acute symptomatic SE increased the 
risk for subsequent epilepsy 3,3-fold compared to brief acute symptomatic 
seizures (Hessdorffer et al, 1998). The risk of unprovoked seizures was 
related to the underlying cause: in anoxic encephalopathy the risk was 18,8-
fold, in a structural lesion 7-fold and in metabolic causes 3-fold. 
Recurrences of SE in adult patients occur in about 13% and in children 
in about 38%, especially when the patient is younger than 5 years, has 
neurological abnormalities and insufﬁcient serum levels of anti-epileptic 
drugs (DeLorenzo et al, 1996). The recurrence rate in children is related to 
the cause of SE (Shinnar et al, 1992).
Prospective studies are needed which will be able to give more adequate 
information about morbidity because of SE itself. Recent prospective 
studies with MRI and neuron-speciﬁc enolase have provided interesting 
information about this subject. 
Magnetic resonance imaging (MRI) studies of patients with SE have 
shown evidence of neuronal damage caused by SE itself. Both in children 
(Stafstrom et al, 1996; Tien and Felsberg, 1995; VanLandingham et al, 
1998; Herrgard et al, 1999) and adults (Tien and Felsberg, 1995; Meierkord 
et al, 1997;Wieshman et al, 1997; Pohlmann-Eden et al, 2004) follow-
up studies with neuro-imaging technics have shown that longstanding 
epileptic discharges can result in neuronal damage, especially in the 
hippocampus. Several types of SE have been mentioned: GCSE (Stafstrom 
et al, 1996), CPSE (Lansberg et al, 1999) and febrile SE (VanLandingham 
et al, 1998). The results of follow-up study with MRI were conﬁrmed by 
the results of neuropathological examinations in a patient with refractory 
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GCSE (Stafstrom et al, 1996; Pohlmann-Eden et al, 2000; Pohlmann-Eden 
et al, 2004). MRI-volumetry in nine adult patients with SE did not show 
progressive volume reduction in the temporal lobe structures when treated 
promptly with a predetermined protocol (Salmenpera et al, 2000). 
In the past less sophisticated means of neuro-imaging were available, 
such as pneumo-encephalography and CT-scan. Some studies suggested a 
relation between SE and neuronal damage (Aicardi, 1969; Gastaut, 1977; 
Aicardi and Chevrie, 1983).
Neuron-speciﬁc enolase (NSE) is a sensitive marker of brain damage 
(neuron damage, not glial cell damage) in stroke, global ischemia and coma. 
An increase of NSE in TCSE and CPSE has been established, but a ﬁrm 
relation between NSE and neuronal damage in SE in clinical studies has not 
been proven. The surprising ﬁnding of elevated NSE in absence SE (ASE) 
raises the question whether it can be a useful tool in the study of the relation 
between SE and neuronal damage (DeGiorgio et al, 1996; Correale et al, 
1998; DeGiorgio et al, 1999).
Factors inﬂuencing outcome of TCSE
a. Aetiology
Outcome is especially determined by its cause (Whitty and Taylor, 1949; 
Rowan and Scott, 1949; Oxbury and Whitty, 1971; Heintel, 1972; Celesia, 
1983; Goulon et al, 1985; Delanty et al, 2001; Claassen et al, 2002). Outcome 
in cases with previous epilepsy is much better (Shinnar, 1993; Lowenstein 
and Alldredge, 1993; Barry and Hauser, 1993). Mortality in patients with 
previous epilepsy was 16%, in patients without previous epilepsy, with a 
high percentage of acute symptomatic causes; mortality was 61% (Barry 
and Hauser, 1993). Some causes, such as anoxia and hypoxia, have a worse 
outcome in comparison to other causes (Treiman, 1993; Towne et al, 1994). 
A retrospective study showed that anoxia had the worst prognosis with 
a mortality rate of 80%; other causes with a bad prognosis were stroke 
and metabolic abnormalities (mortality of 70%). Causes with a relatively 
good outcome were trauma, anticonvulsant withdrawal and alcohol abuse 
(Shinnar, 1993; Lowenstein and Alldredge, 1993; Towne et al, 1994). 
Comparable results were found during a prospective study of SE (DeLorenzo 
et al, 1995). In cases (alcohol abuse; low anti-epileptic drugs; no apparent 
cause) without clear risk factors for persistent organ vulnerability that 
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might lead to death, it is reasonable to presume that death may be related to 
the seizure activity of SE. 
A prospective study showed that the presence of certain co-morbidities 
in adults was related to higher mortality (anoxia 68%, sepsis 55%, tumour 
54%). Mortality increased as the number of co-morbidities increased, 
especially in adults (Towne et al, 1999). The presence of cardiovascular 
disease increased mortality, especially in children (Garnett et al, 2000). 
Outcome is especially determined by the underlying cause, but SE may 
also worsen the prognosis of the underlying condition. In their study of 
patients with SE admitted to the intensive care unit, Goulon and colleagues 
(1985) mentioned a mortality rate of 33% in cases with bacterial meningitis 
without and of 82% in cases with SE. A comparable result was noted in 
cases of SE caused by CVA; morbidity in cases with CVA and SE increased 
three times in comparison to cases with only a CVA and eight times to cases 
with only SE and no CVA (Waterhouse et al, 1998). It is difﬁcult however, 
to ascertain to what extent excess mortality was due to SE or whether SE 
simply reﬂected a greater severity of the underlying condition. 
b. Duration of TCSE 
In experiments using rats duration of 30 minutes appeared to be a limit 
beyond which pathophysiologic changes occurred (Nevander et al, 
1984; Nevander et al, 1985). In humans it is difﬁcult to differentiate the 
independent effects on outcome of underlying cause and duration of SE. 
Some clinical studies have provided evidence of a relation between duration 
of SE and outcome (Rowan and Scott, 1970; Heintel, 1972; Ketz and Meier, 
1979; Aminoff and Simon, 1980; Barois et al, 1985; Towne et al, 1994; 
DeLorenzo et al, 1999).
Neither Rowan and Scott (1970) nor Aminoff and Simon (1980) did ﬁnd 
complications in patients with duration as long as 90 or 120 minutes. There 
was an important increase in morbidity if cases lasted 10 hrs or more, and 
of mortality in cases lasting 13 hrs or more (Rowan and Scott, 1970). A 
poor outcome was more likely as duration of SE increased; insufﬁcient data 
were, however, available to permit ﬁrm conclusions about the relationship 
between duration and outcome (Aminoff and Simon, 1980). 
The retrospective study by Heintel (1972) reported a signiﬁcant increase 
of mortality when duration of SE exceeded 6 hours. Ketz and Meier (1979) 
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indicate that 6 hours is a critical period after which permanent neurological 
morbidity was apt to occur.
Mortality was 4% in 51 cases with duration of 30 minutes-24 hours; 
morbidity and mortality was however, 24% each in 29 cases with duration 
of more than 24 hours (Barois et al, 1985). Mortality in adult patients was 
only 2,7% in cases with a duration of 1 hour or less, whereas mortality was 
32% in cases lasting over one hour (Towne et al, 1994). 
Outcome in patients with prolonged seizures (10-29 minutes) was 
compared to outcome in patients with SE (DeLorenzo et al, 1999). Mortality 
in patients with prolonged seizures was signiﬁcantly lower than in SE. 
Adult patients and elderly, children however not, may die having prolonged 
seizures; mortality increases signiﬁcantly with duration, especially in the 
elderly. In the elderly aetiology was not different in both groups, duration 
was therefore important with regard to outcome. 
Long-term risk for mortality was increased in cases with duration of 
24 hours or more in comparison to cases with duration of less than 2 hours 
(Logroscino et al, 2002)
The relation between outcome and duration should be discussed 
separately for cases where outcome is determined by the underlying cause 
and cases where SE itself has been the main determinant. When outcome 
is especially determined by the underlying cause, damage is present from 
the start of SE and the contribution of continuous seizures will be hard to 
establish. Although several authors have established a relation between 
duration and outcome, only one paper used the distinction between 
underlying cause and SE itself in reporting the relation between outcome 
and duration of GCSE (Aminoff and Simon, 1980).
c. Therapy
First line drugs, such as benzodiazepines and phenytoin, are successful in 
80% of the cases of SE when therapy is started within 30 minutes after 
the start of the seizures; when therapy is started after 2 or more hours, 
ﬁrst line therapy fails in 60% of the cases (Walton and Treiman, 1988; 
Lowenstein and Alldredge, 1993). Therapy delay contributes to a longer 
duration of SE (Whitty and Taylor, 1949; Rowan and Scott, 1970; Treiman et 
al, 1983; Lowenstein et al, 1988). This is also the case for inadequate therapy 
(Delgado-Escueta and Enrile-Bascal, 1983; Celesia, 1983). The signiﬁcance 
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of early treatment with respect to duration of SE has also been illustrated by 
a retrospective evaluation of pre-hospital treatment in children with TCSE; a 
signiﬁcant decrease of duration of SE, of the recurrence rate and of duration 
of hospital stay was established (Alldredge et al, 1995). Improved outcome 
because of pre-hospital treatment were suggested in the prospective Swiss 
study (Coeytaux et al, 2000). 
These results suggest an indirect relation between therapy and outcome; 
therapy delay and quality of therapy are related to duration of SE and because 
of this relation indirectly to outcome. 
The effects of delayed treatment and time to respond to therapy on 
mortality were studied using multi-regression logistic analysis in 242 adult 
patients with GCSE. Both the response to initial therapy and the time to 
initial therapy were important factors in predicting mortality (DeLorenzo 
et al, 1998). 
d. Age
Mortality increases with age (Celesia, 1972; Sung and Chu, 1989; Barry 
and Hauser, 1993; Towne et al, 1994; Delorenzo et al, 1996; Claassen et al, 
2002). Highest mortality rates are present in the elderly with corresponding 
high percentages of acute symptomatic causes. Prognosis of SE in the 
neonate is also especially determined by cause, mortality rates are also very 
high. Mortality in children is 2,5%, in children less than 1 year mortality 
is considerable higher, 13,2% (DeLorenzo et al, 1996; Morton et al, 1998). 
Aicardi and Chevrie (1970; 1983) found that death and sequelae of SE were 
more common in younger infants; the incidence of death and sequelae 
declined from 77% in children of less than 6 months to 46% of older than 
3 years. This was not entirely related to the more frequent occurrence of 
symptomatic status in younger patients: sequelae after cryptogenic SE 
occurred in 35% in children less than 3 years, and in 9% in children older 
than 3 years.
Although a relation between age and incidence of sequelae was noted, 
it appeared a reﬂection of the fact that acute symptomatic SE was far 
more common in the younger age group (Maytal et al, 1989). A stepwise 
regression procedure was used to study the inﬂuence on outcome of factors 
independently; age was not signiﬁcantly related to outcome in children 
(Dunn, 1988; Maytal et al, 1989). It seems more likely that the range of 
causes in children and adults and not age inﬂuences outcome. 
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e. Miscellaneous
Outcome was prospectively investigated in 212 children and 433 adults 
in relation to type of SE: continuous versus intermittent. In adults the 
continuous type was negatively correlated to mortality; in children this 
was not the case. The difference in mortality in the continuous versus the 
intermittent type was not determined by cause, age, seizure type or duration 
(Waterhouse et al, 1998).
Outcome in adult patients appeared worse in cases with high serum 
levels of cortisol (Calabrese, 1993) or high levels of CSF lactate (Calabrese, 
1992).
A genetic factor with respect to outcome may be suspected. A genetic 
predisposition to SE has been suggested by twin studies (Corey et al, 
1998; Corey et al, 2004) and by the higher incidence in non-whites versus 
whites (DeLorenzo et al, 1996). Mortality in whites, on the other hand, 
appeared higher (31%) than in non-whites (17%). Another suggestion to a 
genetic factor in relation to outcome is the genetically determined GABA-
A receptor subunits combination, which shows a rapid modiﬁcation of its 
functional properties during status, resulting in a rapid loss of efﬁcacy 
of benzodiazepines. A genetic factor may explain some of the puzzling 
questions with respect to the relation between outcome and SE. Until now 
no information is present to allow more than a suggestion in this respect.
Prognosis in GCSE is particularly determined by the underlying cause; other 
important factors are duration of SE of more than 1 hr and a continuous type 
of status. Less conclusive, but at least contributing to poor outcome, are 
therapy delay, inadequate therapy and the presence of medical complications 
and/or co-morbidity.
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Electroencephalographic recording in TCSE
In the literature little information is present about electroencephalographic 
ﬁndings in TCSE (Roger, 1974; Stefan, 1990). The EEG in TCSE in the early 
stages shows the classic pattern of isolated tonic-clonic seizures with onset 
of discharges on one side of the scalp in 57% of the cases, whereas in 43% 
of the cases the onset is bilaterally synchronous and symmetrical (Roger 
et al, 1974). The post-ictal depression that commonly follows an isolated 
generalized tonic clonic seizure was seen in only 46% of the cases. 
A distinctive ﬁve-phase temporal evolution in EEG patterns during SE 
has been suggested (Treiman et al, 1990; Handforth et al, 1992; Lothman 
and Bertram, 1993). The following phases are distinguished:
1. Discrete seizures with inter-ictal slowing (clinically tonic-clonic 
seizures).
2. Merging seizures with waxing and waning of amplitude and frequency 
of EEG rhythms (clinically most often focal intermittent tonic and/or 
clonic convulsive activity).
3. Continuous ictal discharges (clinically continuous generalized clonic 
jerks or subtle clonic movements).
4. Continuous ictal discharges with ﬂat periods (clinically overt or subtle 
focal clonic movements or no motor symptoms).
5. Periodic epileptiform discharges (PED) on a ﬂat background.
Retrospective studies could not conﬁrm this typical temporal evolution 
(Lowenstein and Aminoff, 1992; Nei et al, 1999). Some patients remained in 
pattern I of Treiman, no matter the duration of SE. A prospective study with 
serial EEG reported increased mortality in cases with PED’s, although cases 
of SE with PED’s caused by non-compliance or metabolic disturbances had 
good outcome (Garzon et al, 2001). A predictable sequence of EEG patterns 
was not found. In one third the same pattern persisted until resolution of 
status, and in another one third the SE had already resolved at the second 
EEG. The remainder showed a variable EEG pattern without a stereotyped 
sequence. PED was the initial pattern in 14 of 62 SE episodes, a relation 
between duration of status and the incidence of PED’ was not present. PED 
appeared an ictal pattern, which disappeared after treatment, with clinical 
improvement. Other initial EEG patterns were intermittent EEG seizures 
or discrete seizures (44%), merging seizures (18%), and continuous ictal 
discharges (16%).
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In patients with altered consciousness it may be difﬁcult to determine whether 
the underlying cause or SE is the cause of the altered consciousness (Privitera 
et al, 1994). In 74 patients with altered consciousness the EEG conﬁrmed the 
diagnosis of SE: in 42 patients complex partial SE, in 3 myoclonic SE and 
in 29 subtle GCSE. Most cases with subtle GCSE concerned a diffuse brain 
injury rather than evolving from convulsive SE. No signiﬁcant relationship 
could be determined between the EEG pattern (intermittent or continuous 
EEG spiking) and duration of subtle GCSE (Privitera et al, 1994). 
A retrospective study reported the results of emergent EEG in a hospital 
over a period of 52 months (Varelas et al, 2003). The most common reason 
to order the EEG was a change in mental status or coma, especially to rule 
out SE. In 10,7% of these cases SE was present. A history of cardiac or 
respiratory arrest was the only independent risk factor for SE.
EEG monitoring in SE is important too with regard to the evaluation 
of therapy, especially when the patient is artiﬁcially paralysed and 
mechanically ventilated. Persistence of electroencephalographic SE after 
disappearance of overt clinical signs should also be anticipated. The EEG 
is probably under-utilized among patients with SE. It was calculated that 
during the period 1988-1995 only 11% of the patients with SE had an EEG 
during hospitalisation (Trevathan and Rurangirwa, 1999). 
A prospective study of EEG monitoring after SE revealed various 
patterns. Good outcome was present in cases with a normal EEG, whereas 
poor outcome was found in cases with burst suppression, after-status-ictal-
discharge (ASIDS) and to a lesser extent with PED’s, also after correction 
for aetiology. This study showed persistent ictal activity despite control of 
clinical seizure activity and stresses the importance of EEG monitoring to 
determine treatment effects (Jaitly et al, 1997). A prospective EEG study 
in 164 patients, older than 16 years, showed despite disappearance of overt 
clinical signs of GCSE in 14% persistent intermittend or continuous non-
convulsive SE (NCSE). Mortality in this group (51%) was signiﬁcantly higher 
than in cases without NCSE (13%), corrected for age and aetiology. Therapy 
was not evaluated, aggressive treatment of NCSE was suggested to improve 
outcome (DeLorenzo et al, 1998).
In patients with GCSE a burst suppression pattern on the EEG has been used 
as a target for the titration of barbiturate or anaesthetic therapy. It is not clear 
from what source this strategy arises; no studies are available which show a 
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relation between achieving or maintaining burst suppression and outcome. 
One study suggested better results of attaining a ﬂat record in comparison to 
burst-suppression in patients with SE treated with barbiturate anaesthesia 
(Krishnamurthy and Drislane, 1999). A literature study suggested better 
results of background suppression (burst suppression or ﬂat records) with 
pentobarbital in comparison to suppression of seizures with midazolam or 
propofol (Claassen et al, 2002)
Burst suppression (BS) is a periodic EEG pattern characterized by bursts 
of spikes, sharp and slow wave activity during 1-5 sec. followed by periods 
of 2-9 sec. of electrical silence, without variations during either waking-
sleeping status or sensory stimulation. In the pre-term neonate (24-36 w) BS 
may be a normal physiological pattern, but in the a-term neonate (and later) 
BS is always an abnormal pattern expressing an anatomical or functional 
(barbiturate anaesthesia) disconnection between cerebral cortex and deeper 
structures. One should consider two points when one takes BS as guideline 
for barbiturate anaesthesia. First there is a potential of severe hypotension 
with a risk of increased morbidity and mortality (Yaffe and Lowenstein, 
1993). Second epileptic discharges can sometimes remain present despite 
BS. One wonders whether a lower dose would be sufﬁcient too, especially 
when one considers the fact that seizure related neuronal injury is related 
to high-frequency repetitive discharges and not to isolated spike activity 
(Lowenstein et al, 1990). Prospective investigations are necessary to ﬁnd out 
whether a BS pattern is a necessary requirement for sufﬁcient barbiturate 
anaesthesia. 
For a particular individual it is not possible to reliably predict the EEG 
characteristics during status, because of differences in underlying cause, 
systemic physiologic changes and drug treatment, which will all inﬂuence 
the EEG. The suggested temporal evolution in EEG patterns during status 
has not been acknowledged by other studies; a considerable portion of 
the patients remain in a ﬁxed pattern. Some EEG patterns suggest a poor 
outcome, such as PED or burst-suppression.
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3.5.2 Nonconvulsive Status Epilepticus in adult patients
3.5.2.1 Introduction
Prolonged epileptic states without convulsions have been described before 
the EEG era (Clark and Prout, 1903/4). It was not until the introduction 
of the EEG that further progress in understanding these conditions was 
possible. Non-convulsive Status Epilepticus (NCSE) is characterized by 
a clouding of consciousness, confusion, automatisms and amnesia, with 
in accordance to the type of NCSE, speciﬁc EEG abnormalities. In most 
cases there is a clinical evident alteration from baseline in mental status 
or behaviour, together with seizure activity on the EEG. The diagnosis 
NCSE is not always apparent; the clinical presentation may be mistaken 
for a psychiatric disorder (hallucinations- laughing-crying-confusion), a 
metabolic encephalopathy (confusion), post-ictal (lethargy), intoxication, 
or attributed to an infection, a stroke or a brain tumour (Kaplan, 1996; 
Drislane, 1999). This may lead to signiﬁcant delay in the correct diagnosis 
or the diagnosis may even be omitted entirely, when EEG investigation 
is not considered (Kaplan, 1996; Jordan, 1999; Towne et al, 2000). This 
is especially the case in certain patient groups, who show changes in the 
level of consciousness without overt clinical seizure activity, of unknown 
cause. Examples of these patients are patients with mental retardation 
(Shorvon, 1994), patients admitted to the Intensive Care Unit (Young et 
al, 1996; Litt et al, 1998) and patients without manifest clinical signs 
after generalised convulsive SE (Fagan and Lee, 1990; DeLorenzo et al, 
1998). In patients with changes in consciousness, with or without subtle 
motor activity, EEG investigation should be considered, despite the 
presence of an acute brain injury (Privitera et al, 1994; Jordan, 1999). 
Prolonged EEG recording was 5 times more likely to identify NCSE than 
routine EEG (Varelas et al, 2003). The EEG is in most cases conclusive, 
but sometimes difﬁcult to interpret (Kaplan, 1999) or the scalp EEG may 
show only minor changes, whereas depth EEG recording may show CPSE 
(Williamson et al, 1985). In summary, one should consider NCSE in the 
following clinical conditions:
− Apparent prolonged postictal state.
− Prolonged reduction of alertness from an operative procedure or 
neurological insult.
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− Impaired mentation or consciousness with myoclonus of facial muscles 
or nystagmoid eye movements.
− Acute onset of impaired consciousness or ﬂuctuating picture with 
episodes of normal mentation.
− Episodic blank staring, aphasia, automatisms, perseverative activity.
− Aphasia without any structural lesion.
− Other acutely altered behavior without other obvious etiology.
A suspicion of NCSE is the most important clinical indication for performing 
an EEG. When EEG monitoring is not possible, some features are highly 
suggestive for NCSE, such as remote risk factors for seizures, impaired 
mental status and ocular movement abnormalities (Husain et al, 2003). 
In adult patients NCSE is divided in two main groups, Generalized Non-
Convulsive Status Epilepticus (GNCSE) and Complex Partial SE (CPSE), 
which because of their clinical similarities have been discussed together 
by most authors. GNCSE includes Absence SE (ASE) and atypical ASE; the 
latter occurs especially in patients with symptomatic generalized epilepsy 
and mental retardation.
3.5.2.2 Absence Status Epilepticus (ASE)
ASE conﬁrmed by EEG was described ﬁrst by Lennox in 1945, since then 
several reports have appeared which describe ASE under a variety of names: 
Absence SE, petit mal SE, epilepsia minor continua, spike-wave stupor and 
prolonged petit mal automatisms (Shorvon, 1994). At the moment absence 
status epilepticus (ASE) is the most frequent used term to describe a 
prolonged confusional state of varying severity, with a ﬂuctuating level of 
consciousness together with generalized paroxysmal spike-wave activity on 
the EEG (Lob et al, 1967; Andermann and Robb, 1972; Karbowski, 1976; 
Porter and Penry, 1983; Guberman et al, 1986; Dunne et al, 1987). Clinically 
and electroencephalographically a continuous and a discontinuous type may 
be distinguished. Duration of ASE varies from 30 min. to 1 or 2 days (Lob et 
al, 1967; Bauer, 1975; Rohr-Le Floch et al, 1988). Most cases have duration of 
less than 12 hrs (Lob et al, 1967; Guberman et al, 1986; Tomson et al, 1986; 
Tomson et al, 1992). The EEG in typical ASE shows generalized continuous 
paroxysmal activity without focal features. Although the 3 Hz spike-wave 
discharges are the best-known EEG abnormalities, other frequencies are 
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possible too, varying from 0.5 - 6 Hz, regular or irregular (Porter and Perry, 
1983). 
ASE in patients with previous epilepsy may be precipitated by tonic-
clonic seizures, anti-epileptic drug withdrawal, systemic infection, fatigue 
and stress, or may be related to the menstrual or sleep-waking cycle 
(Andermann and Robb, 1972; table 11). 
Typical ASE in syndromes of idiopathic generalized epilepsy (IGE) in 
21 adult patients showed a mean age of onset of ASE of 29,2 years, range 
9-56 years (Agathonikou et al, 1998). The mean number of episodes was 
10,9 (1-40). The mean minimal duration was 3,7hrs (30min-24hrs), the 
mean maximal duration 26,5hrs (30min-10days).
The most important clinical symptom was slight-moderate lowered 
consciousness, with withdrawal, slow ideation, confusion, slowness of 
responses and sometimes experiential phenomena. A ﬂuctuating level of 
consciousness was in only 5 cases present. Myoclonic jerks were found in 
9 patients (peri-oral or eyelid, limbs). Amnesia was variable, complete in 
only 1 patient. In 8 patients ASE preceded GTCS; in 7 patients ASE was 
the ﬁrst sign of epilepsy. An important ﬁnding was the fact that ASE was 
recognized as such in only 4 cases. In 10 patients ASE was ignored. In 3 
patients ASE was misdiagnosed as depression, in 2 as CPSE and in 2 as 
post-ictal confusion. During follow-up study of 3-7 years all but three were 
free of further episodes of ASE for more than 2 years. The majority were 
taking valproate.
In cases without previous epilepsy ASE may be the only or initial 
presentation of idiopathic generalized epilepsy, or occur de novo in elderly 
patients (Amand, 1971; Schwartz and Scott, 1971;Wells, 1975; Ellis and Lee, 
1978; Bateman et al, 1983; Aguglia et al, 1983; Bourrat et al, 1986; Terzano et 
al, 1986; Thomas et al, 1992). A second group consists of ASE as a situation 
related generalized NCSE, caused by e.g. drug withdrawal or by toxic drugs 
(Pritchard and O’Neal, 1984; Elian and Fenwick, 1985; Vollmer et al, 1985; 
Emre and Baumgartner, 1985; Ahmed et al, 1988; Obeid et al, 1988; Sweden 
and Mellerio, 1988). An example of situation related generalized NCSE is 
ASE caused by metrizamide (Pritchard and O’Neal, 1984; Obeid et al, 1988). 
Other toxic causes included tricyclic antidepressants, aliphatic neuroleptics 
or combinations of both (Sweden and Mellerio, 1988). Examples of drug 
withdrawal concerned especially abrupt withdrawal of benzodiazepines 
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(Emre and Baumgartner, 1985; Sweden and Mellerio, 1988). De novo ASE 
in the middle-aged and the elderly (table 12) occurs mostly in females, 
without a history of previous epilepsy (Amand, 1971; Thomas et al, 1992). 
Some are known with previous IGE and develop ASE after a seizure free 
interval of many years. Those without previous epilepsy have in most cases 
an age of more than 60 years (Richard and Brenner, 1980; Sundaram and 
Lowry, 1985). Although in some cases a frontal origin is suggested by 
the electroencephalographic ﬁndings (Ellis and Lee, 1978; Aguglia et al, 
1983; Bourrat et al, 1986), a structural damage has not been found. The 
clinical presentation may be highly suggestive of a psychiatric diagnosis; 
in many patients a prolonged confusion was accompanied by paranoia 
and hallucinations (Wells, 1975; Ellis and Lee, 1978; Bateman et al, 1983; 
Bourrat et al, 1986). Precipitating factors are mentioned in table 12. 
Incidence of ASE
The incidence of ASE is hard to estimate; not all cases are recognized and 
not all cases will be admitted. A history of ASE in patients with generalized 
absence seizures is said to occur in 5-10% of the cases with absence epilepsy 
(Shorvon, 1994). An annual incidence of ASE was calculated at 1 per million 
of the general population. Recent prospective studies found higher incidence 
rates, varying from 4-10 per million (DeLorenzo et al, 1996; Coeytaux et al, 
2000; Knake et al, 2001); the highest incidence rate was in a study restricted 
to only adult patients (Knake et al, 2001).
Males and females seem equally affected; the condition tends to develop 
in the young: most cases are younger than 20 years.
The occurrence of 21 cases of typical ASE in syndromes of idiopathic 
generalized epilepsy (IGE) in 136 adult patients in 5 years suggested a 
prevalence of ASE in IGE of 15,4% (Agathonikou et al, 1998). ASE occurred 
in 24,4% of cases with typical absences alone or in combination with other 
seizure types. The prevalence of typical ASE appeared to be syndrome 
related. 
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Therapy of ASE
Therapy of ASE, including situation related generalized NSE and ASE de 
novo in the elderly, but with the exception of atypical ASE, is prompt and 
successful in most cases. The drugs that are used most are benzodiazepines, 
such as diazepam (Bauer et al, 1982; Guberman et al, 1986; Dunne et al, 1987), 
clonazepam (Kiefer et al, 1982; Dunne et al, 1987) and clobazam (Tinuper 
et al, 1986). Only one study compared two drugs in ASE, clonazepam and 
diazepam (Bülau et al, 1986). The results of both drugs were comparable, but 
less adverse events were mentioned after clonazepam use, in comparison to 
diazepam. Anti-epileptic maintenance therapy is hardly necessary in the 
other elderly patients with ASE de novo (Bourrat et al, 1986, Thomas et al, 
1992).
Episodes of ASE or GCSE in patients with IGE treated with carbamazepine 
and/or phenytoine at therapeutic concentrations were more frequent and 
proved intractable to treatment with valproate or benzodiazepines compared 
to cases treated otherwise (Osorio et al, 2000).
3.5.2.3 Complex partial Status Epilepticus (CPSE)
The ﬁrst description of CPSE authenticated by EEG was in 1956 by Gastaut 
(Gastaut et al, 1956). The clinical presentation has been described extensively 
(Treiman and Delgado-Escueta, 1983; Wieser et al, 1985; Tomson et al, 1986; 
Dunne et al, 1987; Rohr-Le Floch et al, 1988; Tomson et al, 1992). CPSE is a 
prolonged epileptic episode in which ﬂuctuating or frequently recurring focal 
electrographic epileptic discharges, arising in temporal or extra temporal 
regions, result in a confusional state with variable clinical symptoms 
(Shorvon, 1994). Important is the distinction between a continuous type, 
characterized by long-lasting confusion with or without psychotic behaviour 
or automatisms and continuous focal discharges and a discontinuous type 
with recurrent complex partial seizures with circumscribed discharges 
as seen in single complex partial seizures, however without recovering of 
consciousness between the seizures (cycling type). Most cases with CPSE 
(75%) occur in patients with previous epilepsy. A greater part (about 80%) 
of the patients shows automatisms, whereas convulsive signs are present 
in only 35%. A discontinuous type occurs more often (60%) than the 
continuous type. A male or female preference has not been noted. In cases 
with previous epilepsy most patients are between 20 and 50 years of age, 
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in cases without a previous history of epilepsy a preference is present for 
patients older than 50 years.
Prolonged confusion and/or psychosis may be the main manifestation of 
CPSE of extra-temporal (e.g. frontal lobe) origin or may occur at the end of 
the cycling type. The cycling type may originate from the temporal lobe with 
primary or secondary involvement of the amygdalo-hippocampal region, 
but an extra temporal origin is also possible (Delgado-Escueta and Treiman, 
1987). A clinical distinction between CPSE of frontal or temporal lobe origin 
was suggested by Rohr-Le Floch (Rohr-Le Floch et al, 1988). CPSE of frontal 
lobe origin was characterized by confusion and behaviour disturbances, 
whereas CPSE of temporal lobe origin showed confusion and emotional 
disturbances. A recent prospective study described NCSE of frontal origin 
in 10 patients in 5 years from a total of 44 cases with NCSE (Thomas et al, 
1999). The delay in diagnosis was 48 hours (3-96hrs). Three were referred 
to the psychiatric ward (hypomanic state, hysteria), one was diagnosed 
as transient global amnesia, one as alcohol-related. Two groups were 
described: the ﬁrst group consisted of 7 patients with mood disturbances in 
combination with affective disinhibition or affective indifference and subtle 
impairment of cognitive function without overt confusion. The EEG showed 
unilateral frontal ictal pattern and a normal background. The second group 
included 3 cases with impaired consciousness, associated with bilateral 
frontal EEG discharges and abnormal background.
Duration of CPSE varies from 30 min. to 2 weeks; about 40% has a 
duration of less than 24 hrs, another 40% 1 to 10 days. A case of exceptional 
long duration, 7½ months, has been described (Roberts and Humphrey, 
1988). 
The clinical diagnosis of CPSE may be difﬁcult; EEG investigation is 
essential in order to differentiate from e.g. ASE. EEG investigation in 
CPSE, however, is not always conclusive; depth-recording may reveal CPSE, 
whereas scalp recording did not show speciﬁc EEG abnormalities (Wieser, 
1980; Wieser et al, 1985; Williamson et al, 1985). In most cases however, 
surface recording shows speciﬁc epileptic activity, such as continuous 
temporal spikes or spike-wave activity, or there are recurrent seizures with 
or without secondary generalisation. 
The various causes and precipitating factors of CPSE are mentioned in table 
11 and 12.
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Incidence of CPSE
Little is known about the incidence of CPSE. A study in Sweden found an 
incidence of NCSE in adult patients of 1.5 per 100,000 inhabitants; one 
can calculate an incidence of CPSE of 0.67 (Tomson et al, 1992). At least 
15% of patients with active complex partial epilepsy have a history of non-
convulsive episodes (Shorvon, 1994). An annual incidence of CPSE was 
calculated to be 3.5 per 100,000. The prospective study in Virginia found 
an incidence of 1.2 per 100,000; signiﬁcant case under ascertainment was 
however present (DeLorenzo et al, 1996). In a recent prospective study (all 
age groups), including EEG investigation, an incidence of 4.4 per 100,000 
was suggested; this number dropped to 2.8 when areas were included with 
less perfect case-ascertainment (Coeytaux et al, 2000). From a prospective 
study in adults an incidence of 6.9 per 100,000 could be calculated (Knake 
et al, 2001). Extrapolating the number from Switzerland to the Netherlands 
one may expect at least 700 cases of CPSE every year.
Treatment of CPSE
Treatment consists in most cases of phenytoin and/or benzodiazepines. 
Other drugs consisted of phenobarbital, carbamazepine, thiopental, 
chlormethiazole or no therapy at all.
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Table 11: Precipitating factors and causes of CPSE and ASE in patients 
with previous epilepsy, as mentioned in the literature* 
Previous Epilepsy CPSE  
(83 cases)
ASE  
(97 cases)
Following tonic-clonic seizure  9 29
AED withdrawal and non-compliance  6 16
AED withdrawal (presurgical evaluation) 14 --
Systemic infection  1  5
Systemic surgery  2  0
Menstrual cycle, pregnancy  4  7
Sleep-deprivation, fatigue, minor trauma, 
hyperventilation
 0  8
Alcohol  1  5
Intoxication  1  1
CVA  0  1
Trauma  1  0
Brain tumour  1  0
Unknown 43 25
* Absolute numbers
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Table 12: Causes and precipitating factors of CPSE and ASE in patients 
without previous epilepsy as mentioned in the literature* 
No previous epilepsy CPSE 
(61 cases)
ASE 
(44 cases)
ASE de novo in 
the elderly (55 cases)
Intoxication  0 18 13
Crack-cocaine  2  0  0
Drug withdrawal (no AED)  2 16 11
Thyroxine  0  2  0
Electroshock therapy  0  1  0
Fatigue  0  1  0
Metabolic disturbance  0  0  6
Heart failure  0  0  1
Lymphoma  0  0  1
Systemic surgery  0  0  1
CVA 24  0  0 
Brain surgery  3  0  0
Alcohol  2  0  1
Brain tumour  6  0  0
Encephalitis  4  0  0
Leptomeningeal carcinomatosis  1  0  0
Following tonic clonic seizure  2  0  0
Pregnancy  1  0  0
Unknown 14  6 21
* Absolute numbers
3.5.2.4 Special clinical conditions and NCSE
NCSE may be present in patients with coma without overt clinical seizure 
signs. A prospective study in 236 patients reported 19 cases (8%) with 
NCSE; no difference was present in outcome or causes between cases with 
or without NCSE (Towne et al, 2000). 
The relation between outcome and presence of NCSE in elderly patients 
admitted to the ICU with unexplained impairment of consciousness remained 
unclear (Litt et al, 1998). Treatment of NCSE with benzodiazepines was 
even negatively correlated with outcome; this was also true for the presence 
of generalized epileptic discharges.
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Apart from coma, other clinical features in acute brain injury may be 
caused by NCSE: aphasia, mental dullness, limb posturing, abnormal 
eye movements, automatisms and cortical blindness (Jordan, 1999). The 
diagnosis is often unsuspected; the most common presentation is non-
localising coma. 
When adequate recovery after an acute brain lesion such as stroke 
or after seizures does not occur one should consider NCSE, also in cases 
without obvious clinical seizure activity; improvement may be expected after 
therapy with AED (Hilkens and de Weerd, 1995; Drislane, 1999; Claassen 
et al, 2004). Especially in comatose patients prolonged EEG recording (>48 
hours) may be necessary to detect seizure activity (Claassen et al, 2004).
Patients with unexplained or protracted impairment of consciousness 
or altered behaviour after a recognized seizure or GCSE, without overt 
clinical seizure signs may have NCSE (Fagan and Lee, 1990;Young et al, 
1996; Delorenzo et al, 1998; Claassen et al, 2004). Mortality in cases with 
NCSE was signiﬁcantly higher than in cases without NCSE (Young et al, 
1996; Delorenzo et al, 1998). Aggressive treatment of NCSE in these cases 
was suggested (Delorenzo et al, 1998).
3.5.2.5 Outcome in NCSE 
ASE may show a high incidence of recurrence (Agathonikou, 1998; 
Guberman, 1986). 
Outcome is good in all cases; there is no evidence for morbidity or 
mortality in ASE.
Valproic acid prevented recurrence of ASE in a high percentage of 
patients (Berkovic et al, 1989; Agathonikou et al, 1998).
Mortality in NCSE (various types) appeared to be determined by acute 
symptomatic causes, the development of acute complications and severe 
mental status impairment, but not by the type of EEG discharges (Shneker 
and Fountain, 2003).
Most cases with CPSE and morbidity concern patients with acute 
brain injuries; neurological morbidity in cases with previous epilepsy is 
mostly mild and usually improves. Outcome is worse in cases with severe 
neurological damage, whereas in ambulatory cases outcome is in most cases 
good (Kaplan, 1996; Cockerell et al, 1994). One should also consider the 
risk of recurrence (Cockerell et al, 1994). The risk for new-onset ASE and 
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CPSE resulting in chronic epilepsy has not been looked at systematically. 
Neuropathological studies of the effect of SE in humans are scarse; most 
fatal cases are often caused by acute brain injuries. This is especially the 
case in CPSE, because most cases are not fatal, unless associated with acute 
brain injuries. Experimental results in animals have shown that CPSE may 
cause selective neuronal damage, especially in the CA1 and hilar region of 
the hippocampus and in the thalamus (Lothman, 1990; Meldrum, 1993; Ben-
Ari, 1997). The fact that only few reports exists with morbidity in humans is 
in contrast with the data in animal experiments. 
Outcome of NCSE in patients with coma without clear or very mild 
clinical seizure ﬁndings is especially determined by the underlying cause; 
the presence of NCSE in these patients appears to have little inﬂuence 
on outcome (Lowenstein and Aminoff, 1992; Litt et al, 1998; Towne et al, 
2000). In this borderland group the epileptic EEG changes merely reﬂect 
damage from severe brain injuries. This is not the case in patients with 
NCSE after disappearance of overt clinical signs of GCSE (DeLorenzo et 
al, 1998). Outcome in these patients is worse than in those without NCSE. 
Aggressive treatment has been advised, but results are not present. 
In GCSE the prognosis of the underlying condition may worsen because 
of the presence of SE (Goulon et al, 1985; Waterhouse et al, 1998). Whether 
such an effect is present between NCSE and acute brain injury with respect 
to morbidity and mortality has not been proven. On the other hand acutely 
injured neurons are more likely than intact neurons to suffer irreversible 
injury or death when exposed to comparable levels of ischaemic, metabolic 
or hypoxic insults (Miller and Becker, 1982). It is obvious that guidelines 
are necessary for the intensity and duration of anticonvulsant therapy in 
these cases.
What is the evidence for morbidity in CPSE because of the 
epileptic discharges themselves in humans?
a. Clinical case reports
Some case-reports mentioned prolonged memory deﬁcits after CPSE, 
although it was not proven that this deﬁcit was permanent (Engel et al, 
1978; Kitagawa et al, 1979; Guerreiro et al, 2001). One patient was left 
with delusions, requiring psychiatric care after CPSE (Rossum et al, 1985). 
Duration of follow-up was not mentioned. A prospective study with complete 
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neuropsychologic testing before and after SE demonstrated worsening in 
4 cases with GCSE and 5 with CPSE. The differences were, however, not 
signiﬁcant (Dodrill and Wilensky, 1990). Serious morbidity and mortality has 
been reported in 10 cases with CPSE (Krumholz et al, 1995). Three patients 
died (2 of unknown cause, 1 CVA), 4 cases showed morbidity because of 
the underlying cause. Following CPSE three patients with previous epilepsy 
developed memory deﬁcits and in two cases also cognitive loss. The authors 
considered morbidity caused by status itself and was permanent in one 
patient, and persisted for more than 2 years respectively 6 months in the 
other two cases.
Apart from the duration of CPSE, which in most cases of sequelae 
presumed to be caused by CPSE itself was more than 24 hrs, therapy 
delay or inadequate therapy may have been important too; e.g. a patient 
with delusions after CPSE with a duration of 3 days had not been treated 
(Rossum et al, 1985); another patient with CPSE of more than 20 hrs who 
showed a memory deﬁcit and hallucinations after recovery from CPSE had 
been treated after a considerable delay (Kitagawa et al, 1979). 
b. Neuron-speciﬁc enolase (NSE)
NSE is a sensitive marker of brain damage in stroke, global ischaemia and 
coma. Several studies have reported increased levels of NSE in CPSE and 
ASE, the relation between morbidity and SNE levels, however, remains to 
be established (Rabinowicz et al, 1995; DeGiorgio et al, 1996; DeGiorgio et 
al, 1999; Correale et al, 1998).
c. Neuro-imaging
Neuro-imaging ﬁndings during and after CPSE were discussed in three 
patients (Lansberg et al, 1999). Diffusion-weighted MRI (DWI) during 
CPSE demonstrated marked gyriform cortical hyperintensity throughout 
the affected hemisphere; T2-weighted MRI and ﬂuid-attenuated inversion 
recovery images (FLAIR) showed cortical hyperintensity in the abnormal 
regions seen on DWI. The CT-Scan during CPSE demonstrated new regions of 
hypo-attenuation in the affected hemisphere. During CPSE leptomeningeal 
enhancement on post-contrast MRI was present, which may reﬂect alteration 
of the blood-brain-barrier; hyper-perfusion during CPSE in response to the 
elevated metabolic demands was detected with MRA, which demonstrated 
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increased blood ﬂow through cerebral vessels on the affected hemisphere. 
Both ﬁndings disappeared on follow-up MRI. The lesions demonstrated 
with DWI, T2-MRI and CT-scan did not respect vascular territories and 
resolved on follow-up imaging, although some brain injury in two patients 
was demonstrated. This became apparent as enlargement of the lateral 
ventricle and sulci on the affected side (Lansberg et al, 1999).
Corresponding MRI ﬁndings in patients with primary or secondary brain 
tumours should encourage EEG investigation to exclude NCSE (Hormigo et 
al, 2004).
In conclusion it is obvious that clinical evidence for morbidity caused 
by the epileptic discharges themselves in CPSE is scarce, in relation to its 
relative high incidence. 
Some case reports and the results of modern neuro-imaging technics 
demonstrate that neurological morbidity may occur after CPSE, caused 
by the epileptic discharges themselves. The incidence of this problem is 
probably low. Is the small risk of cognitive sequelae in CPSE worth the risk 
of intravenous AED morbidity? Prospective studies are needed to answer 
this question, with better-deﬁned and stratiﬁed patient populations.
3.5.3 Simple Partial Status Epilepticus
 
3.5.3.1 Introduction
Simple Partial Status Epilepticus (SPSE) is characterized by partial seizures 
without impairment of consciousness, without secondary generalization, 
and with preserved neuro-vegetative regulation (Gastaut, 1983). Partial 
seizures with preserved consciousness are called SPSE when continuous 
clinical and electroencephalographic seizures are present for at least 30 
minutes (Delgado-Escueta and Treiman, 1987). The clinical expression 
depends on the region of the brain where the seizures originate, so various 
possibilities exist. The most frequent occurring type of SPSE is somato-
motor, other types are e.g. aphasic and somato-sensory.
3.5.3.2. Somato-motor SPSE
In general neurological practice two groups of patients with somato-
motor SPSE are encountered; both types are in a high percentage caused 
by a symptomatic brain lesion, but may also occur in patients known 
with a history of previous epilepsy: 
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1. Patients with frequently repeated typical somato-motor seizures 
with or without Jacksonian march and with more or less pronounced 
EEG discharges in the Rolandic region. Marked vegetative signs are 
absent (somato-motor SPSE s.s.). In somato-motor SPSE s.s. the seizures 
consist of local muscular contractions with or without Jacksonian march, 
not progressing to tonic-clonic seizures, and are so frequently repeated 
that between the seizures the relaxation of the involved muscles is hardly 
present. The march follows somato-topic organisation of the motor cortex. 
The parts of the body involved most in somato-motor SPSE, especially 
when Jacksonian marches are present, are the face, the eyes and the arms. 
Without a march clonic jerks are seen most in the thumb, the big toe, lips 
or eye-lids (Delgado-Escueta and Treiman, 1987). Somato-motor SPSE is 
the second most common form of SE, after TCSE. Few reviews are present 
which discuss the various features of this entity, most concern epilepsia 
partialis continua (EPC). Roger (1974) described 50 patients with partial 
SE, but only 10 had SPSE without generalisation. Details, such as causes and 
EEG, of this group were not given. 
Another rare type of somato-motor SPSE is adversive SPSE, in particular 
the oculo-clonic form. Patients with oculo-clonic SE have been described 
with continuous nystagmus and contralateral occipital discharges on the 
EEG (Gerstle de Pasquet et al, 1991; Kanazawa et al, 1989).
2. Those with persistent myoclonus of cerebral cortical origin in a limited 
area of the body, present for weeks or months and sometimes in combination 
with somato-motor or tonic-clonic seizures (Epilepsia Partialis Continua, 
EPC). Somato-motor SPSE is synonymous with EPC when myoclonic jerks 
are continuously present in the same body parts engaged by the somato-
motor seizures (Delgado-Escueta and Treiman, 1987; Thomas et al, 1977; 
Schomer, 1993). EPC is characterized by spontaneous regular or irregular 
clonic twitching of cerebral cortical origin, sometimes aggravated by action 
or sensory stimuli, conﬁned to one part of the body, and continuing for hours, 
days or weeks (Obeso et al, 1985). Juul-Jensen and Denny-Brown (1966) 
investigated nine patients with EPC who died because of the underlying 
disease. They suggested a subcortical origin of EPC, but others disagreed 
(Thomas et al, 1977; Löhler and Peters, 1974; Meienberg and Kabowski, 
1977; Shorvon, 1994). Thomas et al (1977) reviewed 32 cases, but included 
heterogeneous groups of patients with various aetiologies; some patients 
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were in a comatose state, others were fully conscious and experienced 
myoclonus for years. 
In EPC the myoclonic jerks and the seizures are produced by the same 
cortical motor area of the brain (Chauvel et al, 1992). Several studies have 
been able to conﬁrm the constant relationship between myoclonic jerks 
and focal EEG spikes in the contralateral central area (Wieser et al, 1977; 
Chauvel et al, 1992). Its nature makes it different from other forms of partial 
SE, which is due to the peculiar architecture of the motor cortex and of its 
special, tight afferent-efferent relations, which support the activation of 
long-loop reﬂexes. This unique mechanism makes EPC a speciﬁc disorder of 
the motor cortex (Chauvel et al, 1992).
Two types of EPC are discerned (Bancaud et al, 1982; Bancaud, 1985). 
The ﬁrst type includes patients of all ages and is caused by a Rolandic 
lesion of various aetiologies (e.g. brain tumours, CVA). Myoclonias appear 
later than the somato-motor seizures. The EEG has normal background 
activities with local spikes or spike-wave activity. Apart from a possible 
progressive course of the underlying cause, the patient remains stable and 
does not exhibit a progressive hemiparesis or dementia. The second type of 
EPC concerns children of 6-10 yrs, with a malignant progressive course of 
illness. It is characterized by partial motor seizures, which become rapidly 
associated with myoclonic jerks. Involvement of muscle groups is frequently 
bilateral and multiple seizure types may be seen. The EEG background 
deteriorates and shows diffuse slow wave activity. Progressive hemiparesis 
and dementia become evident with multiple cerebral lesions on the cerebral 
scan. Prognosis is poor. Evidence for a viral origin of this second type is not 
conclusive; suggestive are signs of a chronic infectious disease (Dulac et al, 
1983) and the results of acyclovir (Ragazzo et al, 1991). The second type of 
EPC has been described also in adult patients (Gray et al, 1987). 
Löhler and Peters (1974) described three cases of EPC of their own and 
159 patients from the literature, in the 75 years since the original description 
of Kojewnikoff in 1895. In the early years, EPC was especially described by 
Russian authors and linked to viral encephalitis (Russian spring-summer 
encephalitis). Another group of patients with EPC, presumably caused by 
a virus, came from Canada. The condition was called Rasmussen’s chronic 
encephalitis but no infective agent has been identiﬁed until now (Oguni et 
al, 1991). Rasmussen’s chronic encephalitis and the Russian spring-summer 
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encephalitis are two distinct entities, both clinically and pathologically; 
both may result in continuous focal motor seizures. Apart from encephalitis 
various other causes have been described such as metabolic disturbances, 
brain tumours, CVA and head trauma. Progressive neurological diseases 
such as mitochondrial encephalomyopathy with lactic acidosis and stroke-
like-episodes (MELAS) should also be considered (Andermann et al, 
1986). Other examples of rare causes of EPC are cryptococcal meningitis 
with EPC of the abdomen (Chalk et al, 1991), EPC following metrizamide 
cisternography (Shiozawa et al, 1981), cortical dysplasia with very therapy-
resistant EPC (Desbiens et al, 1993; Nakken et al, 2005), Sjögren syndrome 
(Bansal et al, 1987), EPC associated with non-ketotic hyperglycaemia (Singh 
and Strobos, 1980).
In a cortex biopsy of a case with EPC type II, Verhagen et al. (1988) found 
patchy necrosis in the deeper cortical layers and the cortico-subcortical 
boundery. Microangiopathy with perivascular lymphocytic cufﬁng was a 
striking ﬁnding, suggestive of an inﬂammatory disorder.
Age distribution shows two peaks, one around twenty and one around sixty 
years. There is no gender preference.
Clinically myoclonic jerks in EPC are especially present in the face 
and in the arms. When present in extremities, distal involvement is more 
frequent than more proximal. The frequency of the myoclonus is in most 
cases 60-90/min. with varying amplitude. They may be rhythmic or 
arrythmic and are in most cases (77%) continuously present. In the jerks 
agonists and antagonists are co-activated unilaterally, and they are by 
deﬁnition spontaneous, but voluntary movement and sensory stimulation 
can worsen the myoclonus, sleep sometimes lessens them (Thomas et al, 
1977; Löhler and Peters, 1974; Biraben and Chauvel, 1997). Neurological 
examination of the patient shows in most cases abnormalities (94%), 
especially motor or sensory. Impairment of consciousness is present in few 
and varies from confusion or drowsiness to stupor and coma. In cases with 
severe impairment of consciousness another type of SE besides EPC may be 
present. Cases with severe impairment of consciousness (coma) may also 
include subtle GCSE or myoclonic SE in coma. This is probably the case in 
several patients from the review of Thomas et al (1977).
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The diagnosis of EPC is primary a clinical one. In cases the EEG shows 
no speciﬁc abnormalities, EEG-EMG back-averaging techniques may 
demonstrate the relation between speciﬁc EEG activity and the resulting 
myoclonus (Hajek et al, 1991; Cowan et al, 1986; Chauvel et al, 1986; Kuroiwa 
et al, 1985). Apart from the CT-scan and the MRI, SPECT (Tatum et al, 1991; 
Katz et al, 1990) and PET (Hajek et al, 1991; Cowan et al, 1986) also may 
demonstrate focal lesions. This may be important with regard to therapy 
because conventional anti-epileptic drug treatment is not very successful 
in EPC and in case of a clear focal origin surgical treatment may offer more 
success in non-progressive cases (type 1 according to Bancaud, 1982).
Caution is needed in cases with focal abnormalities on CT-scan or MRI 
because in some these abnormalities are temporary, due to edema and 
hypervascularisation, which disappear after control of seizures (Dillon et 
al, 1984; Samaritano et al, 1985; Hormigo et al, 2004). 
3.5.3.3 Other types of SPSE
Other types beside somatomotor SPSE or EPC have been described 
(Gastaut, 1983; Stefan, 1990), but mainly in case reports. The scalp EEG is 
often uncharacteristic; PET and SPECT may provide helpful information. 
The following types have been described: somatosensory SPSE (Sailer et 
al, 1991); psychic SPSE (Sailer et al, 1991; Henriksen, 1973); cognitive SPSE 
(Matsuoka et al, 1986; Regard et al, 1985; Hojo and Fukushima, 1979); 
vegetative (or autonomic) SPSE (Sailer et al, 1991); visual SPSE (Barry et 
al, 1985; Oishi et al, 2003); auditory SPSE (Schiffter and Straschill, 1978); 
olfactory-gustatory SPSE (Wieser et al, 1985). Aphasic SE with global 
aphasia (Wells et al, 1992; Thomas et al, 1991; Jongsma and Vanneste, 1991; 
Primavera et al, 1988; Dinner et al, 1981), motor aphasia (Jongsma and 
Vanneste, 1991; Gregory Hamilton and Matthews, 1979 or Wernicke aphasia 
(Knight and Cooper, 1986).
3.5.3.4 Incidence of SPSE and EPC
SPSE and EPC are rare; an estimation of the incidence has not been provided, 
contrary to various other types (Shorvon, 1994). Recent epidemiological 
studies of SE have mentioned incidence numbers of partial SE, but none 
about EPC. Prospective studies suggest an incidence of SPSE of 3.0 – 9.4 
per 100.000 inhabitants (DeLorenzo et al, 1996; Coeytaux et al, 2000; 
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Knake et al, 2001). Extrapolating these ﬁgures to the Netherlands one may 
expect at least 480 cases every year. These numbers will especially concern 
partial motor SE (including many cases with EPC); other types of SPSE are 
less likely to be recognized and reported. 
3.5.3.5 Outcome of SPSE
Outcome of SPSE and EPC depends especially upon the underlying cause. 
Usually the seizures in SPSE are self-limiting, but recurrence is often noted. 
Many cases with EPC continue to show convulsive movements despite 
medical therapy; sometimes surgical excision seems to offer the only hope 
of remission. Emergency treatment of EPC and other types of SPSE, along 
the same lines as described for GCSE, is usually unnecessary and often 
ineffective.
Until recently no convincing evidence was present that SPSE can result 
in secondary neuronal damage in humans. The incidence of SPSE and EPC 
is, however, low and most cases are symptomatic. It has been proven that in 
animals not only focal limbic SE, but also extra-temporal focal seizures can 
cause neuronal damage (Collins and Olney, 1982; Lothman, 1990; Ben-Ari, 
1997). Distant neuronal damage produced by seizure spread (especially in 
the hippocampus) has been observed.
What is the evidence for morbidity because of the epileptic 
discharges themselves in humans with SPSE?
a. Clinical case-report
A female patient of 44 yrs suffered from partial epilepsy, because of a head 
injury. A baseline MRI showed focal atrophy left frontal. She developed 
SPSE, consisting of her habitual seizures every 5-10 minutes, without 
medical complications, with duration of 5 days. When SPSE stopped, 
permanent contra-lateral hemi-paresis was present. MRI after SPSE showed 
no changes. This case-report suggests that prolonged focal ictal activity by 
itself can produce permanent neurological damage (Borchert and Labar, 
1995).
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b. Neuro-pathological investigations
Neuro-pathological investigations of human cases with SPSE or EPC without 
an acute symptomatic cause are hardly available.
A female patient with chronic obstructive pulmonary disease, acute 
pneumonia and systemic hypoxia showed SPSE involving the right arm and 
leg during four weeks. She died because of respiratory insufﬁciency. Neuro-
pathological exam showed neuronal damage (of recent origin) conﬁned to the 
left hemisphere. It was suggested that hypoxia and the increased metabolic 
demand because of SPSE caused this damage (Knopman et al, 1977).
Other case-reports obviously did not die because of simple partial motor 
seizures; they showed other features besides focal motor seizures (several 
medical complications or coma), suggestive of secondary generalisation 
(Soffer et al, 1986; Leiffer et al, 1991; Fujikawa et al, 2000). That is why these 
results cannot be included in the discussion about the relation between SPSE 
and neuronal damage. Neuro-pathological investigations in SPSE, without 
an acute symptomatic cause and without other complicating features, are 
not available at this moment. 
c. Neuro-imaging
Local or distant neuronal damage (seizure spread) has been observed in some 
patients with SPSE: contralateral cerebellar atrophy after SPSE (Duncan et 
al, 1990); neuronal damage in the hippocampus after focal motor SE (Tien 
and Felsberg, 1995; Meierkord et al, 1997); a gliotic area (left subcortical 
pre-central gyrus) after right sided partial-motor SE (Placidi et al, 2001); 
progressive atrophy of the left hippocampus after SPSE characterized by a 
permanent amnestic state (Adam et al, 2001).
Decreased levels of N-acetyl-aspartate (NAA) indicates neuronal loss or 
dysfunction; proton MR spectroscopy (MRS) in a patient with SPSE (visual 
seizures) showed permanent decreased levels of NAA in the occipital region, 
even after one year, probably caused by the continuous epileptic discharges 
during SPSE. Fazekas et al (1995) mentioned a corresponding result in a 
patient with focal motor SE, which persisted after a period of GCSE.
The case-report and the results of modern neuro-imaging techniques 
in SPSE suggest a relation between continuous local discharges and 
corresponding local, but also secondary, neuronal damage. The incidence 
of this complication will probably be low, because aetiology in most cases 
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of SPSE is acute symptomatic and the incidence of SPSE itself is low too. In 
an individual case the probably low risk of neuronal damage will have to be 
balanced against the possible risk of AED morbidity.
3.6  Status Epilepticus in Children
3.6.1 Introduction
The immature brain is more prone to seizures, but less vulnerable to the 
long term effects of prolonged seizures; protection of the developing brain 
from seizure induced damage is, however, not absolute (chapter 3.4.3.) Apart 
from acute neuronal damage, seizures can induce long-lasting, potentially 
adverse functional changes in the immature brain that may not appear 
acutely as injury (Sanchez and Jensen, 2001).
Status Epilepticus (SE) in the neonate differs greatly from that in later 
childhood or adult life, both from the clinical and the electrophysiological 
points of view. Apart from that, the causes and anatomic-pathological 
basis are also distinct. The incidence of seizures in the neonate is very high 
(1,8-5,1 per 1000 live births). It is estimated that about 33% of the neonates 
with seizures show SE. Outcome in neonates is especially determined by 
the aetiology (Mizrahi, 1999). Because of these unique features and the fact 
that we did not include neonates in our study, we will not discuss SE in the 
neonatal period.
3.6.2 Epidemiology
The problems of case-ascertainment have been discussed in section 3.3. In 
children SE is often the ﬁrst epileptic event, reﬂecting the high incidence of 
acute aetiologies and febrile status (Aicardi and Chevrie, 1970; Phillips and 
Shanahan, 1989). The younger the child, the higher the percentage of acute 
symptomatic causes of SE (Phillips and Shahanan, 1989). In 394 children 
SE occurred more often in the age group of less than 2 yr (>40%). In these 
young children an acute symptomatic or febrile cause was present in more 
than 80%, whereas cryptogenic and remote symptomatic causes were more 
common in older children. A history of previous seizures or the presence 
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of previous neurological impairment was more common in older children 
(Shinnar, 1997). The risk of epilepsy following SE is increased in acute and 
remote symptomatic cases, but not in idiopathic SE (Gross-Tsur and Shinnar, 
1993). Epilepsy following SE is present in 20-32% of the children (Maytal 
et al, 1989; Erickson and Koivikko, 1997; Novak et al, 1997; Sillanpää et 
al, 1998). In population-based studies SE was present in 10% (Berg et al, 
2004) to 27% (Sillanpää and Shinnar, 2002) of the children with epilepsy. 
The occurrence of SE did not modify mortality or remission of epilepsy 
(Sillanpää and Shinnar, 2002)
The highest incidence of SE in childhood is in the neonatal period; the 
frequency then falls, to reach a plateau after the ﬁrst 5 years of life. With 
increasing age convulsive activity will be less fragmentary and electroclinical 
correlation will improve. Apart from age, an abnormal cerebral development 
also will inﬂuence the clinical and electrophysiological expression. 
The incidence in the paediatric population can be estimated at 20-38 
per 100.000 (DeLorenzo et al, 1996; Hessdorffer et al, 1998; Coeytaux et al, 
2000). The most frequent type of SE was GCSE (DeLorenzo et al, 1996). The 
incidence in children is higher than in the adult (15-59 years) population, but 
lower than in the elderly (> 60 years). The incidence in very young children 
(< 1 year), however, is the highest of all age groups. The Netherlands has 
a population of 191.000 children of less than 1 year; the total paediatric 
population is 2.858.000 (CBS, 1998). Based on these numbers one can 
calculate the number of children, which will have SE: every year at least 570-
1086 children. In the age group of less than 1 year this number is 257. The 
number of children that will die every year because of SE (and/or because of 
the underlying aetiology) is at least 14-27. 
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3.6.3 Types of status epilepticus
The most frequently occurring type of GCSE is TCSE. Other types of 
generalized SE (tonic SE, clonic SE, myoclonic SE) have been described only 
occasionally because of their relatively rare occurrence (Roger et al, 1972; 
Roger et al, 1974; Gastaut, 1983; Shorvon, 1994; Othahara and Ohtsuka, 
1997). 
Table 13: General characteristics of SE in children. Morbidity referred 
to new neurological problems, including epilepsy
Aicardi/ 
Chevrie 
1970
Hayakawa 
1979
Vigevano 
1985
Yager 
1985
Dunn
1988
Phillips/ 
Shanahan 
1989
Maytal 
1989
Number 239  67  84  52  97 193 193
Type of SE GCSE GCSE GCSE
NCSE
EPSE
GCSE
NCSE
EPSE
GCSE GCSE GCSE
NCSE
EPSE
Duration(min) >60 >60 >30 >30 >30 >30 >30
Age (years) <15 <15 <13 <18 <14 <18 <15
Previous  
Epilepsy (%)
 23  83  16  35  49  29  32
Causes (%)
Acute 
symptomatic
 26  16  42  30  15  43  23
Remote 
symptomatic
 21 −  45  36  57  10  29
Idiopathic  52 −  13  32  28  46  48
Febrile  28 −  6  21  16  32  24
Mortality (%)  11  3  6  6  7  6  3
Morbidity(%)  57  24  21  25  19  ?  9
3.6.3.1 Tonic-Clonic Status Epilepticus (TCSE)
Tonic-clonic and clonic (hemi-clonic) SE are the most prevalent types of 
generalized convulsive SE (Aicardi and Chevrie, 1970; Dulac et al, 1985; 
Vigevano et al, 1985). More than 75% of the children with convulsive SE 
have an age of three years or less (Aicardi and Chevrie, 1970; Fuyiwara et al, 
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1979; Hayakawa et al, 1979). The greater part (50 - 75%) never had seizures 
before (Aicardi and Chevrie, 1970; Fuyiwara et al, 1979; Hayakawa et al, 
1979; Yager, 1988). Except for the studies of Aicardi and Hayakawa neonates 
(age less than 28 days) were excluded in most studies (Aicardi and Chevrie, 
1970; Hayakawa et al, 1979). The types of SE were limited to convulsive 
SE except for the studies of Vigevano et al (1985), Yager et al (1985) and 
Maytal et al (1989), who included cases with non-convulsive SE (NCSE) 
too (table 13). Three other reviews concerning SE in children are rather 
different from the rest; they concern children of 28days- 1year (Cavazzuti et 
al, 1984; Aubourg et al, 1985) or 28days - 2 years of age (Dulac et al, 1985). 
These studies in very young children stressed the high incidence of acute 
symptomatic causes of SE in this age group. Mortality was strikingly low in 
the study of Cavazzuti et al (1984), whereas mortality in the group of Dulac 
et al (1985) was high in comparison to the studies mentioned in table 13, 
concerning children of all age groups and to the study of Morton et al (1998) 
in children aged less than 1 year.
The acute symptomatic group consists of central nervous system 
infections, metabolic problems, anoxia and head trauma (DeLorenzo et al, 
1992; Dulac et al, 1985; Vigevano et al, 1985; Cavazzuti et al, 1984; Aicardi 
and Chevrie, 1970). The prospective study in Virginia (DeLorenzo et al, 1996) 
reported the following causes of SE in children: systemic infections (52%), 
low AED (21%), CVA (10%), remote symptomatic causes (38%), hypoxia 
(5%), metabolic (7%), CNS infection (2%), idiopathic (5%). Mortality was 
only present in cases with systemic infections (5% of this group). Low AED 
levels as a cause of SE in children may be not so frequent as presumed; 
in a group of 51 children with epilepsy and SE in only 9 (18%) all levels 
of AED were sub-therapeutic (Maytal et al, 1996). With respect to the 
pathophysiology, the medical complications and of neuropathology in TCSE 
we refer to chapter 3.4.
3.6.3.2 Febrile status epilepticus (FSE)
FSE is one of the commonest forms of convulsive SE in young children; most 
are younger than 13 months. FSE occurs more often in children with pre-
existing neurological or developmental problems. Febrile seizures occur in 
2-5% of the children; 5% of these have FSE of 30 min duration, 0,5% of 
60min duration (Hauser, 1990). FSE should be distinguished from acute 
symptomatic SE with fever, such as in encephalitis or meningitis.
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The seizures in FSE are clonic or tonic-clonic and are often focal or unilateral. 
FSE can be followed by a Todd’s paresis or occasionally by permanent 
neurological deﬁcit. The risk for subsequent febrile or afebrile seizures is 
increased in neurologically abnormal children with FSE; this is not the case 
in normal children (Maytal et al, 1990).
Until recently, the outcome of FSE appeared to be poor (Aicardi and 
Chevrie, 1970; Aicardi and Chevrie, 1983). Permanent hemiplegia or 
hemiparesis, mental retardation and epilepsy as a result of prolonged FSE 
had been described in a high number of patients; duration appeared a 
critical factor (Aicardi et al, 1969; Roger et al, 1972). More recent studies 
have reported a far better outcome; post-convulsive hemiplegia in FSE 
appeared rare, which is difﬁcult to explain solely by improved therapy. The 
conﬂicting data were due to patient selection bias. 
In a follow-up study in a cohort of 14676 neonates 398 (2,7%) had at 
least one febrile seizure (FS). The risk of later afebrile seizures was much 
greater in children with lengthy febrile seizures (21%) than in children with 
febrile seizures lasting less than 30 minutes (3,4%). This study (Verity et al, 
1993) also mentioned cognitive deterioration after lengthy febrile seizures 
in 2 out of 37 children (morbidity 8%). The author discussed this problem in 
a review about SE associated with fever and, apart from one atypical case, 
found no evidence of poor intellectual outcome in those who had been normal 
before the lengthy attacks (Verity, 1997). Cognitive investigations did not 
show deterioration in children with FSE of 1 hour or more duration (Nelson 
and Ellenberg, 1976) or with FS of long duration (Ellenberg and Nelson, 
1978) or in children with recurrent or prolonged episodes of FS (Verity et al, 
1998). Children with prolonged FS (>20min) did worse in nonverbal tests in 
comparison to single FS and controls. Children with multiple recurrences 
of FS performed poorer in all tests (Kolfen et al, 1998). A prospective study 
from a population survey of 4340 live-birth newborns in Taiwan reported 
that complex or recurring FS were no risk factors for working memory 
deﬁcits (Chang et al, 2001).
Esch et al (1996) mentioned 24% neurological sequelae after FSE. This 
study was retrospective; it concerned 57 children with a ﬁrst episode of FSE 
in 10 years, admitted to a University Hospital. None had previous epilepsy 
or a neurologically abnormality. In 9 speech defects were detected, in 3 
serious neurological sequelae (psychomotor, epilepsy). FSE might have been 
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the ﬁrst presentation of epilepsy in these 3 cases. The neurological sequelae 
were obvious directly after FSE in 5 children, but only much later in 7 cases 
(4-14 months after FSE). This study provided important information about 
long-term follow-up with respect to outcome. A prospective study during 
12 years reported the results of FSE in 180 children, age 1 month-10yrs 
(Shinnar et al, 2001). The results were compared to a group of 244 children 
with FS (168) and complex partial seizures (76). Outcome in this study was 
evaluated at 30 days; no morbidity or mortality was present. Considering 
the results of the study of Esch et al (1996) morbidity during longer follow-
up cannot be excluded, although the prospective population-based studies 
did not provide evidence for this assumption (Verity et al, 1998; Chang et 
al, 2001). 
FSE in children has an overall good outcome in most cases; neuro-
imaging has proven that in some cases neuronal damage may occur because 
of the prolonged seizures themselves (VanLandingham et al, 1998). Pre-
existing alteration of medial temporal lobe structures may be important in 
this respect (Fernandez et al, 1998; Scott et al, 2003). The risk of subsequent 
epilepsy is increased in cases of lengthy FS, compared to simple FS (Maher 
and McLachlan, 1995).
3.6.3.3 Non-Convulsive Status Epilepticus (NCSE)
NCSE consists of GNSE and because of the clinical presentation many 
authors discuss CPSE also as part of NCSE. In most cases NCSE occurs 
in children with previous epilepsy. The diagnosis of NCSE may be very 
troublesome because of the lack of familiarity with NCSE, the subtlety 
of clinical manifestations in some cases and the relatively non-speciﬁc 
nature of the mental changes often seen (Stores et al, 1995; Manning and 
Rosenbloom, 1987).
The clinical presentation may show an obvious change in behaviour with 
reduction in activity, slowness, impairment of consciousness, confusion, 
semi-stupor or pseudo-dementia; sometimes additional ataxia or jerks. 
In other children the change may be more subtle, such as mild clouding 
of consciousness, even in the presence of gross EEG abnormality. Clinical 
features alone are not sufﬁcient to determine the type of NCSE. It is very 
important to consider the diagnosis of NCSE in children with the above-
mentioned clinical features, because therapy may suppress the epileptic 
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activity and improve quality of life. Therapy may also halt further mental 
deterioration. 
GNSE includes typical ASE and atypical ASE.GNSE may present severe 
diagnostic problems, especially in mentally retarded patients. In mentally 
retarded patients with epilepsy, such as children with West or Lennox-
Gastaut syndrome, atypical ASE is the most frequently occurring type of 
GNSE. Other types of SE in these children are TSE, TCSE and MSE.
Atypical ASE
The clinical presentation of GNSE in mentally retarded children is diverse 
and sometimes very subtle. Essential is a change in behaviour and/or 
awareness, in combination with ataxia, dysarthria, drooling, myoclonic 
jerks or twitching and sleep disturbances. EEG investigation is necessary 
and may show several epileptic EEG patterns: multifocal spikes and 
spike-waves, diffuse spike and slow waves or poly-spike and slow waves. 
According to some authors (Dravet et al, 1985; Beaumanoir et al, 1988), 
GNSE in patients with Lennox-Gastaut syndrome (LGS) has no inﬂuence 
on outcome in comparison to patients without GNSE. Several other studies, 
however, have described children with mental deterioration after one or 
more periods of GNSE (Moe, 1971; Doose and Volzke, 1979; Doose, 1983; 
Manning, 1987; Stores et al, 1995). From their papers however a possible 
already present pathological process can not be excluded. A recent study in 
patients with LGS reported that the presence of NCSE in LGS with respect 
to mental outcome is important (Hoffmann-Riem et al, 2000). 
Therapy of atypical ASE is often without effect. Benzodiazepines (BDZ) 
are only helpfull in some cases; an increase of tonic seizures because of BDZ 
has been reported (Livingston and Brown, 1987).
Typical ASE
Typical ASE is relatively rare in children. Most are already known to suffer 
from idiopathic generalized epilepsy with absences and/or generalized 
tonic-clonic seizures, without any neurological impairment. A typical 3 Hz 
pattern may be present, but other more irregular patterns are no exception. 
Most patients are slow, drowsy, show some automatisms or myoclonic jerks. 
Consciousness may vary from a slightly delayed respons to complete lethargy. 
Benzodiazepines are successfull in most cases. Precipitating factors include 
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infections (mostly respiratory), medication problems and stress; in rare 
cases it is provoked by eye-closure (Aguglia et al, 1985). Duration does not 
exceed 24 hours in most cases. Cognitive deterioration after typical absence 
SE in children has not been established.
NCSE in patients with coma without overt clinical seizure 
signs 
In 2 children with coma but without any overt clinical seizure signs, NCSE 
had been diagnosed. No difference was present in outcome or causes 
between cases with or without NCSE (Towne et al, 2000).
Complex partial status epilepticus (CPSE)
CPSE in children is recognized by impairment of consciousness, emotional 
or behavioural problems, lack of response to familiar persons, lip smacking, 
picking at nearby objects and focal clonic activity. EEG investigation is 
necessary, in order to distinguish it from ASE and psychiatric problems. 
Unresponsiveness and brief head nodding seizures may characterize NCSE 
in children with partial epilepsy, resembling atypical ASE (Ohtsuka et al, 
1999). CPSE may also occur in infants (McBride et al, 1981). CPSE in children 
has not been described often; in 8 studies 18 children with CPSE have been 
described, all with EEG conﬁrmation (Mayeux and Lueders, 1978; McBride 
et al, 1981; Balenger et al, 1983; Shalev and Amir, 1983; Mikati et al, 1985; 
Fukunishi et al, 1988; Ogunyemi et al, 1988; Wakai et al, 1995). This group 
of 18 children from different studies had an age from 15 months to 13 years; 
duration in most cases (13) varied from 30 min. to 4 hours, 6 children had a 
duration of more than 7 hours. Two of them had a very long CPSE (one child 
of 2 days, the other of more than 60 days). Previous epilepsy was present 
in 10 cases, previous mental retardation in 10. The recurrent type was the 
most prevalent (10 cases). In most children the cause remained unknown 
(9); other causes were fever (3), head trauma (1) and problems with AED 
(2). One child developed CPSE after removal of a craniopharingeoma. The 
focus of CPSE was the temporal lobe in most cases, three cases showed 
an occipital origin, one child a frontal. Outcome in the total group of 19 
children was good in 14, unknown in 2, one child showed language delay. 
In 2 children without previous epilepsy, unprovoked seizures recurred 
after CPSE. Epilepsy may have been started with CPSE in these cases, not 
caused by CPSE. The case with language delay after CPSE concerned a child 
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of 5 years, without previous epilepsy or mental retardation. The cause of 
CPSE remained unknown. Duration of CPSE was 3 hours, the focus was 
left temporal. A relation between morbidity and CPSE from left temporal, 
although not considered, might have been possible; other causes were 
excluded (Shalev and Amir, 1983).
Apart from complex partial SE, generalized NCSE should be 
distinguished from an acute confusional state (Amit, 1988), from prolonged 
postictal encephalopathy (Biton et al, 1990) and acute confusional migraine 
(Gascon and Barlow, 1970).
3.6.3.4 Simple Partial Status Epilepticus (SPSE)
Simple partial SE is rare in children and is in most cases (75%) somatomotor 
in expression. Consciousness is not impaired. EPC is mainly limited to 
already neurologically impaired children (Bancaud et al, 1982). Two types 
of EPC are discerned (Bancaud et al, 1982; Bancaud, 1985). Progressive 
unilateral encephalopathy of childhood (Rasmussen’s syndrome) is often 
accompanied by EPC; early hemispherectomy should be considered (Vining 
et al, 1993). However, the ultimate outcome can be limited by the progressive 
nature of the underlying cerebral disease. Other types of SPSE in children 
are rarely reported.
3.6.4 Outcome of convulsive SE
The outcome of convulsive SE is especially determined by its cause. Outcome 
in children is better than in adults and the elderly (DeLorenzo et al, 1996). 
In all age groups the underlying cause is the main factor that determines 
outcome. The particular properties of the developing brain, especially the 
neuronal plasticity, are important with respect to the more favourable 
outcome in children.
Other factors of importance are: 
1.  Age (Aicardi and Chevrie, 1970; Dulac et al, 1985; Maytal et al, 1989; 
Phillips and Shanahan, 1989). Both Maytal et al (1989) and Phillips and 
Shanahan (1989) considered this a reﬂection of the greater incidence 
of acute neurological disease in the younger age groups. Mortality in 
children less than 1 year is higher (13,2%) than in children of all age 
groups (Morton et al, 1998).
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2.  Duration (Erikkson et al, 1997; DeLorenzo et al, 1992; Yager, 1988; Dunn, 
1988; Aicardi and Chevrie, 1970). Maytal et al (1989) is the only one who 
mentions duration as a signiﬁcant contributor with respect to outcome 
of SE in the acute symptomatic group only. Duration of SE in relation to 
outcome appeared less important in the prospective study in Virginia. 
In children with prolonged seizures (10-25 min) mortality was absent, 
whereas mortality in SE was 4%. The difference was, however, not 
signiﬁcant. In adults, especially in the elderly, duration was signiﬁcantly 
related to outcome, irrespective of aetiology (DeLorenzo et al, 1999)
3.  In adults the continuous type of SE is negatively correlated to mortality; 
in children this is not the case (Waterhouse et al, 1999).
4.  Outcome is not related to sex, peripheral WBC count, serum glucose, 
arterial pH or CSF WBC count in children (Dunn, 1988). 
Total mortality in 5 studies (table 13) is 5,8% and morbidity 22,7%; acute 
symptomatic causes are present in 84% and 55% respectively (Vigevano 
et al, 1985; Yager, 1988; Phillips and Shanahan, 1989; Maytal et al, 1989; 
Dunn, 1988). Mortality appears to decline since 1970. Mortality of only 
2,5% has been reported by DeLorenzo (1996). However, one has to consider 
differences in the deﬁnition of SE, the time course between SE and death 
or differences in periods after which new neurological signs are depicted. 
The time course in the study of Aicardi and Chevrie (1970) between SE and 
death was 1 year, in Maytal et al (1989) 3 months and in another study 2 
years (Dulac et al, 1985). Vigevano described new neurological signs after 
a period varying from 6 months to 7 years after SE (Vigevano et al, 1985). 
With differences like these it is hard to compare the results. With respect 
to outcome in SE it is very important to distinguish outcome because of the 
underlying cause or because of the longstanding seizure activity itself. It 
is also difﬁcult to distinguish mortality related to the epileptic discharges 
from the effect of the medical complications. 
What results are known from studies that have investigated 
neuronal damage because of SE itself? 
a. Case reports
1.  One of our patients, a boy of six years old and normal development, 
never showed seizures until 2 days after the start of headache and fever. 
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He had convulsive SE during a stay at the home of his grandparents. The 
general practitioner prescribed paracetamol because of the fever. After 7 
hours of convulsive SE he was transferred to a near-by academic hospital, 
still in SE, conﬁrmed by the EEG. Respiratory insufﬁciency was present 
at the presentation. Thiopentone was necessary with a partial result; 
midazolam was successful in the remainder focal seizures. A cause 
could not be found, despite extensive investigations, including MRI. He 
was admitted half a year later to an epilepsy centre because of refractory 
epilepsy, cognitive decline and behaviour problems. A second MRI was 
normal; his IQ was only 60 with global deterioration. The EEG showed 
generalized slow activity (4-6Hz). His seizures reacted favourable to 
the combination of valproate and lamotrigin. At the age of 11 years no 
changes were reported with respect to cognitive functioning. 
 Conclusion: global cognitive decline because of inadequately treated 
GCSE of at least 7 hours duration. 
2.  A child of 5 years developed partial SE of 5 days duration, followed by 
GCSE during 5 days. A Ct-scan made 24 hours before the start of SE, 
because of a ﬁrst partial seizure was normal. The child developed an 
acquired opercular syndrome (anarthria, dysphagia, difﬁculties with 
chewing, bilateral facial weakness, drooling), neuro-imaging during 
follow-up (Ct-scan at age 6, MRI at age 16) showed bilateral parietal 
brain lesions. This case study suggests a relation between brain lesions 
and SE itself (Pascual–Castrovejo et al, 1999).
3.  A boy, 3 yrs, with an uncomplicated medical history, developed 
generalized convulsive SE with duration of 6 weeks. During SE no medical 
complications occurred. He died because of sepsis. During SE MRI was 
performed several times. The ﬁrst MRI showed no abnormalities. At day 
16 the MRI showed T2 hyperintensities in both hippocampi; at day 27 
this was seen too, but also in both amygdala and fornices. He died at day 
44. Pathological examination showed neuron loss and gliosis in both 
hippocampi, especially in CA1, CA3 and CA4 and in the amygdala on 
the right and in the middle layers of the cerebral cortex (Stafstrom et al, 
1996).
b. Retrospective and prospective studies of groups of children
Aicardi (1986): from the original group of 239 children with SE, 118 were 
evaluated in the acute phase and followed for 1 year or more. This retrospective 
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study is difﬁcult to comment: 142 were seen during or immediately following 
SE, 97 were examined weeks to years after SE. The authors did not specify 
the results with regard to these two groups. Mortality some years after SE is 
hard to attribute to SE itself; this study, however, attributes half of 17 deaths 
occurring long after SE to SE itself. The 10 cases that died during their SE 
are not speciﬁed whether they were seen in the acute phase or not. Morbidity 
and mortality related to SE are hard to calculate for this reason. Morbidity 
because of SE was hard to establish; the results in the cryptogenic group are 
worthwhile in this respect: 25% in this group had mental retardation and/
or neurological deﬁcit, which was not present before SE.
Several other reviews about SE in children have reported outcome related 
to SE itself (Dulac et al, 1985; Vigevano et al, 1985; Yager, 1988; Dunn, 1988; 
Maytal et al, 1989; Phillips and Shanahan, 1989; Erikkson and Koivikko, 
1997; Shinnar et al, 2001). Four studies were retrospective (Vigevano et 
al, 1985; Maytal et al, 1989; Phillips and Shanahan, 1989; Erikkson and 
Koivikko, 1997). Mortality because of SE was low: 0-2%. Morbidity varied 
from 0-9%. Morbidity (motor dysfunction, visual ﬁeld deﬁcits, cognitive 
regression) did not include epilepsy following SE (Dulac et al, 1985; Dunn, 
1988; Yager, 1988; Maytal et al, 1989; Erikkson and Koivikko, 1997). In the 
retrospective study of Erikkson and Koivikko (1997) major neurological 
sequela (hemiparesis) that might have been attributed to SE, were present 
in 1 child with FSE (1,5%). The text however, did also mention minor to 
moderate neurological sequelae (cognitive and/or behavioral problems, 
motor deﬁcit) present in 4 children with idiopathic or febrile SE and 
increased disability in one child with FSE. Total morbidity attributed to SE 
can thus be calculated at 7,7% and not 1,5%. Epilepsy following idiopathic 
or febrile SE was present in 7 children; SE might be considered as the initial 
seizure in the evolution of epilepsy, rather than epilepsy being secondary to 
SE.
c. Neuropathology
Neuropathological studies of children who died during or shortly after SE 
have shown acute changes in the hippocampus, cerebellum, the cerebral 
cortex and thalamus. The changes were more striking than in adult 
patients (Scholz, 1951; Meyer, 1955; Small and Woolf, 1957; Norman, 1964; 
Radermecker, 1967; Corsellis and Bruton, 1983; Tien et al, 1995; Stafstrom 
et al, 1996). 
Chapter 3
86
d. Neuro-imaging studies
Pneumo-encephalography in 17 of 19 children with various types of SE 
showed signiﬁcant degrees of ventricular dilatation, which appeared during 
follow-up, resulting from atrophy, not because of pre-existing hydrocephalus 
(Aicardi, 1983; Aicardi, 1969). 
A Ct-scan study in 20 children directly after SE showed local edema in 7 
cases corresponding to the epileptic focus; a control scan several weeks later 
showed local atrophy at that spot, suggesting neuronal damage (Gastaut, 
1977).
In children (Stafstrom et al, 1996; Tien and Felsberg, 1995; 
VanLandingham et al, 1998; Herrgard et al, 1999; Lansberg et al, 1999) 
follow-up MRI-studies have shown that longstanding epileptic discharges 
can result in neuronal damage, especially in the hippocampus. Several 
types of SE have been mentioned: GCSE (Stafstrom et al, 1996; Tien and 
Felsberg, 1995), CPSE (Lansberg et al, 1999) and FSE (VanLandingham et 
al, 1998; Herrgard et al, 1999). These MRI studies have provided evidence 
that neurological damage may be caused by continuous epileptic discharges 
in both GCSE (Stafstrom et al, 1996; Tien and Felsberg, 1995) and CPSE 
(Lansberg et al, 1999). Recent studies of GCSE in children showed temporary 
edema in the hippocampus in febrile SE, but not in non-febrile SE (Scott et 
al, 2002; Scott et al, 2003). During follow-up the volume declined, but it 
remained undetermined whether this was caused by damage or whether it 
concerned a pre-existent small hippocampus. 
e. Neuron-Speciﬁc Enolase (NSE)
Little information is present about NSE in children with SE. No relation was 
present between duration of seizures and the levels of NSE. In the partial 
seizure group, but not in the generalized, cerebrospinal ﬂuid (CSF) levels 
of NSE showed a strong correlation with duration, the same goes for CSF/
serum ratio of NSE (Tanabe et al, 2001). A prospective study in 25 previously 
healthy children with their ﬁrst SE reported normal CSF-NSE values in all; 
increased serum-NSE seemed to be related with long SE, but both seizure 
and neuro-developmental prognosis seemed to be good (Herrgård et al, 
2001).
Several case-reports have shown that SE itself may be very deleterious to 
children. Especially MRI studies have been able to show that neurological 
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damage may be caused by the discharges themselves. NSE-levels in children 
appear not to be useful as a marker for outcome.
3.7 Cognitive deterioration in Children and
 Electrical Status Epilepticus during Slow Sleep
3.7.1 Introduction
Electrical Status Epilepticus during Sleep (ESES) consists of sleep-induced 
paroxysmal EEG activity, lasting several months or years, which may appear 
continuously or discontinuously during sleep and is usually diffuse bilateral. 
ESES is typically of the developmental age, appearing between the age of 3 and 
14 years. The paroxysmal activity may also be present during wakefulness, 
usually in the form of sporadic generalized or focal abnormalities. These cases 
have apparent clinical manifestations, such as typical or atypical absences, 
myoclonic or atonic seizures. The most typical paroxysmal discharges of 
the EEG during sleep are spike-wave (SW) complexes with a frequency of 
1.5-3.5 Hz. ESES can develop in several childhood epileptic conditions, but 
ﬁnds its more peculiar expression in some nosological forms, recognized in 
the classiﬁcation of the International League against Epilepsy (ILAE). The 
better-deﬁned syndromes are Continuous Spikes and Waves during Sleep 
(CSWS) and acquired aphasia or Landau-Kleffner syndrome (LKS). ESES 
may also be present in Benign Childhood Epilepsy with Centro-Temporal 
Spikes (BCECT).
CSWS was ﬁrst described by Patry et al (1971) as subclinical “electrical 
status epilepticus” induced by sleep in children. They described six children 
with epilepsy, who showed cognitive regression and whose EEG during sleep 
showed a pattern of continuous electrical status epilepticus. Later, Tassinari 
et al (1977) used the term “electrical status epilepticus during sleep” in 
children or ESES. In 1983 this acronym was replaced by CSWS (continuous 
spikes and waves during sleep).
Landau-Kleffner Syndrome (LKS) was ﬁrst described in 1957 in six 
children (Landau and Kleffner, 1957). LKS, or acquired epileptic aphasia, is 
characterised in children with epilepsy by verbal auditory agnosia, quickly 
followed by a regression of spontaneous speech, behavioural disorders and 
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an EEG during sleep that is similar in many ways to that of CSWS. In 1989 
both CSWS and LKS were included in the International Classiﬁcation of 
Epilepsies and Epileptic Syndromes of the ILAE.
Epilepsy and epileptiform activity can cause cognitive and behavioural 
disorders. Studies of this relationship have revealed a more or less 
direct time link between cognitive disturbances and the diffuse or focal 
epileptiform abnormalities (Aldenkamp and Arends, 2004). Even (very) 
brief discharges of a few seconds, without clearly perceptible clinical 
symptoms, can result in cognitive retardation (Aarts et al, 1984). In CSWS, 
given the nocturnal epileptic abnormalities, this direct time link between 
epileptiform abnormality and cognitive functioning is not clear. There 
are however several indications that a relationship does exist between 
continuous nocturnal discharges and a regression in cognitive functioning, 
or behavioural problems (Billard et al, 1990; Marescaux et al, 1990; Roulet 
et al, 1991; Jayakar and Seshia, 1991; Roulet Perez et al, 1993; Morrell, 1995; 
Rouselle and Revol, 1995). When evaluating the scientiﬁc research into the 
effects of CSWS on behaviour and on cognitive development we are faced with 
a number of methodological problems. Firstly, the clinical phenomenology 
is still insufﬁciently clearly deﬁned. Secondly, children with CSWS are only 
sporadically neuropsychologically examined before onset of the syndrome, 
which makes pronouncements about an eventual regression problematic. 
Finally, there are major test-psychological differences. Very often only the 
intellectual level is examined and not the other cognitive aspects, such as 
language functions. There is also insufﬁcient conformity in the test material 
employed. Despite these methodological problems, a syndrome description 
does seem to be possible (Billard et al, 1990; Jayakar and Seshia, 1991; 
Rouselle and Revol, 1995; Smith, 1997).
Rouselle and Revol (1995) discussed the results of 209 children with 
ESES and distinguished 4 groups. The degree of epileptic activity during 
sleep was expressed in an index, which is determined by the total duration 
of the continuous epileptic activity in relation to the total non-REM sleep 
duration (spike-wave-index).
1.  Children (35) with epilepsy and a normal initial neurological state, 
without any cognitive deterioration, despite the occurrence of continuous 
epileptic activity during sleep with an average spike-wave-index of 71%. 
The main electrical focus showed rolandic topography.
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2.  Children (33) who developed language deterioration, in 28 corresponding 
to LKS. The average spike-wave-index was 76%, the main electrical 
focus was temporal.
3.  Children (99) with an initial normal neurological state who developed 
global cognitive deterioration and severe epilepsy. The average spike-
wave-index was 80%, frontal regions were the main focus of paroxysmal 
abnormalities.
4.  Children (42) with focal or diffuse brain lesions who showed global 
deterioration, with an average spike-wave-index of 80% and a frontal 
main focus. This group has been described the least accurately and is 
mostly included in the third group. 
The ﬁrst group has been described by Aicardi and Chevrie (1982) and 
reviewed by Panayiotopoulos (1999) as atypical benign partial epilepsy of 
childhood. 
Children from the second group have been described as Landau-Kleffner 
sydrome, children from the third and fourth group as CSWS. In this review 
the term ESES will be used only to make clear the presence of an electrical 
status epilepticus during sleep, which may be present in several syndromes 
with different clinical presentations.
3.7.2 Children with global deterioration, behavioural
 problems and continuous epileptic activity during 
 slow sleep: CSWS (Billard et al, 1990; Jayakar and Seshia, 
 1991; Tassinari et al, 1992; Bureau, 1995; Rouselle and Revol, 
 1995; Smith, 1997; Veggiotti et al, 1999)
Continuous spikes and waves during slow sleep (CSWS) is an age related 
childhood syndrome characterized by the triad of (1) continuous spikes and 
waves during slow sleep, (2) seizures, and (3) cognitive decline. In a small 
number of children, however, seizures never occur. 
The incidence and prevalence of CSWS is unknown. A Japanese study 
found a CSWS pattern in 0.5% of the children with epilepsy studied 
(Morikawa et al, 1989). A family history of epilepsy is uncommon. It occurs 
more often in boys than in girls. In 20% to 30% of patients there is evidence 
of pre-existent brain damage, caused for example by meningitis or a birth 
trauma. In 30% of patients the CT-scan or MRI shows abnormalities. 
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Stage I (before discovery of CSWS): The majority (80%) of the children 
is known with previous partial epilepsy, with mainly partial motor seizures 
or sometimes unilateral SE. Other seizure types are less often reported 
and include absences, generalized tonic-clonic seizures or complex partial 
seizures. The onset of the epilepsy occurs between the 1st and the 10th year, 
with an average age of 4 to 5 years. Most (75%) have no previous cognitive 
handicap or behavioural problem. The EEG shows focal or multifocal spike- 
and slow-wave activity or generalized spike-wave activity. During sleep 
the epileptic activity increases, sleep patterns and cyclic organisation are 
preserved.
Stage II (CSWS): The diagnosis CSWS is made around 1 to 2 years 
after the onset of the epilepsy. The children are then between 4 and 14 years 
old, with an average age of 8 years. Seizure exacerbation is often present, 
with various seizure types, including atypical absences, absence SE, atonic 
or clonic seizures, oro-facial and generalized tonic clonic seizures. Tonic 
seizures are never noted. Cognitive regression manifests itself in (usual-
ly serious) diffuse and/or speciﬁc deterioration, primarily of language 
functions but also of temporo-spatial orientation and memory. Behavioural 
problems are present with concentration disorders, hyperkinesia, aggression 
and inhibition disorders. 
The EEG during daytime shows abundant slow spike-wave activity, 
focal and/or multifocal spike and/or spike-wave activity. The main epileptic 
focus is often frontal or parieto-occipital. The EEG during sleep shows 
continuous diffuse bilateral slow spike-wave activity (1½-2 Hz, sometimes 
3-5 Hz). Poly-spike-wave activity or bursts of fast rhythmic activity are 
absent. This pattern only disappears in the REM phase, during which the 
same focal activity may be seen as in the daytime. The various sleep stages, 
with the exception of the REM-phase, cannot be distinguished. The spike-
wave index ranges from 85-100%. The duration of the nocturnal pattern is 
not always easy to determine and requires a complete sleep registration. 
These symptoms persist for anything from a few months to several years 
(Bureau, 1995). One study mentions an average duration of 18.6 months 
with complete recovery, and of 22.3 months in children with partial recovery 
(Dalla Bernadina et al, 1989). 
Stage III (remission): Around the 12th year the EEG during sleep 
normalises. In one third of patients the epilepsy persists. In 50% of patients 
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the cognitive prognosis is unfavourable (Bureau, 1995; Praline et al, 2003). 
The prognosis is better in patients with a shorter CSWS duration (Dalla 
Bernadina et al, 1989; Bureau et al, 1990). A link with the severity of the 
epilepsy has not been proven; nor could the presence or absence of cerebral 
lesion or the age at which the diagnosis CSWS was made be related to the 
prognosis (Tassinari et al, 1992).
Treatment results of CSWS
The anti-epileptic drugs valproate and/or benzodiazepines have a positive 
effect in some cases with CSWS and cognitive regression (Smith, 1997; 
Yasuhara et al, 1991). Incidental positive results have been reported with 
corticosteroids, ACTH, ethosuximide, clomipramine and amphetamine 
(Maresceaux et al, 1990; Billard et al, 1990; Okuyaz et al, 2005). Negative 
results, or even deterioration, have been reported with carbamazepine, 
phenytoin, and phenobarbital (Boel and Casaer, 1989; Maresceaux et al, 
1990; Veggiotti et al, 1999).
3.7.3 Children   with    acquired    speciﬁc    cognitive    disorders 
 and continuous  epileptic  activity  during  sleep
The best-known group is with speciﬁc language disorders, the Landau-
Kleffner Syndrome (LKS). There are also occasional reports of children 
with ESES and other speciﬁc cognitive disorders, such as dyspraxia and 
non-verbal learning disorders, speciﬁc attention disorders and acquired 
opercular syndrome (Billard et al, 1994; Motte et al, 1994; Shafrir and 
Prensky, 1995).
LKS or acquired epileptic aphasia is a severe, partly reversible, age-
related childhood clinical syndrome with mainly linguistic decline and 
neuropsychological abnormalities as the main clinical symptoms. The ﬁrst 
description has been reported by Landau and Kleffner (1957) under the 
name acquired aphasia with convulsive disorder. In the literature about 
300 cases have been described. The prevalence of this rare syndrome is 
not known; one study mentioned a prevalence of 0,2% in a cohort of 440 
children with epilepsy (Kramer et al, 1998). A family history of epilepsy is 
present in 12% of the children with seizures; this is reduced to 5% in cases 
without seizures. Boys are twice likely to suffer from it than girls.
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Seizures occur in three-quarters of the patients, but these are usually 
infrequent and of good prognosis. Seizure onset is between 4 and 6 years. 
Seizure types include partial motor and generalized tonic-clonic, other types 
have been less often described (atypical absences, atonic, complex partial). 
Isolated or single SE may occur. Subtle seizures have been reported during 
video-EEG recording and are characterized by isolated clonic deviation of 
the eyes or subjective behavioural manifestations (Morrell, 1995).
The EEG during daytime is characterized by mainly posterior temporal 
foci of sharp and slow waves, which are often multifocal and bisynchronous. 
The EEG during slow sleep shows continuous diffuse spike-wave activity, but 
with a lower index than in CSWS (average 76%). The main activating focus 
has been located in the intrasylvian region of the dominant hemisphere 
(Morrell, 1995; Paetau et al, 1999). The EEG normalises after the age of 15 
years. 
The neuropsychological dysfunction is speciﬁc, namely an acquired 
aphasia (Landau and Kleffner, 1957; Hirsch et al, 1990; Paquier et al, 
1992; Deonna and Roulet, 1995; Smith, 1997). Most of the children are 
initially normal and achieved developmental milestones at appropriate 
ages, including speech. The language disorder begins with a regression in 
language comprehension (verbal auditory agnosia), followed by problems 
of expression that occasionally result in total mutism. Apart from language 
regression short-term auditory memory disturbances have been noted 
(Robinson et al, 2001). If the language disorder begins after the age of 
nine, the nature of the disorder is more expressive than receptive and the 
prognosis is more favourable (Gerard et al, 1993). Sometimes the symptoms 
are confused with autism or deafness. The ﬂuctuating course of LKS with 
exacerbations and remissions makes any assessment of treatment results 
problematic. Most (80%) of the children present behavioural disorders, 
such as hyperactivity and aggression, in which it is not clear to what extent 
these are secondary to the communication problem. Behaviour disturbance 
may be associated with the presence of frontal lobe discharges in the awake 
EEG (Robinson et al, 2001). Diagnostic imaging techniques such as CT-scan 
or MRI usually show no abnormalities. 
Language and other neuropsychological disturbances gradually 
improve at the same age as the disappearance of EEG epileptiform activity. 
The prognosis is favourable for 30% of the children; the rest show no or 
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only partial recovery. Half of the children continue to present serious social 
problems. The prognosis is worst in children with a very young age of onset 
and in children with considerable delay in treatment. Sometimes there is a 
spontaneous recovery, but this does not occur when the clinical picture has 
been present for more than a year. Language outcome was good in only three 
of eighteen cases; all had impaired short-term memory at follow-up. No 
child with duration of the electrical status epilepticus during sleep lasting 
more than 3 years had normal language outcome (Robinson et al, 2001).
Treatment of LKS
The treatment of seizures in LKS does not present many problems. 
Treatment is instituted to reduce the epileptiform EEG abnormalities on 
the assumption that these are responsible for the cognitive and behavioural 
abnormalities. Valproate, ethosuximide, benzodiazepines and cor-
ticosteroids have produced positive results, but not always permanent (De 
Marco, 1988; Maresceaux et al, 1990; Lerman et al, 1991; Aykut-Bingol et al, 
1996; Yalcin et al, 1995). Incidental positive results have been reported with 
felbamate, nicardipine-nimodipine, sulthiam and intravenous treatment 
with gamma globulins (Pascual-Castroviejo et al, 1992; Yalcin et al, 1995; 
Glauser et al, 1995; Fayad et al, 1997; Lagae et al, 1998; Mikati and Saab, 
2000). In a group of 18 children with LKS AED had no effect on language 
or behaviour; corticosteroid therapy was successful in two of nine cases 
with respect to seizures, behaviour and language (Robinson et al, 2001). 
Some anti-epileptic drugs appear to have an adverse effect: carbamazepine 
and phenytoin; phenobarbital had no effect (Maresceaux et al, 1990). Most 
authors advice to start with valproate, ethosuximide and benzodiazepines, 
alone or in combination; when this fails corticosteroids are started. Duration 
of corticosteroid therapy depends on the results and may be months to years, 
in order to avoid escape (Maresceaux et al, 1990). 
Some children with LKS have been successfully treated neurosurgically 
with multiple subpial transections (Morrell, 1995; Sawhney et al, 1995; Irwin 
et al, 2001). Morrell (1995) applied this technique to 14 patients with LKS. 
Several techniques were used to establish the area of primary epileptogenic 
activity. The Methohexital Suppression Test (MST) and the intracarotid 
amobarbital test provided information about the driving hemisphere. The 
origin of the epileptic discharges could be established with dipole mapping 
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and simultaneous recording of EEG and MEG (magneto-encephalography). 
The origin appeared to be located on the dorsal surface of the superior 
temporal gyrus, essentially in the auditory association cortex, which was 
conﬁrmed by electrocorticography during the MST procedure. MST of 
this unilateral Sylvian site resulted in disappearance of the epileptiform 
discharges bilaterally (Morrell, 1995). The intrasylvian location of the 
pacemaker in LKS has been conﬁrmed by other studies (Paeteau et al, 1999). 
The 14 children with LKS, who underwent MST by Morrell et al (1995), were 
subject to a follow-up study (Grote et al, 1999). Eleven children showed 
signiﬁcant improvement on measures of receptive or expressive vocabulary. 
The most obvious difference between children who did and did not show 
signiﬁcant improvement was the length of time between surgery and the 
most recent evaluation. Patients tested 2 or more years after surgery showed 
signiﬁcant more improvement than if tested a few months after surgery. 
Signiﬁcant improvement did not occur when tested within 6 months after 
surgery. All children continued to have reduced auditory attention span. 
The effects of surgery are difﬁcult to disentangle from the natural history 
of LKS. 
MST was also applied to 5 children with LKS with dramatic effects on 
seizures and behaviour and only minor effects on language (Irwin et al, 
2001). Improvement of language occurred in all 5 children, but none to an 
age-appropriate level. The mean length of the period with ESES was 4.6 
years with a range from 3 to 6 years. MST did have an important effect 
on behaviour, which, according to the authors, justiﬁes the procedure. The 
timing of surgery in patients with LKS requires further study; intervention 
within 3 years was suggested.
3.7.4 Pathogeneses of CSWS and LKS
The cause of these age-related syndromes is unclear. It has proved impossible 
to point to any speciﬁc cerebral lesions that could be held responsible for the 
syndrome in a range of patients. Comprehensive examination of numerous 
patients has so far yielded inconclusive results. Many researchers consider 
the prolonged epileptic discharges to be responsible for the speciﬁc cognitive 
problems or overall deterioration. The EEG shows bilateral synchrony 
arising from an epileptic focus; the initial topography and the duration of the 
A review of the literature on status epilepticus
95
continuous epileptic activity during slow sleep causes the neuropsychological 
disorder (Paeteau et al, 1999). It is known that the basal network of the brain 
develops between the ages of 1 to 8 years. If disturbances take place during 
this period, this may result in permanent impairment of this network. The 
number of axons and synapses in this age group is approximately twice 
as many as in adults. Abundant epileptic activity causes a reinforcing of 
synaptic contacts that should normally disappear during this period. This 
causes disturbance of the normal functioning of the area in which this 
epileptic activity is concentrated. In the case of CSWS this is probably the 
frontal region, which results in disorders of various higher cognitive and 
behaviour regulatory functions. In LKS it is the temporal lobe that results 
in speciﬁc language disorders. Over time this dysfunction can spread across 
a wider area of the brain and thus give rise to other disorders. Because the 
epileptic activity is bilateral the disturbed function cannot be taken over by 
the contra-lateral homotopic cortex (Smith, 1997). If the continuous local 
EEG abnormalities during sleep do not spread but remain local, cognitive 
disorders are less often described (Galletti et al, 1992). 
Bilateral synchrony from an epileptic focus as an important feature of the 
pathogeneses of CSWS and LKS has been demonstrated by the following 
results:
a.  Intravenous injections of benzodiazepines cause disappearance of the 
continuous spike-wave series (which indicates, amongst other things, 
that this is no sleep variation) and emphasise a clear frontal focus in 
children with global deterioration (Tassinari, 1995; Kobayashi et al, 
1988).
b.  The autonomous epileptic focus from which the secondary bilateral 
synchrony arose could be determined by means of methohexital 
suppression test, intracarotid amytal, EEG dipole mapping, MEG and 
electrocorticography during MST (Jayakar and Seshia, 1991; Park et al, 
1994; Morrell, 1995; Patil and Andrews, 1998; Paeteau et al, 1999).
c.  Involvement of the temporal lobe in LKS has been demonstrated by 
SPECT studies (Guerreiro et al, 1996) and PET studies (Rintahaka et al, 
1995; Da Silva et al, 1997). A PET study in CSWS demonstrated a focus 
right temporo-parietal (Park et al, 1994).
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A link between ESES and the cognitive or behaviour disturbances has been 
demonstrated by the following results:
a. If the ESES pattern on the EEG disappears (under the inﬂuence of AED 
for example) cognitive functioning and behaviour improves (Pelliccia 
et al, 1989; Maresceaux et al, 1990; Roulet et al, 1991; Yasuhara et al, 
1991).
b.  The results of multiple subpial transection in LKS (Morrell, 1995; 
Sawhney et al, 1995; Irwin et al, 2001).
Other researchers argue for a link with a speciﬁc cause, such as a tumour 
or an inﬂammation. (Perniola et al, 1993; Solomon et al, 1993; De Volder et 
al, 1994). Pathological anatomical examination of received material has so 
far revealed nothing speciﬁc (Cole et al, 1988; Smith et al, 1992). There is 
thus sufﬁcient reason to postulate that it is the age at which the syndrome 
develops, the localisation of maximum epileptic activity and the bilateral 
spread of the epileptic activity that determine the clinical picture and not a 
particular aetiology.
An interesting study in 4 children with LKS showed a reduction of 
36-51% in the cortical volume of the superior temporal areas, using MRI 
volumetric analysis. These areas correspond to the auditory association 
cortex. There was no left or right hemispheric preponderance, but the 
volume reduction was greater on the side with more epileptiform activity 
in two children (Takeoda et al, 2004). The focal atrophy may explain why 
long-term prognosis is often poor. Further research is necessary to answer 
the essential question whether the atrophy is the cause of LKS or the 
consequence of excitotoxicity.
3.7.5 Differential diagnosis
Pervasive development disorder and autism: Although children with these 
disorders may also show epileptic abnormalities on the EEG, there is no 
cognitive regression and no CSWS. Autistic epileptiform regression (AER) is 
an exception to this rule. These children often show epileptic abnormalities 
on the EEG, usually multifocal and over a wider area than in LKS. Multiple 
subpial transections have proved successful in a number of these children, 
suggesting a relation between epileptic activity and cognitive regression 
(Patil and Andrews, 1998). 
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Lennox-Gastaut Syndrome (LGS): Patients with LGS more often present 
neurological abnormalities and mental retardation from an early age. These 
children do have tonic seizures. The EEG during sleep shows an increase 
of slow spike and wave, but not to the same extent as in CSWS. The EEG 
during sleep also shows fast discharges, which does not occur in CSWS.
Benign Childhood Epilepsy with Centrotemporal Spikes (BCECT): On the 
EEG during sleep this syndrome can show a strong increase in epileptic 
activity. This is sometimes continuous, but with a lower index than in CSWS. 
The focus of the EEG activity in BECT lies in the centro-temporal areas. 
Until recently cognitive disorders were seldom reported in children with 
BCECT. A few recent studies mention cognitive problems (visual perception, 
attention and short term memory) and behaviour disturbances in BCECT 
(Weglage et al, 1997; Croona et al, 1999; Ong and Wyllie, 2000). A relation 
between cognitive deﬁcits and the frequency of the spikes has been suggested 
(Weglage et al, 1997). A single cognitive proﬁle was not identiﬁed. Children 
with difﬁculties at school improved together with improvement of the EEG 
(Deonna et al, 2000). In two children with Benign Childhood Epilepsy with 
Occipital Spikes (CEOP) continuous occipital spike-wave activity during 
the day (which disappeared with eye opening) and continuous generalized 
spike-wave activity during sleep was demonstrated, with a disruption of 
their epilepsy and behaviour accompanied by overall cognitive regression 
(Tenembaum et al, 1997). 
3.8 Status Epilepticus in Mentally Retarded
 Patients
3.8.1 Prevalence and incidence of Status Epilepticus (SE) in 
 Mental Retardation (MR)
The prevalence of Mental Retardation (MR) in the general population has 
been subject of several studies (Roeleveld et al, 1997). The true prevalence 
rate for mild mental retardation (MMR, IQ 50-70) appeared much more 
difﬁcult to estimate than for severe mental retardation (SMR, IQ <50). The 
variation in prevalence rates of MR has been reported also in studies dealing 
with the occurrence of epilepsy in patients with MR. Life-time history of 
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epilepsy in MR varies between 14-24%. The variation in overall prevalence 
rates of epilepsy in MR is partly explained by the use of different deﬁnitions 
for diagnosing epilepsy and by the problem of case ascertainment. The 
prevalence of epilepsy in MR depends on the age group, the severity of MR 
and the associations with other neurological disorders. The prevalence of 
epilepsy in MR at age 10 was 1.9 per 1000, at age 22 years 2.1 per 1000 
(Airaksinen et al, 2000). The cumulative incidence of epilepsy in MR was 9, 
11, 13 and 15% at age 5, 10, 15 and 22 years, respectively (Goulden et al, 1991). 
In patients with MMR epilepsy was present in 15 %, in patients with SMR in 
45 % (Steffenburg et al, 1996). The prevalence of epilepsy in MMR increases 
when cerebral palsy is present or a postnatal cause had been established 
(Aikraksinen et al, 2000). 
According to Shorvon (1994) the risk of status epilepticus (SE) in patients 
with epilepsy and mental retardation is high. Little information about 
prevalence and incidence of SE in patients with MR is available, however. 
Some studies mentioned the prevalence of SE in a group of patients with 
MR:
− In 98 children (6-12 years) with MR and epilepsy SE occurred in 
37 patients (37 %), the recurrence rate was 35 %. Convulsive SE was 
present in 32 patients, non-convulsive in 5. (Steffenburg et al, 1996).
− In population of children and adults with MR and epilepsy the prevalence 
of convulsive SE was 18.7 % (Forsgren et al, 1990). 
− At 22 years of age 12,5 % of patients with MR and partial epilepsy had a 
history of SE (Airaksinen et al, 2000).
These ﬁgures are not very different from those in the total population. 
Hauser (1990) reported that 20% of patients with epilepsy from the total 
population would experience an episode of status epilepticus within 5 years 
of initial diagnosis of epilepsy. In a long term follow-up study of 245 children 
with epilepsy 32% showed status epilepticus (Sillanpåå et al, 1998). It should 
be noted, however, that many cases of SE in patients with MR would not be 
documented. This is especially the case for non-convulsive status epilepticus 
(NCSE), a diagnosis easily overlooked in patients with MR. 
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3.8.2 Types of SE in MR
In a retrospective study 39 mentally retarded patients with 86 episodes of 
SE were gathered in 8 years (Phillips et al, 1996). All were institutionalized 
developmentally disabled clients admitted to the acute care unit. All were 
known with previous epilepsy, 17 showed recurrent episodes of SE. The most 
frequent occurring type was tonic-clonic SE (88%), followed by myoclonic 
SE (7%), partial motor SE (3%), tonic SE and complex partial SE (1%). 
Causes or precipitating factors included intercurrent illness (41%), low anti-
epileptic drugs levels (17%), idiopathic (38%) and other (3%).
The most occurring type of SE in MR is Tonic-Clonic Status Epilepticus 
(TCSE). The clinical features and pathophysiology have been described 
(Shorvon, 1994). Some types of SE occur almost exclusively in MR such as 
atypical absence SE, tonic SE (TSE) and minor motor SE (Shorvon, 1994). 
Various syndromes with epilepsy and MR frequently show one or several types 
of SE. The best-studied type is Lennox-Gastaut-Syndrome (LGS). Patients 
with LGS have a high incidence of clinical evident SE (Beaumanoir et al, 
1988). TSE and atypical absence SE are the most frequently occurring types 
of SE in LGS. SE could be precipitated by under stimulation or polytherapy. 
Preceding SE, the patient showed an increase of tonic seizures during sleep, 
with slowness or tiredness during daytime. An increase of irritability was 
possible too. Various types of SE could be present; all showed confusion 
and could be accompanied by hypotonia, myoclonic jerks, tonic or astatic 
seizures. The EEG showed generalized slow spike-wave activity or diffuse 
10 Hz activity followed by slow spike-wave activity. Duration of SE varied 
from several hours to several weeks. Older patients with LGS also showed 
generalized convulsive SE. A syndrome with many clinical resemblances 
to LGS is myoclonic-astatic epilepsy (Doose syndrome). Patients with this 
syndrome have high incidence of absence SE.
The diagnosis of NCSE in MR may offer serious problems (Shorvon, 
1994; Brodtkorp, 1993).
The calculated annual incidence, 100-200 per million, suggests that 
many cases of NCSE will be overlooked with subsequent consequences for 
quality of life and cognitive deterioration. 
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Consciousness in NCSE may vary from a slightly decreased level to stupor. 
A spectrum of various other signs may be present: agitation, confusion, 
automatisms, apraxia, regressive behaviour, incontinence, tremor or 
myoclonic jerks. It is obvious that changes in the clinical presentation of 
patients with MR should raise the question whether NCSE may be present. 
EEG investigation should be considered, especially when other clinical 
features accompany changes in the level of consciousness. EEG investigation 
is also important to distinguish NCSE from post-ictal confusion or pseudo-
SE (Drake et al, 1992) and to establish the type of NCSE, CPSE or atypical 
ASE. Myoclonic SE (MSE) of long duration occurs in children with severe 
myoclonic epilepsy and in myoclonic epilepsy with non-progressive 
encephalopathy. MSE in patients with progressive myoclonic epilepsies 
has a comparable clinical expression as primary MSE. In these patients 
MSE may be precipitated or excacerbated by action or startle. Prognosis 
depends on the underlying cause (e.g. mitochondrial encephalopathy with 
ragged-red-ﬁbres, Lafora body disease and Unverricht-Lundborg disease), 
although not in all cases a speciﬁc cause can be found. MSE may also be 
present in patients with symptomatic generalized epilepsy, such as Lennox-
Gastaut syndrome (secondary MSE). This type has been reported as minor 
motor status (Brett, 1966). Secondary MSE is often asymmetrical and shows 
a variable extent of impairment of consciousness. Variable symmetric and 
asymmetric myoclonic jerks are seen in the limbs, trunk and eyes. Most 
children are obtunded and drooling; speech is absent or slurred. Sudden 
atonia may occur. Walking is unsteady (pseudo-ataxia). The EEG shows 
multifocal spikes and spike-wave discharges. Treatment is unsuccessful in 
most cases, and prognosis is poor. The clinical presentation and the results 
of EEG investigations make it sometimes difﬁcult to distinguish this type of 
MSE from atypical ASE (Othahara and Ohtsuka, 1997). 
3.8.3 Outcome of SE in MR
Outcome of convulsive SE in MR has not been subject of a separate study. Little 
is known about the causes of convulsive SE in MR. Morbidity in TSE is not 
known, mortality about 3%. It is not clear, however, whether or not cerebral 
damage results from Tonic SE. One case showed cognitive deterioration 
after TSE (Somerville and Bruni, 1983). Outcome of NCSE in MR is not 
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known. According to some authors (Dravet et al, 1985; Beaumanoir et al, 
1988), GNSE in patients with Lennox-Gastaut syndrome has no inﬂuence 
on outcome in comparison to patients without GNSE. Several other studies, 
however, have described children with mental deterioration after one or 
more periods of GNSE (Moe, 1971; Doose and Volzke, 1979; Manning, 1987; 
Stores et al, 1995). From their papers, however, a possible already present 
pathological process cannot be excluded. A recent study in patients with 
Lennox-Gastaut syndrome reported that the severity of mental retardation 
was related to the occurrence of NCSE, odds ratio 25 (Hoffmann-Riem et 
al, 2000).
3.8.4 Therapy of SE in MR
Therapy of convulsive SE in MR has not been a separate subject of research. 
Several authors have discussed therapy of NCSE in MR; the results were 
often disappointing (Shorvon, 1994; Brodtkorp et al, 1993; Beaumanoir et 
al, 1988; Brett, 1986). The use of ketamine, a NMDA-receptor antagonist, in 
NCSE may be of value (Mewasingh et al, 2003).
3.8.5 Conclusions
SE in MR has speciﬁc characteristics:
− The incompleteness of cerebral development.
− Speciﬁc aetiology of MR.
− Some types of SE occur only in MR.
− Some syndromes of epilepsy and MR show a high incidence of SE.
− Results of therapy of some types of SE. 
It is concluded that characteristics and incidence numbers of SE in the 
general population cannot simply be extrapolated to persons with MR. 
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3.9 Treatment of Generalized Convulsive Status
 Epilepticus
3.9.1 Introduction
First line drugs, such as benzodiazepines (BDZ) and phenytoin (PHT), are 
successful in 80% of the cases when therapy is started within 30 minutes 
after the start of the seizures; when therapy is started after 2 or more 
hours, ﬁrst line therapy fails in 60% of the cases (Walton and Treiman, 
1988; Lowenstein and Alldredge, 1993). Many authors state that therapy 
delay contributes to a longer duration (Treiman et al, 1983; Lowenstein et 
al, 1988). This is also the case for inadequate therapy (Delgado-Escueta and 
Enrile-Bascal, 1983; Celesia, 1983). Experimental results in animals have 
stressed the importance of adequate treatment of the medical complications 
occurring during the course of GCSE (Meldrum et al, 1973; Meldrum et al, 
1974; Siesjo and Wieloch, 1986). In these experiments it was shown that 
early intubation, mechanical ventilation and artiﬁcial paralysation (after 
1 hr) lessen the degree of hyperthermia and acidosis and prevent muscle 
necrosis, with less risks of renal failure and cardiac arrhythmias. In human 
studies the degree of metabolic acidosis did not correlate with outcome, 
hyperthermia on the other hand, caused a worse outcome (Aminoff and 
Simon, 1980). Treatment-protocols have been developed; although it is 
generally agreed that a long duration of SE aggravates outcome, the use 
of a time-schedule is still limited (Delgado-Escueta and Bajorek, 1982; 
Treiman, 1989; Working group on SE USA, 1993; Chin et al, 2003; Pellock 
et al, 2004). 
3.9.2 Which   drug  should   be   used   during   the   various   phases 
 of  generalized  convulsive  status  epilepticus?
3.9.2.1 Premonitory stage
Benzodiazepines (BDZ) are the drugs of ﬁrst choice for treatment in the 
premonitory stage and in the early phase of SE because of their speed of 
action and the relative absence of adverse effects. The choice which of the 
available BDZ should be used for treatment of SE is not based on clear 
differences with respect to clinical effect, because these differences are not 
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clearly established (Sorel et al, 1981; Tassinari et al, 1983; Treiman et al, 
1983; Leppik et al, 1983; Giang and McBride, 1988; Andermann et al, 1992; 
Appleton et al, 1995; McCormick, 1999; Qureshi et al, 2002). The choice will 
be determined by previous experiences, pharmacokinetic parameters and 
the presence of facilities for resuscitation. During the premonitory stage 
seizures become increasingly frequent or severe, treatment may prevent 
the evolution into true SE. Emergency situations require rapid intravenous 
administration of an appropriate AED; one frequently encounter situations 
in which adequate venous access is not available (home settings, long-term 
care facility) or would entail signiﬁcant time delays, especially in children. 
In such settings an alternative parenteral route would be desirable. Rectal 
administration of diazepam (Cereghino et al, 1998; Dreyfuss, 1998), buccal 
(Scott et al, 1997; Scott et al, 1998; Scott, 1999; Fernando et al, 2000) or 
subligual midazolam and nasal midazolam (O’Regan et al, 1996; Scheepers 
et al, 2000; Mahmoudian and Zadeh, 2004) are effective and safe modes 
of treatment during this stage. Before or during transport to the hospital 
paramedics may administer intravenous lorazepam or diazepam, with a 
preference for lorazepam (Lowenstein et al, 1999; Alldredge et al, 2001). 
When intravenous (i.v.) access is difﬁcult (e.g. small children) midazolam 
intramuscular (i.m.) may be considered (Chamberlain et al, 1997). The 
use of i.m. AED in the acute treatment of SE is limited to midazolam, with 
clinical effects within 2-3 min (Egli and Albani, 1981). One should anticipate 
respiratory depression after i.m. midazolam. Fos-phenytoin i.m. has a 
relatively slow onset of action, which limits its use for acute treatment of SE. 
The i.m. administration of fos-phenytoin in the prehospital situation, before 
transport to the hospital, appears to be safe and limits therapy delay. 
The use of paraldehyde (PA) is limited to rectal administration in the 
pre-hospital phase, as an alternative or sequel to diazepam or in situations 
where facilities for resuscitation are not available (Browne, 1983).
3.9.2.2 Early status epilepticus (0-30 min)
Once SE has developed, the patient should be admitted to the local hospital, 
with facilities for resuscitation and EEG monitoring. There is limited 
information about comparative prospective trials of different anti-epileptic 
drugs in the early phase of SE. 
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In a prospective double blind trial 395 adult patients with overt GCSE 
and 113 with subtle GCSE were randomly assigned to receive intravenous 
Lorazepam (LZP), Phenobarbital (PB), PHT or Diazepam (DZP) followed 
by PHT (Treiman et al, 1998). LZP was signiﬁcantly more effective than 
PHT in overt GCSE, other comparisons did not show signiﬁcant differences. 
Infusion-time is shortest in LZP (4,4min), followed by PB (16,6min), PHT 
(33min) and DZP+PHT (42min). No signiﬁcant differences were noted 
with respect to side effects. When the initial drug fails, little was gained 
by using other standard AED. One should consider rapid addition of i.v. 
general anaesthesia if initial treatment fails (Treiman, 1997). The results 
of this prospective study suggest that LZP is the drug of ﬁrst choice in the 
early phase of GCSE with regard to effect, speed of infusion-time and ease 
of use. It was striking that PB, which enters the brain slowly, was not less 
effective than LZP. Treatment with DZP should be combined with PHT to 
avoid recurrence of seizures within 10-20 min. PHT as the only drug in this 
stage is not recommended because of the slow onset of action and the long 
infusion-time. 
Together with BDZ, phenytoin (PHT) is a ﬁrst-line drug in the treat-
ment of GCSE. The advantage of PHT is its lack of sedative and respiratory 
depressant effect and the long duration of action. A disadvantage is the delay 
of onset of action, 10-20 min. In 80% of the patients the effect is present 
within 20 min (Cloyd et al, 1980). Duration of action after a loading dose is 
about 24 h or more. Recently fos-phenytoin (fos-PHT), which is watersoluble, 
has been tested in GCSE (Legarda et al, 1993; Boucher, 1996; Browne, 1996; 
Wilder, 1996; Pryor, 2001). Fos-PHT is rapidly and completely hydrolysed 
in the blood by phosphatases and converted to PHT (1,5 mg fos-PHT= 1mg 
PHT). The dose of fos-PHT (PE) is expressed as the amount of PHT when 
converted in the body (PE= PHT equivalent). Intramuscular administration 
is also possible. Conversion-time is 7-15 min intravenous and 30 min 
intramuscular. Therapeutic levels are reached after 10min (i.v.) and within 
30 min after i.m. administration. Local irritation has been rarely reported 
after i.m. administration (1-7%); 20cc have been tolerated fairly (Pryor, 
2001).The advantages of fos-PHT in comparison to PHT are a higher speed 
of loading, less local irritation after i.v. administration, the possibility of 
i.m. use and no cardiac rhythm complications (Fischer et al, 2003). 
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Although penetration of phenobarbital (PB) into the brain is relatively 
slow, clinical effects have been established within minutes (Goldberg and 
McIntyre, 1983). Blood levels over 20 mg/l are necessary; to abolish all ictal 
activity, much higher levels (over 70 mg/l) may be necessary (Walton and 
Treiman, 1989). The drawback of PB is the possible respiratory depression 
and its very long duration of action. Other adverse effects are sedation and 
less frequently hypotension. High dose PB therapy, with blood levels over 
70 mg/l was successful in children, although response latency was not 
mentioned and outcome poor (Crawford et al, 1988). A signiﬁcant shorter 
median cumulative convulsion duration and a signiﬁcant shorter median 
response latency was reported in comparison with DZP and PHT i.v. (Shaner 
et al, 1988). PB is a highly effective AED with a rapid onset and a prolonged 
action, with high concentrations in the active epileptic focus.
The use of lidocaine in GCSE until now has been limited to cases 
refractory to other drugs (De Giorgio et al, 1992; Pascual et al, 1992; 
Aggarwal and Wali, 1993). In patients with respiratory problems or in 
cases when respiratory support is not possible, lidocaine can be considered 
(Pascual et al, 1988). If successful, the effect is present within minutes; 
refractory cases after 1 injection hardly respond to repeat injections or an 
infusion. When seizures reappear after a ﬁrst successful injection, infusion 
may be considered. Because of possible cardiovascular effects, monitoring 
of ECG and bloodpressure is necessary. 
3.9.2.3 Established stage of status epilepticus (30-60 min.)
Patients in this stage of SE carry great risks for medical complications; 
treatment should occur at the Intensive Care Unit (ICU). Treatment until 
this stage will have consisted in most cases of BDZ and/or PHT. There are 
no adequate comparative trials of anti-epileptic drugs (AED) in this stage 
available. Several possible ﬁrst-line drugs may be considered: PHT or fos-
PHT, PB, MDZ-infusion and valproate (VPA). 
MDZ infusion has been successful in both children and adults, also in 
cases refractory to LZP, PHT or PB (Kumar and Bleck, 1992; Parent and 
Lowenstein, 1994; Claassen et al, 2001; Ozdemir et al, 2005). Seizure 
recurrence after control of SE should be anticipated, however (Singhi et al, 
2002).
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The use of VPA i.v. in SE has not been established, but is promising (Giroud et 
al, 1993; Czapinski, 1995; Seth and Gidal, 2000; Naritoku and Sinka, 2001; 
Limdi et al, 2005; Pohlmann-Eden et al, 2005). The onset of action has been 
shown to be more rapid than expected (Giroud and Dumas, 1988; Giroud 
et al, 1993; Peters and Pohlmann-Eden, 1999; Ueberall et al, 2000; Yu et 
al, 2003). The use of VPA i.v. appeared safe, also in elderly (Devinsky et al, 
1995; Ramsay et al, 1997; Wheless et al, l998; Sinha and Naritoku, 2000). 
In children VPA i.v. can be safely infused over a 30min period (Alvarez et 
al, 1999). In elderly VPA showed similar efﬁcacy in SE than PHT, although 
one should pay attention to possible side effects: trombocytopenia, cardiac 
arrhytmias, hyperammonemia and liver failure (Wedel et al, 2000). Further 
research is necessary to establish its place in the treatment protocol.
3.9.2.4 Refractory status epilepticus (after 60-90 min)
When seizures do not respond to one or two treatment regimens and 
continue 60-90 min after initiation of therapy in the stage of established SE, 
SE is considered refractory. Full anaesthesia is required, some have advised 
to start anaesthesia earlier (Treiman, 1997). First line drugs in this stage 
are thiopental and propofol, both with a considerable potential for adverse 
events. Adequate comparable trials of suitable drugs are not available. 
Thiopental may cause severe adverse events, especially during prolonged 
infusion. In comparison to propofol it showed a signiﬁcantly longer time to 
seizure control (Stecker et al, 1998). 
The use of thiopental in GCSE was described ﬁrst in 1967 (Brown and 
Horton, 1967). Various case reports and reviews have appeared since then 
(Osorio and Reed, 1980; Orlowski et al, 1984; Lowenstein et al, 1988; Ness, 
1990). The results of barbiturate coma are variable because of underlying 
diseases and the duration of GCSE previous to thiopental treatment. 
Most case reports or reviews concerning barbiturate coma in refractory 
GCSE describe patients who fail to respond to common ﬁrst line-drugs 
such as DZP and/or PHT. A large number of these patients have an acute 
symptomatic cause of GCSE (Yaffe and Lowenstein, 1993). A unanimously 
accepted protocol is not present. Characteristics of the EEG such as burst-
suppression nor the blood-levels, can be used to predict therapeutic efﬁcacy. 
A relation between drug-level and EEG, between drug-level and effect 
and between EEG and effect could not be established (Osorio and Reed, 
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1989). In patients with EEG-burst-suppression, clinical seizures were still 
present, whereas in other patients seizures were stopped without burst-
suppression. Adjustment has to be based on the presence of clinical seizures 
and or electrical seizures. Because the duration of bursts and of suppression 
segments during thiopental treatment are very variable, they cannot be 
related with the end of SE. One study suggested better results of attaining 
a ﬂat record in comparison to burst-suppression in patients with SE treated 
with barbiturate anaesthesia (Krishnamurthy and Drislane, 1999).
Most authors advise thiopental treatment after 1 - 2 h of GCSE, refractory 
to common ﬁrst line drugs, and the use of EEG-monitoring (aiming at burst-
suppression or an iso-electric-EEG) as a guideline. Duration of thiopental 
treatment should be limited because of the danger of severe adverse events 
(hypotension, paralytic ileus, various infections such as sepsis, increase 
of pCO2) and the lack of evidence that prolonged treatment offers better 
results. Especially patients with previous respiratory or cardiovascular 
problems may be poor candidates for barbiturate coma. Apart from the 
anticonvulsant effects, thiopental may lower intracranial pressure and 
cerebral metabolic rate of oxygen and glucose (CMR-O2 and CMR-gluc). 
The drug has a strong tendency to accumulate; recovery times may be very 
protracted. Treatment with thiopental implies admission at the Intensive 
Care Unit because of the need for mechanical ventilation, the possible use 
of vasopressors, a Swan-Ganz-catheter and the treatment of other possible 
medical complications, either related to the severity of SE and/or to the use 
of thiopental itself.
Propofol infusion during SE has been described in several patients, 
refractory to ﬁrst and/or second line drugs, such as DZP, clonazepam (CZP), 
PHT, PB, thiopental and chlormethiazole (Yanny and Christmas, 1988;Wood 
et al, 1988; Thomas and Morgan, 1989; MacKenzie et al, 1990; Kapadia and 
Grant, 1990; Borgeat et al, 1994; McBurney et al, 1994; Rosetti et al, 2004). 
Propofol and high dose barbiturates showed comparable results, but the 
time to seizure control was signiﬁcantly lower in the propofol group than in 
the barbiturate patient group (Stecker et al, 1998). In adult patients propofol 
and MDZ had comparable results in refractory SE (Prasad et al, 2001). In 
both children and adults propofol may cause metabolic acidosis, progressive 
myocardial failure, progressive hypoxia and rhabdomyolysis (Hanna and 
Ramundo, 1998; Cremer et al, 2001). Administration requires intensive 
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care facilities, including the possibility of mechanical ventilation. Prolonged 
infusion (> 24 hrs) of both thiopental and propofol should be avoided. 
Miscellaneous drugs used after failure of thiopental or propofol include 
chlormethiazole, etomidate and inhalation anesthetics
Chlormethiazole (CTZ) is a sedative-hypnotic drug with rapid anti-
epileptic effects and is freely soluble in water (Laxenaire et al, 1966; Bentley 
and Mellick, 1975; Lingham et al, 1981). It may be successful in cases 
refractory to BDZ, PB and thiopental (Nouailhat et al, 1985). Monitoring 
blood pressure, ECG and EEG is necessary. Haemodynamic monitoring 
(Swan Ganz) in cases of high doses is needed because of the large volumes 
of infusion. The possibility of mechanical ventilation should be present. 
CTZ has never been subjected to a formal comparative study. In most case 
reports it was used in combination with other drugs. The delay in onset of 
action may be 1 h, although a more rapid onset of action has been mentioned 
(5-30 min). Continuous infusion of CTZ is necessary to prevent recurrence 
of seizures (distribution half time 30 min.). 
Etomidate is a short acting non-barbiturate carboxylated imidazole with 
hypnotic and anticonvulsant effects. Conﬂicting results are present with 
regard to treatment of GCSE (Starre, 1980; Yeoman, 1989). On the other 
hand etomidate may cause involuntary muscle contractions, tremor and 
hypertonia at induction of sedation. Co-administration of opoids or BDZ is 
frequently necessary with continuous infusion of etomidate to avoid muscle 
contractions or even convulsive activity (Grant and Hutchinson, 1983). 
The use of etomidate in cases of delirium tremens caused myoclonia and 
generalized tonic-clonic seizures in 5 of 7 patients with EEG conﬁrmation 
of the epileptic nature (Nickel and Schmickaly, 1985).
The use of inhalation anaesthetics in GCSE is rare. The drawbacks 
of halothane are serious haemodynamic adverse events and potential 
hepatotoxicity. Isoﬂurane (0.5 - 2%) may offer a possibility in refractory 
cases (Kofke et al, 1989; Mirsattari et al, 2004). Althesin is an i.v. anesthetic 
consisting of two steroid derivates (alphaxalon, alphadolone). Only 2 studies 
report success in GCSE (Munari et al, 1979). 
 
A review of the literature on status epilepticus
109
3.9.3 Treatment according to protocol
Treatment of SE according to protocol has been increasingly promoted 
(Delgado-Escuate and Bajorek, 1982; Leppik, 1986; Treiman, 1989; Working 
group on SE U.S.A, 1993; Advanced Life Support Group, 1997; The Status 
Epilepticus Working Party, 2000). This does not always result however, in 
clinical application of treatment of SE according to protocol (Martland et 
al, 1998; Chin et al, 2003). A study in UK showed little agreement about 
treatment of SE in children; guidelines were absent or inadequate in 14 
different centres, in only 5 speciﬁc timing for drug treatment was mentioned 
(Martland et al, 1998). Cascino et al (2001) mentioned also the inappropriate 
use of therapeutic regimens. In the retrospective evaluation of therapy in 
184 cases, 72% received appropriate prompt medical treatment; in 76% the 
dose was less than recommended. The dose of the second treatment was 
inadequate in 80%.
It is considered essential by many to have a protocol with an adequate time 
schedule, in order to prevent unnecessary delay and to help to make a good 
choice between the various available drugs. This choice will be determined 
by speed of onset of action, duration of action and possible adverse effects. 
The anti-epileptic drugs used in the various phases may differ from one 
hospital to another, mainly based on previous experiences. Until recently 
comparative trials were lacking, contributing to the divergence in the used 
drugs. The current protocol has been based on the available literature 
on this subject, with special attention to available adequate comparative 
information and added with own experiences, especially when adequate 
comparative information was lacking (table 14a and 14b). 
3.9.3.1 Pre-hospital treatment
GCSE most often starts outside the hospital; adequate information about 
the clinical presentation and duration is important. Physical examination 
may reveal signs of respiratory depression, motor asymmetries or external 
wounds. The treatment of choice with BDZ i.v. may enhance the risk of 
respiratory depression, whereas intravenous access will be difﬁcult because 
of the convulsions. Rectal administration of DZP solution is the treatment 
of choice. Alternatives are midazolam (MDZ) i.m. and MDZ nasal or buccal. 
The use of BDZ i.v. by paramedics in the pre-hospital phase appeared safe 
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(Lowenstein et al, 1999; Alldredge et al, 2001) and in children caused a 
signiﬁcant decrease of duration of SE and of admission (Alldredge et al, 
1995). Intramuscular administration of fos-PHT may be considered to 
prevent treatment delay. When seizures persist 10 minutes after the rectal 
administration of DZP a second dose should be given and the patient should 
be transported to a local hospital with intensive care facilities. Recurrence 
of seizures after rectal administration of DZP after 20 - 30 min. is possible. 
Also in this case re-administration of the same amount of DZP and transport 
to the hospital is necessary. When the patient reaches the emergency room 
of a hospital all the measures taken in the pre-hospital phase and the 
transport to the hospital make it quite likely that at least one hour will have 
gone by since the onset of the GCSE. 
3.9.3.2 Hospital treatment
On arrival at the hospital (emergency room) careful observation and 
physical examination is necessary. Prompt treatment of respiratory 
depression, hypotension and hyperthermia prevents unnecessary damage. 
Start oxygen supply and prevent aspiration by lateral semiprone position; 
apply an intravenous catheter; in some cases early intubation is necessary. 
Because of the probable high levels of catecholamine concentrations 
ﬂuid administration in cases of hypotension is more appropriate than 
vasopressors (Benowitz et al, 1986). Treatment of acidosis will depend on 
systemic effects; even profound acidosis, however, has not been correlated 
with subsequent neuronal damage (Simon, 1985). In the mean time AED 
treatment should have been started; BDZ i.v. are ﬁrst choice because of the 
speed of action and their few adverse events. LZP the choice of preference 
in the early phase of SE. The dose in adults is 2- 4 mg (< 2mg/min) and 
in children 0,05-0,10 mg/kg (< 2mg/min). In the Netherlands clonazepam 
(CZP) is used more often than LZP. DZP is not advised because of the high 
incidence of seizure recurrence; when used it must be combined with PHT 
loading. The dose of CZP is initially 1 mg in 30 sec; when seizures persist 
after the ﬁrst 1 mg, repeated injections of 1 mg every 1 - 2 min. should 
be given. Failure, however, after 10 minutes of CZP use, means that PHT 
loading should be started. 
Apart from AED treatment other measures may have to be taken: in 
alcoholics and completely unknown patients thiamine 50 mg i.v. and i.m., 
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and glucose (50 ml 50%) administration is advised. Alcohol withdrawal 
is an increasing, although no major, cause or precipitating factor in GCSE 
(Pilke et al, 1984; Leppik et al, 1990). Apart from a thiamine deﬁciency, 
hypoglycaemia may be present too in alcoholics. Hypoglycaemia as a cause 
of GCSE or seizures has been reported (Malouf, 1985).
Thirty min. after admission to the emergency room, treatment according 
to this protocol will have stopped seizures in a large percentage of the patients. 
A part of them, especially elderly patients, have already been transported 
to the Intensive Care Unit (ICU), because of necessary monitoring (PHT 
loading) or mechanical ventilation. All those who still show seizures are 
transported to the ICU. Whenever possible, EEG monitoring should start as 
soon as possible, in order to monitor the effects of treatment and to establish 
a possible persistence of electrographic seizure activity. 
3.9.3.3 Intensive Care Unit
Before considering barbiturates, a continuous infusion of MDZ might be 
considered. During MDZ infusion intubation and mechanical ventilation 
may be necessary. EEG-monitoring is necessary to investigate the presence 
of epileptic discharges because electrical status epilepticus will also have 
to be treated even if motor signs are subtle or absent. If half an hour after 
arrival at the ICU the GCSE persists (and in some cases earlier), all patients 
should be intubated, curarized and mechanically ventilated in order to 
prevent or treat medical complications. Normo-ventilation is advised; 
hyperventilation is not necessary in most cases, whereas severe hypocapnia 
(PCO2 = 2Kpa) may prolong seizure duration (Bergsholm et al, 1984). Little 
is gained by using standard AED’s as subsequent treatment when the ﬁrst 
drug fails; rapid addition of general anaesthesia if the initial treatment fails 
appears logical (Treiman et al, 1997).
If seizures are still present (EEG-monitoring) after the use of MDZ 
infusion, general anaesthesia with propofol or thiopental treatment should 
be started. Others promote the use of PB before anaesthesia. Thiopental 
is administered via a central venous line. EEG monitoring is necessary, 
the dose of thiopental will be aimed at the amount which causes burst-
suppression. When necessary because of hypotension, dopamine and/or 
dobutamine is started, via a second central venous line. Loading of thiopental 
is usually completed in 1 hour; the duration of continuous infusion depends 
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on therapeutically success. We suggest to taper thiopental slowly after 12 
h; when seizures reappear, another period of burst-suppression is started, 
which will be maintained for 24 h and if necessary for 48-72 h. Failure after 
this is a grave sign; after 72 hours unsuccessful treatment switching to 
other drugs should be considered. Arterial blood pressure, and if possible 
intracranial pressure must be monitored. Haemodynamic monitoring (Swan 
Ganz) is useful.
Propofol is an alternative for barbiturate anaesthesia, with overall 
less serious adverse events and a much faster recovery. After a loading 
dose (2 mg/kg) a continuous infusion is started (5-10 mg/kg/hr), guided 
by the EEG. The dose should be reduced as soon as possible (to 1-3 mg/
kg/hr) because of danger of metabolic acidosis, myocardial failure and 
rhabdomyolysis. We suggest tapering 12 hours after seizure activity is 
halted. The use of propofol requires the same ICU facilities as thiopental: 
the possibility of assisted ventilation, monitoring of arterial blood pressure, 
EEG monitoring, monitoring central venous pressure.
Although case reports have described success of drugs in patients 
refractory to barbiturate coma the overall results are variable and generally 
disappointing. Important in this respect is the fact that most patients 
refractory to the above mentioned protocol concern acute symptomatic 
cases with an inherent grave prognosis. The literature on drugs used 
in cases refractory to barbiturates or propofol is limited to case-reports, 
adequate comparative trials are completely lacking. Examples of therapy in 
this stage are treatment with CTZ, isoﬂurane and etomidate. Other reported 
possibilities are VPA, LZP infusion and MDZ infusion. Prior experience 
with a certain drug may be decisive then. Our own experience with CTZ is 
limited but not unfavourable, in contrast to our experiences with etomidate. 
The possibilities of calcium-entry-blockers (nimodipine, ﬂunarizine) and 
NMDA-receptor-antagonists (MK-801, CGP-40116, NPC-17742, ketamine) 
should be further investigated, because they offer possible improvement of 
outcome, especially in these refractory cases (Bertram and Lothman, 1990; 
Walton, 1993; Walton and Treiman, 1994; Fujikawa et al, 1994; Borris et al, 
2000; Yen et al, 2004).
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Table 14a: Treatment of GCSE in adults according to protocol
Pre-hospital – Make sure you are dealing with seizures.
– Diazepam solution rectal: 10–30mg (0,5mg/kg).
– Check for causes or complications that make hospitalisation 
  mandatory. 
– Put patient in a lateral semi prone position.
– When seizures persist 10 minutes after diazepam introduction 
  arrange transportation to a hospital. 
Hospital 
Emergency Room: 
0-10 min.
– Observation, physical examination.
– Establish an airway, oxygen by mask.
– Lorazepam 2-4 mg i.v. or Clonazepam i.v. 1 mg. every 1-2 min. 
  Until seizures stop or respiratory depression becomes evident.
Hospital 
Emergency Room: 
10-30 min.
– Treatment of respiratory depression, hypotension, hyperthermia.
– Insert in-dwelling intravenous and arterial catheter.
– Blood for arterial blood-gas, anti-epileptic drug levels, glucose, 
  electrolytes, renal and hepatic function test, CPK, full blood 
  picture, drug-screen.
– Glucose 50% i.v. 50 ml, Thiamine HCL 50 mg. i.v. and i.m.
– If Lorazepam or Clonazepam fails after 10 min., start phenytoin-
  sodium 15-18 mg/kg, 50 mg/min.
– If half an hour after admission seizures continue: transport to      
  ICU.
Intensive Care 
Unit: 30-60 min.
– Endotracheal intubation; muscle relaxation (vecuronium), EEG 
  monitoring.
– Mechanical ventilation (normo-ventilation).
– Midazolam infusion: bolus 0,1-0,3 mg/kg (5-10 mg, 4mg/min), 
  followed by 0,05-0,40 mg/kg/hr.
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Table 14b: Treatment of GCSE in adults according to protocol
Intensive Care Unit: 
after 60 min.
– Thiopental 10-30mg/kg (50-100mg i.v. every 2-5 min), 
  maintenance dose 5-20 mg/kg/hr or Propofol bolus 2mg/kg, 
  followed by infusion 5-10mg/kg/hr, reducing to 
  1-3mg/kg/hr (EEG guided).
– EEG monitoring, Swan Ganz catheter.
– If possible intracranial pressure monitoring.
– If necessary dopamine, dobutamine (hypotension).
– Adjust ventilation (PCO2 may increase).
– Moderate hypothermia (35°C).
Intensive Care Unit: 
after 12 hours.
– Taper thiopental or propofol after 12 hr
– If seizure activity reappear increase thiopental or propofol 
  until burst- suppression and maintain another 24 hr 
– (If necessary a ﬁnal thiopental or propofol period of 
  48 hours).
Still no success: 
Consider one of the 
following drugs (in 
order of authors 
preference):
– Chlormethiazole.
– Inhalation anesthesia (isoﬂurane).
– Etomidate.
During treatment 
protocol:
– Establish the cause of GCSE (medical history, blood and 
  CSF investigation, CT-scan/MRI, EEG).
– Treatment of aspiration.
– Prevent thrombosis, keratitis, gastric ulcer (stress).
– Continue or start maintenance therapy of anti-epileptic 
  drug.
Chapter 4
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Summary
We report data from 346 admissions for generalized convulsive Status 
Epilepticus (GCSE) in the Netherlands; 68% had had previously epilepsy. 
Outcome was determined by underlying cause, duration of more than four 
hours, the presence of more than one medical complication and the quality 
of therapy and management. Clonazepam, diazepam and phenytoin were 
most frequently used for treatment.
4.1 Introduction
Until 1962 no attempt has been made to achieve a classiﬁcation or a proper 
deﬁnition of Status Epilepticus (SE). The conference in 1962 in Marseille 
on SE proposed a deﬁnition, which was approved by the ILAE in 1970: 
“A condition characterized by an epileptic seizure which is so frequently 
repeated or so prolonged as to create a ﬁxed and lasting epileptic condition” 
(Gastaut, 1967). At the symposium in Santa Monica in 1980 a minimum 
duration of 30 min was added. SE thus currently encompasses a seizure 
of any type with a minimum duration of 30 min. and a succession of 
generalized convulsive seizures without regaining consciousness (Delgado-
Escueta et al, 1983). Most patients with Generalized Convulsive Status 
Epilepticus (GCSE) can easily be treated with benzodiazepines (BDZ) 
and/or phenytoin (PHT). Cases refractory to common ﬁrst- and second-
line anti-epileptic drugs (AED) are mainly caused by acute symptomatic 
neurologic problems, such as brain tumours, encephalitis, cerebro-vascular 
accidents (CVA), head trauma and metabolic disturbances. In most such 
patients GCSE is the only (isolated) or presenting (initial) sign of epilepsy. 
GCSE can also occur in patients with previous epilepsy (intercurrent SE), 
precipitated by systemic infections, non-compliance, sleep deprivation and 
a miscellaneous group of more rare possibilities (Rowan and Scott, 1970; 
Heintel, 1972; Aminoff and Simon, 1980; Janz, 1983; Pilke et al, 1984; 
Goulon et al, 1985). Outcome in GCSE is especially determined by cause 
(Whitty and Taylor, 1949; Rowan and Scott, 1970; Oxbury and Whitty, 1971; 
Heintel, 1972; Celesia, 1983; Goulon et al, 1985). Acute symptomatic causes 
are more prevalent in older age groups, with corresponding worse outcome 
(Celesia et al, 1972; Sung and Chu, 1989). In cases admitted to the Intensive 
Care Unit (Goulon et al, 1985) a striking difference in mortality was noted 
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between the group of patients with an acute symptomatic cause (46%) and 
with previous epilepsy (8,6%). Outcome in cases with previous epilepsy is 
much better, whether aetiology was idiopathic, a chronic non-progressive 
encephalopathy or a remote symptomatic cause. The relation of SE duration 
to outcome is unclear. In an experimental animal setting pathophysiologic 
changes occurred after 30 min. Nevertheless some patients with SE duration 
of 90 or 120 min did not have problems (Rowan and Scott, 1970; Aminoff 
and Simon, 1980). Rowan and Scott (1970) reported increased morbidity 
in cases with duration of 10 hrs or more and mortality in cases of 13 hrs or 
more. Aminoff and Simon (1980) reported poorer outcome in cases with a 
duration of more than 120 min. De Lorenzo also noted a critical duration of 
GCSE with regard to outcome: mortality was only 5% in cases with duration 
of 1 hr or less, whereas mortality was 35% in cases of more than 60 minutes 
(De Lorenzo et al, 1987). A relation between duration of SE and outcome was 
not established by Clark and Prout (1903), Goulon et al (1985) and French 
et al (1988). Contributing to a longer SE duration are therapy delay (Whitty 
and Taylor, 1949; Rowan and Scott, 1970; Treiman et al, 1983; Lowenstein 
et al, 1988) and/or inadequate therapy (Delgado-Escueta and Enrile-Bascal, 
1983; Celesia, 1983). Treatment according to a protocol might prevent this 
and improve outcome (Treiman et al, 1983). The sooner the AED treatment is 
initiated, the better the results (Walton and Treiman, 1988). Animal studies 
support the importance of adequate treatment of the medical complications 
during GCSE (Meldrum and Brierley, 1973; Meldrum et al, 1973; Meldrum 
et al, 1974; Siesjo and Wieloch, 1986). In human, the degree of metabolic 
acidosis did not correlate with outcome, whereas hyperthermia correlated 
with a poorer outcome (Aminoff and Simon, 1980). Despite optimal control 
of the various parameters such as pO2, pCO2, pH, blood pressure, and 
temperature in animal studies, neuronal damage occurred in substantia 
nigra pars reticularis after 30 min and in the third and fourth layer of the 
cerebral cortex or in special areas (CA1, CA4) of the hippocampus after 45-
60 min (Nevander et al, 1984; Nevander et al, 1985; Meldrum, 1983; Siesjo 
and Wieloch, 1986). Calcium accumulation and excitatory aminoacids were 
important, although hypermetabolism, energy failure and lactate accu-
mulation also played a role in producing the major neuronal damage in the 
substantia nigra. 
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We studied treatment practice and outcome of GCSE in The Netherlands 
paying particular attention to the contribution to outcome of duration, 
existence of medical complications and quality of therapy on outcome. 
Methods have been described in chapter 2.
4.2 Results
The Netherlands have a total population of nearly 15 million people, about 
100.000 have epilepsy. SIG data for SE between 1980 and 1987 and our data 
for the same period are shown in ﬁg. 1. The SIG data showed an average 
annual frequency of GCSE of 344, with a standard deviation (SD) of 82 (SIG, 
1989). The reported annual mortality because of GCSE during the same 
period in cases of 15 yrs of age and older is 24, with SD 4 (CBS, 1989).
We identiﬁed 576 admissions for SE (all types), with 346 admissions 
for GCSE. Some general aspects of SE in relation to the hospital type are 
presented in table 1.
In smaller hospitals the number of acute symptomatic cases is lower 
than in university clinics or larger hospitals. The reverse is true for the 
occurrence of medical complications.
A striking feature is the number of incorrect diagnosis of SE, namely 118. 
These cases are documented as SE, reported as such to SIG, whereas ﬁle-
investigation made clear that SE was not the case. In 75 cases it concerned 
a single seizure (63,5%), in 18 cases serial seizures (15,3%), in 12 cases the 
patient was known with previous epilepsy without any seizure problem at 
admission (10,2%) and in the remaining 13 cases various problems were 
present, but not related to epilepsy (11,0%). All further data concern the 
cohort of 458 patients who fulﬁlled our criteria for the diagnosis of SE.
If we restrict ourselves to GCSE (346 admissions), a slight male 
preference is noted and an increase in older age groups in the asymmetrical 
GCSE (table 2). The 346 admissions comprised 292 patients; 242 patients 
with one, thirty with two, six with three, four with four and one patient 
with ten admissions. Those who had more than 2 periods of GCSE were all 
patients with previous epilepsy, caused by head trauma, a chronic non-pro-
gressive encephalopathy, CVA or a progressive neurological disease. In 236 
cases it concerned patients with previous epilepsy and 110 cases did not. 
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The causes of previous epilepsy in 236 cases of GCSE are presented in table 
3. The 83 patients with a chronic non-progressive encephalopathy were 
mentally retarded and known with previous epilepsy. For most patients, the 
cause of the encephalopathy could not be established. The 8 patients with 
a progressive neurological disease of 1 case each of Alpers disease, Lafora 
body disease and a non-speciﬁed mitochondrial encephalomyopathy; in 
the remaining patients the cause was unknown. The miscellaneous group 
comprised multiple sclerosis (one), chronic psychiatric disease (one), 
autoimmune disease (two) and renal failure (one).
Fig. 1: Total number of SE reported to the SIG (SIG-data) and of this 
study, divided in the various types of SE*
Number of SE in the Netherlands Total number of SE
Total 3263 Total 576
GCSE 2751 GCSE 346
EPSE 337 EPSE 47
NCSE 175 NCSE 65
NO-SE 118
SIG-data  (1980-1987) This study  (1980-1987)
* GCSE = Generalized Convulsive Status Epilepticus; EPSE = Elementary Partial Status 
Epilepticus; NCSE = Non Convulsive Status Epilepticus; NO-SE = diagnosis of Status 
Epilepticus appeared wrong
Table 1: General aspects of SE in relation to hospital type (1980-1987)
University
Clinic (6)
Large
Hospital (2)
Small
Hospital (4)
Epilepsy
Centre (2)
Average number of beds  890  717  460  –
Total number of SE (576)
Conﬁrmed number of SE (458)
 300
 247
 113 
  67
  98
  90 
 65
 54 
Previous epilepsy (%)  66,0  52,0  69,0  100 
Mental Retardation (%) 17,5 7,0 28,0 39,0
Medical complications (%)
Acute symptomatic cause (%)
 47,0 
34,0 
 31,3 
 34,3 
 29,1
 22,2 
 9,3
 3,7
Morbidity (%)
Mortality (%)
 18,5
 11,7
 10,4
 11,9
 7,7
 6,7
 1,9
 1,9
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Table 2: Distribution of age, gender and type in 346 admissions because 
of GCSE* 
Type of SE Male Female Age 
15-30
Age 
30-50
Age 
>50
GC-symmetrical 128 91 65 91 63
GC-a-symmetrical 67 53 32 24 64
Myoclonic 3 2 3 2 0
Tonic 0 2 1 1 0
Total   198   148    101   118  127
*Absolute numbers
Table 3: Causes of previous epilepsy in 236 cases of GCSE
Cause  N (%)
Chronic non-progressive encephalopathy   83 (35,2)
Head trauma  21 (8,9)
CVA  19 (8,0)
Post-operative (cerebral tumour, cyst, hygroma)  12 (5,1)
Progressive neurological disease   8 (3,4)
Encephalitis/meningitis   7 (3,0)
Alcohol   6 (2,5)
AVM/aneurysm   2 (0,9)
Miscellaneous   5 (2,1)
Idiopathic generalized epilepsy   6 (2,5)
Unknown  67 (28,4)
Total  236 
Causes of GCSE and outcome
Previous epilepsy. Many patients (68%) had previous epilepsy (table 4). For 
a few patients an acute symptomatic cause was responsible for the GCSE 
(table 5a). The toxic causes (table 5a) consisted of amipaque (myelography), 
phenytoin-intoxication and carbamazepine-intoxication (one with a serum 
level 28 with good outcome and another with a serum level 32 mg/l, dead). 
Among the precipitating factors of GCSE problems with AEDs were the most 
prevalent (65), sometimes with fatal results (6,2% of these cases). Other 
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precipitating factors were alcohol, often combined with AEDs problems, 
and systemic infections. In 42,5% of the cases with previous epilepsy the 
cause or precipitating factor remained unknown. 
Outcome in patients with previous epilepsy was favourable in 85,5%; 
morbidity was 8,5%, mortality 6% (table 4).
No previous epilepsy. The causes in patients without previous epilepsy 
but with a preceding neurological morbidity at least 3 months before the 
occurrence of SE were classiﬁed as remote symptomatic (table 5b). The 
acute symptomatic causes in patients without previous epilepsy are presen-
ted in table 5c. The types of brain tumour (table 5c) were varied and 
included: malignant lymphoma (two), metastases of sarcoma and of other 
malignant tumors (three), astrocytoma (grade 3 and 2-3), malignant menin-
geoma, corpus callosum glioma and tumors not further characterized (two). 
Metabolic problems (in table 5c) included hyperglycemia, renal failure with 
hypertension, hypokaliemia (2,2 mM in one case and 2,0 mM in another) 
and hyponatremia (121 mM). Toxic causes (table 5c) included 1 case each of 
cyclosporin, amipaque (myelography), cancer chemotherapy, maprotillin-
intoxication, ethylene-glycol-intoxication, lidocaine and two cases of drug 
abuse. Morbidity and mortality in acute symptomatic cases was 23,3% each 
(table 4, 5c). Morbidity in remote symptomatic cases was 19%, mortality 
14,3% (table 4, 5b).
Table 4: Causes of GCSE in relation to outcome in cases with and 
without previous epilepsy*
Outcome Good (263) Morbidity (45) Mortality (38)
Previous Epilepsy (236)  202  20  14
Acute Symptomatic
Precipitating factors
 Non-compliance
 Alcohol
 Systemic infections
Unknown
Progressive neurological disease
 7
 56
 14
 22
 100
 3
 3
 5
 0
 2
 7
 3
 4
 
 4
 0
 2
 3
 1
No Previous Epilepsy (110)  61  25  24
Acute symptomatic
Remote symptomatic
 47
 14
 21
 4
 21
 3
* Absolute numbers
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Table 5a: Acute symptomatic causes of GCSE in patients with previous 
epilepsy*
Outcome Good (7) Morbidity (3) Mortality (4)
CVA 1 3 1
Encephalitis 0 0 1
Head trauma 1 0 1
Brain Tumour 1 0 0
Toxic 3 0 1
Cardiac arrest 1  0  0
* Absolute numbers
Table 5b: Remote symptomatic causes of GCSE in patient without 
previous epilepsy*
Outcome Good (14) Morbidity (4) Mortality (3)
CVA 6 3 2
Encephalitis 1 0 0
Head trauma 2 1 0
Multiple sclerosis 1 0 0
Brain surgery 2 0 0
Chronic encephalopathy 2 0 1
* Absolute numbers
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Table 5c: Acute symptomatic causes of GCSE in patients without 
previous epilepsy*
Outcome Good (47) Morbidity (21) Mortality (21)
CVA 10 4 10
Encephalitis/meningitis 1 2 1
Metabolic 3 2 0
Head trauma 3 3 1
Brain tumour 5 4 2
Toxic 5 3 0
Alcohol 4 0 0
Cardiac arrest 0 0 4
Sleep-deprivation/
exhaustion
2 1 0
Hypoxia 0 1 0
Multiple sclerosis 1 1 0
Withdrawal 
benzodiazepines
1 0 0
Progressive neurological 
disease
1 0 0
Brain abscess 1 0 0
Systemic infection 5 0 0
Unknown 5 0 3
* Absolute numbers
Morbidity
The sequelae occurring after GCSE are presented in table 6. Decline of 
cognitive functions included persistent memory deﬁcit, especially present in 
the group where SE-itself was responsible for morbidity. The miscellaneous 
group consisted of renal failure (because of SE), epilepsy, depressive mood, 
dysarthria, continuation of SE (further information was not present because 
of transport to another hospital) and hemi-anopsia (cause unknown).
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Table 6: Morbidity after GCSE because of SE itself (SE) and underlying 
cause. In some cases the exact cause remained unknown (unknown)*
Morbidity SE (12) Cause (24) Unknown (9)
Paresis 3 7 3
Cognitive Deterioration 4 8 3
Aphasia 2 0 0
Impairment of Consciousness 2 1 0
Ataxia 0 0 1
Miscellaneous  1 8 2
* Absolute numbers
Duration of GCSE and outcome
In 201 cases information about duration of GCSE was present. The causes of 
morbidity and mortality were divided in SE, cause and unknown. A relation 
between outcome and duration was evident in cases which GCSE itself was 
responsible for morbidity and mortality (table 7). When the underlying 
cause is responsible, duration seems not important; the damage is already 
present at the beginning. New neurological signs caused by the SE appeared 
in most cases after 4 hours, as did mortality in cases caused by GCSE (13 of 
the 15 cases). This was especially true after 8 hrs (12 cases).
Table 7: Relation between outcome and duration of GCSE; relative 
numbers*
Outcome Good Morbidity Mortality
SE Cause Un- 
known
SE Cause Un- 
known
Duration
< 2 hrs (73) 77,0 0 12,3 5,5 1,4 2,7 1,4
2 - 4 hrs (61) 80,3 1,6 6,6 1,6 1,6 8,2 0
4 - 6 hrs (13) 84,6 0 7,7 0 7,7 0 0
6 - 8 hrs ( 9) 66,7 11,1 0 0 0 22,2 0
8 - 12 hrs ( 5) 40,0 20,0 0 0 40,0 0 0
12 - 20 hrs ( 9) 55,6 11,1 11,1 0 22,2 0 0
> 20 hrs (31) 35,5 19,4 6,5 3,2 25,8 9,7 0
Total 100 (201) 69,5 5,0 8,5 3,0 7,5 6,0 0,5
* Absolute numbers between brackets
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Medical complications and outcome
Medical complications in GCSE are to be expected in cases with duration of 
2 hrs or more. We investigated the occurrence of medical complications in 
relation to outcome. In 41% one or more medical complications were present: 
hyperthermia (>38,5 °C), cardiac arrhythmias including cardiac arrest, 
respiratory insufﬁciency, aspiration, acidosis (<7,0; 7,0-7,1; 7,1-7,2; 7,2-7,3), 
hypotension, rhabdomyolysis, renal failure, hepatic failure and intracranial 
hypertension. Renal or hepatic failure and rhabdomyolysis were observed 
in cases with several medical complications. The increase of CPK was over 
10000 U/L in three patients, with myoglobin in the urine; one patient had 
values of more than 150000 U/L. One patient had rhabdomyolysis with 
a CPK increase of only 1809 U/L with the presence of myoglobin in the 
urine.
The existence of more than one medical complication was related to 
poor outcome (table 8). Most important were respiratory insufﬁciency and 
aspiration, although cardiac arrhythmias and hypotension also contributed 
to a poor result. In severe cases renal or hepatic failure and/or intracranial 
hypertension were very grave signs (table 9). Although acidosis and 
hyperthermia may contribute to less favourable results, a relation between 
the degree of acidosis or hyperthermia could not be established. 
Table 8: Number of medical complications in relation to outcome; 
relative numbers*
Outcome Good Morbidity Mortality
Complications SE Cause Un- 
known
SE Cause Un- 
known
No (204) 85,3 2,0 6,4 2,0 1,0 2,0 1,5
1 ( 82) 73,2 4,9 9,8 2,4 2,4 6,1 1,2
>1 ( 60) 48,3 6,7 5,0 5,0 28,3 5,0 1,7
* Absolute numbers between brackets
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Table 9: Medical complications in GCSE in relation to outcome, relative 
numbers*
Outcome Good Morbidity Mortality
Complications SE Cause Un- 
known
SE Cause Un- 
known
No (204) 85,3 2,0 6,4 2,0 1,0 2,0 1,5
Respiratory 
insufﬁciency (58)
48,3 6,9 5,2 5,2 24,1 8,6 1,7
Hyperthermia (48) 56,3 14,6 8,3 2,1 12,5 6,3 0
Acidosis (43) 60,5 4,7 7,0 7,0 14,0 7,0 0
Aspiration (21) 42,9 9,5 9,5 0 33,0 4,8 0
Renal and/or  
hepatic failure (20)
15,0 15,0 5,0 10,0 42,9 5,0 5,0
Hypotension (17) 53,0 0 11,8 5,9 23,5 0 5,9
Cardiac Arrythmias 
(13)
61,5 7,7 0 0 23,1 7,7 0
Intracranial  
hypertension (4)
25,0 0 0 0 75,0 0 0
Rhabdomyolysis (4) 25,0 25,0  0  0 50,0 0 0
* Absolute numbers between brackets
Therapy and management of GCSE
We tried to determine the effect of quality of the therapy of GCSE on 
outcome. In 263 admissions with good outcome, therapy was good or suf-
ﬁcient in 85,6%, and was insufﬁcient in 10,3% (table 10), mainly because of 
inadequate dosage of AEDs (8%). In patients with sequelae (45 admissions) 
inadequate therapy was evident in 22,2%. 
In cases where morbidity was due to SE itself insufﬁcient therapy was 
even more frequent (50%). Of the total number of patients who died (38) 
therapy was insufﬁcient in 44,7%. In cases due to SE itself these results 
were again worse, occurring in 62% with insufﬁcient dosage of AEDs the 
major problem (table 10).
We determined last administered AED either before successful cessation 
of SE or before death: BDZ and/or PHT were administered most frequently 
(table 11). Thiopental, clorazepate and etomidate were administered when 
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BDZ and PHT were without effect; chlormethiazole was administered after 
failure of thiopental.
Table 10: Therapy in relation to outcome; absolute numbers
Outcome Good (263) Morbidity (45) Mortality (38)
Therapy SE Cause Un- 
known
SE Cause Un- 
known
Good 225 6 21 8 8 11 2
No therapy 11 0 0 0 0 0 0
Inadequate (total) 27 6 3 1 13 3 1
Dose 21 0 2 0 9 1 1
Route  5 0 0 0 0 0 0
Delay 1 3 1 0 0 0 0
No ventilation 0 2 0 0 2 2 0
No EEG 0 1 0 1 2 0 0
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Table 11: Last given therapy in GCSE*
Therapy Number
No therapy 15
Diazepam i.v. 58
 rectiole 9
 i.m. 2
 + PHT 29
Clonazepam i.v. 82
 i.m. 2
 + PHT 26
PHT i.v. shot 44
 i.v. loading 36
 i.m. 2
Midazolam i.v.  4
Clorazapate infusion  6
Etomidate infusion  5
Thiopentone i.v. shot  3
 infusion 16
Chlormethiazole infusion 2 
Chloralhydrate rectal 2
Lidocaine i.v.  1
Other 2 
Total admissions  346
* Absolute numbers
4.3 Discussion
Between 1980-1987 every year about 344 ± 82 admissions occur for GCSE 
in the Netherlands (population 15 million) in patients of 15 yrs of age and 
older (SIG, 1989). We studied 346 admissions for GCSE, gathered from 12 
hospitals and two epilepsy centres, spread all over the country. We showed 
that the numbers of patients with GCSE as reported by the SIG are relatively 
high, because in a considerable number the diagnosis appeared wrong (118 
cases from a total of 576). In larger hospitals and University Clinics the 
relative numbers of acute symptomatic causes is higher in comparison to 
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smaller hospitals and epilepsy centres, with comparable worse outcome. 
Transfer of therapy resistant and more complicated cases to University and 
larger hospitals with more facilities may contribute to this result.
The distribution of GCSE in male or female patients shows some 
preference for the male (57,2%). Some of the reports in the literature conﬁrm 
this male predominance (Heintel, 1972; Aminoff and Simon, 1980; Celesia, 
1983); other reports show no difference (Clark and Prout, 1903; Rowan and 
Scott, 1970; Pilke et al, 1984; Goulon et al, 1985). In patients of 50 years 
and older a high percentage of acute symptomatic causes is present (65%), 
in agreement with previous reports (Celesia, 1972; Heintel, 1972; Sung and 
Chu, 1989). 
Of the 346 admissions for GCSE, 236 were known with previous epilep-
sy. Patients with more than one episode of GCSE all had previous epilepsy. 
The causes of previous epilepsy, shown in table 3, were mainly chronic non-
progressive encephalopathy or unknown. 
Outcome in cases of GCSE caused by an acute neurological cause, 
whether in patients known with previous epilepsy or without previous 
epilepsy, appears comparable (table 4).
Important with regard to outcome in patients with previous epilepsy are 
non-compliance (and other AED problems) and systemic infections. Precipi-
tating factors were similar to those previously reported (Rowan and Scott, 
1970; Heintel, 1972; Aminoff and Simon, 1980; Pilke et al, 1984; Goulon 
et al, 1985). That AED non-compliance may be fatal should be stressed. 
The difference in outcome between patients with and without previous 
epilepsy is striking (table 4 and 5) and agrees with previous reports, but 
we observed a lower frequency of brain tumours (Oxbury and Whitty, 1971; 
Roger et al, 1974; Janz, 1983; Pilke et al, 1984), which was more comparable 
to frequencies observed more recently (Aminoff and Simon, 1980; Cele-
sia, 1983; Goulon et al, 1985). The frequency of CVA was similar to that in 
previous reports (Aminoff and Simon, 1980; Pilke et al, 1984; Goulon et 
al, 1985). Other causes did not signiﬁcantly differ from those in previous 
reports.
To investigate the contribution of GCSE itself to outcome, we made 
a distinction between cases in which outcome was determined by the 
underlying cause and cases in which GCSE was the main determinant. When 
we considered duration of GCSE with regard to outcome, the importance of 
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such a distinction becomes clear. Although other authors showed a relation 
between duration and outcome (Rowan and Scott, 1970; Heintel 1972), only 
Aminoff and Simon (1980) made a distinction between underlying cause 
and SE itself.
We established a relation between outcome and duration, especially 
in cases where GCSE itself was responsible. Duration of four hours or 
more caused an increase in morbidity and mortality, comparable to the 
data of Aminoff and Simon (1980) and in agreement with experimental 
results (Meldrum, 1983; Lothman, 1990). Some authors failed to establish 
a relation between outcome and duration, which may be explained by the 
lack of differentiation between underlying cause and the effect of SE itself 
(Goulon et al, 1985; French et al, 1988).
The importance of prompt treatment of medical complications during 
GCSE has been stressed (Glaser, 1983; Meldrum, 1983; Simon, 1985; 
Lothman, 1990). We have shown a major negative contribution to outcome 
when more than one medical complication was present. In particular, 
respiratory insufﬁciency (and aspiration), cardiac arrhythmias and 
hypotension are related to a negative outcome. Patients with renal and/or 
hepatic failure or with rhabdomyolysis had an especially bad outcome; these 
conditions usually occur in combination with other medical complications. 
We did not establish a relation between the degree of acidosis (Aminoff 
and Simon, 1980) or between the degree of hyperthermia and outcome. 
Intracranial hypertension was measured in only a few cases; three of these 
four patients died.
Important to the existence of several medical complications was 
inadequate management: “A major mistake is to wait for a drug to work” 
(Simon, 1985). Of patients who died 44,7% had had inadequate AED therapy, 
22,2% of those with sequelae and in only 10,3% with good outcome. 
The general mode of treatment was rather similar in all hospitals: 
BDZ and/or PHT, followed (when necessary) by thiopentone, and in fewer 
cases, by clorazepate or etomidate. Chlormethiazole was only used when 
thiopentone was without success.
Our results show that outcome in GCSE is particularly determined by the 
underlying cause, but also inﬂuenced by a duration of more than four hours, 
by the existence of 1 or more medical complications and by insufﬁcient 
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therapy. A treatment protocol, including a time schedule, can be used to 
prevent unnecessary delay, promotes a logical sequence of administration 
of the various AEDs and contributes to a better outcome (Treiman et al, 
1983; Scholtes et al, 1993). An example of such a protocol is presented in 
table 14a-14b (chapter 3.9).

Chapter 5 
Non-Convulsive Status Epilepticus: 
Causes, Therapy and Outcome in  
65 patients
J Neurol Neurosurg Psychiatr 1996; 61: 93-95
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Summary
The incidence of Non-Convulsive Status Epilepticus (NCSE) in The Nether-
lands is not known. We studied 40 cases with Complex Partial Status 
Epilepticus (CPSE) and 25 with Absence Status Epilepticus (ASE), from 
12 hospitals and 2 epilepsy centres, spread all over the country during the 
period 1980-1987. We restricted ourselves to adult patients (older than 15 
years). The clinical presentation made distinction between CPSE and ASE 
possible in a number of cases. Focal clinical signs were more frequent in 
CPSE; a ﬂuctuating level of consciousness was more often present in ASE. 
All cases, but one, with ASE and most cases with CPSE (28) were known 
with previous epilepsy. Outcome in ASE was good in all. Outcome in CPSE 
was determined by underlying cause and quality of therapy. In one patient 
morbidity appeared to be caused by the discharges themselves.
5.1 Introduction
Non-convulsive Status Epilepticus (NCSE) is characterized by a clouding 
of consciousness, confusion, automatisms and amnesia, with speciﬁc EEG 
abnormalities in accord with the type of NCSE. In adult patients NCSE is 
divided in two main groups, generalized NCSE and complex partial status 
epilepticus (CPSE), which because of their clinical similarities have been 
discussed together by most authors. Generalized NCSE includes absence 
status epilepticus (ASE) and atypical absence SE. ASE was described ﬁrst 
by Lennox in 1945, since then several reports have appeared which describe 
ASE under a variety of names: absence SE, petit mal SE, epilepsia minor 
continua, spike-wave stupor and prolonged petit mal automatisms. At 
the moment ASE is the most frequent used term to describe a prolonged 
confusional state of varying severity, with a ﬂuctuating level of consciousness 
together with generalized paroxysmal activity on the EEG (Andermann and 
Robb, 1972; Porter and Penry, 1983; Guberman et al, 1986). In this paper 
ASE is equivalent to generalized NCSE. The ﬁrst description of CPSE was 
in 1956 by Gastaut (Gastaut et al, 1956). Others have described the clinical 
presentation extensively (Richard and Brenner, 1980; Treiman and Delgado-
Escueta, 1983; Williamson et al, 1985; Tomson et al, 1986; Delgado-Escueta 
and Treiman, 1987; Tomson et al, 1992).
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This study concerns patients admitted to hospitals. Methods have been 
described in chapter 2. We tried to ﬁnd out how the diagnosis of a particular 
type of NCSE had been made and we were especially interested in clinical 
presentation, management and outcome. Some cases with NCSE will 
not be diagnosed, or will not be sent to a hospital if the NCSE subsided 
spontaneously. Others are known to have had previous epilepsy or previous 
episodes of NCSE and immediate hospitalisation is not always required. 
5.2 Results
We found in 12 hospitals and 2 epilepsy centres a total number of 65 
admissions for NCSE, 40 with CPSE and 25 with ASE. The distribution of 
age and gender is presented in table 1. The patients with CPSE are mainly 
from university clinics (22) and epilepsy centres (16), cases with ASE from 
small and large general hospitals (10) and epilepsy centres (10).
Table 1: Distribution of age and gender in patients with CPSE and 
ASE*
Age Age 15 - 30 Age 30 -50 Age > 50
Male Female Male Female Male Female
CPSE 
Previous epilepsy (28)
No previous epilepsy (12)
9
0
3
1
5
1
3
2
5
3
 3
 5
ASE 
Previous epilepsy (24)
No previous epilepsy (1)
 
5
1
4
0
0
0
1
0
 
4
0
10
 0
* Absolute numbers 
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Absence Status Epilepticus (ASE)
The number of admissions because of ASE was 25 in 18 patients. One female 
patient of 72 years had six admissions and two patients had two admissions 
each. Only one patient had no history of previous epilepsy (table 1). Two 
patients with ASE were mentally retarded; the EEG showed continuous 
spike-slow-wave activity (atypical ASE).
The clinical presentation of ASE was characterized by a state of altered 
consciousness. Some appeared alert, but responsiveness was impaired. 
Others behaved strangely; they were laughing without obvious reason 
and showed myoclonic jerking of eyelids. Some showed automatisms, 
either environmentally induced or spontaneous. A few patients were very 
drowsy and did not speak; others were withdrawn and showed stereotypic 
automatisms such as smiling and head nodding. A state of confusion with 
ﬂuctuating level of consciousness was present in 8. Two patients were 
incontinent for urine; both were very drowsy. One patient wandered around 
and showed myoclonic jerks especially in the arms.
EEG investigation conﬁrmed the diagnosis of ASE in 21 cases. Continuous 
bilateral spike-wave activity of 2-3 Hz was present in 10 patients; continuous 
bilateral poly-spike-wave activity was found in 7 cases. In two patients a 
discontinuous EEG-pattern was present with bilateral spike-wave-activity 
of 2½-4 Hz. In two patients with atypical absence SE slow-spike-wave-
activity had been found. In two patients no EEG had been performed; both 
were known with previous idiopathic generalized epilepsy with absence 
seizures.
EEG investigation had conﬁrmed the diagnosis of ASE in four admissions 
of a female patient of 72 years; during two further admissions EEG investiga-
tions had been considered unnecessary.
Precipitating factors of ASE in the 24 cases with previous epilepsy 
consisted of antiepileptic drug withdrawal or non-compliance (10), systemic 
infection (1) and stress (1); in 11 cases no cause could be found. One patient 
exhibited several periods during one admission of ASE each time recurring 
after defecation. The cause of ASE in one patient without previous epilepsy 
remained unknown.
Outcome in ASE was good in all patients, irrespective duration of SE. 
Duration was less than two hours in eight, including one case of atypical 
ASE; between two and twenty hours in ten, 24 hours in four, 48 hrs in two 
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(including the other case of atypical ASE) and 14 days in one patient. Last 
given therapy of ASE is presented in table 2.
The quality of therapy appeared insufﬁcient in three patients; outcome was 
good all the same.
Complex Partial Status Epilepticus (CPSE)
CPSE concerned 40 admissions in 37 patients; 3 male patients had 2 admis-
sions each and were all three known with previous epilepsy. A male or 
female preference in CPSE was not present. Most patients without previous 
epilepsy were older than 50 years of age (table 1). Those with a history of 
previous epilepsy were all known with complex partial seizures, with or 
without secondary generalized seizures.
CPSE followed one or more tonic-clonic seizures in ten patients, a tonic-
clonic seizure occurred during CPSE in one patient and ended CPSE in two 
patients.
The clinical presentation of CPSE was characterized by confusion and 
slowness in response, together with stereotypic and/or complex automa-
tisms. Focal clinical signs, such as clonic jerking of 1 arm, were present 
in almost half of the cases, whereas tonic deviation of eyes and head was 
present in another 15%.
About 50% of the patients showed a succession of complex partial 
seizures; between the seizures the patients remained confused or un-
responsive. Others remained in a continuous state of confusion and were 
both withdrawn without initiative and hardly responsive, or appeared 
restless with various automatisms, such as lip smacking and picking at 
clothes or objects. Two appeared to have hallucinations. Staring (motion-
less) was seen in only 2 patients.
EEG investigation had been done in 18 patients. Focal epileptic activity 
was present in 10 patients, conﬁrming the diagnosis of CPSE. Patients with 
bilateral slow wave activity (2) or bilateral spike-slow wave or poly spike-
wave activity (4) were all known with previous partial epilepsy. In 15 cases 
with previous partial epilepsy EEG investigation had not been done and 
the diagnosis of CPSE had been based on clinical presentation in a patient 
known with partial epilepsy. In 7 patients without previous epilepsy the 
diagnosis of CPSE had been made without EEG investigation based on 
clinical presentation together with an acute or remote symptomatic cause 
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with obvious focal characteristics and on the results of anti-epileptic drug 
treatment. 
In patients with previous epilepsy problems with therapy such as non-
compliance were the most frequent precipitating factor (12 cases). On two 
occasions systemic infection, on one occasion stroke, and another one stress 
triggered the CPSE. In 12 cases the cause remained unknown. 
In patients without previous epilepsy various acute symptomatic causes 
were present: stroke (two), brain tumour (two), pneumococcal meningo-
encephalitis (one), carcinomatous meningitis and lung cancer (one), digoxine 
intoxication (one), pneumococcal pneumonia (one), and a case without a 
clear cause.
Three patients had remote symptomatic causes: multiple sclerosis, global 
cerebral atrophy and chronic dialysis and aluminium encephalopathy.
Outcome in cases with previous epilepsy was good in all but one, a 78 
years old man who had successful treatment stopping his CPSE but died 
four days later because of aspiration pneumonia, acquired during the SE.
In patients without previous epilepsy six had sequelae after CPSE: 
paresis because of underlying cause (two), persistent cognitive disturbances 
because of underlying cause (one) and of unknown cause (one) and persistent 
impaired consciousness of unknown cause (one).
The CPSE itself caused morbidity in a female patient (74 years) who 
developed CPSE lasting 24 hours after digoxine intoxication; she was 
confused with jerking of the right arm, alternating with short periods of 
staring. After treatment with AED and recovery from CPSE this patient 
exhibited word ﬁnding problems and a memory deﬁcit. Patients with 
morbidity were, except for one (38 years), older than 60 years. In patients 
without previous epilepsy one patient of 67 died because of the underlying 
cause (lung cancer and carcinomatous meningitis).
Duration of CPSE was less than two hours in 17, between two and 
four hours in nine, between four and twelve in ﬁve, one to three days in 
seven patients, four 4 days in one and 16 days in another patient. When 
the underlying cause was responsible for morbidity (three patients), the 
damage is present at the start of CPSE; in two of these three cases duration 
of CPSE was less than 2 hrs. The patient with morbidity because of CPSE 
itself remained in status for 24 hrs. Notwithstanding duration of CPSE from 
20 hours to 16 days all patients except one had a good outcome.
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Last given therapy that ended CPSE is presented in table 2. The quality 
of therapy was studied in order to examine the relation between outcome 
and therapy. In 32 cases with good outcome therapy was inadequate in 4 
patients (12½%). In 6 cases with sequelae therapy was insufﬁcient in three. 
In one of these patients this may have contributed to persistent morbidity 
because of CPSE itself, because when phenytoin i.v. had no success, an 
attempt to initiate carbamazepine therapy was started, but loading was not 
employed. Though eventually the patient got out of CPSE, the delay was 
probably too long. Another patient with insufﬁcient therapy concerned a 38 
years old man with CPSE caused by pneumococcal meningitis with duration 
of 4 days. Every two minutes he showed a seizure (EEG conﬁrmed). He was 
treated with phenytoin i.v. (no loading), clonazepam 6 mg/hr during two 
days and 6 x 100 mg i.v. phenobarbital. He suffered a persistent paresis of 
the left arm that was in accordance to the EEG focus. In this case it was 
difﬁcult to judge whether the infection or the CPSE contributed most to the 
paresis.
The third case with insufﬁcient therapy concerned a male patient of 79 
years who presented with CPSE of 35 minutes duration followed by persistent 
depressed level of consciousness. The EEG showed various periods of 
generalized SE. Treatment consisted of phenytoin loading, 1 mg clonazepam 
and 8 mg diazepam i.v., without any effect on the electric SE. This patient 
was known with prostate carcinoma with metastases. A cerebral metastasis 
could not be found. Outcome was waited for without active intervention and 
the patient was transferred to a nursing home.
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Table 2: Last given therapy in CPSE and ASE*
Treatment of NCSE CPSE ASE
No treatment 4 2
Diazepam i.v. 6 6
rectal 3 2
Clonazepam i.v. 13 8
i.m. 0 1
rectal 1 2
Phenytoin i.v.shot 6 2
 loading 2 0
Thiopental 1 0
Chloralhydrate 2 0
Other drugs 2 2 
* Absolute numbers
5.3 Discussion
The literature on NCSE is extensive but sometimes confusing. Even some 
patients with previous partial epilepsy have been described as having ASE 
instead of CPSE (Niedermeyer et al, 1979; Guberman et al, 1986; Tomson et al; 
1986). Others draw general conclusions about patients with NCSE, whereas 
different types of NCSE are present (Guberman et al, 1986; Fagan and Lee, 
1990). The distinction on clinical grounds alone between the various types 
of NCSE is difﬁcult, but some clinical features favour the diagnosis of CPSE 
(focal clinical signs, tonic deviation of eyes and head), whereas others are 
more present in ASE (ﬂuctuating level of consciousness, rhythmic blinking). 
The EEG in NCSE is necessary to differentiate between the various types 
of NCSE but also to distinguish NCSE from e.g. a psychiatric diagnosis. 
Generalized epileptic discharges or the absence of epileptic activity do not 
exclude CPSE, however.
Most admissions in our study were for CPSE, which conﬁrms the 
conclusion of Tomson et al (1992) that CPSE is more frequent than previously 
reported. This may be caused by the fact that the ICD-9 did not include 
CPSE. 
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Age distribution in cases of CPSE showed no preference in patients with 
previous epilepsy, but in cases without previous epilepsy most patients were 
older than 50 years of age.
Clinical presentation and causes of CPSE were in accordance with the 
literature. A relation between outcome and duration could not be establ-
ished. Morbidity after CPSE is often caused by the aetiology, such as a stroke 
or brain tumour, less often by the continuing discharges themselves (Engel 
et al, 1978; Treiman and Delgado-Escueta, 1988). Morbidity because of 
CPSE was suggested in one case. In our group of CPSE inadequate therapy 
may very well have contributed to a worse outcome in 3 cases.
In ASE all but one patient had idiopathic generalized epilepsy. In ASE we 
did not ﬁnd a female preference, although women outnumbered men in the 
elderly age group. In our patient group with ASE no cases were present with 
situation related ASE or ASE de novo in the elderly. Precipitating factors 
in ASE were in accordance to the literature, the same goes for therapy and 
outcome. Duration was less than 24 hrs in 70% of the cases.
Although outcome in ASE was good in all cases, several showed inadequate 
therapy. 
While examining the patient records in the participating hospitals 
we were struck by the variety of treatments employed to stop SE. Some 
procedures were clearly inadequate.
We recommend the same protocol as that used in generalized convulsive 
SE (Scholtes et al, 1993).

Chapter 6
Simple Partial Status Epilepticus: causes, 
therapy and outcome in 47 patients
J Neurol Neurosurg Psychiatr 1996; 61: 90-92.
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Summary
We conducted a retrospective case-note review of 47 patients of 15 years 
and older who had sustained simple partial status epilepticus (SPSE) in 
the Netherlands between 1980 and 1987. In 46 patients the type of SPSE 
was somatomotor (in four adversive) and in one aphasic with visual and 
auditory hallucinations. SPSE was more common over the age of 50. Six of 
27 patients with previous epilepsy had an acute symptomatic cause. In 20 
patients without previous epilepsy stroke was the most frequent cause (75%). 
Outcome was especially determined by the underlying cause. In one patient 
the continuing epileptic activity may have caused neuronal damage.
6.1 Introduction
Simple Partial Status Epilepticus (SPSE) is characterized by partial seizures 
without impairment of consciousness or secondary generalization, and 
with preserved neurovegetative regulation (Gastaut, 1983). The clinical 
expression depends on the region of the brain where the seizures originate. 
The most frequent type of SPSE is somatomotor. Other types include aphasic 
and somatosensory. Partial seizures with preserved consciousness are called 
SPSE when continuous clinical and electro-encephalographic seizures are 
present for at least 30 minutes (Delgado-Escueta and Treiman, 1987).
In general neurological practice two groups of patients with SPSE prevail:
1.  Those with a succession of simple partial seizures with Jacksonian 
march, without persistent segmental myoclonus (somatomotor SPSE).
2.  Those with persistent myoclonus in a limited area of the body, present 
for weeks or months and sometimes in combination with somatomotor 
or tonic-clonic seizures (Epilepsia Partialis Continua). 
Both types are usually caused by a symptomatic brain lesion, but may also 
occur in patients known with a history of previous epilepsy.
Somatomotor SPSE is synonymous with Epilepsia Partialis Continua 
(EPC) when myoclonic jerks are continuously present in the same body parts 
affected by the somatomotor seizures (Delgado-Escueta and Treiman, 1987; 
Thomas et al, 1977; Schomer, 1993). Most case studies or reviews concern 
EPC; other types of SPSE have only rarely been described (Schomer, 1993; 
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Lohler and Peters, 1974; Juul-Jensen and Denny-Brown, 1966; Meienberg 
and Karbowski, 1977; Andermann et al, 1986). As part of a study on SE in 
The Netherlands we were able to study retrospectively 47 adult patients 
of SPSE. Methods have been described in chapter 2. We were particular 
interested in the various types of SPSE, the causes, EEG ﬁndings, therapy 
and outcome.
6.2 Results
The admissions we retrieved covering a period of eight years concerned 47 
patients, 27 were known with a history of epilepsy. The causes of previous 
epilepsy were symptomatic in 18, whereas in nine patients the cause 
remained unknown. In ﬁve patients SPSE ended with a generalized tonic-
clonic seizure, in seven a tonic-clonic seizure preceded SPSE. In our material 
a female preponderance of 30 versus 17 males was found (table 1).
Table 1: Distribution of age and gender*
Male Female Age 15-30 Age 30-50 Age >50
17 30 2 14 31
* Absolute numbers 
Types of SPSE
Apart from one patient with aphasic SE all showed somatomotor SPSE; 
four of these had adversive SPSE. The facial musculature was involved in 
38 patients, alone (eight) or in combination with the eyes (one), an arm 
(seven), platysma (two), and an arm and a leg (20). In four patients jerking 
was limited to an arm (one), a hand (two) or the abdominal wall (one).
The patient with aphasic SPSE was a woman aged 67, known with 
previous epilepsy (caused by stroke), who developed SPSE with duration of 5 
days. The clinical presentation consisted of aphasia, acoustic hallucinations 
(strange sounds, music, voices), left sided headache and visual hallucinations 
(red balls before right eye). She remained alert and showed on the EEG 
recurrent epileptic seizures starting left occipital with a 13 Hz sharp wave 
activity, changing to spike-wave activity (3-4 Hz) and spreading over the 
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left hemisphere. Sometimes a start was seen in the left paracentral region. 
Further investigations could not establish a cause. When the EEG showed 
that the SPSE had been arrested the patient continued to exhibit persistent 
word-ﬁndings problems and a slight verbal memory deﬁcit. 
In 26 of 46 patients with somatomotor SPSE, frank seizures were 
evident without documented continuous myoclonus. The remainder, 20, 
showed more or less continuous clonic or myoclonic jerks, corresponding to 
EPC. When we compared the patients of EPC to those without continuous 
myoclonus, no differences were found between these two groups of patients 
with regard to outcome, number of patients with previous epilepsy or 
causes.
During SPSE EEG investigation was made in only thirteen patients 
that showed abnormal ﬁndings corresponding to the clinical expression in 
twelve of them. However, speciﬁc epileptic discharges were present in only 5 
patients. Brain CT-scan was performed in all; MRI, PET or SPECT in none.
Causes of SPSE
In 27 patients with previous epilepsy six developed SPSE because of a 
new neurological problem: metastases (two), stroke (one), pneumococcal 
meningitis (one), osteomyelitis of the skull (one) and hypocalcaemia (one). 
Compliance problems (anti-epileptic drugs) were only present in three 
patients. In three patients a systemic infection was considered to be the 
precipitating factor. In 15 patients the cause remained unknown.
In 20 patients without previous epilepsy stroke appeared the most 
prominent cause (14). In three patients a brain tumour had been found, 
while in another three patients a cause could not be established.
Duration of SPSE
Duration was less than two hours in 13 patients, between two and four 
hours in 12, between four and 20 hours in four and longer than 20 hours 
in 18 patients. Half of these had duration of one to three days, the other 
half between three and 14 days. Exceptional long duration (7 weeks or more 
than 1 year) was seen in three patients with continuous focal myoclonic 
jerks (EPC).
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Outcome of SPSE
Four patients died, all due to cerebral infarction. Morbidity after SPSE 
was present in 10 patients and consisted of paresis (four), aphasia (two), 
psychiatric disturbance (one), cognitive impairment (two) and persistent 
impairment of consciousness (one). Morbidity was mainly due to the 
underlying cause (six patients); in three patients the exact cause of morbidity 
could not be established. Morbidity in one patient was attributed to SE itself. 
In the patients with sequelae because of the underlying cause (six), four had 
had a cerebral infarction, one a subdural haematoma and one an intracere-
bral haematoma. The patients with sequelae of unknown cause were all 
known with previous epilepsy.
Table 2: Causes of EPSE in relation to outcome*
Causes of EPSE Outcome good Morbidity Mortality 
Previous Epilepsy (27)
Acute Neurological Cause  6 0 0
Anti-epileptic Drugs  3 0 0
Systemic Infection  2 1 0
Unknown 12 3 0
Total 23 4 0
No Previous Epilepsy (20)
Stroke  4 6 4
Brain tumour  3 0 0
Unknown  3 0 0
Total 10 6 4
* Absolute numbers 
Treatment
Last therapy administered just before SPSE ended or given as a last try 
consisted mainly of benzodiazepines, in particular (40%) clonazepam or 
clonazepam with phenytoin. Other drugs were intravenous phenytoin, 
diazepam, lidocaine, etomidate infusion, thiopental infusion, carbamazepine 
and intravenous calcium in a case of hypocalcaemia. In this last case calcium 
was immediately successful, whereas diazepam and clonazepam failed.
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When outcome is related to quality of therapy we found in patients with good 
outcome that therapy was inadequate in 21%; in patients with morbidity in 
40%, and in patients with fatal outcome in 50%.
6.3 Discussion
SPSE is relatively rare and most case reports and reviews concern EPC, 
also named somatomotor SPSE (Schomer, 1993). We did not ﬁnd speciﬁc 
differences between patients with continuous clonic or myoclonic activity 
and patients with partial motor seizures with regard to cause, outcome and 
the presence of previous epilepsy. Our ﬁndings differ from those published 
for the frequency of previous epilepsy in patients with SPSE. Duration of 
SPSE in our series was generally shorter than mentioned in the literature 
and we differ with respect having a higher prevalence of female patients.
The cause of SPSE in our 20 patients without previous epilepsy was 
stroke in 70%, a brain tumour in 15% and unknown in another 15%. Two 
of the latter patients had a chronic psychiatric disease and one a remote 
symptomatic cause (subarachnoidal haemorrhage some years earlier). 
But also in patients with previous epilepsy an acute neurological problem 
appeared a prominent cause (22%). 
No correlation could be established between outcome and duration. 
Outcome was mainly determined by the underlying cause. In three patients 
the cause of morbidity remained unknown. All three were known with 
previous epilepsy; one was suspected to have a brain lesion, but the exact 
nature was not known; another was known with mental retardation and the 
third had epilepsy because of stroke and a new cerebrovascular accident 
was suggested but this could not be determined with certainty. Only in one 
case SPSE itself as a cause of morbidity was likely.
Continuing seizure activity as a cause of morbidity in partial SE has been 
established in complex partial SE (Engel et al, 1978). SPSE as a cause of 
morbidity only has been suggested in some other patients (Knopman et al, 
1977; Duncan et al, 1990).
In SPSE, like in GCSE (Scholtes et al, 1994) we found that therapy was more 
often inadequate in patients with less good outcome, but the number of 
patients with mortality or morbidity was too low to draw conclusions.
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Treatment of SE irrespective of type should occur according to protocol 
(Scholtes et al, 1993). During treatment adequate medical care with special 
attention for the respiration is essential. The cause of SPSE should be 
established as soon as possible, maintenance therapy with anti-epileptic 
drugs should be continued or started. In therapy-resistant patients surgical 
treatment may be considered (Bancaud et al, 1982).

Chapter 7
Status Epilepticus in Children
Seizure 1996; 5: 177-184.
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Summary
Aetiology and outcome of status epilepticus (SE) in children are different 
in comparison with adult patients. The main characteristics of SE in 112 
children (age 6 months- 15 years) are presented, with special attention to 
age, duration of SE, causes, medical complications and therapy. The greater 
part of these children was known with previous epilepsy, a considerable 
number with mental retardation. Outcome in convulsive SE is inﬂuenced by 
cause, duration, age, the occurrence of medical complications and quality 
of treatment. Outcome in non-convulsive SE is good and does not seem to 
be inﬂuenced by the treatment strategy. The use of a therapy protocol may 
prevent unnecessary delay and contribute to a better outcome.
7.1 Introduction
Status epilepticus (SE) is a major neurological and medical emergency 
requiring treatment to prevent signiﬁcant brain damage and possible 
mortality. SE is a seizure with a minimum duration of 30 min; any seizure type 
may extend to SE. A succession of generalized convulsive seizures without 
regaining consciousness is considered SE too (Delgado-Escueta et al, 1983). 
The limit of 30 min. is not a random choice; beyond that period various 
pathophysiologic changes occur, starting in the substantia nigra (Nevander 
et al, 1984; Nevander et al, 1985). These pathophysiologic changes occur 
mainly in generalized convulsive SE (GCSE) and are important with regard 
to outcome. Because of various unique features of SE in the neonatal brain 
we discuss SE only in children beyond the neonatal period. In the general 
population both the very young and the elderly represent the populations 
most at risk for developing SE. The number of cases has a slight peak at 
<1 year of age and gradually decline until early adulthood (DeLorenzo 
et al, 1992). Mortality in children is lower (2-3%) than in adult patients 
(25%); mortality increases with age and depends on the underlying cause 
(DeLorenzo et al, 1992). The causes of SE are divided in idiopathic, remote 
symptomatic, febrile, acute symptomatic and progressive encephalopathy. 
Children without previous epilepsy are relatively younger, with longer 
seizure duration and a longer postictal coma. SE is the initial presentation 
of epilepsy in 8-12% and occurs in 10-20% during the course of epilepsy, 
Status Epilepticus in Children
153
especially in cases of symptomatic epilepsy. Recurrent SE occurs mainly 
in children with an underlying neurological abnormality (Shinnar et al, 
1992). The risk of epilepsy following SE is increased in acute and remote 
symptomatic cases, but not in idiopathic SE (Gross-Tsur and Shinnar, 
1993). The classiﬁcation of SE follows the classiﬁcation of seizures (Gastaut, 
1983). 
In children, excluding neonates, generalized convulsive SE (GCSE) is 
the most frequent occurring type (Aicardi and Chevrie, 1970; Dulac et al, 
1985; Vigevano et al, 1985). The greater part (50 - 75%) never had seizures 
before (table 1). The outcome of GCSE is especially determined by its cause. 
Outcome is worse in the acute symptomatic group in comparison with the 
idiopathic group or with patients with a chronic encephalopathy. Other 
factors of importance are age (Aicardi and Chevrie, 1970; Dulac et al, 1985) 
and duration of SE (Aicardi and Chevrie, 1970; Yager, 1988; Dunn, 1988; 
DeLorenzo et al, 1992). A signiﬁcant contribution of duration with respect 
to outcome of SE was noted only in the acute symptomatic group (Maytal 
et al, 1989). A relationship between cause and mortality has been found 
especially in cases caused by tumours, but also by anoxia and metabolic 
problems (DeLorenzo et al, 1992). Fever alone, not associated with central 
nervous system infections was not associated with signiﬁcant morbidity or 
mortality. Acidosis, glucose level or sex have no inﬂuence on outcome. 
Generalized Nonconvulsive Status Epilepticus (GNSE) include typical 
absence SE and atypical absence SE; Encephalopathy related to Electrical 
Status Epilepticus during Sleep (ESES) or Epilepsy with Continuous Spike-
Waves during slow wave Sleep (CSWS) and Landau-Kleffner syndrome (LKS) 
are syndromes occurring only in children. The international classiﬁcation of 
epilepsies and syndromes has included both CSWS and LKS as syndromes 
undetermined whether focal or generalized. For practical reasons we have 
chosen to discuss both syndromes in relation to GNSE. GNSE may present 
severe diagnostic problems, especially in mentally retarded patients. EEG 
investigation is necessary and may show several epileptic EEG patterns. 
Typical absence SE is relatively rare in children. Most are already 
known to suffer from idiopathic generalized epilepsy with absences and/
or generalized tonic-clonic seizures, without any neurological impairment. 
Precipitating factors include infections (mostly respiratory), medication 
problems and stress. Duration does not exceed 24 hours in most cases. Apart 
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from complex partial SE, generalized NSE should also be distinguished from 
an acute confusional state caused by fever, trauma or metabolic problems 
(Amit, 1988), and from prolonged postictal encephalopathy (Biton et al, 
1990).
CSWS was described for the ﬁrst time in 1971 by Patry et al (1971); a 
more detailed description was published by Tassinari et al (1985). During 
CSWS severe mental deterioration may occur, together with behaviour 
disturbances. Recovery is possible, but considerable residual dysfunction 
has been reported (Jayakar and Seshia, 1991). Acquired epileptiform aphasia 
in children (Landau-Kleffner syndrome) is characterized by a progressive 
language disturbance that is most probably caused by epileptic discharges 
that occur especially during sleep (Deonna, 1991). 
Partial elementary SE is rare in children and is in most cases (75%) 
somatomotor in expression. Consciousness is not impaired. When myoclonic 
jerks persist between the partial seizures, Epilepsia Partialis Continua is 
present (EPC). EPC is mainly limited to already neurologically impaired 
children (Bancaud et al, 1982).
Complex partial SE in children is recognized by impairment of 
consciousness, emotional or behavioural problems, lack of response to 
familiar persons, lip smacking, picking at nearby objects, focal clonic activity. 
EEG investigation is necessary, in order to distinguish it from absence SE. 
Complex partial SE may also occur in infants (McBride et al, 1981). 
This study was prompted by the experience that in the different hospitals 
where the author worked rather divergent opinions about the care for status 
epilepticus (SE) were encountered. Furthermore, SE was generally considered 
a frightening condition implying an important association with mortality or 
at least morbidity, which did not seem to be corroborated in actual practice. 
First the literature was reviewed, next 112 cases of children admitted in a 
number of Dutch hospitals or treated in Special Centres for Epilepsy were 
collected and studied with respect to population characteristics, type of 
SE, causes, duration of the status, medical complications and strategy of 
therapeutic measures. Methods have been described in chapter 2.
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Table 1: General characteristics of SE in children from the literature
Aicardi
1970
Hayakawa 
1979
Vigevano 
1985
Yager 
1988 
Dunn
1988 
Phillips 
1989
Maytal 
1989 
Number 239 67 84 52 97 193 193
Duration of SE >60 >60 >30 >30 >30 >30 >30
Age (yrs) <15 <15 <13 <18 <18 <14 <18
Previous Epilepsy 
(%)
23 83 16 35 49 29 32
Causes (%)
Acute symptomatic 26 16 42 30 15 43 23
Chronic 
encephalopathy
21 – 45 36 57 10 29
Idiopathic 52 – 13 32 28 46 48
Fever 28 – 6 21 16 32 24
Mortality (%) 11 3 6 6 7 6 3
Morbidity (%) 57 24 21 25  19 ? 9
7.2 Results
In the Netherlands, with a population of about 15 million people, according 
to the SIG every year about 144 children are admitted because of SE (SIG, 
1989). Most of these, i.e. 85%, are reported to have had generalized convulsive 
SE (GCSE). During our study of SE several hospitals in The Netherlands we 
found 112 children. One third had been admitted to the ICU (table 2).
The greater part (67%) was known with previous epilepsy. About half 
of the total group (54%) were mentally retarded. Of these, only 2 never had 
seizures before, and both presented with GCSE.
Generalized Convulsive SE (GCSE)
Most patients had GCSE (82), among them one with tonic and three with 
myoclonic SE. GCSE was strikingly asymmetrical in 33 patients.
The number of patients with previous epilepsy was 51; 41 were known 
with mental retardation. In patients with previous epilepsy a progressive 
neurological disease was considered responsible for convulsive SE in 5 cases: 
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Alpers disease (one), neuronal ceroidlipofucsinosis (one), mitochondrial 
encephalomyopathy (two), unknown cause (one).
The cause remained unknown in 23 patients. Precipitating factors were 
systemic infection in 16 cases (13 patients younger than 5 years), problems 
with anti-epileptic drugs in ﬁve patients and in one stress. In one patient a 
growing porencephalic cyst caused SE.
In 31 cases without previous epilepsy we found the following causes: 
acute symptomatic causes were present in 26 cases and consisted of viral 
encephalitis (herpes simplex in three, varicella in one, virus unknown in 
four), bacterial meningitis (pneumococcus in two), hypoxia (caused by 
respiratory infection in four), Rye-syndrome (one), metabolic disturbance 
(dehydration in one), toxic cause (CO in one, cytostatic drugs in one, 
carbamazepine in one, measles vaccination in one), cerebral contusion 
(four) and a space occupying lesion due to a ruptured AV-anomaly (one). In 
ﬁve cases febrile SE was present.
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Table 2: Main characteristics of 112 children with SE
Age 6 months - 1 yr 1 – 5 yrs 5 - 15 yrs
Ward IC Ward  IC Ward IC
Male (54) 0 5  8  9  27 5
Female (58) 2 2 13 10 25 6
Epilepsy Yes (75) 1 0 17 9 40 8
No (37) 1 7 4 10 12 3
Mental Retardation Yes (57) 0 0 13 8 32 4
No (55) 2 7 8 11 20 7
GCSE (82) 2 7 18 19 27 9
NCSE (27) 0 0 3 0 22 2
EPSE (3) 0 0 0 0 3 0
Causes Previous epilepsy (75)
Acute symptomatic 0 0 0 0 0 1
Medication problems 0 0 0 2 8 0
Systemic infections 0 0 9 6 1 2
Unknown 1 0 7 1 27 3
Progressive neurological disease 0 0 0 1 5 1
No previous epilepsy (37)
Acute symptomatic 0 6 1 9 6 3
Remote symptomatic/Chronic 
encephalopathy
0 0 0 0 2 0
Unknown 0 0 1 0 3 1
Febrile 1 1 3 0 0 0
* When admission to the Intensive Care was necessary the patient is categorized IC; if not 
as ward. Epilepsy and mental retardation refer to the situation before the occurrence of 
SE
Non-Convulsive SE (NCSE)
NCSE consisted of CSWS in four patients, typical absence SE in only two 
(both initial), atypical absence SE in six and complex partial SE in 15 patients. 
This group of 15 patients was surprisingly large: in three the distinction 
with atypical absence was difﬁcult, an EEG was not performed, all 3 were 
mentally retarded. The clinical presentation, however, was suggestive. In 
another eight patients the clinical distinction was obvious; in the remaining 
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four clinical presentation and EEG diagnosis were in accordance with the 
diagnosis of complex partial SE.
The two patients with typical absence SE were a boy and a girl with an 
age between 5 and 15 years. The cause of SE remained unknown. All cases 
with atypical absence SE had previously been diagnosed with epilepsy and 
mental retardation; ﬁve were between 5 - 15 years of age, only one between 
1 - 5 years. The cause or precipitating factors remained unknown.
Most patients with complex partial SE (twelve) were known to have 
suffered previous epilepsy and eight with mental retardation. In cases 
without previous epilepsy (three) viral meningitis caused SE in one patient, 
in another patient a remote symptomatic cause was present (cerebral 
infarction); a systemic infection with fever was present in the third patient. 
Precipitating factors included medication problems in ﬁve.
Partial status epilepticus
The three patients with elementary partial SE (EPSE) were ﬁve, eight and 
twelve years of age; two were known to have epilepsy and a progressive 
neurological disorder of unknown origin. The third patient had EPSE 
because of a head trauma and never had seizures before.
Duration of SE
Duration of GCSE did not differ much in patients with or without pre-
existing epilepsy (table 3). In ﬁve cases a succession of generalized convulsive 
seizures was present, without regaining consciousness, the exact duration 
was not documented.
In NCSE (excluding cases with CSWS) cases with a longer duration were 
more prevalent in patients with previous epilepsy in comparison to cases 
without previous epilepsy.
Duration of CSWS was more than 2 years in all four cases; duration of 
EPSE was weeks in two and 21 months in one patient.
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Table 3: Duration of SE in cases without and with previous epilepsy*
Duration SE No previous epilepsy (35) Previous epilepsy (65)
GCSE NCSE GCSE NCSE
< 2 hrs 17 3 26 5
2 - 8 hrs 7 2 9 4
> 8 hrs  6 0 12 9
* Absolute numbers. Excluded are cases with EPSE (3), CSWS (4) and 5 cases with 
inadequate documentation of seizure duration
Duration and outcome
Duration of GCSE appears very variable; the shorter the duration, the less 
the number of cases with sequelae or death. A brief duration (30 - 60 min.) 
accounts for 18% of morbidity (two cases) and 9% of mortality (one case). If 
duration is between 2 and 8 hours, 27% of morbidity and 18% of mortality is 
present. Duration of 8 hours or more accounts for half of the morbidity and 
27% of mortality.
If one considers only cases in which the cause of morbidity or mortality 
can be directly attributed to SE and not to the underlying disease, then 
there is no morbidity prior to two hours duration and only one patient died. 
Again, only after more than 8 hours duration over half of the morbidity and 
mortality cases due to SE are encountered.
Cause and outcome
Overall outcome is worse in patients with an acute symptomatic cause (table 
4). Acute symptomatic causes were more prevalent in children admitted to 
the Intensive Care Unit (60%) in comparison to those admitted to a regular 
ward (13%). Morbidity (10 out of 11) and mortality (all) occurred mainly 
in children admitted to the Intensive Care. The cause associated with 
the highest mortality was anoxia (all four died); in meningo-encephalitis 
morbidity was 40%, no one died. All cases with febrile SE or SE caused 
by head trauma had good outcome. Cases with a metabolic cause or space-
occupying lesion had either morbidity or died, but the number of cases was 
low.
New neurological signs occurring during or after GCSE are presented 
in table 5.
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In NCSE mental deterioration was obvious in two cases with CSWS. One 
patient developed complex partial status with a duration of hours because of 
a viral meningitis and complained of word ﬁndings problems that resolved 
in a period of 2 years. Whether this was due to the epileptic discharges or to 
an encephalitic lesion remains unknown. This patient was not known with 
previous epilepsy.
Table 4: Outcome of SE in children in relation to type of SE and cause* 
Good Morbidity Mortality
SE Cause Un- 
known
SE Cause Un- 
known
GCSE
Acute symptomatic (31) 55 6.5 3.2 16.1 3.2 9.8 6.5
Previous epilepsy
With MR (41) 85 2.4 4.9 7.3 0
Without MR (10) 80 0  0 0 10 10 0
NCSE
No previous epilepsy (5) 80 0 0 20 0 0 0
Previous epilepsy
With MR (14) 85.7 14.3 0 0 0 0 0
Without MR (8) 100 0 0 0 0 0 0
* EPSE was excluded. Relative numbers (absolute numbers between brackets). MR= 
mental retardation
Table 5: Morbidity in convulsive SE*
New neurological signs SE Cause Unknown
Persistent myoclonic jerks 0 2 1
Aphasia and blindness 1 0 0
Paresis of the arm 0 1 0
Cognitive problems/hemiparesis 0 0 1
Hemiparesis 1 0 1
Vegetative state 1 0 0
Other 0 0 2
Total 3 3 5
* Absolute numbers
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Medical complications and outcome
Medical complications included respiratory insufﬁciency, hyperthermia, 
acidosis, hypotension, intracranial hypertension, and renal and hepatic 
failure. Outcome is worse in patients with 1 or more medical complications 
(table 6). Especially deleterious complications in children were respiratory 
insufﬁciency and intracranial hypertension. Medical complications occurred 
almost exclusively in convulsive SE, i.e. in 25 patients. The remaining two 
patients suffered from complex partial SE; outcome was good in both. 
In six children with GCSE intracranial pressure (ICP) was monitored; 
in one patient the results were normal. In ﬁve children, however, severe 
intracranial hypertension was present: three patients died (two because of 
SE, one because of underlying cause), two patients had new neurological 
problems. In two children the rise of the intracranial pressure was preceded 
by the start of an electro-encephalographic seizure.
Therapy and outcome
During our investigation we tried to establish the quality of the therapy of SE 
in relation to outcome. Insufﬁcient therapy in GCSE may have contributed 
to outcome in 13% of the patients; this is not the case in NCSE (table 7).
Table 6: Outcome in children in relation to the presence of medical 
complications*
Medical complications Outcome Good Morbidity Mortality
No 70 (57) 88 9 3
1 12 (10) 80 20 0
>1 18 (15) 13 27 60
* No complications (no), one complication (1), more than one complication (>1). Relative 
numbers. (absolute numbers between brackets)
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Table 7: Quality of therapy in relation to outcome*
Outcome Good Morbidity Mortality 
Therapy GCSE
Good (59)    81,3   8,5   10,2
Insufﬁcient (23)    52,2  26,1   21,7 
Therapy NCSE
Good (15)    93,3   6,7 0
Insufﬁcient or none (8) 100 0 0
* Relative numbers. Absolute numbers between brackets. Exclusive CSWS (4) and EPSE 
(3).
7.3 Conclusions
The total number of 112 children with various types of SE from different 
types of hospitals (including 2 epilepsy centres) spread all over the country 
does permit us to investigate several questions with regard to SE in children, 
such as cause, therapy and outcome.
The greater part (82) had GCSE, especially tonic-clonic SE. We found 
causes and precipitating factors in agreement to other studies (Aicardi and 
Chevrie, 1970; Dulac et al, 1985; Vigevano et al, 1985; Yager, 1988; Dunn, 
1988; DeLorenzo et al, 1992). Our group however showed a higher percentage 
of previous epilepsy and mental retardation. 
The younger age group showed relatively more cases with acute symptomatic 
causes; the younger the age, the worse the outcome: in children less than 
one year outcome is good in three out of nine (33%), in children 1 - 5 years 
in 29 out of 40 (72.5%) and in children 5 - 15 years in 53 out of 63 (84%). The 
cause is the main determinant with respect to outcome, not age. This agrees 
with the ﬁnding that outcome is worse when admitted to the Intensive Care 
and by the fact that the percentage acute symptomatic causes in patients 
admitted to the Intensive Care is higher than in patients admitted to a 
regular ward. Causes associated with poor outcome are brain tumours, 
anoxia and metabolic problems (DeLorenzo et al, 1992). We conﬁrmed this 
especially with regard to anoxia.
The relation between outcome and duration had been investigated also 
by others (Aicardi and Chevrie, 1970;Yager, 1988; Dunn, 1988; Maytal et 
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al, 1989; DeLorenzo et al, 1992). In our group we found that outcome in 
convulsive SE was worse when duration exceeds 8 hours; when we consider 
only cases with SE as the sole determinant for outcome we found that a 
duration of more than two hours already contributed to a worse outcome. 
Duration of SE did not depend on the cause. In cases of NCSE duration was 
generally longer.
Outcome in NCSE was favourable in most cases; mental deterioration in 
CSWS is part of the syndrome and the word ﬁndings problems after CPSE 
in a patient with viral meningitis were temporary. The number of cases 
with CPSE (ﬁfteen) stresses the fact that CPSE occurs more frequently than 
acknowledged until now.
The low number of cases with EPSE makes it difﬁcult to draw 
conclusions. That is why we only mention the main features we found in 
these 3 patients.
The relation between medical complications and outcome in children 
has not been reported before in the literature. Experimental results 
in animals have stressed the importance of adequate treatment of the 
medical complications occurring during the course of GCSE (Meldrum, 
1983; Siesjo and Wieloch, 1986). According to the literature in adults the 
degree of metabolic acidosis did not correlate with outcome, hyperthermia 
caused a worse outcome (Aminoff and Simon, 1980). In accordance with 
the results in 346 adult patients with GCSE (Scholtes et al, 1994) we found 
that outcome in children with GCGE is worse with one or more medical 
complications. Especially intracranial hypertension appeared to be a 
signiﬁcant negative factor. In cases with difﬁcult to treat SE and medical 
complications, intracranial pressure should be monitored, also because 
epileptic discharges appeared to cause a rise of intracranial pressure in two 
of our patients. A corresponding relation between intracranial pressure and 
epileptic discharges has been found by others (Tsementzis et al, 1979; Gabor 
et al, 1983) and in one of our adult patients.
The quality of therapy was questionable in 23 cases of GCSE and in 8 
cases of NCSE. Especially in the convulsive cases this may have contributed 
to outcome. When insufﬁcient, outcome was good in only 12 of the 23 cases 
(52%), whereas in cases of good therapy outcome was good in 81%. In cases 
of insufﬁcient therapy morbidity was 26% (in cases of good therapy 8.5%) 
and mortality 22% (versus 10.2% in cases of good therapy).
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Therapy should be prompt and according to a protocol, including a time 
schedule, to prevent unnecessary delay. Together with an adequate choice 
of the anti-epileptic drug and prevention of medical complications this may 
contribute to a more favourable outcome for children with SE (Scholtes et 
al, 1993).
Chapter 8
Cognitive Deterioration and Electrical 
Status Epilepticus during Slow Sleep
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Summary
The results of long-term follow-up of 10 children with global or speciﬁc 
cognitive deterioration and on the electroencephalogram an electrical status 
epilepticus during sleep (ESES) are presented. They have been referred 
because of cognitive deterioration and underwent repeated neurological 
and neuropsychological examinations and all-night electroencephalography 
(EEG). A previous cognitive level was known or could be estimated in all. A 
Continuous Spikes and Waves during Sleep (CSWS) syndrome was present 
in 7 children, with global cognitive deterioration in 4 and more speciﬁc 
cognitive decline in 3, and a Landau-Kleffner syndrome (LKS) in another 3 
children. Two children never had seizures, while the other had localisation-
related epilepsy. No children had aggravation of clinical seizures. However, 
therapy was disappointing. Cognitive dysfunction did not respond to 
valproate and/or benzodiazepines in nine of the ten children. A relation with 
a frontal epileptic focus could be found in 5 of 7 children with CSWS, and 
with a left temporal focus in 2 of 3 children with LKS. The ESES persisted 
in CSWS during 5-9 years and in LKS during 1-5 years, and disappeared at 
puberty. Good cognitive recovery after disappearance of ESES occurred in 
only one child, partial recovery in four. Unfavourable prognosis of cognitive 
deterioration seems related to the long duration of the ESES and/or early 
onset of the epileptic activity. The authors are of the opinion that cognitive 
deterioration in children, with or without manifest epileptic seizures, should 
imply EEG investigation during sleep.
 
8.1  Introduction
Electrical Status Epilepticus during Sleep (ESES) consists of sleep-induced 
continuous paroxysmal discharges of spike-wave (SW) complexes with 
a frequency of 1.5-3.5 Hz on the electroencephalogram (EEG). ESES may 
appear continuously or discontinuously during sleep and is usually diffuse 
and bilateral. ESES can last several months or years and typically occurs 
during an important developmental period of childhood, between the age of 
3 and 14 years. ESES can be found in several childhood epileptic conditions, 
but has its most peculiar expression in two speciﬁc age-related and self-
limited disorders, recognized by the Commission on the Classiﬁcation 
and Terminology of Seizures of the International League against Epilepsy 
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(ILAE): the Continuous Spikes and Waves during Sleep (CSWS) and the 
acquired epileptic aphasia or Landau-Kleffner syndrome (LKS). CSWS 
was ﬁrst described by Patry et al (1971) as a subclinical “electrical status 
epilepticus” induced by sleep in children. They described six children 
with epilepsy and cognitive regression, whose EEG during sleep showed a 
pattern of continuous electrical status epilepticus (Patry et al, 1971). Later 
they introduced the neurophysiological term “electrical status epilepticus 
during sleep” (ESES) (Tassinari et al, 1977). In 1983 the acronym CSWS 
was reserved to describe the clinical condition and ESES for the associated 
nocturnal EEG abnormality (Billard et al, 1990; Jayakar and Seshia, 1991; 
Tassinari et al, 1992; Bureau, 1995; Roussele and Revol, 1995; Smith, 1997; 
Veggiotti et al, 1999).
Landau and Kleffner described in 1957 an acquired aphasia in six 
children with a convulsive disorder (the Landau and Kleffner Syndrome, 
LKS) (Landau and Kleffner, 1957). LKS is a severe, partly reversible, age-
related childhood clinical syndrome, characterized by verbal auditory 
agnosia, quickly followed by a regression of spontaneous speech, in 3 of 4 
cases seizures and behavioural disorders, and in all cases a sleepEEG which 
is similar in many ways to that in CSWS (Landau and Kleffner, 1957; Hirsch 
et al, 1990; Paquier et al, 1992; Deonna and Roulet, 1995; Smith, 1997). 
There are also occasional reports of children with ESES and other 
speciﬁc cognitive disorders, such as dyspraxia and non-verbal learning 
disorders, speciﬁc attention disorders and acquired opercular syndrome 
(Billard et al, 1994; Motte et al, 1994; Shafrir and Prensky, 1995).
It is well accepted that epileptiform activity can cause cognitive and 
behavioural disorders. A more or less direct time link exists between cognitive 
disturbances and the diffuse or focal epileptiform abnormalities. Even brief 
discharges of a few seconds, without clearly perceptible clinical symptoms, 
so-called subclinical discharges, can result in cognitive dysfunction, known 
as transient cognitive impairment (Aarts et al, 1984). In CSWS, there are 
several indications that a relationship exists between continuous nocturnal 
discharges and a regression in cognitive functioning and/or behavioural 
problems (Billard et al, 1990; Tassinari et al, 1992; Smith, 1997; Veggiotti et al, 
1999). However, scientiﬁc research is faced with a number of methodological 
problems. First, the clinical phenomenology is ill deﬁned. Second, children 
with CSWS are only sporadically neuropsychological examined before onset 
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of the syndrome, which makes conclusions about regression sometimes 
problematic. Third, there are major differences in the psychological tests 
that have been used. In many cases, only the intellectual level is examined 
and not other cognitive functions, such as language, attention and memory. 
Moreover, there is insufﬁcient conformity in the employed tests. Despite 
these methodological restrictions, a syndrome description does seem 
possible (Jayakar and Seshia, 1991; Roulet et al, 1991; Roussele and Revol, 
1995; Morrell, 1995).
Over the past 10 years, we treated and followed ten children with 
cognitive deterioration, behavioural problems and a sleep-EEG that showed 
continuous epileptic activity; two children never had clinical seizures. 
The same protocol for examination and treatment was applied in all ten 
children. The results of long-term follow-up of these children are presented 
and discussed in relation to the literature.
8.2  Methods
All children referred to our clinic because of cognitive deterioration 
underwent a diagnostic protocol, including evaluation of the clinical 
history, physical examination, standard EEG and whole night sleep-EEG 
registration, neuropsychological examination, and neuro-imaging (MRI or 
CT-scan). 
The degree of epileptic activity during sleep was measured and expressed 
in an index, which was deﬁned by the total duration of continuous epileptic 
(diffuse slow SW) activity in relation to the total slow sleep duration with the 
exception of the REM-phase. The term ESES has been used when the index 
was 85% or more, according to Tassinari et al (1977). CSWS was diagnosed 
when there was a global or speciﬁc cognitive deterioration and LKS when there 
was speech deterioration (acquired aphasia) due to a verbal agnosia, in both 
conditions together with ESES. All patients underwent neuropsychological 
tests, in order to assess their general intellectual functioning, language 
functions, attention and concentration, memory functions and visual spatial 
abilities. The selection of tests used was dependent on patient’s factors such 
as age and general mental abilities. During the follow-up, sleep-EEG and 
neuropsychological examination were repeated at least twice. 
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8.3  Results
The main characteristics of the children in our study are listed in the table 
I-a and I-b.
In all children, other causes of cognitive deterioration, except ESES, 
have been excluded.
Seven children fulﬁlled the criteria of CSWS, 4 patients (patient 1-
3 and 5) had a global cognitive deterioration and 3 (patient 4, 6, 7) had a 
more speciﬁc cognitive decline. LKS was diagnosed in 3 children (patient 
8-10). Pre-existent cognitive levels, determined by neuropsychological 
investigations, were known in 4 CSWS children, in the other 3 CSWS and 3 
LKS cases the cognitive levels could be estimated based on the performances 
at school. In all children cognitive functioning was better before than during 
the CSWS or LKS period. 
Patients 1, 2 and 5 showed typical ESES, associated global deterioration 
and severe behavioural problems. Despite the same EEG pattern, patient 
3 presented a less severe clinical picture. Patients 4, 6 and 7 had ESES, 
more speciﬁc cognitive impairment and behavioural problems. Patient 4 
manifested a relatively great language dysfunction in the beginning of the 
CSWS, but the verbal disability was not verbal agnosia, typical for LKS. 
Patient 6 showed regression of non-verbal functions, with severe impairment 
of visual-spatial tests. Her proﬁle ﬁts with a non-verbal learning disorder 
(NLD). This was also true, but to a lesser degree, for patient 7. The clinical 
presentation of patients 8, 9 and 10 matches that of LKS. However, these 
three children did not present behavioural problems. 
Birth was eventful in eight of the children: breech birth in two, vacuum 
extraction in two, forceps in two, caesarean section in one, and premature 
birth in one. Pre-existent brain damage (meningitis, cerebral haemorrhage, 
hydrocephalus) was mentioned in the medical history of four children, all 
with CSWS. A previous cognitive deﬁcit was present in none of the CSWS 
or LKS children. CT-scan was normal in three patients (patient 1, 4, 10) 
and MRI in two (patient 6 and 8). In one patient with LKS neuro-imaging 
had not been performed. MRI showed discrete atrophy of the right frontal 
area in patient 2, CT showed underdevelopment of the right hemisphere 
and a hypodensity of the right parietal lobe in patient 3, a hydrocephalus in 
patient 5, and hypodensity of the right frontoparietal region in patient 7. 
Chapter 8
170
The diagnosis epilepsy was made at an age of 2½ to 7 years, with the 
exception of patients 5 and 8, who never had epileptic seizures. All children 
with seizures had partial epilepsy, with complex partial seizures (patient 1, 
4, 9, 10), secondary generalized tonic-clonic seizures (patient 2, 3), or partial 
motor seizures (patient 7); patient 6 had atonic seizures and myoclonic jerks. 
Two patients even had partial status epilepticus. Tonic seizures were not 
observed. In all children with seizures the EEG before the start of CSWS or 
LKS showed focal abnormalities. During the clinical course of CSWS and 
LKS the epileptic seizures did not grew worse; the seizure frequency was 
daily in patient 4, but only sporadic or zero in the other children.
After the disappearance of the nocturnal ESES pattern at puberty 
(ages 13 to 14 years), seizures persisted in patient 4 (sporadically nocturnal 
seizures) and in patient 6 (monthly nocturnal seizures). 
CSWS with global deterioration showed a frontal focus in two patients 
(patient 2 and 3) and maximal epileptic activity in the left hemisphere in the 
other two (patient 1 and 5). The patient with a relatively greater language 
regression (patient 4) showed a preferred left frontocentral localisation. 
Patient 6 with the NLD-proﬁle usually had maximum epileptic activity over 
the right frontocentral and to a lesser extent left frontal region. Patient 7 
with also a NLD-proﬁle showed a right frontal focus. In two LKS children 
(patient 8 and 9) a left (fronto-) temporal focus was reported. In the third 
LKS child (patient 10) a maximal epileptic activity over the right fronto-
central region was noted.
Age at diagnosis of CSWS varied from 5.9 to 13 years, age at diagnosis 
of LKS from 4.6-6.6 years. In eight children (patient 1, 2, 5-10) there was 
moderate to serious cognitive regression, in two this was less pronounced 
(3, 4). The two children who were older at the time of diagnosis of CSWS (13 
and 10 years) had no or only slight behaviour disturbance and only slight 
cognitive regression (patient 3 and 4). Behaviour problems in the seven 
children with CSWS were severe in ﬁve, slight in one and absent in one. 
Severe behaviour problems consisted of hyperkinetic disorder, attention 
deﬁcit, and oppositional and aggressive behaviour. Patient 4 with slight 
behaviour problems had periodic outbursts of anger. Behaviour problems 
were absent in the three cases with LKS. All cases with severe cognitive 
regression showed severe behaviour problems. The main epileptic focus was 
frontal in three of ﬁve CSWS children with severe behaviour problems. 
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The duration of the ESES pattern in the CSWS patients was 5-9 years and 
in the LKS patients 1-5 years. Cognitive recovery was complete in only one 
patient (patient 4) and partial in four patients (2, 3, 8 and 10); ﬁve patients 
(1, 5, 6, 7 and 9) showed no recovery. No clear link could be established 
between the degree of recovery and the duration of the CSWS pattern. 
Behavioural disturbances disappeared after resolution of the ESES pattern 
in all, although patient 4 continued to have social problems. 
The ultimate goal of treatment of CSWS and LKS is the disappearance 
of the ESES pattern, which is supposed to be the cause of cognitive 
regression. The effect of ﬁrst line anti-epileptic drugs (AEDs), valproate 
and benzodiazepines, was disappointing in 9 of 10 children; only patient 
9 reacted favourably to valproate. A few children even showed an adverse 
behavioural reaction (patients 2, 4 and 5). A more aggressive therapy has 
been applied in patients 6-8. Patients 6 and 7 have been prescribed all 
currently accepted AEDs in cases of ESES (valproate, benzodiazepines, 
lamotrigine), but also corticosteroids and intravenous immunoglobulines. 
No patients were surgery candidates. The duration of CSWS was the shortest 
(4 years) in patient 6, but had no positive effect on cognition, while patient 
8, with duration of ESES of 1 year, had a good cognitive recovery.
8.4  Discussion
The aetiology and pathophysiological mechanisms of the age-related 
syndromes CSWS and LKS are unclear. An (auto) immunological mechanism 
has been suggested in cases responding to corticosteroids or 
immunoglobulins. Many researchers consider the prolonged nocturnal 
epileptic discharges to be responsible for the speciﬁc or overall cognitive 
deterioration. It is known that neurological damage can occur as a result 
of generalised convulsive status epilepticus and memory disorders after 
complex partial status epilepticus, corresponding to the area of maximum 
epileptic activity (Nevander et al, 1985; Engel et al, 1978). In the non-
convulsive generalised status epilepticus or absence status, no neurological 
deﬁcit has been described. On the contrary, if the ESES pattern during 
sleep disappears after years, spontaneously or under the inﬂuence of AEDs, 
cognitive functioning and behaviour may improve, but complete recovery is 
rare (Roulet et al, 1991; Maresceaux et al, 1990; Yasuhara et al, 1991). 
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The degree of maturation of the cortical network of the brain is high 
between the ages of 1 to 8 years. Disturbances taking place during this 
period may result in permanent impairment of this network. The earlier 
the epileptic disturbance occurs, the greater the functional deﬁcit. The type 
of functional deﬁcit is dependent of the area in which this epileptic activity 
is concentrated. In most of the CSWS patients this is the frontal region 
(Kobayashi et al, 1988; Tassinari, 1995), and in LKS patients the temporal 
lobe (Morrell, 1995; Paetau et al, 1999). Over time this dysfunction can 
spread across a wider area of the brain and give rise to other disabilities. 
Because the epileptic activity is bilateral, the disturbed function cannot be 
taken over by the contra lateral homotopic cortex (Smith, 1997). 
In none of the children in this study a speciﬁc cause could be found, but 
in all the severe nocturnal EEG abnormalities give a plausible explanation 
for the cognitive regression. Eight patients had localised epilepsy and 
two, without epileptic seizures, an asymmetrical EEG. In all the children 
the sleep-EEG normalised at puberty. A preference for frontal epileptic 
discharges in CSWS and for left temporal discharges in LKS could be 
conﬁrmed in our study. In one of the LKS children nocturnal continuous 
epileptic activity was more pronounced over both occipital regions. Our 
CSWS patients showed global deterioration in four cases; one patient showed 
a relatively greater language dysfunction, but not corresponding to typical 
LKS. Two children showed regression of non-verbal functions, with severe 
impairment on visual-spatial tests. Both showed a main right frontal focus 
of epileptic activity, which is in agreement with the supposed pathogenesis 
of this syndrome. 
Some researchers have suggested a possible role for cerebral pathology, 
such as a cerebral tumour or inﬂammation (Perniola et al, 1993; Solomon et 
al, 1993; De Volder et al, 1994). According to the literature, approximately 
25% of the CSWS children have evidence of a pre-existent brain damage, 
caused for example by a meningitis or birth trauma, and 30% have an 
abnormal cerebral CT or MRI scan (Billard et al, 1990; Jayakar and 
Seshia, 1991; Tassinari et al, 1992; Bureau, 1995; Roussele and Revol, 1995; 
Smith, 1997; Veggiotti et al, 1999), while in 75% of the CSWS children no 
previous cognitive handicap or behavioural problem is mentioned. Most 
LKS children are initially normal and achieved developmental milestones, 
including speech, at appropriate ages. Cerebral CT or MRI usually shows 
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no abnormalities (Landau and Kleffner, 1957; Hirsch et al, 1990; Paquier 
et al, 1992; Deonna and Roulet, 1995; Smith, 1997). Neuropathological 
examination in LKS has not revealed abnormalities until now (Cole et al, 
1988; Smith et al, 1992). In our patient group, it was striking that the number 
of children with perinatal problems was high (8 of 10 cases). Perhaps this 
was due to the systematic questioning on the perinatal condition. Neuro-
imaging was normal in two LKS children and three CSWS children, while 
in the other four CSWS children only minor non-speciﬁc abnormalities were 
found. 
The age at onset of CSWS and LKS and the observed seizure types in our 
children are in accordance with data reported in the literature (Landau and 
Kleffner, 1957; Billard et al, 1990; Jayakar and Seshia, 1991; Paquier et al, 
1992; Tassinari et al, 1992; Bureau, 1995; Roussele and Revol, 1995; Deonna 
and Roulet, 1995; Smith, 1997; Veggiotti et al, 1999; Robinson et al, 2001). 
The average age at onset of ﬁve cases with CSWS was 7.1 years (from 3 to 
9). Two other cases with CSWS had a relative late onset at 10 and 13 years, 
with no or only slight cognitive decline or behaviour disturbances. Outcome 
in these two children was, despite a long duration of ESES (6 and 9 years), 
favourable. The age at onset in the three LKS children was 4.6-6.6 years. 
Clinical seizures are not obligatory signs for the diagnosis CSWS or LKS. 
Two children in our group never had seizures. It has been reported that, 
when CSWS children show cognitive regression, seizures may become more 
frequent (Tassinari et al, 1992); in LKS, seizures are infrequent and respond 
well to therapy. In our group most children had only sporadic or even no 
seizures. 
The duration of ESES and cognitive outcome seem correlated. Duration 
of ESES in CSWS varies from a few months to several years (Bureau, 1995). 
In one third of the patients, despite the disappearance of ESES, epilepsy 
persists after puberty. In half of the patients cognition does not ameliorate. 
The prognosis is better in patients with a shorter CSWS duration (Dalla 
Bernardina et al, 1989; Bureau et al, 1990) and cognitive deterioration is 
less when the age at onset of CSWS is after the age of 8-9 years. A direct 
correlation with the severity of the epilepsy has not been proven, nor could 
the presence or absence of a cerebral lesion or the age at which the diagnosis 
CSWS is made be related to the prognosis (Tassinari et al, 1992). In LKS, 
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the mean duration of ESES is from 12 to 96 months (32). Language and 
other neuropsychological dysfunctions gradually improve parallel with the 
disappearance of ESES. Prognosis concerning verbal recovery is favourable 
in 30% of the children. The others show only partial or no recovery. Prognosis 
is worst in children with a long duration of ESES and in children in whom 
the treatment was delayed (Grote et al, 1999; Irwin et al, 2001). No LKS 
child with a duration of ESES of more than 3 years had normal language 
outcome (Robinson et al, 2001). This is perhaps the reason that children 
with later onset of LKS (or shorter ESES duration) have in general a better 
outcome (Gerard et al, 1993).
In our study, all CSWS and LKS children had an ESES index of 80% or 
more. Duration of the ESES pattern in our CSWS group varied from 4.1 to 
9 years, without any correlation with cognitive outcome. Outcome in our 
CSWS and LKS children was poor, but the duration of CSWS was relatively 
long. Prognosis was better when the age of onset was over 9 years. One LKS 
child recovered completely and had the shortest ESES period (1 year), also 
one CSWS child had a good outcome, despite a lengthy ESES duration (6 
years). This child had an age at onset of 10 years, which may have been 
important in this respect. One child with CSWS made a partial cognitive 
recovery; it also was relatively old at onset (13 years) but had a lengthy 
ESES duration (9 years). The two children with LKS and partial recovery 
had ESES duration of 4.5-4.9 years, which is probably too long for complete 
language recovery (Robinson et al, 2001). In one patient with LKS persistent 
impaired auditive memory was noted after partial recovery of the language 
function. This has also been reported in two studies with larger groups of 
LKS patients (Robinson et al, 2001; Grote et al, 1999). 
Behavioural problems with attention deﬁcit, hyperkinesia, aggression, 
impulsivity and lack of inhibition are often present in CSWS (Billard et al, 
1990; Jayakar and Seshia, 1991; Tassinari et al, 1992; Bureau, 1995; Roussele 
and Revol, 1995; Smith, 1997; Veggiotti et al, 1999) and in LKS (Landau and 
Kleffner, 1957; Hirsch et al, 1990; Paquier et al, 1992; Deonna and Roulet, 
1995; Smith, 1997). A relation with frontotemporal EEG abnormalities has 
been suggested (Robinson et al, 2001). 
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Behaviour disturbances in our CSWS children were corresponding to those 
reported in the literature. Behaviour normalised after disappearance of 
the ESES pattern, even after long-standing ESES; normalisation was not 
correlated to restoration of cognition. In contrast to most patients described 
with LKS, our three LKS children did not show behaviour problems, despite 
the presence of frontal EEG abnormalities in two of them. 
Treatment with valproate and/or benzodiazepines is the ﬁrst choice and 
may have a positive effect on CSWS (Smith, 1997; Yasuhara et al, 1991). 
Incidental positive results have been reported with corticosteroids, ACTH, 
ethosuximide, clomipramine and amphetamine (Billard et al, 1990; 
Maresceaux et al, 1990). Negative results, or even deterioration, have been 
reported with carbamazepine, phenytoin, and phenobarbital (Boel et al, 
1989; Maresceaux et al, 1990; Veggiotti et al, 1999). Seizures in LKS are 
in general responsive to standard AED therapy. In some cases valproate, 
ethosuximide, benzodiazepines and corticosteroids have some positive 
effects on ESES and aphasia, but not always permanent (De Marco, 1988; 
Maresceaux et al, 1990; Lerman et al, 1991; Yalcin et al, 1995; Aykut-Bingol 
et al, 1996; Robinson et al, 2001). Incidental positive results have been 
reported with felbamate, nicardipine-nimodipine, sulthiam and intravenous 
treatment with immunoglobulins (Pascual-Castroviejo et al, 1992; Glauser et 
al, 1995; Fayad et al, 1997; Lagae et al, 1998). Carbamazepine and phenytoin 
have adverse and phenobarbital no effect on aphasia (Maresceaux et al, 
1990). Some children with LKS have been successfully treated with multiple 
subpial transections (Morrell, 1995; Sawhney et al, 1995; Irwin et al, 2001). 
The results of therapy on cognitive functions in our group of patients with 
the ﬁrst choice AEDs were disappointing. Only one case with LKS and a 
relatively short ESES duration reacted favourably to corticosteroids. 
Based on the literature and our results, it is obvious that children with 
CSWS or LKS should be treated according to a protocol. Special attention 
should be given to a narrow time schedule, in order to prevent permanent 
deﬁcit (Dalla Bernardina et al, 1989; Bureau et al, 1990; Grote et al, 1999; 
Robinson et al, 2001). If the condition is not recognised or is neglected, 
it may result in irreversible cognitive regression and behaviour problems. 
In any child with unexplained cognitive regression, the following tests 
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should be performed: EEG registration during sleep (entire night), neuro-
psychological examination, and paediatric-neurological examination; other 
possible causes of ESES should be excluded. The treatment of CSWS and 
LKS is complex, because of medical and psychological problems. Therefore, 
best results can be achieved by a multidisciplinary approach. 
Once the diagnosis has been made, treatment should start as soon as 
possible, taking as a guideline a protocol in which, apart from medication, 
attention is given to the behavioural problems, adequate counselling and 
parent guidance. If ﬁrst choice drugs (valproate and/or benzodiazepines, 
such as clonazepam or clobazam) fail, start with corticosteroids but be 
alert to possible hormonal side effects. When the results are disappointing, 
consider intravenous immunoglobulins. Neurosurgery (subpial transsection) 
in specialised centres has been proposed within three years after the 
start of the cognitive regression (Irwin et al, 2001). Given the relatively 
low incidence of this condition, pooling of experience and knowledge is 
important. Treatment should preferably be given on an outpatient basis, 
with support and guidance for the caregivers of the child. In exceptional 
cases the behavioural problems can be so severe that a clinical setting with 
child psychiatry expertise is necessary. 
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Addendum: clinical case histories CSWS and LKS
Patient 1: This boy was born in 1982. He developed normally during his 
ﬁrst years. The onset of epilepsy occurred at the age of 4 years. He developed 
sporadically occurring complex partial seizures with a favourable reaction 
to valproate. At the age of 6½ years he was evaluated in our centre because 
of learning and behavioural disturbances. The diurnal EEG showed diffuse 
spike and poly-spike wave activity in short and long series, maximal above 
the left hemisphere. EEG during sleep showed, with the exception of the REM 
phase, continuous spike wave (SW) activity with a frequency of 1.5-3.5/sec, 
left more clearly than right. The SW index was more than 85%. Psychological 
examination revealed a diffuse cognitive dysfunction with a total IQ of 85. 
Comprehensive metabolic examination revealed no abnormalities; CT-scan 
was normal. Benzodiazepines (clobazam, lorazepam) proved ineffective and 
aggravated the behavioural problems. At the age of 8 years the behavioural 
problems increased. His cognitive level had meanwhile further regressed 
to a total IQ of 59. Ethosuximide brought a slight improvement to the EEG 
during sleep pattern, but had no inﬂuence on the clinical picture. With 
lamotrigine the nocturnal epileptic activity decreased from continuous to 
approximately half of the sleep period. The clinical picture continued to be 
characterised however by serious behavioural problems, nor was there any 
cognitive improvement. By the age of 13 years the EEG pattern was almost 
completely normalised; during the night only sporadic epileptic activity. 
The behaviour problems disappeared completely. His learning skills had 
improved slightly, but his intellectual level remained unchanged (total IQ 
60).
Patient 2: This girl was born in 1982. As newborn baby she had meningitis, 
caused by a haemolytic streptococcus. At the age of 4 years and 10 months 
she had a ﬁrst tonic-clonic seizure with convulsions primarily in the left half 
of the body. A CAT scan was normal. The EEG revealed left parietal local 
spike wave activity with spreading to the central, occipital and temporal 
areas. She was prescribed fenytoin. Because of concentration disturbances 
fenytoin was replaced by valproate at the age of 6 years and 6 months. 
This now caused substantial behavioural problems. Carbamazepine was 
prescribed. One month later she had a tonic-clonic seizure of ten minutes 
followed by hours of reduced awareness, with attendant automatisms. With 
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these symptoms she was hospitalised elsewhere. The EEG at that moment 
showed a seriously disturbed pattern with many bilateral synchronous 
spike wave series. Acetazolamide had no effect, ethosuximide aggravated 
behavioral problems. The patient was subsequently admitted to our clinic. 
At this time the EEG showed continuous spike wave activity with a frequency 
of 2 to 2½ Hz, both diurnal and nocturnal, which had a preference for left 
frontal. Diazepam reduced this spike wave activity. With the stopping of 
carbamazepine this pattern of continuous spike wave activity disappeared, 
although there was still some diffuse epileptic activity. Neuropsychological 
examination revealed a low-average level. For some time the patient did quite 
well without medication, but then at the age of 7 years and 5 months she had 
another tonic-clonic seizure, followed by increasing behavioural disorders, 
decreasing school performance and poor memory recall. The diurnal EEG 
again showed much bilateral spike wave activity from 2 to 3 Hz with series 
of up to ten seconds. This activity was continuously present during sleep, 
with the exception of the REM phase. The SW index was greater than 85%. 
Comprehensive metabolic examination, CAT scan, skin sample, Evoked 
Potentials and an EMG revealed no abnormalities. Benzodiazepines had 
no effect, valproate and barbiturates aggravated the behavioural problems. 
Her cognitive level had meanwhile regressed to a total IQ of 42. In the light 
of her adverse reaction to various anti-epileptic drugs, it was decided to 
discontinue medication. Over the subsequent years the clinical picture 
slowly improved. At the age of 13 years and 9 months nothing exceptional 
was to be seen on either the diurnal or the nocturnal EEG. She was at that 
time attending a Jena plan school and showing an improvement in her 
scholastic skills. Except for the Rickham reservoir and some atrophy right 
frontal, the MRI revealed nothing unusual.
Patient 3: This boy was born in 1973 by vacuum extraction. At the age 
of four days he had ﬁts with cyanosis and apnoea. At the same time a 
hemiparesis left developed. The cause was an intra-cranial haemorrhage. 
At the age of 2 years he was walking and speech was also progressing nicely. 
At the age of 5 years he had a ﬁrst tonic-clonic seizure. He was prescribed 
valproate and carbamazepine. He subsequently had approximately one 
major seizure per year and also had occasional ` absences’. At primary school 
he was an average pupil until the age of 10 years. His development then 
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stagnated and he was placed in a school with special assistance. At the age 
of 13 years he was evaluated in our centre because of learning disturbances. 
The diurnal EEG was asymmetric to the disadvantage of the right without 
speciﬁc abnormalities. During sleep however there was continuous spike 
wave activity of 2 Hz, with a maximum right frontal, with the exception 
of the REM phase. Neuropsychological examination revealed a verbal IQ 
of 59 and a non-verbal IQ of 63. Treatment with benzodiazepines had no 
effect. Discontinuation of anti-epileptic drugs made him much more alert. 
At the age of 22 years the epileptic activity appeared to have completely 
disappeared. He is now taking driving lessons and functions adequately as 
a gardener at a sheltered workplace.
Patient 4: This girl was born in 1978 by vacuum extraction. At the age of 
1 year she had a ﬁrst non-febrile tonic-clonic seizure. No medication was 
given. At the age of 7 years she presented a complex partial status epilepticus 
of several hours with reduced awareness, tonic cramps, right more than left, 
and confusion. A CT-scan was normal. The EEG showed epileptic activity 
left parieto-temporal. There was a high-average level of intelligence with a 
relative language deﬁcit. Anti-epileptic drugs prescribed included fenytoin, 
carbamazepine and valproate in combination with ethosuximide. At the age 
of 10 years she was evaluated in our centre in connection with outbursts 
of anger and increase of the seizures accompanied by blank staring and 
automatisms. The EEG showed local epileptic activity left fronto-central. 
When the ethosuximide was stopped her behaviour improved markedly. She 
did however continue to have daily seizures. An EEG during sleep showed 
continuous bilateral spike wave activity, with the exception of the REM 
phase; there was less epileptic activity in the right-posterior area. The SW 
index was more than 85%. Apart from valproate, she was prescribed ben-
zodiazepines. These proved to have no effect. Her scholastic skills declined 
and her intelligence level dropped to low-average (IQ of 86). At the age 
of 16 years the EEG normalised and the diurnal absences stopped. Her 
intellectual ability restored itself to an average level (IQ of 105), she did 
however continue to have social problems and sporadic nocturnal attacks.
Patient 5: This girl was born in 1979 by forceps extraction. At the age of 
seven weeks she developed a streptococcus meningitis. In connection with 
a hydrocephalus, she was given a drain. Her development was slightly 
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retarded and until her 4th year she was prescribed prophylactic fenytoin. 
At the age of 6 and 8½ years there was a drain dysfunction. She was again 
prescribed prophylactic an anti-epileptic drug, this time valproate. At the 
age of 7 years she had a low-average level of intelligence with a total IQ 
of 90. In connection with behavioural problems and difﬁculties at school, 
further examination in our centre followed at the age of 9 years. By means of 
psychological examination a total IQ of 60 was now determined. The diurnal 
EEG showed paroxysms of spike wave activity in the left hemisphere. During 
sleep diffuse, left predominantly continuous epileptic activity was seen with 
the exception of the REM phase. The SW index was more than 85%. The 
diagnosis CSWS was made. When the valproate was stopped the behavioural 
disorders disappeared. By her 14th year the EEG pattern, both diurnally 
and nocturnally, had more or less normalised. Her cognitive ability however 
had only marginally improved (total IQ 72).
Patient 6: This girl was born in 1987 by caesarean section. Development 
was normal. At the age of eight months she had a febrile convulsion. At 2½ 
years she also began to have non-febrile seizures and later also myoclonia 
and atonic seizures. She was put on valproate, to which she reacted 
favourably until her 5th year, when she developed status epilepticus with 
myoclonia, reacting poorly to anti-epileptic drugs. During her 7th year 
cognitive regression became apparent. Further psychological examination 
revealed a performance decline. At the age of 4 years her IQ was 125, at 
the age of 7 years it was 86, with a verbal IQ of 95 and a non-verbal IQ 
of 78. At the age of 9 years her IQ had further declined to 63, verbal 77 
and non-verbal 55. An EEG at the age of 6 years did not yet reveal a CSWS 
picture pattern. Half a year later however there was a nocturnal pattern 
of continuous epileptic activity, especially right centro-frontal and to a 
lesser extent left frontal. The SW index was more than 85%. Various anti-
epileptic drugs were without effect. Corticosteroid therapy (prednisone) 
had a positive effect on her cognitive functioning, but unfortunately this 
turned out to be temporary; after discontinuation the situation deteriorated. 
A second course of prednisone again had a reasonably positive effect on 
her epilepsy and cognitive functioning. Compulsive eating turned out to 
be a great problem. When she was on prednisone, the EEG during sleep 
showed a marked improvement. This once again deteriorated when the 
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prednisone was discontinued. Further metabolic examination and magnetic 
resonance imaging (MRI) showed no abnormalities. In connection with 
the seriousness of the clinical picture, it was mutually agreed to determine 
whether the patient was eligible for surgical treatment (multiple subpial 
transection). Further examination revealed however that there were at 
least two independent epileptic foci, right fronto-central and left frontal. 
After this revelation, the surgical option was no longer considered. During 
treatment with intravenous gamma-globulins (age 10 years 8 months) there 
was a marked reduction in epileptic activity during sleep, but without any 
improvement in the cognitive situation. An increase in the frequency of the 
epileptic seizures was reported during this phase, primarily nocturnal. This 
could be treated with lamotrigine.
Patient 7: This girl (1990) was born prematurely. Breathing problems 
were present postpartum and she was given a drain in connection with 
hydrocephalus. CT-scan examination showed hypodensity right fronto-
parietal, probably the result of a haemorrhage. The onset of epilepsy occurred 
at the age of 4½ years, with convulsions in the left hand without loss of 
awareness. Later these convulsions spread over the whole left body half. She 
was treated with carbamazepine, later in combination with clobazam. The 
EEG showed increasing local epileptic activity right temporal. The attacks 
continued however and were now accompanied by lowered awareness. 
Other anti-epileptic drugs (oxcarbazepine, vigabatrin, valproate) also had 
no effect. At the age of 5 years 9 months the attacks were reacting favourably 
to oxcarbazepine and clobazam. It was then that scholastic and behavioural 
problems were reported. An EEG during sleep showed continuous epileptic 
activity, with the exception of the REM phase. The SW index was more than 
85%. During the daytime there was diffuse spike wave activity and also 
local epileptic discharges right frontal. CSWS was diagnosed. Treatment 
with gamma globulins and later with prednisone had no effect. The last EEG 
during sleep showed continuous epileptic activity in the form of diffuse, but 
predominantly right, spike wave activity during 65% of the sleep period. 
Her cognitive level dropped from a total IQ of 72 at 5 years 9 months (with 
signiﬁcantly weaker non-verbal scores) to an IQ of 43. From a cognitive point 
of view the right hemisphere continued to present the most problems.
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Patient 8: This girl was born in 1989 by forceps extraction, in connection 
with foetal distress. At the age of 3½ years she was given speech therapy 
because of a language development deﬁcit. During her 5th year her 
development came to a relatively sudden halt; she withdrew into herself 
and barely communicated anymore. Psychological examination revealed 
few non-verbal problems, but a language development test turned out to 
be impossible. Audiological examination revealed nothing exceptional. 
The MRI showed no abnormalities. Diurnal EEG examination showed 
a great many diffuse epileptic discharges. The EEG during sleep showed 
continuous diffuse bilateral spike wave activity, with the exception of the 
REM phase. This phase showed left-fronto-temporal local high-voltage 
slow activity. There were no epileptic seizures. On the basis of the clinical 
symptoms and the EEG, the diagnosis Landau-Kleffner Syndrome was 
made and the patient was put on valproate. This had no result. Intermittent 
corticosteroid treatment was then started. In the ﬁrst week she was given 1 
mg dexamethason, in the second week 0.5 mg. After this the dexamethason 
was stopped. After ﬁve days of treatment a marked improvement in the 
clinical picture occurred. A regression became apparent after nine weeks, a 
second regression after nine weeks, a third regression after sixteen weeks, 
a fourth after twelve weeks, and a last after eleven weeks. Each regression 
reacted well to dexamethason. After the ﬁnal course of dexamethason the 
language problems stayed away deﬁnitively. An EEG at 9½ years was normal. 
Psychological examination at 9 years showed that the language deﬁcit had 
been substantially but not completely eliminated: language comprehension 
remained somewhat retarded, auditive memory also remained weak. After a 
few years of special education for hearing impaired children with language 
deﬁcit this patient was able to resume regular primary education.
Patient 9: This patient was born in 1988 in breech presentation. She 
developed normally until her ﬁrst year. Hearing problems were then 
suspected, but had not been conﬁrmed by an E.N.T. specialist. At 18 months 
a relatively retarded speech-language development was suspected. She had 
her ﬁrst epileptic attack at the age of 4 years, with convulsions in the right 
hand and impaired consciousness. The EEG showed an epileptic focus left 
temporal with spreading to the rear. No EEG during sleep was made at 
this time. Linguistic examination revealed a language development deﬁcit 
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of more than a year, with regard to both expression and comprehension. 
Psychological examination determined an IQ level of 77, with hyperactivity 
and poor memory recall. In connection with the epilepsy she was put on 
carbamazepine. Six months later both diurnal and nocturnal EEGs showed 
bilateral occipital continuous epileptic activity. The combination of the 
clinical picture and EEG results suggested Landau-Kleffner Syndrome. At 5 
years 2 months, with carbamazepine as medication, the EEG was unchanged. 
Language comprehension had increased by one year, language production 
remained stagnant at 3-3½ years. As she got older she progressed but only 
slowly. At 9 years 4 months the EEG was more or less normal with only 
sporadic sharp activity left central. Language production then scored at 5.1 
years and language comprehension at 6.3-7.7 years.
Patient 10: This girl (1982) developed relatively normally during her ﬁrst 
4 years. During her 4th year she was examined for suspected deafness. 
Hearing tests were inconclusive. Her hearing problems continued despite 
a tonsillectomy, an adenotomy and the placing of tubes. Complex partial 
seizures with vomiting were reported from her 5th year. She also developed 
progressive word ﬁnding problems, articulation problems and concentration 
problems. Comprehensive examination by a paediatric neurologist followed 
at the age of 6 years 6 months. Comprehensive metabolic examination, 
CT-scan and SPECT did not reveal any abnormalities. The diurnal EEG 
showed epileptic activity right fronto-central, with spreading to the front 
and rear but also to the left. During sleep the epileptic activity increased 
considerably: continuous generalised diffuse spike wave activity during 
50% of the sleep period, with the exception of the REM phase. During this 
phase there was only epileptic activity on the right. On the basis of the 
clinical symptoms (auditory agnosia, acquired aphasia) and the EEG results, 
Landau-Kleffner Syndrome was diagnosed. Treatment with carbamazepine 
resulted in a worsening of the clinical picture: linguistic communication 
became impossible; she only produced noises. Exploratory psychological 
examination determined a non-verbal level in accordance with her age. 
The EEG now showed continuous epileptic activity during more than 80% 
of the sleep period, with the exception of the REM phase. Carbamazepine 
was replaced by valproate, partly because of the continuing complex partial 
seizures. This resulted in the cessation of the seizures and a slow but steady 
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alleviation of the language problems. At the age of 9 years and 8 months the 
EEG during sleep still showed continuous epileptic activity during 50% of the 
sleep period. By the age of 11 years and 11 months the epileptic abnormalities 
had disappeared. During her 14th year psychological examination showed 
a good development of scholastic skills. Her non-verbal scores were then 
average (97), but there was still a language comprehension deﬁcit.
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Summary
Status epilepticus in patients with mental retardation has not often been 
subject of a separate study. We present the results of status epilepticus in 113 
adults and 57 children with mental retardation. The most frequent type was 
tonic-clonic status epilepticus, both in adults and children. Most patients 
with tonic-clonic status epilepticus had previous epilepsy. In only two adult 
cases and in one child an acute symptomatic cause was present. Causes 
included systemic infections and low anti-epileptic drugs levels. The other 
cases were idiopathic. Outcome was comparable to cases without mental 
retardation but with previous epilepsy, and not related to duration of status 
epilepticus. Outcome in patients with one or more medical complications 
was poor; this was especially true for children. Particular types of status 
epilepticus, occurring especially in mental retardation, include tonic and 
atypical absence status epilepticus. Within the group of non-convulsive 
status epilepticus a considerable number of cases with complex partial 
status epilepticus were present. 
9.1 Introduction
According to Shorvon (1994) the risk of status epilepticus (SE) in patients 
with epilepsy and mental retardation (MR) is high (Shorvon, 1994). Little 
information about prevalence and incidence of SE in patients with MR is 
available, however, some studies mentioned the prevalence; these ﬁgures 
are not very different from those in the general population (Forsgren et al, 
1990; Phillips et al, 1996; Steffenburg et al, 1996; Hauser, 1990; Sillanpää 
et al, 1998). It is possible that many cases of SE in patients with MR are not 
documented. This is supposed to be the case especially for non-convulsive SE 
(NCSE), a diagnosis easily overlooked in patients with MR, with an annual 
incidence estimated to be 100-200 per 1.000.000 persons in the general 
population (Shorvon, 1994; Brodtkorp et al, 1993). Little is known about the 
causes of tonic-clonic SE (TCSE) in MR. Outcome of generalized convulsive 
SE (GCSE) in MR has not been subject of a separate study. Outcome of 
NCSE in MR is uncertain. Some studies failed to show an effect of NCSE on 
outcome in MR (Dravet et al, 1985; Beaumanoir et al, 1988), while others 
described cognitive deterioration after one or more periods of NCSE (Moe, 
1971; Doose and Völzke, 1979; Hoffmann-Riem et al, 2000). 
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Therapy of GCSE in MR has not been the subject of separate research. 
In contrast, several authors discussed treatment of NCSE in MR, but the 
results were often disappointing (Shorvon, 1994; Brodtkorp et al, 1993; 
Beaumanoir et al, 1988; Brett, 1966). 
We have performed a retrospective study of SE in MR to investigate 
whether speciﬁc features were present, which were different from SE 
in the population without MR. We were particularly interested in causes 
and outcome of TCSE in MR. In accordance with the deﬁnition of SE, as 
proposed at the symposium at Santa Monica, we included only cases with 
a minimum seizure duration of 30 minutes or an established succession of 
generalized convulsive seizures without regaining consciousness between 
the seizures (Delgado-Escueta et al, 1983). The classiﬁcation of the various 
types of SE occurred according to seizure type (Gastaut, 1983). Causes of 
SE included acute symptomatic causes, a progressive neurological disorder 
and unknown. Many patients with MR will have previous epilepsy, caused 
by a remote symptomatic neurological problem; we considered the cause of 
SE in these patients unknown (and not remote symptomatic) when an acute 
symptomatic cause or a progressive neurological disorder was not found. 
Our cohort of patients in 12 hospitals and 2 epilepsy centres amounts to 576 
adult cases and 112 children. Mental retardation was present in 113 adult 
patients and in 57 children. The level of MR could be estimated on the basis 
of ﬁle information.
9.2  Results
In the total group, 24.75% had MR, in the children group 53%. Patients with 
MR were more prevalent in the epilepsy centres and the small hospitals 
(table 1-a and 1-b). SE in MR showed a male preference in both adults and 
children. Generalized convulsive SE (GCSE) was the most frequent type of 
SE: 81% in adults and 66,7% in children (table 2). Mental retardation was 
moderate to severe in most patients. Only two adults (27 and 28 years of 
age) and one child (11 years) with GCSE never had seizures before; the cause 
of SE in both adults remained unknown, encephalitis was the cause in the 
child. In eight adult patients with MR the diagnosis SE appeared wrong: 
four with serial seizures, three with only one seizure of usual duration, and 
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one patient was known with previous epilepsy, but did not have a seizure 
when he was admitted. The diagnosis SE was correct in all children. 
Table 1-a: Hospital type and Status Epilepticus (SE) in adult patients in 
the Netherlands
Hospital type University 
(6)
Large 
(2)
Small 
(4)
Epilepsy 
centre (2)
Admissions 300 113  98  65
Number of SE 247  67  90  54
Number of SE/year  5.4  4.5  4.7  3
Previous epilepsy (%)  66  52  69 100
MR (%)  18  7  28  39
Table 1-b: Hospital type and status epilepticus in children
Hospital type University 
(6)
Large 
(2)
Small 
(4)
Epilepsy 
centre (2)
Number of SE  77  3  6  26
Previous Epilepsy (%)  53 100 100 100
MR (%)  37 100  33  88
Table 2: Age and type of SE in patients with MR*
Type of SE Age 1-5 Age 5-15 Age 15-30 Age 30-50 Age >50
GCSE 18 20 42 37  13
EPC  1  1  1  4  0
NCSE  1 16  7  1  0
No SE  0  0  4  3  1
Total 20 37 54 45  14
* Absolute numbers. GCSE= Generalized Convulsive SE; EPC= Epilepsia Partialis 
Continua; NCSE= Non-Convulsive SE; No SE= wrong diagnosis of SE.
Generalized Convulsive Status Epilepticus (GCSE)
In 91 of 92 adult patients (15-71 yrs) TCSE was present; one patient had 
myoclonic SE (MSE) of unknown cause. Recurrent TCSE occurred in 5 
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patients. In 36 children TCSE was present; one child showed tonic SE (TSE) 
of unknown cause and another child with tuberous sclerosis MSE, cause 
also unknown. The causes of GCSE are presented in table 3. The cause was 
unknown in most adult cases; in two adult patients a new neurological 
problem, a cerebral infarction (CVA), caused GCSE. These two patients 
were known with previous epilepsy; one patient had a good outcome, the 
other showed persistent hemiparesis after GCSE. In children systemic 
infections with fever appeared the main cause of GCSE; in about 43% the 
cause remained unknown. In one child, in who encephalitis was the cause 
of GCSE, the outcome was good. Low levels of AED as a cause of GCSE were 
more frequently found in adults than in children.
GCSE was continuous in 59 adults (64%) and in 35 children (92%). 
Outcome in continuous GCSE was good in 81.4% of the adults and in 97% of 
successive SE. Duration of GCSE varied from 30min to more than two days. 
Duration was less than 4 hours in 74% of the children and in 66% of the 
adults. A relation between outcome and duration could not be established. 
Outcome is mentioned in table 4. Morbidity in eight adults, seven with 
continuous GCSE, was caused by the underlying aetiology in two and by SE 
itself in four patients. Morbidity in eight adults consisted of hemiparesis 
(three), impaired consciousness (one), renal disturbance (one), cognitive 
deterioration (one), persisting myoclonic jerks (one). One patient was 
transferred in SE to another hospital. Morbidity caused by SE itself in 
adults consisted of hemiparesis (two), renal disturbance (one) and cognitive 
deterioration (one). SE itself caused mortality in two of four adults with 
continuous GCSE, whereas the underlying aetiology was responsible in one 
patient. SE itself caused morbidity in one of two children with continuous 
GCSE. In children morbidity consisted of aphasia with visual disturbance in 
one (because of SE itself) and persistent myoclonic jerks in another patient 
(of unknown cause). Mortality in three children (all with continuous GCSE) 
was caused in all three by SE itself.
Adult patients with previous epilepsy but without MR had comparable 
outcome to patients with MR; in children without MR outcome appeared 
worse than those with MR, but the number (13) of this group is too low to 
allow ﬁrm conclusions (Table 4). 
Medical complications during GCSE occurred in 33,7% of adult patients 
and in 30% of the children. Medical complications consisted of aspiration, 
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respiratory insufﬁciency, acidosis, hyperthermia and liver failure. Outcome 
in cases without medical complications was better than in patients with one 
or more medical complications, especially in children (Table 5).
Therapy was adequate in adults in 75 patients, with good outcome in 
89,3%. Therapy was inadequate in 15 adult patients, with good outcome in 
80%. In two cases the quality of therapy was hard to deﬁne. In children 
therapy was adequate in 25, with good outcome in 80%. Therapy was 
inadequate in 13, with good outcome in 92,4%.
Inadequate therapy consisted of diazepam i.m., phenytoin i.m., no 
loading-dose of phenytoin, no therapy or insufﬁcient dose.
In both adults and children benzodiazepines (BDZ) and/or phenytoin 
(PHT) were the most frequent used anti-epileptic drugs (AED) to terminate 
GCSE: in 80 adults and 30 children. Other AED in adults were thiopental 
(four), chlormethiazole (one), etomidate (one), chloralhydrate (one); in one 
case all drugs failed, in four no therapy was instituted. In children other 
drugs consisted of phenobarbital (one), thiopental (two), valproate (one); in 
four children all drugs failed.
Table 3: Causes of GCSE in adult patients and children with MR*
Causes of GCSE Adults (92) Children (38)
Unknown 64 16
Low levels of AED 22  3
Systemic infections  4 12
CVA  2  0
Progressive neurological disease   0  5
Encephalitis  0  1
Stress  0  1
* Absolute numbers 
Status Epilepticus in Mentally Retarded Patients: Causes and Outcome in 170 patients
193
Table 4: Outcome (%) in GCSE in adult patients and children*
Outcome 
Good
Morbidity Mortality 
GCSE adults total group (346) 76 13 11
GCSE adults previous epilepsy, no MR (144) 84,7  8,3  6,9
GCSE adults and MR (92) 87  8,7  4,3
GCSE total group children (82) 75 12,5 12,5
GCSE children and MR (38) 86,9  5,2  7,9
GCSE children previous epilepsy, no MR (13) 77  7,7 15,3
* Absolute numbers between brackets
Table 5: Medical complications in relation to outcome (%) in GCSE*
Medical complications Outcome Good Morbidity Mortality 
Adults (92)
No complications (61) 91,8 4,9 3,3
1 or more (31) 77,4 16,1 6,5
Children (38)
No complications (27) 96,3 3,7 0,0
1 or more (11) 63,6 9,1 27,3
* Absolute numbers between brackets
Epilepsia Partialis Continua (EPC)
EPC was present in ﬁve adults and two children. Duration varied between 
two hours and two years. Outcome in the adults was good in three; one 
patient with a brain tumour has hemiparesis; one patient continued to show 
EPC. Both children died.
Non-Convulsive Status Epilepticus (NCSE)
In the eight adults with NCSE, CPSE was present in seven and atypical ASE in 
one. All were known with previous epilepsy. NCSE in the 17 children consisted 
of CPSE in eight, atypical ASE in seven; 2 children with pre-existent MR 
developed continuous spikes and waves during sleep (CSWS). All children 
with NCSE were known with previous epilepsy of unknown cause, except for 
one child with Andermann syndrome, who showed atypical ASE. The adult 
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patient and the children with atypical ASE showed continuous slow spike-
wave activity with the highest amplitudes in both fronto-temporal regions 
on the EEG. In four adults and six children with CPSE the diagnosis was 
made on clinical grounds (partial seizures in patients known with previous 
partial epilepsy) because no EEG investigation has been performed during 
SE. In three adults and two children with CPSE, the EEG investigation 
conﬁrmed SE. In both children with CSWS, repeated overnight EEGs 
showed continuous diffuse spike-wave activity in more than 85% of the 
total sleep duration, with the exception of the REM-phase. 
The cause of NCSE in children was unknown in 11; in six cases low 
AED levels appeared responsible. In adults NCSE was caused by systemic 
infections in two, low AED levels in four, a progressive neurological disease 
in one, whereas the cause remained unknown in another case.
Duration of CPSE in adults varied from less than two hours in two 
patients to more than two weeks in one; the duration in the case with 
atypical ASE was 2 days. Duration of atypical ASE in children was more 
than one day in six cases; ﬁve children with CPSE had duration of less than 
four hours and in two cases of two days.
Therapy was adequate in 60% of both adults and children with NCSE. 
NCSE in adults was terminated with BDZ in six, with thiopental in one and 
with PHT in another. No therapy given in two children, carbamazepine in 
one, chloralhydrate in one, PHT in one, whereas various drugs were without 
effect in another child, and BDZ in the remainder. Outcome was good in all 
cases, except in two children with CSWS who showed persistent cognitive 
decline.
9.3 Discussion
Little information can be found in the literature about the incidence, causes 
and outcome of SE in patients with MR. These patients are probably included 
in the total group of patients with SE (DeLorenzo et al, 1996; Hesdorffer et 
al, 1998; Coeytaux et al, 2000; Knake et al, 2001), but it is not correct to 
extrapolate the results in the total group to patients with MR. There are several 
arguments to state that SE in MR may present special characteristics with 
respect to clinical presentation, causes and outcome: the incompleteness of 
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cerebral development, the presence of speciﬁc aetiology, the fact that some 
MR-syndromes often show particular types of NCSE (Angelmann syndrome; 
Lennox-Gastaut syndrome) and that some types of SE (atypical ASE, TSE) 
occur almost exclusively in patients with MR. Another problem of SE in MR 
is that not all cases will be admitted to a hospital, and that documentation 
is incomplete. This is especially the case for NCSE in MR (Shorvon, 1994). 
A great part of NCSE is probably not recognized. It is also possible that not 
all patients institutionalised in an asylum with a TCSE will be admitted to 
a hospital, when local out-of-hospital treatment proved successful. Cases 
with TCSE who have been admitted to a hospital are resistant to AED of 
ﬁrst choice, show medical complications or have been treated inadequately. 
The patients in our study represent the more resistant and/or complicated 
cases of SE in MR. 
Our study was part of a large retrospective study of SE in the Netherlands. 
From a total group of 576 adults and 112 children with various types of SE 
we discussed the results in 113 adults and 57 children with MR and SE. 
GCSE was the most frequent type of SE in both adults (81,4%) and children 
(66,7%) with MR. NCSE was represented more in children (29,8%) than 
in adults (7,1%). EPC and NCSE were not found in the elderly group. The 
diagnosis of presumed GCSE appeared wrong in eight adults. The group 
of MR patients with GCSE was characterized by the high percentage of 
previous epilepsy (98,2% in both adults and children). In only two adults 
and one child an acute symptomatic cause was present. Causes of GCSE in 
adults included low levels of AED (24%) and systemic infections (4,3%), but 
in the majority the cause of SE remained unknown (69,5%). 
In mentally normal patients with previous epilepsy, acute symptomatic 
causes (8,3%) and systemic infections were more prevalent and the unknown 
cases (32%) less. The number of cases with low levels of AED (30%) was 
comparable to patients with MR, although in the group without MR non-
compliance was more often mentioned in this respect. In a considerable 
number of patients without MR alcohol (9,7%) was reported as cause of 
SE, a feature not present in MR (Scholtes et al, 1994). With respect to the 
causes of GCSE in children with previous epilepsy, with or without MR, no 
differences were found in the rates of systemic infections, low levels of AED 
or the number of unknown cases. A progressive neurological disorder as a 
cause was only present in MR (Scholtes et al, 1996). Outcome in GCSE did 
not differ from cases with previous epilepsy without MR. 
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Several factors that may contribute to outcome in GCSE were investigated. 
The most important factor with regard to outcome is the underlying cause 
(Lowenstein and Alldredge, 1993; Barry and Hauser, 1993). Our group of 
patients were in most cases known with previous epilepsy and showed a low 
number of acute symptomatic causes. Other factors with respect to outcome 
are duration (Aminoff and Simon, 1980; Barois et al, 1985) or treatment of 
SE (Lowenstein and Alldredge, 1993; Delgado-Escueta and Enrile-Bascal, 
1983). Our study could not ﬁnd a relation between duration of GCSE or the 
quality of therapy and outcome. Perhaps the low level of intelligence makes 
subtle cognitive morbidity unnoticed. The presence of one or more medical 
complications was related to poor outcome, especially in children. 
There was a relation between outcome and SE itself in six adults and 
four children. Morbidity because of SE itself was present in 4,3% of the 
adults with MR and in 2,6% of the children; mortality because of SE itself 
was 2,1% in adults and 7,9% in children. Compared to the patients with SE 
without MR from our large SE-study, no differences were found between 
children with or without MR with respect to the contribution of SE itself 
to outcome. In adults more patients without MR died because of SE itself 
(13,2%) than adults with MR (2,1%); the rates of morbidity because of SE 
itself were comparable in adults. 
Most cases with GCSE concerned TCSE. Speciﬁc types of SE in MR 
were limited to atypical ASE (1 adult and 7 children) and TSE (1 child). 
The number of cases with CPSE in both adults and children was striking. 
One may criticize our assumption that cases with previous partial epilepsy 
and NCSE were categorized as probable CPSE, despite the absence of 
EEG investigation during SE. It seems, however, acceptable to make the 
diagnosis of (probable) CPSE, based on the clinical presentation with focal 
neurological signs in a patient with documented previous partial epilepsy 
(and not symptomatic generalized epilepsy), together with the results of 
anti-epileptic drug treatment. These features make another diagnosis of 
atypical ASE (especially in patients with symptomatic generalized epilepsy), 
post-ictal confusion or pseudo-SE most unlikely. 
This study has shown that outcome of SE in MR patients admitted to a 
hospital is comparable to patients with previous epilepsy but without MR. 
The assumption that especially the more resistant and/or complicated cases 
with SE in MR are admitted to a hospital, suggests that outcome of SE in MR 
is not poorer but rather more favourable than in non-retarded people. 
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The present results call for a prospective population based study of SE in MR 
to overcome the drawback of this retrospective study. Case-ascertainment in 
patients with MR is difﬁcult. Therefore, cooperation with caregivers working 
in hospitals or asylums for patients with MR, with general practitioners (who 
take care of patients with MR who live at home) and with paediatricians is 
mandatory in this respect.

Chapter 10
Admissions to the Intensive Care Unit 
because of Generalized Convulsive  
Status Epilepticus
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Summary
We studied 110 adults and 35 children admitted to the Intensive Care Unit 
because of Generalized Convulsive Status Epilepticus (GCSE). Causes of 
GCSE in adult patients with previous epilepsy were non-compliance and 
systemic infections, in children systemic infections. Acute symptomatic 
causes in adult patients without previous epilepsy were stroke, intoxication, 
metabolic disturbances and brain tumours; in children the main causes 
were bacterial meningitis and viral encephalitis. In comparison to cases 
with GCSE not admitted to the ICU outcome was worse. Especially cause 
and the number of medical complications determined outcome. Especially in 
children more severe cases with GCSE occurred, which caused a signiﬁcantly 
worse outcome in children with previous epilepsy. 
10.1 Introduction
Admission to the Intensive Care Unit (ICU) because of status epilepticus (SE) 
may be necessary especially when medical complications, such as respiratory 
insufﬁciency, are present, or when anaesthesia is mandatory to control SE. 
Few studies describe characteristics of adult patients and children with SE 
admitted to the ICU (Goulon et al, 1985; Nouailhat et al, 1985; Barois et 
al, 1985; Lacroix et al, 1994; Eriksson and Koivikko, 1997; Holtkamp et al, 
2005). Other studies describe treatment of SE in the ICU in small cohorts of 
patients with anti-epileptic drugs such as midazolam, thiopental or propofol 
(Osorio and Reed, 1980; Orlowski et al, 1984; Lowenstein et al, 1988; Ness, 
1990; Kumar and Bleck, 1992;Yaffe and Lowenstein, 1993; Parent and 
Lowenstein, 1994; Stecker et al, 1998; Claassen et al, 2001; Prasad et al, 
2001; Claassen et al, 2002).
Most adult patients admitted to the ICU because of SE are not known 
with previous epilepsy, show a large percentage of acute neurological insults 
and a high morbidity and mortality rate (Goulon et al, 1985; Nouailhat et 
al, 1985; Yaffe and Lowenstein, 1993). Outcome is especially determined by 
the underlying cause; a relation with duration of SE was not always present 
(Goulon et al, 1985; Nouailhat et al, 1985). A drawback of these studies 
was the inclusion of different types of SE, which make it difﬁcult to draw 
conclusions about outcome (Goulon et al, 1985; Barois et al, 1985). 
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In children generalized convulsive status epileptics (GCSE) occurs especially 
in the younger age group without previous epilepsy (Aicardi and Chevrie, 
1970; Yager, 1988; Philips and Shanahan, 1989; Lacroix et al, 1994; Eriksson 
and Koivikko, 1997) and outcome is especially determined by the underlying 
cause, age, but also by duration of SE (Aicardi and Chevrie, 1970; Barois et 
al, 1985; Dunn, 1988; Yager, 1988; Maytal et al, 1989; Philips and Shanahan, 
1989; Lacroix et al, 1994; Eriksson and Koivikko, 1997). Acute neurological 
causes are more frequent in the younger age groups (Philips and Shanahan, 
1989; Lacroix et al, 1994; Eriksson and Koivikko, 1997). 
GCSE may be the reason for admission to the ICU, but SE may also occur 
during the stay at the ICU because of another medical problem (Goulon 
et al, 1985; Nouailhat et al, 1985). Apart from clinical evident cases of 
convulsive SE, non-convulsive SE may be diagnosed in cases with impaired 
consciousness of unknown cause, without clinical evident seizure activity 
(Young et al, 1996; Lowenstein and Alldredge, 1992; Litt et al, 1998; Towne 
et al, 2000; Varelas et al, 2003). 
This retrospective study was part of our investigation about therapy and 
outcome of SE in the Netherlands (chapter 2). We studied 110 adults and 
35 children admitted because of GCSE to the ICU. We investigated causes 
and outcome of patients with GCSE admitted to the ICU and compared the 
results to patients not admitted to the ICU. Only patients with minimum 
seizure duration of 30 minutes or an established succession of generalized 
convulsive seizures without regaining consciousness between the seizures 
were included. Those who developed SE during their stay at the ICU and 
cases with non-convulsive SE or elementary partial SE were not included. 
The effects of the administered anti-epileptic drugs could be adequately 
studied in 41 adult patients and 35 children. The documentation of the 
results of the various drugs used before and during their stay at the ICU to 
treat SE was adequate in these patients. In the other adult patients especially 
the drugs used to terminate SE had been adequately mentioned, but those 
used earlier with less details.
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10.2 Results
Age, gender and number of patients with previous epilepsy are presented in 
table 1.
Table 1. Age, gender and number of previous epilepsy of patients 
admitted to the ICU*
Male Female Previous 
Epilepsy
Age 
15-30
Age 
30-50
Age 
>50
Adult patients 61 49 66 (60,0%) 36 39 35
Male Female Previous 
epilepsy
Age 
<1
Age 
1-5
Age 
5-15
Children 20 15 14 (40,0%)  6 20  9
* Absolute numbers.
The number of adult patients with previous epilepsy was higher (60%) than 
in the group of children (40%). Precipitating factors, responsible for GCSE 
in adult patients with previous epilepsy were non-compliance and systemic 
infections with fever (table 2). The patients with a progressive neurolog-
ical disease were suspected to have a mitochondrial encephalopathy. Other 
causes included a patient with carbamazepine intoxication (level 32 mg/l), 
who died because of GCSE.
In adult patients without previous epilepsy CVA was a prominent 
cause, especially in the older age group. Toxic causes included ethylene-
glycol-intoxication with several medical complications and good outcome, 
amipaque (after caudography) and cyclosporine; metabolic causes included 
hyperglycaemia (level >36 mmol/l), hypokaliaemia (2,0 mmol/l) and 
hypocalciaemia (1,38 mmol/l). Brain surgery had been performed in a 
patient with a meningeoma and in a patient with a craniopharyngeoma. 
One patient with a brain tumour (malignant meningeoma) developed GCSE 
during radiotherapy.
In children systemic infection was the main precipitating factor in cases 
with previous epilepsy (table 2). In children without previous epilepsy 
bacterial meningitis and viral encephalitis were the most important causes 
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of SE. Three of them had herpes simplex encephalitis, all with good outcome. 
Two children with laryngo-bronchitis had a cardiac arrest and had to be 
resuscitated; both died. Two children developed severe hypoxia (one shortly 
after a cardiac operation, one because of a severe pulmonary infection); 
both died. The toxic causes consisted of one case of CO-intoxication (this 
patient died) and a patient who had been treated with cytostatica because 
of a medulloblastoma. This last patient showed cognitive disturbances after 
GCCE. The metabolic problem included a case with severe hypernatraemia 
(sodium level 160 mmol/l), who developed GCSE during rehydration.
Table 2: Causes and precipitating factors of GC-SE*
Adults Age <1 Age 1-5 Age 5-15
Previous epilepsy 66 0  8 6
Non compliance/lowering AED 16 0 2 1
Systemic infection 11 0 5 2
Progressive degenerative disease 4 0 0 0
Alcohol 5 0 0 0
Head trauma 2 0 0 0
Other 5 0 0 1
Unknown 23 0 1 2
No previous epilepsy 44 6 12 3
CVA 15 0 0 0
Toxic 5 0 1 1
Metabolic 4 1 0 0
Cardiac arrest 3 0 0 0
Brain surgery 2 0 0 0
Head trauma 2 0 2 0
Meningitis/encephalitis 3 2 4 2
Brain tumor 4 0 0 0
Multiple sclerosis 2 0 0 0
Unknown 4 1 0 0
Hypoxia/resuscitation 0 2 2 0
Systemic infection 0 0 3 0
* Absolute numbers.
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Table 3: Outcome in GCSE*
Outcome Good Morbidity Mortality 
Adults
Total (110) 56,3 20,9 22,7
Previous epilepsy (66) 66,7 15,1 18,2
No previous epilepsy (44) 40,9 29,5 29,5
Children
Total (35) 42,8 25,7 31,4
Previous epilepsy (14) 42,9 21,4 35,7
No previous epilepsy (21) 42,8 28,6 28,6
Non-ICU adults: Total (236)  82,7 9,6 7,6
Previous epilepsy (169)  92,3  5,9  1,8
No previous epilepsy (67)  58,2 19,4 22,4
Non-ICU children: Total (47)  95,7  4,3 0
Previous epilepsy (37) 100  0  0
No previous epilepsy (10) 80 20  0
* Non-ICU refers to patients (GCSE) not admitted to the ICU.
Outcome appeared to grow worse with increased duration in children, 
most evident after 2 hours. This was evident when SE itself had determined 
outcome. When outcome had been determined by the underlying cause, a 
relation with duration could not be established in both children and adults. 
The relation between outcome and duration in adults was less evident for 
total morbidity and mortality. When restricted to cases where SE itself 
had determined outcome, morbidity increased especially after 2 hours 
and mortality after 8 hours. In adult cases with morbidity and mortality 
determined by SE itself, duration of GCSE was in most cases longer than 8 
hrs (66,7 % of the cases with morbidity, 60 % of mortality). In children poor 
outcome determined by SE itself occurred in 75% of the cases with duration 
longer than 8 hours.
In children and adult patients outcome was worse when more than one 
medical complication was present (table 3). 
Treatment of patients with GCSE in the ICU consists not only of adequate 
administration of anti-epileptic drugs but also of monitoring of ventilation, 
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blood pressure and heart rate and subsequent treatment of present 
abnormalities. The same goes for other possible medical complications such 
as acidosis, hyperthermia, and renal failure in cases of rhabdomyolysis. 
Based on information from the literature epidural intra-cranial pressure 
(ICP) monitoring was started (5 adult patients and 10 children) in complicated 
cases treated in a university medical centre. All patients with ICP-monitoring, 
except one, showed increased ICP with values varying from 40-100mmHg 
(normal less than 15). In several cases cerebral perfusion pressure (CPP) 
was at times almost zero, or at least too low for sufﬁcient brain circulation. 
In one adult and in one child we found a relation between the start of a seiz-
ure (EEG monitoring) and the subsequent rise of ICP. Outcome in patients 
who had ICP-monitoring was poor. Only one adult patient and one child had 
a good outcome, whereas three adults and 7 children died. 
Outcome in cases who needed mechanical ventilation was poor. Mortality 
in children was 46,4% and in adults 41,9%. No patients died in cases that 
did not need mechanical ventilation. 
Table 4: Relation between outcome and medical complications*
Outcome Good Morbidity  Mortality
Complications children Total SE Total SE 
No (17)  64,7 29,4 5,9  5,9  0
  1 (2) 100  0 0  0  0
> 1 (16)  12,5 25,0 6,25 62,5 31,25
Complications adults 
No (33) 63,6 27,3 0  9,1  0
  1 (31) 74,2 19,3 3,2  6,4  3,2
> 1 (46) 39,1 17,4 8,7 43,5 28,3
* Absolute numbers between brackets
The effects of the administered anti-epileptic drugs were studied in 41 adult 
patients and 35 children (table 4). In cases with good outcome (16 adults, 15 
children) therapy was insufﬁcient in 27%, in cases with sequel (12 adults, 9 
children) in 31,5% and in patients who died (13 adults, 11 children) in 54%. 
No differences were present between adults and children. Therapy was good 
in the two cases with sequel because of SE and in 5 of the 7 cases that died 
Chapter 10
206
because of SE. The quality of therapy did not inﬂuence outcome in cases 
with morbidity or mortality caused by SE itself.
The number of patients who were successfully treated with BDZ 
(especially diazepam and clonazepam, in some cases clorazepate) was low. A 
few patients (3 children) showed a positive effect during clorazepate infusion, 
whereas thiopental was not successful in these cases. The number of success-
fully treated cases with PHT was also low, but proper loading was done in 
only a few patients. Phenobarbital (PB) in children was ineffective in all 
cases, possibly because of a low dose. Thiopental was used only in cases when 
BDZ, PHT or PB was ineffective. Chlormethiazole had been tried in 3 adult 
patients (2 successful) and 2 children (1 effective) after the use of thiopental. 
Etomidate was used only after failure of thiopental. The miscellaneous drugs 
consisted of valproate, carbamazepine and acetozalomide. In one adult case 
GCSE subsided without further intervention; this patient showed no effect 
of BDZ and PHT. In 7 adult patients and 8 children all therapy was without 
any evident effect; they died. 
Drugs used in the other adult patients to terminate GCSE consisted of: 
BDZ (24%), PHT (20,3%), PHT+BDZ (8,5%), thiopental (22%), etomidate 
(10,2%) and chlormethiazole (1,7%). In 13,5% none of the administered 
drugs were successful.
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Table 5: Anti-epileptic drug therapy in GCSE*
Adults (41) Children (35)
Used Successful Used Successful
Benzodiazepines i.v. 44 17 33 12
Phenytoin shot i.v. 23 1 22 2
loading 6 0 1 0
i.m. 1 0 0 0
+ BDZ 4 4 0 0
Phenobarbitone i.v. 2 0 20 0
i.m. 2 0 2 0
Thiopental shot i.v.  1  0  2  2
infusion 11 7 16 10
Chlormethiazole infusion  5  4  2  1
Etomidate infusion 2 0 3 0
Chloralhydrate rectal 0  0  5  0
Miscellaneous 1 0 3 0
* Absolute numbers
Morbidity (20,9%) and mortality (22,7%) in the adult patient group, but also 
in children, 25.7% respectively 31,4%, were both especially determined by 
the underlying cause.
Morbidity and mortality in adult patients with previous epilepsy were 
lower than in patients without previous epilepsy, but worse than in patients 
with previous epilepsy not admitted to the ICU (table 5). Outcome was 
worse than in cases not admitted to the ICU; the difference in cases without 
previous epilepsy admitted versus not admitted to the ICU, was not as 
obvious as in children. This underlines the signiﬁcance of the underlying 
cause with respect to outcome in adults. It was striking that outcome in the 
group of children with previous epilepsy was just as bad as those without 
previous epilepsy (table 5). Outcome in children not admitted to the ICU was 
far better, also for those without previous epilepsy. This may be explained 
by the fact that cases admitted to the ICU suffered from more severe GCSE. 
Morbidity in children of less than one year was 33%, and in children of 1-5 
yrs 30%; mortality was 50 and 30% respectively. In older children (5-15 yrs) 
morbidity and mortality was 11% respectively 22%. 
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Morbidity because of SE per se in adult patients was 4,5%, in children 8,5%; 
for a group of 236 adult patients, not admitted to the ICU, 2.8% and for 
children 0%. Mortality because of SE per se in adult patients was 11,8% and 
in children 14,3%. In the non-ICU group this was only 3.6% for adults and 
0% in children. These ﬁgures also make clear that cases admitted to the ICU 
suffer from a more severe GCSE.
10.3  Discussion
Admittance because of GCSE to the ICU was necessary because of failure 
of ﬁrst line drugs (BDZ, PHT) or the occurrence of medical complications 
such as respiratory insufﬁciency. Outcome was especially determined by 
the underlying cause, both for adults and children. These results conﬁrm 
earlier reports (Aicardi and Chevrie, 1970; Goulon et al, 1985; Nouailhat et 
al, 1985; Barois et al, 1985; Dunn, 1988; Yager, 1988; Philips and Shanahan, 
1989; Maytal et al, 1989; Lacroix et al, 1994; Eriksson and Koivikko, 1997; 
Claassen et al, 2002). The less favourable outcome in the very young child 
or in the older age group and in patients without previous epilepsy is in 
accordance with this result. Causes and precipitating factors were not 
very different from other reports. Causes with a poor outcome were CVA 
and cardiac arrest in adult patients and in children resuscitation after 
laryngo-bronchitis and hypoxia and pneumococcal meningo-encephalitis. 
In children outcome was also related to the severity of SE, reﬂected by the 
results in children with previous epilepsy and by the results of therapy in 
cases where SE itself had determined outcome. We demonstrated a clear 
worse outcome in cases admitted to the ICU in comparison to those not 
admitted to the ICU. Apart from underlying cause, the seriousness of the 
cases with GCSE admitted to the ICU may be important with respect to this 
difference.
The relation between outcome and duration can best be discussed 
separately for cases where outcome is determined by the underlying cause 
and cases where SE itself has been the main determinant. When outcome 
is especially determined by the underlying cause, damage is present from 
the start of SE and the contribution of continuous seizures will be hard to 
establish.
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Although a relation between duration and outcome has been suggested 
by several authors (Rowan and Scott, 1970; Aminoff and Simon, 1980; 
Barois et al, 1985; DeLorenzo et al, 1987; Eriksson and Koivikko, 1997), 
few described the distinction between underlying cause and SE itself in 
reporting the relation between outcome and duration of GCSE (Aminoff 
and Simon, 1980). Our study suggests a negative relation between duration 
of more than 2 hrs and outcome, especially in cases where SE itself was res-
ponsible for morbidity or mortality.
Others have already demonstrated that therapy delay (Rowan and Scott, 
1970; Treiman et al, 1983; Lowenstein et al, 1988) contributes to a longer 
duration of SE, the same goes for inadequate therapy (Delgado-Escueta 
and Enrile-Bascal, 1983). Our observations about the role of medical 
complications and the quality of therapy conﬁrm these ﬁndings. Our 
results also show that some patients with GCSE appear difﬁcult to treat, 
despite adequate measures. These cases suffer from a severe type of GCSE, 
contributing to increased morbidity and mortality.
Treatment of SE should occur according to protocol, including a time 
schedule and an adequate choice of available AED (Scholtes et al, 1993). BDZ 
and PHT remain ﬁrst line drugs, with adequate loading of PHT. In the ICU 
thiopental is an important drug when the ﬁrst line drugs fail; our results 
have shown beneﬁcial effects of thiopentone in difﬁcult to treat cases with 
GCSE. Recent alternatives are midazolam or propofol infusion, but adequate 
trials comparing the results of various drugs in refractory SE are not yet 
available. In some cases even a forth or ﬁfth drug appeared to be successful 
to terminate SE. EEG monitoring is very important, especially in cases that 
have been paralysed (mechanical ventilation), but also to adjust therapy. We 
have observed that in some cases the simultaneous recording of the EEG 
and ICP-monitoring a relation exists between seizures and the subsequent 
rise of ICP, which has been reported earlier (Tsementzis et al, 1979; Gabor 
et al, 1984). ICP monitoring may have important therapeutic consequences, 
because cerebral perfusion pressure may reach a critical threshold. 
Outcome in patients admitted to the ICU because of GCSE is worse than 
in cases not admitted to the ICU. Apart from serious acute symptomatic 
causes, the severity of SE appeared also important with respect to outcome, 
stressing the importance of treatment according to protocol. 
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11.1 Introduction
Experiences with cases of status epilepticus (SE), refractory to ﬁrst-line 
anti-epileptic drugs (AED), treated at the intensive care unit (ICU), initiated 
this study. Despite the presence of adequate medical literature about the 
pathophysiology and treatment of SE (Aminoff and Simon, 1980; Delgado-
Escueta et al, 1983), patients with SE were treated without the presence of a 
protocol, even in the neuro-intensive care unit of a University hospital.
Most cases with SE are successfully treated with ﬁrst-line AED, refractory 
cases occur less often. On the one hand this might explain the absence of 
such a treatment protocol, on the other hand it should have been the reason 
to initiate a protocol, especially in an University training hospital, where 
difﬁcult to treat cases are often referred to. Another reason became evident 
when treatment according to protocol had been suggested (Scholtes and 
Dries, 1986), which caused opposition among several senior staff members; 
they preferred to stick to their own method. Based on our experiences the 
intention to promote therapy of SE according to protocol seemed logical, the 
criticism or opposition to introduction appeared a phenomenon that is often 
encountered during a process of transformation into a rational or evidence 
based protocol. 
After the ﬁrst attempt to initiate treatment of SE according to protocol 
an investigation was started to evaluate outcome and treatment of SE in 
the Netherlands. At that moment no data about this subject were available 
in the Netherlands. The foreign literature at that moment contained only 
retrospective, highly selective, studies with patients from university 
hospitals or specialized inpatient services, with considerable differences in 
age groups. Several drawbacks of these studies, apart from the retrospective 
nature, were apparent: 
– The inclusion of different age groups.
– No distinction in patients with or without previous epilepsy.
– The inclusion of different types of SE.
– Variable duration of follow-up.
– Discussions about outcome without distinction between cases with 
or without previous epilepsy or between the different types of SE or 
without a relation with underlying cause and SE itself.
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Recent prospective studies did not entirely overcome these problems, 
outcome was still reported irrespective the type of SE or the presence or 
absence of previous epilepsy. This was illustrated by the differences in 
outcome between the study from Germany (Knake et al, 2001) and the study 
from the USA (DeLorenzo et al, 1996). These differences appeared to be, 
at least partly, determined by differences in the numbers of patients with 
convulsive SE.
Information about the incidence of SE was not available at the start of 
this study and has been provided only recently by some prospective studies 
(DeLorenzo et al, 1996; Coeytaux et al, 2000; Knake et al, 2001).
We traced as many as possible admissions because of SE to a number of 
hospitals during the period 1980-1987. Included were only cases consistent 
to the current deﬁnition (Delgado-Escueta et al, 1983). The various types 
of SE were divided according to the current classiﬁcation of SE (Gastaut, 
1967).
In order to trace patients with SE in the several hospitals in the 
Netherlands we used dismissal diagnoses, coded according to the 
International Classiﬁcation of Diseases of the World Health Organisation, 
the ICD-9, implemented by SIG and the hospitals in the Netherlands. This 
classiﬁcation appeared to have limitations, because only three types of SE 
had been coded: petit-mal SE (code 345.2), grand-mal SE (code 345.3) and 
Epilepsia Partialis Continua (code 345.7). A separate code for e.g. complex 
partial (CPSE) or tonic SE (TSE) was not available. Still we did ﬁnd a 
considerable number of cases with CPSE, although the dismissal code was 
different, such as petit mal SE or even grand-mal SE.
We encountered several other problems:
– A considerable number of cases with a wrong diagnosis of SE (No-SE).
– A wrong diagnosis of the type of SE, such as cases with elementary 
partial SE (EPSE) classiﬁed as CPSE, generalized convulsive SE (GCSE) 
or as petit mal SE.
– Duration of SE was not always recorded; in such cases duration could 
often be estimated with the help of information about transport and/or 
treatment duration. Only cases with known duration were included in 
the discussion about the relation between outcome and duration.
– Information about treatment initiated by the general practitioner or 
ambulance personnel was not always available.
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– The number of seizures in successive SE was not always noted.
– Not all registered cases with SE could be traced.
The completeness of documentation of dismissal diagnoses in the hospitals 
we visited varied widely, which did not depend whether it was an academic 
hospital or not. In fact, the smaller hospitals appeared well organized in this 
respect and showed no or very few cases with No-SE. Some other features 
were striking, such as inconsistent loading of phenytoin or inconsistent EEG 
monitoring. This was especially the case in some of the academic hospitals. 
A treatment protocol was present in only one academic hospital and one 
epilepsy centre; it was not always followed, however. The other academic 
hospitals treated at random, possibly depending who was in charge as senior 
staff member. 
Other investigators have mentioned the problem of a correct diagnosis 
of epileptic seizures or SE; SE was not recognized or the diagnosis appeared 
incorrect in a signiﬁcant number of cases (Handforth et al, 1993; Garnett 
et al, 1994; Berger et al, 1999). They stressed the importance of the 
expertise of the neurologist or the 24-hour SE-Team in these sometimes-
complex situations. In that way these problems we encountered, such as 
the incompleteness of ﬁles or the number of wrong diagnosis of SE (No-SE) 
appeared to be not very different from other studies in the literature. 
Several studies have attempted to quantify the frequency of SE in various 
clinical populations. These surveys were until recently retrospective with 
inherent inaccuracies. Apart from the retrospective nature of most studies, 
there are several other potential problems one should consider:
– The diagnosis of SE in clinical practice is not always apparent. 
– The diagnosis is not always considered, especially non-convulsive SE in 
mentally retarded patients or patients with confusion, mistaken for a 
psychiatric diagnosis.
– A number of cases will not reach a hospital; they are treated outside 
neurological services. 
– SE in patients already admitted because of another medical problem 
will not always be documented as such.
– Duration of seizures will not always be recorded; short status episodes 
may be categorized as seizures, not as SE. 
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– In clinical practice therapy is not awaited for, but is instituted especially 
when an acute exacerbation is present in a patient known with previous 
epilepsy, or when serial seizures are present. An incorrect dismissal 
diagnosis of SE is not rare in these cases.
Recent prospective studies have mentioned the problem of under-
ascertainment (DeLorenzo et al, 1995; Knake et al, 2001). Many cases of SE 
will not be brought to the attention of the adult and paediatric neurological 
staff and remain unidentiﬁed. Apart from these reasons we have mentioned 
the lack of adequate coding possibilities for types of SE. For all these reasons 
it is impossible to detect all cases of SE in a certain year.
Nevertheless, our study provided information about patients with SE, 
which is not present in the available, also recent, literature: 
– Differences in outcome in cases with or without previous epilepsy.
– Causes of SE in patients with or without previous epilepsy.
– The relation between outcome and the presence of medical 
complications.
– The relation between outcome and duration of SE.
– The relation between outcome and treatment of SE.
– The relation between outcome and the underlying cause or SE itself.
– Information about SE in mentally retarded patients.
– Information about treatment of GCSE in the ICU.
In collaboration with Dr. G. Zielhuis of the Department of Epidemiology, 
we made the following assumption: a case with SE will be admitted to a 
hospital and documented by SIG; not all cases will be registered, such as 
cases with SE already hospitalised because of another medical problem or 
non-complicated cases, e.g. from asylums of mentally retarded patients or 
cases which have not been recognized as such. The study was thus focussed 
on more complicated cases, which had to be admitted to a hospital. Based on 
the number of documented cases by the SIG it was concluded that a number 
of 500 cases should be sufﬁcient to answer the questions we posed at the 
start of this study.
Our cohort of patients from 12 hospitals and 2 epilepsy centres, spread 
all over the country, amounts to 576 adult patients and 112 children with 
various types of SE. This sample, representative for the situation in the 
Netherlands, has been used for further analysis of causes, therapy and 
outcome of SE in the Netherlands. 
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11.2 Results in adult patients (chapter 4-6)
In contrast to other reports, we studied outcome of SE in relation to the type 
of SE and the presence of previous epilepsy or not (table 1). Outcome per 
seizure type presents striking differences, especially when a distinction is 
made in cases with or without previous epilepsy. 
The underlying cause is of major importance:
– Outcome of GCSE in cases with previous epilepsy is comparable to cases 
without previous epilepsy, when SE was caused by an acute symptomatic 
cause.
– Outcome in large and academic hospitals was less favourable than in 
smaller hospitals and epilepsy centres, reﬂected by the higher percentage 
of acute symptomatic cases and referral of more complicated cases.
Outcome in cases without SE (No-SE) appeared comparable to cases with 
previous epilepsy in the total group of SE and to cases with previous epilepsy 
from the group with GCSE (table 1). 
By deﬁnition SE does not contribute to outcome in cases with No-SE. 
This group is especially composed of patients with some sort of epileptic 
problem (single seizure, serial seizures or just known with epilepsy). 
Morbidity and mortality in cases with No-SE was in all cases related to 
a speciﬁc cause: CVA (3), aspiration pneumonia, cerebral tumour (2), 
hypotension, Alzheimer disease, encephalitis, head trauma, progressive 
neurological disease of unknown origin and pseudo-tumour cerebri. If we 
compare the No-SE group with the total SE and the GCSE group one might 
conclude that the presence of SE is related to a worse outcome (table 1). This 
may be related to more severe cases of acute symptomatic cases in the SE 
group or to a negative contribution of SE itself or both.
TCSE is the most frequent occurring type of SE. Recent prospective 
studies suggest an incidence of TCSE of 5-30 per 100.000. Based on these 
numbers one may expect at leat 1000 patiënts with TCSE every year in the 
Netherlands. 
Causes and precipitating factors of TCSE in adults were in accordance 
with the literature.
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Apart from underlying cause we could demonstrate that outcome is 
worse when duration of SE was longer, when medical complications were 
present and when therapy was inadequate, especially in cases where SE 
itself was important to outcome. Some medical complications appeared 
more deleterious than others, especially respiratory insufﬁciency. We have 
shown that also in cases without medical complications patients may die 
because of SE, although this is not frequent (1-2%). We have investigated 
cases whose death or morbidity might have been preventable, such as cases 
with obvious inadequate therapy (waiting too long before initiating therapy; 
no ventilation and death because of respiratory insufﬁciency; continuous 
electrical SE without adjustment of therapy; insufﬁcient anticipation of the 
potential lethal medical complications). On the other hand we came across 
cases with optimal treatment that nevertheless died because of SE. 
Considering the recent prospective epidemiological studies one can 
estimate the total annual number of cases of SE in the Netherlands, but also 
the number of cases with TCSE in adults (Knake et al, 2001). We calculated 
an annual number of 636 adult cases with TCSE; our study suggests an 
annual morbidity and mortality because of SE in cases with inadequate 
therapy (chapter 4) in 10 respectively 24 cases, which may be prevented 
with the help of therapy according to protocol.
It is well known that the diagnosis of NCSE in clinical practise may be difﬁcult 
and often even not considered. In a recent prospective study, with 24 hour 
EEG-monitoring possibilities, an incidence of 4.4 per 100.000 was reported 
(Coeytaux et al, 2000); other studies mentioned lower ﬁgures (0.65-1.2 per 
100.000), but acknowledged signiﬁcant case under-ascertainment (Tomson 
et al, 1992; DeLorenzo et al, 1996). Based on the ﬁgures from Switzerland 
one may expect about 700 cases with CPSE and 96 with ASE every year in 
the Netherlands.
Our retrospective study reported the results in 65 cases with NCSE, 40 
with CPSE and 25 with ASE. The nature of this study and the fact that it 
concerned only cases admitted to hospitals, suggest a high number of more 
cases with NCSE, not admitted and/or not recognized as such, especially 
present in particular groups of patients (elderly or mentally retarded). Our 
group of patients with NCSE is one of the largest published until now.
We conﬁrmed the good prognosis of ASE in all cases, despite inadequate 
therapy in some. Causes or precipitating factors of ASE were comparable to 
those mentioned in the literature.
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Outcome in CPSE was especially determined by the underlying cause; 
the difference in outcome in cases with and without previous epilepsy 
was striking (table 1). All patients with previous epilepsy, except one had 
good outcome. This elderly patient died because of aspiration pneumonia 
acquired during CPSE. SE itself caused morbidity (memory deﬁcit and word 
ﬁndings problems) in one patient without previous epilepsy; morbidity in 
the other 5 cases was determined with certainty by the underlying cause in 
3 patients. Death in one case without previous epilepsy was also determined 
by its cause. To mention only total morbidity (15%) and mortality (5%) in 
CPSE, irrespective the presence of previous epilepsy or not, would have 
had less signiﬁcance. A relation between outcome and duration could not 
be established. Quality of therapy was more often inadequate in cases with 
morbidity; in three patients this might have contributed to a worse outcome. 
During our investigation it was striking that therapy of NCSE was variable 
or even clearly inadequate. In cases with longstanding CPSE morbidity 
because of SE itself should be considered. Modern neuro-imaging techniques 
may provide more information and may contribute to the discussion about 
treatment of CPSE.
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Table 1: Outcome of status epilepticus (SE) for the total adult group and 
per type of SE*
Outcome in adult patients Good Morbidity Mortality 
Total SE Total SE 
No-SE (118) 86.4 5.1 – 8.5 –
Previous epilepsy (69) 91.3 1.4 7.2
No previous epilepsy (41) 78.0 12.2  9.8
SE total (458) 76.0 14.7 4.8 9.5 5.1
Previous epilepsy (314) 87.0 6.4 3.8 6.4 3.5
No previous epilepsy (144) 57.0 19.8 2.1 22.6 8.5
GCSE (346) 76.0 13.0 3.5 11.0 6.1
Previous epilepsy (236) 85.5 8.5 3.8 6.0 4.3
No previous epilepsy (110) 55.5 22.7 2.7 21.8 9.9
GCSE (346)
MR (92) 87.0 8.7 4.3 4.3 2.2
No-MR (254) 72.0 14.6 3.1 13.4 7.5
No-MR previous epilepsy (144) 84.7 8.3 3.5 6.9 5.6
No-MR no previous epilepsy (110) 55.9 22.5 2.7 21.6 9.9
GCSE
Admitted at ICU (110) 56.3 20.9 4.5 22.7 11.8
Previous epilepsy (66) 66.7 15.1 7.5 18.2 16.6
No Previous epilepsy (44) 40.9 29.5 0 29.5 4.5
Non-ICU (246) 82.7 9.6 2.8 7.6 3.6
CPSE (40) 80.0 15.0 2.5 5.0 2.5
Previous epilepsy (28) 96.4 0 0 3.5 3.5
No previous epilepsy (12) 41.6 50.0 8.3 8.3 0
ASE (25) 100 0 0  0  0
SPSE (47) 70.2 21.3 2.1 8.5 0
Previous epilepsy (27) 85.2 14.8 3.7 0 0
No previous epilepsy (20) 50.0 30.0 0 20 0
* No-SE: wrong diagnosis of SE. GCSE: generalized convulsive SE; MR: mental retardation; 
ICU: intensive care unit; non-ICU: not admitted at the ICU; CPSE: complex partial SE; 
ASE: absence SE; SPSE: simple partial SE.
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The incidence of SPSE has been reported recently in several prospective 
studies; based on these studies, one may expect an annual number of about 
480 cases in the Netherlands. Most cases will be somatomotor, how many 
cases will correspond to EPC is unknown. Other types of SPSE are less likely 
to be recognized and reported.
We studied 47 patients with SPSE; somatomotor type was present in 46, 
and 20 of these corresponded to EPC. It was striking that also in cases with 
previous epilepsy the cause was often acute symptomatic. Stroke was a very 
prominent cause in cases without previous epilepsy. Outcome was mainly 
determined by the cause of SPSE; this was true for all 4 patients who died 
and for 6 of 10 patients with morbidity. In one patient morbidity (aphasia) 
after SPSE was considered to be caused by SE itself. Outcome could not be 
related to duration of SE; therapy was more often inadequate in cases with 
morbidity or mortality. 
11.3 Results in children (chapter 7 and 8)
We discussed SE in children separately from adults because of known 
differences in causes and outcome in comparison to adult patients. We 
studied 82 children with GCSE (table 2). Acute symptomatic causes were 
rare in children with previous epilepsy; previous epilepsy was especially 
present in children older than 1 year, which is in accordance with the 
literature. Outcome in children of less than 1 year was worse than in older 
children and outcome in children without previous epilepsy was far worse 
than in patients with previous epilepsy, both reﬂecting the contribution of 
acute symptomatic causes.
Apart from the underlying cause, we have shown that a longer duration, 
the presence of more than one medical complication and inadequate therapy 
may contribute to a worse outcome.
Children without medical complications may die because of SE itself, 
although this was the case in only 1.8%. The relation between outcome and 
medical complications in children has not been reported before; especially 
deleterious were respiratory insufﬁciency and intra-cranial hypertension. 
Therapy was inadequate in two children with morbidity because of SE and 
in none of those who died because of SE. 
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Table 2: Outcome of GCSE in children
Outcome in children Good Morbidity Mortality 
Total SE Total SE
GCSE (82) 73.2 13.4 3.7 13.4 6.1
Previous epilepsy (51) 84.3 5.9 1.9 9.8 7.8
No previous epilepsy (31) 54.8 25.8 6.4 19.4 3.2
GCSE (82) 75.0 12.5 3.7 12.5 6.1
MR (38) 86.9 5.2 2.6 7.9 7.9
No-MR (44) 61.4 20.5 4.5 18.2 4.5
GCSE at the ICU (35) 42.8 25.7 2.9 31.4 8.6
Previous epilepsy (14) 42.9 21.4 0 35.7 22.2
No previous epilepsy (21) 42.8 28.6 3.8 28.6  3.8
GCSE non-ICU
Total (47) 95.7  4.3 0  0  0
* GCSE: generalized convulsive SE; MR: mental retardation; ICU: intensive care unit; 
non-ICU: not admitted at the ICU.
Prognosis of NCSE in children was favourable in most cases; CPSE was 
present in 15 patients, typical ASE in only two and atypical ASE in six. Most 
children with CPSE were known with previous epilepsy (12).
During our study we came across some children with cognitive 
deterioration and electrical status epilepticus during sleep, Continuous 
Spikes and Waves during Sleep (CSWS) and acquired aphasia or Landau-
Kleffner syndrome (LKS). The diagnosis in clinical practice is often difﬁcult 
and treatment disappointing. In all the children in our group a plausible 
link could be made between cognitive regression and the EEG disturbances 
during sleep. CSWS or LKS could also be present without clinically manifest 
seizures. In contrast to information from the literature, aggravation of 
clinical seizures did not occur and treatment with ﬁrst line drugs (valproate 
and/or benzodiazepines) was without any effect on cognition. With such a 
small group it was difﬁcult to discuss the relation between prognosis and 
duration of CSWS or severity of epilepsy. It was, however, striking that 
duration of CSWS in this group was relatively long and cognitive prognosis 
of most of the children poor. Prognosis appeared more favourable when the 
age of onset was more than 9 years. The treatment of this syndrome is not 
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simple, both from a medical point of view and with regard to the serious 
behavioural problems. Good results are best achieved by a multidisciplinary 
approach within a specially adapted treatment environment. If this condition 
is not recognised or is neglected it may result in irreversible damage with 
serious cognitive and behavioural problems. An EEG during sleep must be 
made when children have an unexplained cognitive regression.
11.4 Results in patients with mental retardation
 (chapter 9)
We have performed a retrospective study of SE in MR to investigate whether 
speciﬁc features were present, which were different from SE in the population 
without MR. We were particularly interested in causes and outcome of the 
various types of SE in MR.
We discussed the results in 113 adults and 57 children with MR and 
SE. GCSE was the most frequent type of SE in both adults (81,4%) and 
children (66,7%) with MR, which is in accordance with the literature. NCSE 
was present in a larger group of children (29,8%) than in adult patients 
(7,1%). EPC and NCSE did not occur in the elderly group. The diagnosis of 
SE appeared wrong in eight adults, presumed to have had GCSE. The group 
of patients with MR and GCSE was characterized by the high percentage 
of previous epilepsy. Previous epilepsy was present in 98,2% of both the 
adults and the children with GCSE. In only two adults and one child an 
acute symptomatic cause was present. Causes of GCSE in adults included 
low levels of AED (24%) and systemic infections (4,3%), but in the majority 
the cause of SE remained unknown (69,5%). Outcome in GCSE did not differ 
from cases with previous epilepsy without MR (table 1 and 2). One should 
take into account that minor cognitive decline after GCSE in patients with 
MR cannot be ruled out. Several factors that may contribute to outcome 
in GCSE were investigated. The underlying cause as the main factor with 
respect to outcome could not be acknowledged, because most of the patients 
were known with previous epilepsy and showed a low number of acute 
symptomatic causes. Our study could not ﬁnd a relation between duration 
of GCSE or the quality of therapy and outcome. The presence of one or more 
medical complications was related to poor outcome, especially in children. 
The relation between outcome and SE itself was evident in six adults and 
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four children. Morbidity because of SE itself was present in 4,3% of the 
adults with MR and in 2,6% of the children; mortality in adults because 
of SE itself was 2,2% and in children 7,9%. In children no differences were 
found between cases with or without MR with respect to the contribution of 
SE itself to outcome. In adults more patients without MR died because of SE 
itself (7,5%) than adults with MR (2,1%); the rates of morbidity because of 
SE itself were comparable in adults (table 1). 
This study has demonstrated that patients with MR and SE, who had to be 
admitted to a hospital, showed comparable outcome to patients without MR 
but with previous epilepsy. These more complicated cases of SE in patients 
with MR have a favourable outcome, provided that medical complications 
are anticipated and properly treated.
11.5 Results of patients with GCSE treated at the 
 ICU (chapter 10)
Most patients with SE (80-85%) are treated adequately with benzodiazepines 
(BDZ) and/or phenytoin (PHT). SE refractory to these drugs is frequently 
caused by an acute neurological insult. Admission to the Intensive Care 
Unit (ICU) may be necessary especially when medical complications, such 
as respiratory insufﬁciency, are present, or when anaesthesia is mandatory. 
Few studies describe cohorts of patients with SE admitted to the ICU (Goulon 
et al, 1985; Nouailhat et al, 1985; Barois et al, 1985; Lacroix et al, 1994; 
Erikkson and Koivikko, 1997; Holtkamp et al, 2005). A drawback of these 
studies was the inclusion of different types of SE. Most patients admitted 
to the ICU because of SE are not known with previous epilepsy; they show 
a large percentage of acute neurological insults and a high morbidity and 
mortality rate. Outcome is especially determined by the underlying cause. 
We studied 110 adults and 35 children admitted to the Intensive Care Unit 
because of Generalized Convulsive Status Epilepticus (GCSE). Causes of 
GCSE in adult patients with previous epilepsy were non-compliance and 
systemic infections, in children systemic infections. Acute symptomatic 
causes in adult patients without previous epilepsy were stroke, intoxication, 
metabolic disturbances and brain tumours; in children the main causes were 
bacterial meningitis and viral encephalitis. In comparison to cases with 
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GCSE not admitted to the ICU outcome was worse. Cause and the number 
of medical complications especially determined outcome. Especially in 
children more severe cases with GCSE occurred, which caused a signiﬁcantly 
worse outcome in children with previous epilepsy. 
We conﬁrmed the less favourable outcome in the very young child or in 
the older age group and in patients without previous epilepsy. Causes and 
precipitating factors were not very different from other reports. The number 
of patients with previous epilepsy and an acute symptomatic cause (4.5%) 
was not very different from the total group of patients with previous epilepsy 
(5.9%). Causes with a poor outcome were CVA and cardiac arrest in adult pa-
tients and in children resuscitation after laryngo-bronchitis and hypoxia and 
pneumococcal meningo-encephalitis. Outcome in adult cases with previous 
epilepsy was better than without previous epilepsy (table 1), this was not 
the case in children (table 2). Outcome in cases not admitted to the ICU was 
better, with less morbidity and mortality because of SE itself (table 1). This 
may indicate that patients with GCSE admitted to the ICU are more severe 
cases of SE, especially in children. EEG monitoring at the ICU is important, 
especially in cases that have been paralysed (mechanical ventilation), but 
also to adjust therapy. With the help of simultaneous recording of the EEG 
and ICP-monitoring we have observed a relation between seizures and the 
subsequent rise of ICP, which has been reported earlier (Gabor et al, 1984; 
Tsementzis et al, 1979). ICP monitoring may also have important therapeutic 
consequences, especially when cerebral perfusion pressure reaches a critical 
threshold. 
Outcome in patients admitted to the ICU because of GCSE is worse than 
in cases not admitted to the ICU. Apart from serious acute symptomatic 
causes, the severity of SE appeared also important with respect to outcome, 
stressing the importance of treatment according to protocol. 
11.6 Conclusions
This study has several drawbacks, related to the retrospective nature. 
However, in comparison to other retrospective studies, it provided more 
adequate information with respect to the differentiation in age groups, 
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types of SE and the presence of previous epilepsy or not. We discussed 
outcome not only in relation to the type of SE, the presence of previous 
epilepsy or not, but also in relation to duration of SE, the presence of 
medical complications or not and the quality of treatment, which has not 
been subject of earlier studies. The number of patients of our study was 
sufﬁcient to make suggestions how to improve the care of difﬁcult to treat 
cases with SE, taken into account the results of outcome and the various 
contributing factors in this respect. This descriptive study has been able to 
make clear that outcome of the various types of SE is especially determined 
by its cause, but also that outcome may improve, provided that one takes 
notice of medical complications and adequate treatment. These ﬁndings 
promote therapy according to protocol, with special emphasis on duration, 
potential lethal medical complications and adequate therapy. An example 
of such a protocol has been discussed and presented in chapter 3.9. This 
protocol has been the basis of later directives, developed by a study group of 
the association of the Dutch neurologists (Donselaar et al, 2001).
Some indices of severity may be introduced, which have been 
determined by known contributing factors to outcome (table 3). It is known 
and acknowledged by our results that prognosis of ASE is always good; the 
index of severity will be zero for this type of SE. Prognosis for GCSE may 
be unfavourable, so the index will be two. In this way one can discuss the 
indices for the presence of an acute symptomatic cause or not, the presence 
of previous epilepsy or not, duration of SE and the start of treatment. After 
admission of a patient with SE the various indices may be determined, 
which may promote prompt admission to the ICU and treatment according 
to protocol especially in cases with a severity index of more than 4.
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Table 3: Indices of severity
0 1 2
Type of SE ASE CPSE SPSE GCSE
Number of medical complications None 1 >1
Acute symptomatic cause Not present – Present 
Previous epilepsy Present Not present –
Duration of SE < 60 min 60-120 min >120 min
Start of treatment Within 30 min – After 120 min
Our study is unique in the Netherlands. Until now only some case reports 
have been published, regarding GCSE (Frederiks, 1969; Hootsmans, 1954; 
Lorentz De Haas, 1960; Verjaal and Goor, 1969; van Huffelen, 1983), ASE 
(Visser, 1970), SPSE with aphasia as the main symptom (Jongsma and 
Vanneste, 1991), CPSE (Storm and Casteelen, 1999), the Landau-Kleffner 
Syndrome (Stroink et al, 1997) and treatment of SE with clonazepam (van 
Huffelen and Magnus, 1976). The importance of a treatment protocol has 
been stressed in one review in the Dutch medical literature, based on a 
foreign symposium (van Huffelen, 1983). 
Our study has shown that gaps are present in the knowledge about 
adequate treatment of SE, but also in the recognition of the various types 
of SE. The results of this study may contribute to ﬁll these gaps, and call 
for further prospective investigations, with speciﬁc attention to the elderly 
and patients with mental retardation. The reason for the speciﬁc attention 
is that it is very likely that many cases of SE, especially NCSE, have not 
been recognized as such in the elderly and patients with MR. With the 
current economy less attending personnel will be available, with obvious 
implications for the care of patients with epilepsy and/or some type of SE. 
Also, the current possibilities for proper coding of the various types of SE 
are not sufﬁcient, which may contribute to inadequate registration.
The Netherlands is a small country with an excellent healthcare and 
an adequate relation between the number of physicians and the number 
of inhabitants. Considering the number of inhabitants one may expect a 
high number of new cases with SE every year. Foreign prospective studies 
suggest at least 3000 cases of SE, possibly even higher (6000-10000). These 
numbers would suggest that in a local hospital SE would be diagnosed in 
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at least 2-4 patients every month, which will appear unexpectedly high to 
many neurologists in the Netherlands. These foreign numbers even do not 
include a considerable number, which could not be ascertained. That is 
why it would be very important to ﬁnd out the true incidence of the various 
types of SE in the Netherlands, with special emphasis on morbidity and 
mortality. Prospective investigations will require adequate cooperation 
between neurologists, general practitioners, physicians taking care of 
patients with mental retardation and psychiatrists. In some parts of the USA 
24 hour SE-teams are available for diagnosis and treatment of all patients 
with the various types of SE. Such an approach offers many advantages for 
prospective studies, although the problem of under-ascertainment will not 
be completely solved (DeLorenzo et al, 1996). A prospective study offers 
possibilities for further investigation on the various aspects of SE in the 
Netherlands, including incidence. A major subject should be a prospective 
trial of treatment of SE, when ﬁrst line drugs fail; information on this subject 
is not available, not only in the Netherlands, but also not abroad.
Several centres in the Netherlands have proven to be able to perform 
and present excellent research in other ﬁelds of epileptology. That is why the 
situation in the Netherlands provides ideal opportunities for prospective 
studies of various aspects of SE, such as:
– The incidence of the various types in the general population, the elderly 
or in patiënts with MR. 
– Trials of treatment of refractory SE. 
– The consequences of NCSE in MR. 
– Cognitive consequences of SE in various clusters of patients.
– Neuro-imaging studies that may contribute to the knowledge about 
pathophysiology of SE and the discussion about the deﬁnition of SE.
Considering the recent developments in ﬁnance of the Dutch healthcare with 
the introduction of Diagnose Behandel Combinaties (DBC), it is essential to 
provide separate DBC-codes for SE. Treatment of patients with SE may take 
considerable time and effort, and involve considerable expense due to drugs 
and potential ICU-care (Penberthy et al, 2005). Separate codes for SE will 
also contribute to improvement of registration.
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Inleiding
Deze studie werd geboren uit frustraties die ontstonden tijdens de 
behandeling van patiënten met status epilepticus (SE), welke niet 
reageerden op de gebruikelijke eerste keus middelen, zoals diazepam en/of 
fenytoine en waarbij de behandeling vaak willekeurig bleek te verlopen. Ook 
op de Intensive Care Unit (ICU) van een academisch ziekenhuis verliep de 
behandeling van SE niet of nauwelijks geprotocolleerd en er werd weinig 
rekening gehouden met de pathofysiologie van SE. Dat was niet alleen het 
geval in dat academisch ziekenhuis, doch gezien de bevindingen bij patiënten 
welke uit andere ziekenhuizen werden overgenomen, ook elders. Ervaringen 
met enkele ernstige gevallen van SE resulteerde in een eerste versie van een 
therapieprotocol (Scholtes en Dries, 1986) en de start van een retrospectief 
onderzoek naar de aanpak in andere ziekenhuizen in Nederland. 
Ten tijde van het begin van de studie waren er geen gegevens bekend 
over de diverse aspecten van SE in Nederland, zoals de oorzaken, de 
incidentie en prevalentie, de medische complicaties welke kunnen optreden, 
de behandeling, de morbiditeit en de mortaliteit. Er waren enkele studies 
gepubliceerd door Nederlandse auteurs, welke voornamelijk afzonderlijke 
patiënten betroffen met een bepaald type SE, zoals GCSE (Frederiks, 1969; 
Hootsmans, 1954; Lorentz De Haas, 1960; Verjaal and Goor, 1969; van 
Huffelen, 1983), ASE (Visser, 1970), en behandeling van SE met clonazepam 
(van Huffelen and Magnus, 1976). Er was slechts één overzichtsartikel 
gepubliceerd over de behandeling van SE volgens protocol, overigens 
gebaseerd op een buitenlandse conferentie over dit onderwerp (van Huffelen, 
1983). De buitenlandse literatuur op dat moment bestond voornamelijk uit 
retrospectieve en selectieve studies met patiënten uit universiteitsklinieken 
of gespecialiseerde centra. Deze studies hadden, naast het retrospectieve 
karakter zelf, diverse nadelen: 
1. Grote verschillen in de duur van de follow-up.
2. Het bespreken van de resultaten zonder een onderscheid te maken in 
type SE of leeftijdsgroep.
3. Geen onderscheid in patiënten die al bekend waren met epilepsie of 
niet.
4. Geen onderscheid in morbiditeit/mortaliteit ten gevolge van de 
onderliggende oorzaak of SE zelf.
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Recente prospectieve studies hebben deze nadelen niet helemaal kunnen 
verhelpen (DeLorenzo et al, 1996; Knake et al, 2001). Zo werd bijvoorbeeld 
mortaliteit nog steeds vermeld los van het type SE, terwijl bekend was dat 
de resultaten bij complex partiële SE (CPSE) over het algemeen gunstiger 
zijn dan bij gegeneraliseerde convulsieve SE (GCSE).
Incidentiegegevens waren ten tijde van de aanvang van de studie beperkt 
tot schattingen; enkele recente studies hebben hierover wel prospectieve 
gegevens kunnen verstrekken (DeLorenzo et al, 1996; Coeytaux et al, 2000; 
Knake et al, 2001) 
We begonnen de gegevens te verzamelen van zoveel mogelijk patiënten met 
SE opgenomen in diverse ziekenhuizen en epilepsiecentra in Nederland 
in de periode 1980-1987. Patiënten werden alleen in de studie opgenomen 
indien zij voldeden aan de gangbare deﬁnitie van SE. Ten einde de 
patiënten te kunnen opsporen werd gebruikt gemaakt van de registratie 
van de ontslagdiagnose, gecodeerd volgens de ICD-9, zoals die werd 
gehanteerd door de ziekenhuizen in Nederland en door de SIG, Stichting 
Informatievoorziening Gezondheidszorg. Deze codering heeft echter 
beperkingen, er kunnen slechts drie typen SE worden geregistreerd: petit 
mal SE (code 345.2), grand mal SE (code 345.3) en EPC (code 345.7). Een 
aparte code voor CPSE of tonische SE is er gewoon niet. We vonden overigens 
diverse gevallen met CPSE, terwijl de ontslagcode heel anders was, zoals 
petit mal SE of zelfs grand mal SE. 
Tijdens het onderzoek werden diverse problemen gesignaleerd:
1. Onvoldoende coderingsmogelijkheden voor de diverse typen SE.
2. Onjuiste ontslagdiagnosen (20%).
3. Het voorkomen van een onjuiste classiﬁcatie van het type SE.
4. De duur van SE kon niet altijd worden achterhaald. De duur werd in dit 
soort gevallen geschat op basis van informatie over transport naar het 
ziekenhuis en/of duur behandeling.
5. Informatie over behandeling door huisarts of ambulance personeel 
bleek schaars.
6. Niet alle geregistreerde gevallen konden worden opgespoord.
7. Gevallen met SE gezien in consult op andere dan neurologische 
afdelingen waren niet of nauwelijks op te sporen.
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De registratie van de patiënten met SE vertoonde nogal grote verschillen 
in zorgvuldigheid per ziekenhuis. De kleinere ziekenhuizen bleken hierbij 
de minste fouten te scoren en vertoonden ook de minste hoeveelheid 
patiënten met een onjuiste diagnose van SE (No-SE). Een protocol voor de 
behandeling van SE was slechts aanwezig in één academisch ziekenhuis en 
een epilepsiecentrum. Dat betekende overigens niet dat dit protocol dan 
ook gevolgd werd. Andere onderzoekers hebben ook melding gemaakt van 
het gegeven dat de diagnostiek van epileptische aanvallen of van SE in de 
praktijk problemen kan opleveren; SE werd niet herkend of de diagnose bleek 
incorrect in een relatief groot aantal van de patiënten (Handforth et al, 1993; 
Garnett et al, 1994; Berger et al, 1999). De onderzoekers beklemtoonden het 
belang van de aanwezigheid van een neuroloog of van een 24-uur SE-Team in 
deze soms complexe situaties. De problemen welke wij tegenkwamen, zoals 
het aantal gevallen No-SE, zijn dus deels herkenbaar uit andere studies.
Verschillende studies hebben een poging gedaan het voorkomen van SE 
in diverse populaties te onderzoeken. Deze studies waren tot voor kort 
voornamelijk retrospectief, met alle daar aan gekoppelde nadelen. Daarnaast 
moet men echter ook aan andere problemen denken:
– De diagnose SE is in de praktijk niet altijd makkelijk te stellen. 
– De diagnose SE wordt niet altijd overwogen, met name niet NCSE bij 
verstandelijk gehandicapten of bij patiënten met verwardheid.
– Een aantal patiënten worden buiten het ziekenhuis behandeld. 
– SE bij patiënten, opgenomen vanwege een ander medisch probleem, 
wordt vaak niet als zodanig geregistreerd.
– Duur van de aanvallen wordt niet altijd vastgelegd; korte perioden SE 
kunnen dan als aanvallen worden geregistreerd, niet als SE. 
– In de klinische praktijk wacht men niet met de behandeling tot men 
voldoet aan de deﬁnitie; veelal begint men na een aanvalsduur van 5-10 
minuten, bij een excacerbatie van een patiënt bekend met epilepsie of 
bij een serie aanvallen. Een onjuiste ontslagdiagnose SE is hierbij niet 
zeldzaam.
Recente prospectieve studies hebben ook melding gemaakt van het 
probleem dat een groot aantal van de gevallen met SE niet te achterhalen 
zijn (DeLorenzo et al, 1995; Knake et al, 2001). Ook bij prospectieve studies 
Samenvatting en bespreking
233
zullen dus veel gevallen niet worden vastgelegd. Daarnaast is er dus ook nog 
het probleem van de codering. Het zal dus duidelijk zijn dat het erg moeilijk 
is alle gevallen met SE in een bepaald jaar op te sporen. 
Onze studie heeft belangrijke informatie opgeleverd, welke in de literatuur, 
ook de recente, niet aanwezig is: 
– Verschillen in resultaat bij patiënten bekend met of zonder epilepsie.
– Oorzaken SE in patiënten bekend met of zonder epilepsie.
– De relatie tussen resultaat en de aanwezigheid van medische 
complicaties.
– De relatie tussen resultaat en duur SE.
– De relatie tussen resultaat en de behandeling van SE.
– De relatie tussen resultaat en onderliggende oorzaak dan wel de gevolgen 
van SE zelf.
– Informatie over SE in verstandelijk gehandicapten.
Met onderkenning van de beperkingen werd getracht informatie te verza-
melen over patiënten die vanwege SE in een ziekenhuis moesten worden 
opgenomen. Wij gingen er hierbij vanuit dat een patiënt met SE in een 
ziekenhuis werd opgenomen en geregistreerd door het SIG. Niet alle gevallen 
zullen echter worden geregistreerd. Gebaseerd op de gegevens van het SIG 
werd, in overleg met Dr. G. Zielhuis van het instituut voor epidemiologie, 
aangenomen dat een aantal van 500 gevallen met SE voldoende zou zijn 
om de verschillende vragen van de studie te kunnen beantwoorden. Van in 
totaal 576 volwassenen en 112 kinderen, afkomstig uit 12 ziekenhuizen en 2 
epilepsie-centra konden gegevens geëvalueerd worden.
Resultaten bij volwassenen (hoofdstuk 4-6)
Opvallend was het gegeven dat de diagnose SE in 20% van de gevallen, als 
zodanig gerapporteerd aan het SIG, niet correct was (tabel 1). 
De onderliggende oorzaak bleek de belangrijkste bepalende factor te zijn 
met betrekking tot het uiteindelijk resultaat van de behandeling van GCSE. 
Dit bleek bijvoorbeeld uit het feit dat de resultaten bij patiënten bekend 
met epilepsie vergelijkbaar waren met die van patiënten zonder epilepsie, 
indien de oorzaak van GCSE acuut symptomatisch was. De resultaten van 
patiënten waarbij de diagnose SE incorrect (No-SE) bleek te zijn, waren 
vergelijkbaar met die van patiënten bekend met epilepsie uit de totale 
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groep SE en uit de groep GCSE (tabel 1). De morbiditeit en de mortaliteit 
in de No-SE groep werd geheel bepaald door een speciﬁeke oorzaak, zoals 
CVA, hersentumor, trauma capitis of encephalitis. De totale morbiditeit en 
mortaliteit in de gehele groep SE, alsmede in de GCSE groep bleek hoger 
dan in No-SE, waarbij men zou kunnen concluderen dat de aanwezigheid 
van SE zelf een negatieve bijdrage levert aan het uiteindelijke resultaat. Dit 
kan ook beïnvloed worden door de aanwezigheid van meer ernstige acuut 
symptomatische pathologie in de SE groep of door beiden.
Tonisch-clonische SE (TCSE) is de meest voorkomende vorm van GCSE en 
van alle typen SE. Recente prospectieve studies suggereren een incidentie 
van TCSE van 5-30 per 100.000 (DeLorenzo et al, 1996; Coeytaux et al, 
2000; Knake et al, 2001). Dit betekent per jaar tenminste 1000 gevallen van 
TCSE in Nederland.
De resultaten van 346 opnamen vanwege GCSE bleken negatief te worden 
beïnvloed door de aanwezigheid van een acute symptomatische oorzaak, 
maar ook door de aanwezigheid van meer dan 1 medische complicatie, door 
een duur van SE van meer dan 4 uur en door een inadequate behandeling. 
De invloed van deze laatste 3 factoren was met name duidelijk indien SE zelf 
verantwoordelijk was voor de morbiditeit of mortaliteit. Enkele medische 
complicaties, zoals respiratoire insufﬁciëntie, bleken schadelijker te zijn 
dan anderen. Ook werden gevallen beschreven welke overleden aan de 
gevolgen van SE zelf, terwijl er geen medische complicaties aanwezig waren. 
Dit gebeurde overigens niet vaak (1-2%). De oorzaken van TCSE waren 
vergelijkbaar met die uit de literatuur.
De behandeling van GCSE bestond voornamelijk uit benzodiazepines en\
of fenytoine. De resultaten in de grotere ziekenhuizen waren minder gunstig 
dan in de kleinere of de epilepsiecentra, hetgeen samenhing met het hogere 
percentage acute symptomatische oorzaken en medische complicaties. 
Indien men de resultaten van recente prospectieve studies extrapoleert 
op Nederland, dan kan per jaar ongeveer een aantal van 636 volwassenen 
met TCSE worden verwacht (Knake et al, 2001). Vanuit dit getal en onze 
resultaten m.b.t. de kwaliteit van de behandeling kan worden berekend dat 
per jaar 10 gevallen met morbiditeit en 24 doden kunnen worden vermeden, 
indien de behandeling wel adequaat verloopt. Hierbij kan een protocol een 
ondersteuning bieden.
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Tabel 1: Resultaten status epilepticus (SE) bij volwassenen per type*
Resultaten bij volwassenen Goed Morbiditeit Mortaliteit 
Totaal SE Totaal SE 
No-SE (118) 86.4 5.1 – 8.5 –
Bekend met epilepsie (69) 91.3 1.4 7.2
Niet bekend epilepsie (41) 78.0 12.2  9.8
SE totaal  (458) 76.0 14.7 4.8 9.5 5.1
Bekend epilepsie (314) 87.0 6.4 3.8 6.4 3.5
Niet bekend epilepsie (144) 57.0 19.8 2.1 22.6 8.5
GCSE (346) 76.0 13.0 3.5 11.0 6.1
Bekend epilepsie(236) 85.5 8.5 3.8 6.0 4.3
Niet bekend epilepsie(110) 55.5 22.7 2.7 21.8 9.9
GCSE (346)
MR (92) 87.0 8.7 4.3 4.3 2.2
No-MR (254) 72.0 14.6 3.1 13.4 7.5
No-MR bekend epilepsie (144) 84.7 8.3 3.5 6.9 5.6
No-MR niet bekend epilepsie (110) 55.9 22.5 2.7 21.6 9.9
GCSE
Opname ICU  (110) 56.3 20.9 4.5 22.7 11.8
Bekend epilepsie (66) 66.7 15.1 7.5 18.2 16.6
Niet bekend epilepsie (44) 40.9 29.5 0 29.5 4.5
Non-ICU (246) 82.7 9.6 2.8 7.6 3.6
CPSE (40) 80.0 15.0 2.5 5.0 2.5
Bekend epilepsie  (28) 96.4 0 0 3.5 3.5
Niet bekend epilepsie (12) 41.6 50.0 8.3 8.3 0
ASE (25) 100 0 0  0  0
SPSE (47) 70.2 21.3 2.1 8.5 0
Bekend epilepsie  (27) 85.2 14.8 3.7 0 0
Niet bekend epilepsie (20) 50.0 30.0 0 20 0
* SE. No-SE: onjuiste diagnose SE. GCSE: gegeneraliseerde convulsieve SE; MR: mentale 
retardatie (verstandelijke handicap); ICU: intensive care unit; non-ICU: niet opgenomen 
in ICU; CPSE: complex partiële SE; ASE: absence SE; SPSE: simpele partiële SE.
De diagnostiek van NCSE blijkt in de klinische praktijk niet altijd eenvoudig 
en zelfs niet altijd overwogen. Een prospectief onderzoek in Zwitserland, 
met 24 uur mogelijkheden voor EEG registratie, vond een incidentie van 
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4.4 per 100.000 (Coeytaux et al, 2000). Andere onderzoekers vonden lagere 
cijfers, doch onderkenden het probleem dat niet alle gevallen te achterhalen 
zijn (Tomson et al, 1992; DeLorenzo et al, 1996). Op basis van de gegevens 
uit Zwitserland kan men per jaar in Nederland 700 gevallen verwachten met 
CPSE en 96 met ASE.
Patiënten met NCSE werden, zoals gebruikelijk in de literatuur, verdeeld 
in gevallen met ASE en CPSE. Een probleem bleek het feit dat niet in alle 
gevallen van CPSE een EEG werd verricht. De diagnose werd gesteld op 
basis van het klinisch beeld, de voorgeschiedenis en het resultaat van de 
behandeling. De groep bestond uit 40 gevallen met CPSE en 25 met ASE. 
Alle patiënten met ASE hadden een goed resultaat, ondanks dat de 
behandeling niet altijd adequaat genoemd kon worden. De oorzaken van 
ASE bleken vergelijkbaar te zijn met die uit de literatuur.
De morbiditeit van CPSE werd met name bepaald door de onderliggende 
oorzaak. Bij één patiënt werd aannemelijk gemaakt dat de persisterende 
geheugenstoornis na CPSE veroorzaakt werd door de ontladingen zelf. Er 
was een groot verschil in resultaat tussen patiënten met of zonder epilepsie 
(tabel 1). Alle patiënten met CPSE bekend met epilepsie hadden een goed 
resultaat, één uitgezonderd. Deze oudere patiënt overleed aan de gevolgen 
van aspiratie-pneumonie, welke hij had opgelopen tijdens CPSE. 
Een relatie met de duur van SE of de behandeling kon niet worden 
aangetoond. De therapie was in gevallen met morbiditeit niet altijd adequaat; 
in drie gevallen heeft dit bijgedragen aan het resultaat.
De behandeling van CPSE verliep in de diverse ziekenhuizen erg 
wisselend en was vaak inadequaat. In gevallen met langdurige CPSE 
dient men rekening te houden met mogelijke morbiditeit als gevolg van de 
ontladingen zelf. MRI onderzoek kan hierbij meer informatie verschaffen en 
bijdragen aan de discussie rond de behandeling van CPSE.
SPSE is relatief zeldzaam. De eerder genoemde prospectieve studies suggereren 
een aantal van ongeveer 480 patiënten per jaar in Nederland. Uit ons 
onderzoek bleek dat de diagnose niet altijd correct gesteld was. Onze groep 
van 47 is een van de grootste in de literatuur. Ten opzichte van de gegevens 
uit de literatuur vonden wij een hoger percentage vrouwen, een kortere 
duur en een hoger percentage patiënten die reeds epilepsie hadden. Met 
uitzondering van 1 patiënt met afasie als uiting van partiële SE hadden alle 
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andere een somato-motore expressie. Tussen de continue vorm (EPC) en die 
in aanvallen was geen verschil m.b.t. de kliniek, oorzaken of het resultaat 
van de behandeling. Een belangrijke bevinding was het feit dat in 20% van 
de gevallen die al bekend waren met epilepsie, een nieuw medisch probleem 
(tumor, CVA) verantwoordelijk was voor de SPSE. Bij patiënten niet bekend 
met epilepsie bleek CVA de meest voorkomende oorzaak te zijn van SPSE. 
De resultaten werden grotendeels bepaald door de oorzaak. Bij 1 patiënt 
bleek dat SE zelf verantwoordelijk was voor de morbiditeit (afasie).
Resultaten bij kinderen (hoofdstuk 7 en 8)
De diverse typen SE werden bij 112 kinderen beschreven in de leeftijd van 
28 dagen tot 15jaar. GCSE (82) bleek de meest voorkomende vorm van SE 
te zijn. De resultaten van GCSE werden met name bepaald door de oorzaak. 
Andere factoren waren de duur en de aanwezigheid van medische complica-
ties (>1), terwijl de kwaliteit van de behandeling niet duidelijk scoorde. 
De resultaten bij kinderen jonger dan 1 jaar bleken minder gunstig 
dan die bij oudere kinderen, hetgeen gerelateerd was aan het frequenter 
voorkomen van acuut symptomatische oorzaken bij het jonge kind. Ook 
kinderen zonder medische complicaties konden door SE zelf overlijden, 
hoewel dit weinig voorkwam (1.8%).
De relatie met medische complicaties werd tot nu toe niet beschreven 
bij kinderen; de meest schadelijke waren respiratoire insufﬁciëntie en 
intracraniële drukverhoging.
In de groep met NCSE (27) hadden 15 kinderen CPSE, 2 typische en 6 
atypische ASE. De meeste kinderen met CPSE waren bekend met epilepsie. 
De resultaten bij NCSE waren veelal goed; 1 patiënt vertoonde na CPSE een 
lichte afasie. 
De resultaten bij 7 kinderen met CSWS en 3 met Landau-Kleffner 
syndroom (LKS) waren ongunstig; slechts 1 kind vertoonde een compleet 
cognitief herstel. Dit leek samen te gaan met een lange duur van het ESES 
patroon in de slaap. De prognose bleek gunstiger bij een debuutleeftijd 
van meer dan 9 jaar. Niet alle kinderen met CSWS of LKS waren bekend 
met epilepsie. De behandeling met eerste keus middelen als valproaat of 
benzodiazepines bleek in de meerderheid in het geheel niet aan te slaan. Bij 
kinderen met onbegrepen cognitieve achteruitgang dient EEG onderzoek in 
de slaap te gebeuren.
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Resultaten bij verstandelijk gehandicapten (hoofdstuk 9)
Het onderzoek van SE bij de verstandelijk gehandicapten (VG) was er op 
gericht na te gaan of er bij deze doelgroep speciﬁeke kenmerken aanwezig 
waren die anders waren t.o.v. de doorsnee bevolking. Ook bij VG was GCSE 
de meest voorkomende vorm, bij zowel volwassenen als kinderen. De 
grote meerderheid met GCSE bleek tevoren al bekend te zijn met epilepsie 
(98,2%). Een acute symptomatische oorzaak was slechts aanwezig bij twee 
volwassenen en een kind. De resultaten bij GCSE waren vergelijkbaar met 
patiënten zonder VG, indien bekend met epilepsie (tabel 1). Eventuele discrete 
cognitieve achteruitgang kan bij deze doelgroep niet uitgesloten worden, 
dit valt in de praktijk minder op dan bij mensen zonder VG. De resultaten 
werden negatief beïnvloed door de aanwezigheid van 1 of meer medische 
complicaties, met name bij kinderen. Een relatie met de duur van SE of de 
kwaliteit van de behandeling kon niet worden aangetoond. Bij volwassenen 
zonder VG overlijden meer patiënten (7.5%) aan de gevolgen van SE zelf dan 
volwassenen met VG (2.1%). De resultaten bij VG lijken niet ongunstig, zeker 
als men aanneemt dat het de meer gecompliceerde gevallen zullen zijn, daar 
een behoorlijk aantal behandeld wordt in hun eigen woonomgeving. De 
resultaten kunnen verder verbeterd worden door betere aandacht voor de 
medische complicaties.
Tabel 2: Resultaten GCSE in kinderen*
Resultaten bij kinderen Goed Morbiditeit Mortaliteit 
Totaal SE Totaal SE
GCSE (82) 73.2 13.4 3.7 13.4 6.1
Bekend epilepsie (51) 84.3 5.9 1.9 9.8 7.8
Niet bekend epilepsie (31) 54.8 25.8 6.4 19.4 3.2
GCSE (82) 75.0 12.5 3.7 12.5 6.1
MR (38) 86.9 5.2 2.6 7.9 7.9
No-MR (44) 61.4 20.5 4.5 18.2 4.5
GCSE in de ICU (35) 42.8 25.7 2.9 31.4 8.6
Bekend epilepsie (14) 42.9 21.4 0 35.7 22.2
Niet bekend epilepsie (21) 42.8 28.6 3.8 28.6  3.8
GCSE non-ICU
Totaal (47) 95.7  4.3 0  0  0
* GCSE: gegeneraliseerde convulsive SE; MR: mentale retardatie (verstandelijke 
handicap); ICU: intensive care unit; non-ICU: niet opgenomen in ICU.
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GCSE in de Intensive Care Unit (hoofdstuk 10)
De meeste patiënten met SE kunnen goed worden behandeld met 
benzodiazepines en/of fenytoine. Opname in de ICU kan nodig zijn vanwege 
medische complicaties, zoals respiratoire insufﬁciëntie, of wanneer 
anesthesie nodig is. Er zijn enkele studies bekend die patiënten beschrijven 
die vanwege SE behandeld werden op de ICU (Goulon et al, 1985; Nouailhat 
et al, 1985; Barois et al, 1985; Lacroix et al, 1994; Erikkson and Koivikko, 
1997; Holtkamp et al, 2005). Een nadeel van deze studies is dat men 
verschillende types door elkaar heen beschrijft, hetgeen de resultaten 
moeilijk beoordeelbaar maakt. 
We konden de resultaten bestuderen bij 110 volwassenen en 35 kinderen 
die vanwege GCSE moesten worden opgenomen in de ICU. Oorzaken bij 
volwassenen, bekend met epilepsie waren non-compliance en algemene 
infecties; bij kinderen voornamelijk algemene infecties. Bij volwassenen, 
niet bekend met epilepsie vonden we CVA, intoxicaties, metabole stoornissen 
en hersentumoren; encephalitis en meningitis waren bij kinderen frequente 
oorzaken. De minder gunstige resultaten bij het jonge kind, bij ouderen 
en bij patiënten niet bekend met epilepsie kwamen overeen met die uit de 
literatuur. De oorzaken van GCSE waren vergelijkbaar met eerdere studies. 
Oorzaken van GCSE met een slechte prognose waren bij volwassenen CVA 
en hartstilstand, bij kinderen resuscitatie na laryngo-bronchitis, hypoxie 
en pneumococcen-meningitis. De resultaten bij patiënten die moesten 
worden opgenomen in de ICU waren minder gunstig dan indien opname 
in de ICU niet nodig was. Dit had enerzijds te maken met het hoger 
percentage acuut symptomatische oorzaken, maar ook met de ernst van de 
GCSE zelf, met name bij kinderen (tabel 1, tabel 2). Dit werd ondersteund 
door het feit dat de resultaten bij kinderen, bekend met epilepsie, net zo 
ongunstig waren als die bij kinderen zonder epilepsie. Ook het gegeven 
dat de morbiditeit en de mortaliteit ten gevolge van SE zelf bij patiënten 
opgenomen in de ICU hoger zijn dan bij patiënten niet opgenomen in de 
ICU, ondersteunt deze conclusie. EEG monitoring op de ICU is van belang 
bij patiënten met GCSE, welke worden beademd en gecurariseerd, ten einde 
de behandeling adequaat te kunnen vervolgen. Tijdens de behandeling 
werd EEG monitoring gelijktijdig verricht met intracraniële druk (ICP) 
monitoring in 5 volwassenen en 10 kinderen met ernstige GCSE, waarbij 
enkele malen een relatie werd vastgesteld tussen epileptische aanvallen en 
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stijging van de ICP. Ook werd diverse malen vastgesteld dat de ICP dermate 
kon stijgen dat de cerebrale perfusie druk (CPP) kritisch werd verlaagd. Dit 
gegeven heeft consequenties voor de behandeling van ernstige gevallen van 
GCSE. De onderliggende oorzaak is de belangrijkste bepalende factor ten 
aanzien van de morbiditeit en de mortaliteit. Daarnaast blijkt dat er op de 
ICU patiënten worden opgenomen met een meer ernstig verlopende vorm 
van GCSE, waarbij verbetering van de behandeling in een vroegere fase de 
uiteindelijke resultaten kan verbeteren.
Slotconclusies
Deze studie heeft een aantal nadelen vanwege het retrospectieve 
karakter. In vergelijking met andere studies hebben we betere informatie 
kunnen verschaffen over diverse aspecten van SE, door differentiatie 
in leeftijdsgroepen, typen SE en de aanwezigheid van epilepsie of niet. 
De resultaten werden daarnaast ook besproken in relatie tot duur SE, de 
aanwezigheid van medische complicaties en de kwaliteit van de behandeling. 
Een dergelijke benadering was hiervoor niet eerder gepubliceerd. Het aantal 
patiënten dat we konden bestuderen, 576 volwassenen en 112 kinderen, 
was volgens de epidemioloog Dr.G.Zielhuis voldoende om deze gegevens te 
bespreken. Een prospectieve studie zou een betere opzet zijn geweest, maar 
de kwantiteit en de kwaliteit van het materiaal zijn voldoende om conclusies 
te trekken en aanbevelingen te doen. De Nederlandse literatuur over SE 
is schaars en bevat weinig eigen materiaal; deze studie vult als zodanig 
duidelijk een leemte op. Deze beschrijvende studie heeft kunnen aantonen 
dat de resultaten van de diverse typen SE met name worden bepaald door 
de onderliggende oorzaak. De morbiditeit en de mortaliteit kunnen worden 
verlaagd indien men bij de behandeling rekening houdt met de medische 
complicaties en adequate behandeling. Een snelle en adequate behandeling 
is en blijft essentieel. Dit kan het beste geschieden door de behandeling 
volgens protocol te laten verlopen, met aandacht voor de duur, de medische 
complicaties en adequate keuze voor anti-epileptica. Een voorbeeld van een 
protocol werd beschreven en besproken in hoofdstuk 3.9. Dit protocol werd 
de basis van de later ontwikkelde richtlijnen voor de behandeling van SE, 
opgesteld door de Nederlandse Vereniging voor Neurologie (Donselaar et al, 
2001).
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Men kan bij de behandeling factoren introduceren welke de ernst van het 
probleem nader deﬁnieert. Zoals uit ons onderzoek is gebleken zijn deze 
factoren de aanwezigheid van medische complicaties of niet, de oorzaak, 
bekend zijn met epilepsie of niet, de duur van SE, het moment van de start 
van de behandeling en het type SE (tabel 3). Het is bekend dat de resultaten 
van ASE altijd goed zijn. ASE als type SE scoort dan 0 punten. De resultaten 
van GCSE kunnen ongunstig zijn, vandaar de score 2. Op deze manier 
worden de diverse risico factoren in een getal uitgedrukt. De ernst van de 
situatie bij opname bepaalt dan of behandeling volgens protocol moet lopen 
en opname in de ICU bespoedigd moet worden. Volgens de tabel 3 is dit 
zeker te adviseren bij een score van 4 of hoger.
Tabel 3: Indicatoren van ernst
Indicator 0 1 2
Type SE ASE CPSE SPSE GCSE
Aantal medische complicaties Geen 1 >1
Acute symptomatische oorzaak Niet aanwezig – Aanwezig 
Bekend epilepsie Aanwezig Niet aanwezig –
Duur SE < 60 min 60-120 min >120 min
Start behandeling Binnen 30 min – Na 120 min
Onze studie is uniek in Nederland. Niet eerder werd SE in Nederland zo 
uitgebreid met zoveel patiënten beschreven. We hebben aangetoond dat er 
hiaten aanwezig zijn in de kennis omtrent de juiste behandeling van SE, 
maar ook in de herkenning van verschillende typen SE. De resultaten van 
ons onderzoek kunnen bijdragen deze hiaten op te vullen en vragen om 
verdere prospectieve onderzoeken, met speciale aandacht voor ouderen en 
verstandelijk gehandicapten. Het is namelijk erg aannemelijk dat bij deze 
twee doelgroepen SE vaak wordt gemist, met name NCSE. Met de huidige 
economische ontwikkelingen zal minder verzorgend personeel voor hen 
aanwezig zijn, hetgeen consequenties zal hebben voor de kwaliteit van zorg 
voor ouderen en verstandelijk gehandicapten met epilepsie of een vorm van 
SE. 
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Prospectief onderzoek vergt goede samenwerking van de neurologen met 
huisartsen, artsen werkzaam in de zwakzinnigenzorg en met psychiaters. In 
de USA heeft men in bepaalde regio’s een 24-uurs-SE-team aangesteld, die 
op elk moment van de dag beschikbaar is voor de opvang van patiënten met 
SE, waardoor ook het verzamelen van prospectieve gegevens makkelijker is 
geworden. Ook met deze aanpak bleek overigens een hoog percentage van de 
gevallen niet geregistreerd te kunnen worden (DeLorenzo et al, 1996).
Deze studie heeft inzicht kunnen verschaffen in oorzaken van de 
diverse typen van SE, maar ook in factoren die negatief bijdragen aan de 
resultaten, zoals een lange duur, meerdere medische complicaties en een 
inadequate behandeling. Ook heeft deze studie laten zien dat de registratie 
van ontslagdiagnosen moet verbeteren. Enerzijds klopt de ontslagdiagnose 
in 20% van de gevallen niet, hetgeen een zorgvuldigheidsprobleem is in de 
ziekenhuizen, anderzijds kan een relatief vaak voorkomende vorm als CPSE 
niet eens geregistreerd worden, hetgeen een aanpassing vergt van de ICD-
codering.
Nederland is een compacte regio met een uitstekende gezondheidszorg 
en een goede verhouding tussen het aantal artsen en het aantal inwoners. 
Er vindt op diverse plaatsen hoogwaardig onderzoek plaats omtrent diver-
se aspecten van epilepsie. Gezien het aantal inwoners in Nederland kan 
men elk jaar een hoog aantal gevallen met SE verwachten; prospectieve 
onderzoeken suggereren een jaarlijks aantal van tenminste 3000 patiënten, 
waarschijnlijk nog veel meer (6.000-10.000). Dit aantal impliceert dat een 
plaatselijk ziekenhuis in Nederland elke maand 2-4 gevallen met SE zal zien, 
hetgeen voor veel neurologen een hoog aantal zal lijken. 
Gezien het bovenstaande zijn er voldoende randvoorwaarden aanwezig 
om diverse vragen over SE aan te pakken. Een belangrijk onderdeel van 
prospectief onderzoek zou een trial moeten zijn naar de behandeling van 
SE, niet reagerend op eerste keus middelen. Informatie over dit onderwerp 
is er niet, ook niet in de buitenlandse literatuur. De situatie in Nederland is 
ideaal voor prospectieve onderzoeken naar diverse aspecten van SE, waarbij 
men kan denken aan:
– De incidentie van de diverse typen van SE in de algemene populatie, bij 
ouderen en bij verstandelijk gehandicapten. 
– Trial naar de behandeling van refractaire SE. 
– De gevolgen van NCSE bij verstandelijk gehandicapten. 
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– Cognitieve gevolgen van SE in diverse clusters van patiënten.
– Neuro-imaging studies welke kunnen bijdragen aan de kennis van de 
pathophysiologie van SE en aan de discussie over de deﬁnitie van SE.
De huidige ontwikkelingen in de ﬁnanciering van de gezondheidzorg hebben 
Diagnose Behandel Combinaties (DBC’s) naar voren gebracht, maar er is 
geen aparte DBC-code voor SE. Men moet hierbij echter bedenken dat de 
behandeling van SE zeer arbeidsintensief kan zijn, met veel extra kosten 
voor medicatie en behandeling op de ICU (Penberthy et al, 2005). Een aparte 
code voor SE is hiermee een logische stap, hetgeen ook een ondersteuning 
kan zijn voor de registratie van het aantal gevallen met SE.
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